Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-13-436620.txt : 20131112 0001193125-13-436620.hdr.sgml : 20131111 20131112061309 ACCESSION NUMBER: 0001193125-13-436620 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20130930 FILED AS OF DATE: 20131112 DATE AS OF CHANGE: 20131112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000315545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900031917 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-09410 FILM NUMBER: 131206657 BUSINESS ADDRESS: STREET 1: 7327 OAK RIDGE HWY STREET 2: SUITE B CITY: KNOXVILLE STATE: TN ZIP: 37931 BUSINESS PHONE: 865-769-4011 MAIL ADDRESS: STREET 1: 7327 OAK RIDGE HWY STREET 2: SUITE B CITY: KNOXVILLE STATE: TN ZIP: 37931 FORMER COMPANY: FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC DATE OF NAME CHANGE: 20011126 FORMER COMPANY: FORMER CONFORMED NAME: SPM GROUP INC DATE OF NAME CHANGE: 19920703 10-Q 1 d612308d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2013

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000-09410

PROVECTUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)


Nevada		90-0031917
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee		37931
(Address of principal executive offices)		(Zip Code)

866-594-5999

(Registrant’s telephone number, including area code)

N/A

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ¨ Yes x No

The number of shares outstanding of the registrant’s common stock, par value $.001 per share, as of September 30, 2013, was 139,974,331. The number of shares outstanding of the registrant’s 8% convertible preferred stock, par value $.001 per share, as of September 30, 2013, was 746,666. The number of shares outstanding of the registrant’s Series A 8% convertible preferred stock, par value $.001 per share, as of September 30, 2013, was 2,958,334.

TABLE OF CONTENTS


PART I FINANCIAL INFORMATION

Cautionary Note Regarding Forward-Looking Statements			1
Item 1. Financial Statements (unaudited)
Condensed Consolidated Balance Sheets			2
Condensed Consolidated Statements of Operations			3
Condensed Consolidated Statements of Stockholders’ Equity			4
Condensed Consolidated Statements of Cash Flow			8
Notes to Condensed Consolidated Financial Statements			9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			15
Item 3. Quantitative and Qualitative Disclosures About Market Risk			17
Item 4. Controls and Procedures			17

PART II OTHER INFORMATION

Item 1. Legal Proceedings			18
Item 1A. Risk Factors			18
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			18
Item 3. Defaults Upon Senior Securities			19
Item 4. Mine Safety Disclosures			19
Item 5. Other Information			19
Item 6. Exhibits			20

SIGNATURES			21

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined under U.S. federal securities laws. These statements reflect management’s current knowledge, assumptions, beliefs, estimates, and expectations and express management’s current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date of this Quarterly Report on Form 10-Q, and we undertake no obligation to update such statements after this date.

Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2012, and elsewhere in this Quarterly Report on Form 10-Q), and the following:

•

our ability to license our dermatology drug product candidate, PH-10, on the basis of our Phase 2 atopic dermatitis and psoriasis results, which are in the process of being further developed;

•

our determination, based on guidance of the Food and Drug Administration (FDA), whether to proceed with or without a partner with a Phase 3 trial of PV-10 to treat recurrent melanoma and the costs associated with such a trial, unless the path to approval of PV-10 is accelerated, and whether Breakthrough Therapy Designation acceptance is viable and enables an accelerated path;

•

our determination whether to license PV-10, our recurrent melanoma drug product candidate, and other solid tumors such as liver cancer and cancers metastatic to the liver, if such licensure is appropriate considering the timing and structure of such a license, or to commercialize PV-10 on our own to treat recurrent and metastatic melanoma and other solid tumors such as liver cancer and cancers metastatic to the liver; and

•

our ability to raise additional capital if we determine to commercialize PH-10 and/or PV-10 on our own, although our expectation is to be acquired by a prospective pharmaceutical or biotech concern prior to commercialization.

PART I FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS.

PROVECTUS PHARMACEUTICALS, INC.

(A Development-Stage Company)

CONDENSED CONSOLIDATED BALANCE SHEETS


	September 30, 2013 (Unaudited)			December 31, 2012
Assets
Current Assets
Cash and cash equivalents	$	8,253,591		$	1,221,701
Prepaid expenses and other current assets		45,284			—

Total Current Assets		8,298,875			1,221,701
Equipment and furnishings, less accumulated depreciation of $427,615 and $422,965		31,829			29,829
Patents, net of amortization of $7,292,837 and $6,789,497, respectively		4,422,608			4,925,948
Other assets		27,000			27,000

	$	12,780,312		$	6,204,478

Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable — trade	$	202,464		$	243,435
Accrued compensation and payroll taxes		98,720			—
Accrued consulting expense		61,282			61,283
Other accrued expenses		180,001			206,706

Total Current Liabilities		542,467			511,424
Long-Term Liability
Warrant liability		3,514,622			1,299,570

Total Liabilities		4,057,089			1,810,994

Stockholders’ Equity
Preferred stock; par value $.001 per share; 25,000,000 shares authorized including; 8% convertible preferred stock, 746,666 and 2,478,185 shares issued and outstanding, respectively, liquidation preference $0.75 (in aggregate $570,585 and $1,896,117, respectively); Series A 8% convertible preferred stock, 2,958,334 shares issued and outstanding in 2013, liquidation preference $0.75 (in aggregate $2,246,855)		3,705			2,478
Common stock; par value $.001 per share; 250,000,000 authorized; 139,974,331 and 118,427,925 shares issued and outstanding, respectively		139,974			118,428
Paid-in capital		138,032,870			122,625,654
Deficit accumulated during the development stage		(129,453,326	)		(118,353,076	)

Total Stockholders’ Equity		8,723,223			4,393,484

	$	12,780,312		$	6,204,478

See accompanying notes to condensed consolidated financial statements.

PROVECTUS PHARMACEUTICALS, INC.

(A Development-Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	Three Months Ended September 30, 2013			Three Months Ended September 30, 2012			Nine Months Ended September 30, 2013			Nine Months Ended September 30, 2012			Cumulative Amounts from January 17, 2002 (Inception) Through September 30, 2013
Revenues
OTC product revenue	$	—		$	—		$	—		$	—		$	25,648
Medical device revenue		—			—			—			—			14,109

Total revenues		—			—			—			—			39,757
Cost of sales		—			—			—			—			15,216

Gross profit		—			—			—			—			24,541
Operating expenses
Research and development		1,296,654			1,129,921			2,815,519			4,352,940			45,914,372
General and administrative		2,185,756			2,296,637			6,864,865			7,228,225			73,050,754
Amortization		167,780			167,780			503,340			503,340			7,292,837

Total operating loss		(3,650,190	)		(3,594,338	)		(10,183,724	)		(12,084,505	)		(126,233,422	)
Gain on sale of fixed assets		—			—			—			—			55,075
Loss on extinguishment of debt		—			—			—			—			(825,867	)
Investment income		293			310			576			1,325			653,793
(Loss) gain on change in fair value of warrant liability		(902,798	)		1,246,917			(917,102	)		1,435,898			4,995,099
Net interest expense		—			—			—			—			(8,098,004	)

Net loss		(4,552,695	)		(2,347,111	)		(11,100,250	)		(10,647,282	)		(129,453,326	)
Dividends on preferred stock		(38,690	)		(43,884	)		(1,188,648	)		(145,709	)		(12,026,710	)

Net loss applicable to common shareholders	$	(4,591,385	)	$	(2,390,995	)	$	(12,288,898	)	$	(10,792,991	)	$	(141,480,036	)

Basic and diluted loss per common share	$	(0.03	)	$	(0.02	)	$	(0.10	)	$	(0.10	)

Weighted average number of common shares outstanding — basic and diluted		131,573,656			113,166,988			126,503,388			112,073,836

See accompanying notes to condensed consolidated financial statements.

PROVECTUS PHARMACEUTICALS, INC.

(A Development-Stage Company)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)


	Preferred Stock				Common Stock						Paid in capital			Accumulated Deficit			Total
	Number of Shares		Par Value		Number of Shares			Par Value			Paid in capital			Accumulated Deficit			Total
Balance, at January 17, 2002		—	$	—		—		$	—		$	—		$	—		$	—
Issuance to founding shareholders		—		—		6,000,000			6,000			(6,000	)		—			—
Sale of stock		—		—		50,000			50			24,950			—			25,000
Issuance of stock to employees		—		—		510,000			510			931,490			—			932,000
Issuance of stock for services		—		—		120,000			120			359,880			—			360,000
Net loss for the period from January 17, 2002 (inception) to April 23, 2002 (date of reverse merger)		—		—		—			—			—			(1,316,198	)		(1,316,198	)

Balance, at April 23, 2002		—	$	—		6,680,000		$	6,680		$	1,310,320		$	(1,316,198	)	$	802
Shares issued in reverse merger		—		—		265,763			266			(3,911	)		—			(3,645	)
Issuance of stock for services		—		—		1,900,000			1,900			5,142,100			—			5,144,000
Purchase and retirement of stock		—		—		(400,000	)		(400	)		(47,600	)		—			(48,000	)
Stock issued for acquisition of Valley Pharmaceuticals		—		—		500,007			500			12,225,820			—			12,226,320
Exercise of warrants		—		—		452,919			453			—			—			453
Warrants issued in connection with convertible debt		—		—		—			—			126,587			—			126,587
Stock and warrants issued for acquisition of Pure-ific		—		—		25,000			25			26,975			—			27,000
Net loss for the period from April 23, 2002 (date of reverse merger) to December 31, 2002		—		—		—			—			—			(5,749,937	)		(5,749,937	)

Balance, at December 31, 2002		—	$	—		9,423,689		$	9,424		$	18,780,291		$	(7,066,135	)	$	11,723,580
Issuance of stock for services		—		—		764,000			764			239,036			—			239,800
Issuance of warrants for services		—		—		—			—			145,479			—			145,479
Stock to be issued for services		—		—		—			—			281,500			—			281,500
Employee compensation from stock options		—		—		—			—			34,659			—			34,659
Issuance of stock pursuant to Regulation S		—		—		679,820			680			379,667			—			380,347
Beneficial conversion related to convertible debt		—		—		—			—			601,000			—			601,000
Net loss for the year ended December 31, 2003		—		—		—			—			—			(3,155,313	)		(3,155,313	)

Balance, at December 31, 2003		—	$	—		10,867,509		$	10,868		$	20,461,632		$	(10,221,448	)	$	10,251,052
Issuance of stock for services		—		—		733,872			734			449,190			—			449,923
Issuance of warrants for services		—		—		—			—			495,480			—			495,480
Exercise of warrants		—		—		132,608			133			4,867			—			5,000
Employee compensation from stock options		—		—		—			—			15,612			—			15,612
Issuance of stock pursuant to Regulation S		—		—		2,469,723			2,469			790,668			—			793,137
Issuance of stock and warrants pursuant to Regulation D		—		—		1,930,164			1,930			1,286,930			—			1,288,861
Beneficial conversion related to convertible debt		—		—		—			—			360,256			—			360,256


	Preferred Stock				Common Stock				Paid in capital			Accumulated Deficit			Total
	Number of Shares		Par Value		Number of Shares		Par Value		Paid in capital			Accumulated Deficit			Total
Issuance of convertible debt with warrants		—		—		—		—		105,250			—			105,250
Repurchase of beneficial conversion feature		—		—		—		—		(258,345	)		—			(258,345	)
Net loss for the year ended December 31, 2004		—		—		—		—		—			(4,344,525	)		(4,344,525	)

Balance, at December 31, 2004		—	$	—		16,133,876	$	16,134	$	23,711,540		$	(14,565,973	)	$	9,161,701
Issuance of stock for services		—		—		226,733		227		152,058			—			152,285
Issuance of stock for interest payable		—		—		263,721		264		195,767			—			196,031
Issuance of warrants for services		—		—		—		—		1,534,405			—			1,534,405
Issuance of warrants for contractual obligations		—		—		—		—		985,010			—			985,010
Exercise of warrants and stock options		—		—		1,571,849		1,572		1,438,223			—			1,439,795
Employee compensation from stock options		—		—		—		—		15,752			—			15,752
Issuance of stock and warrants pursuant to Regulation D		—		—		6,221,257		6,221		6,506,955			—			6,513,176
Debt conversion to common stock		—		—		3,405,541		3,405		3,045,957			—			3,049,362
Issuance of warrants with convertible debt		—		—		—		—		1,574,900			—			1,574,900
Beneficial conversion related to convertible debt		—		—		—		—		1,633,176			—			1,633,176
Beneficial conversion related to interest expense		—		—		—		—		39,529			—			39,529
Repurchase of beneficial conversion feature		—		—		—		—		(144,128	)		—			(144,128	)
Net loss for the year ended 2005		—		—		—		—		—			(11,763,853	)		(11,763,853	)


	Preferred Stock				Common Stock				Paid in capital		Accumulated Deficit			Total
	Number of Shares		Par Value		Number of Shares		Par Value		Paid in capital		Accumulated Deficit			Total
Balance, at December 31, 2005		—	$	—		27,822,977	$	27,823	$	40,689,144	$	(26,329,826	)	$	14,387,141
Issuance of stock for services		—		—		719,246		719		676,024		—			676,743
Issuance of stock for interest payable		—		—		194,327		195		183,401		—			183,596
Issuance of warrants for services		—		—		—		—		370,023		—			370,023
Exercise of warrants and stock options		—		—		1,245,809		1,246		1,188,570		—			1,189,816
Employee compensation from stock options		—		—		—		—		1,862,456		—			1,862,456
Issuance of stock and warrants pursuant to Regulation D		—		—		10,092,495		10,092		4,120,329		—			4,130,421
Debt conversion to common stock		—		—		2,377,512		2,377		1,573,959		—			1,576,336
Beneficial conversion related to interest expense		—		—		—		—		16,447		—			16,447
Net loss for the year ended 2006		—		—		—		—		—		(8,870,579	)		(8,870,579	)

Balance, at December 31, 2006		—	$	—		42,452,366	$	42,452	$	50,680,353	$	(35,200,405	)	$	15,522,400
Issuance of stock for services		—		—		150,000		150		298,800		—			298,950
Issuance of stock for interest payable		—		—		1,141		1		1,257		—			1,258
Issuance of warrants for services		—		—		—		—		472,635		—			472,635
Exercise of warrants and stock options		—		—		3,928,957		3,929		3,981,712		—			3,985,641
Employee compensation from stock options		—		—		—		—		2,340,619		—			2,340,619
Issuance of stock and warrants pursuant to Regulation D		—		—		2,376,817		2,377		1,845,761		—			1,848,138
Debt conversion to common stock		—		—		490,000		490		367,010		—			367,500
Net loss for the year ended 2007		—		—		—		—		—		(10,005,631	)		(10,005,631	)

Balance, at December 31, 2007		—	$	—		49,399,281	$	49,399	$	59,988,147	$	(45,206,036	)	$	14,831,510
Issuance of stock for services		—		—		350,000		350		389,650		—			390,000
Issuance of warrants for services		—		—		—		—		517,820		—			517,820
Exercise of warrants and stock options		—		—		3,267,795		3,268		2,636,443		—			2,639,711
Employee compensation from stock options		—		—		—		—		1,946,066		—			1,946,066
Net loss for the year ended 2008		—		—		—		—		—		(10,269,571	)		(10,269,571	)

Balance, at December 31, 2008		—	$	—		53,017,076	$	53,017	$	65,478,126	$	(55,475,607	)	$	10,055,536
Issuance of stock for services		—		—		796,012		796		694,204		—			695,000
Issuance of warrants for services		—		—		—		—		1,064,210		—			1,064,210
Exercise of warrants and stock options		—		—		3,480,485		3,480		2,520,973		—			2,524,453
Employee compensation from stock options		—		—		—		—		870,937		—			870,937
Issuance of stock and warrants pursuant to Regulation D						10,116,653		10,117		6,508,571		—			6,518,688
Net loss for the year ended 2009		—		—		—		—		—		(12,322,314	)		(12,322,314	)

Balance, at December 31, 2009		—	$	—		67,410,226	$	67,410	$	77,137,021	$	(67,797,921	)	$	9,406,510
Issuance of stock for services		—		—		776,250		776		855,837		—			856,613
Issuance of warrants for services		—		—		—		—		1,141,593		—			1,141,593
Exercise of warrants and stock options		—		—		3,491,014		3,491		3,100,189		—			3,103,680
Issuance of common stock pursuant to Regulation S		—		—		559,000		559		418,691		—			419,250
Issuance of common stock and warrants pursuant to Regulation D		—		—		11,168,067		11,169		6,335,820		—			6,346,989


	Preferred Stock						Common Stock				Paid in capital			Accumulated Deficit			Total
	Number of Shares			Par Value			Number of Shares		Par Value		Paid in capital			Accumulated Deficit			Total
Issuance of preferred stock and warrants pursuant to Regulation D		13,283,324			13,283			—		—		4,204,107			—			4,217,390
Preferred stock conversions into common stock		(7,893,326	)		(7,893	)		7,893,326		7,893		—			—			—
Employee compensation from stock options		—			—			—		—		3,759,650			—			3,759,650
Net loss for the year ended 2010		—			—			—		—		—			(18,552,102	)		(18,552,102	)

Balance, at December 31, 2010		5,389,998		$	5,390			91,297,883	$	91,298	$	96,952,908		$	(86,350,023	)	$	10,699,573
Issuance of stock for services		—			—			350,000		350		332,400			—			332,750
Issuance of warrants for services		—			—			—		—		945,116			—			945,116
Exercise of warrants and stock options		—			—			7,185,522		7,185		6,616,126			—			6,623,311
Issuance of common stock and warrants pursuant to Regulation D		—			—			9,905,062		9,905		7,031,334			—			7,041,239
Sale of non-controlling interest in Pure-ific Corporation and warrants		—			—			—		—		443,500			—			443,500
Preferred stock conversions into common stock		(1,858,333	)		(1,859	)		1,858,331		1,859		—			—			—
Employee compensation from stock options		—			—			—		—		3,368,950			—			3,368,950
Net loss for the year ended 2011		—			—			—		—		—			(19,434,699	)		(19,434,699	)

Balance, at December 31, 2011		3,531,665		$	3,531			110,596,798	$	110,597	$	115,690,334		$	(105,784,722	)	$	10,019,740
Issuance of stock for services		—			—			550,000		550		455,950			—			456,500
Issuance of warrants for services		—			—			—		—		1,512,026			—			1,512,026
Issuance of common stock and warrants pursuant to Regulation D		—			—			6,227,647		6,228		4,784,316			—			4,790,544
Preferred stock conversions into common stock		(1,053,480	)		(1,053	)		1,053,480		1,053		—			—			—
Employee compensation from stock options		—			—			—		—		183,028			—			183,028
Net loss for the year ended 2012		—			—			—		—		—			(12,568,354	)		(12,568,354	)

Balance, at December 31, 2012		2,478,185		$	2,478			118,427,925	$	118,428	$	122,625,654		$	(118,353,076	)	$	4,393,484
Issuance of stock for services		—			—			475,000		475		311,525			—			312,000
Issuance of warrants for services		—			—			—		—		1,527,518			—			1,527,518
Exercise of warrants and stock options		—			—			43,750		44		20,956			—			21,000
Issuance of common stock and warrants pursuant to Regulation D		—			—			18,854,470		18,854		12,185,320			—			12,204,174
Issuance of preferred stock and warrants pursuant to Regulation D		3,400,001			3,400			—		—		1,248,650			—			1,252,050
Preferred stock conversions into common stock		(2,173,186	)		(2,173	)		2,173,186		2,173		—			—			—
Dividends on preferred stock		—			—			—		—		(29,063	)		—			(29,063	)
Employee compensation from stock options		—			—			—		—		142,310			—			142,310
Net loss for the nine months ended September 30, 2013		—			—			—		—		—			(11,100,250	)		(11,100,250	)

Balance, at September 30, 2013		3,705,000		$	3,705			139,974,331	$	139,974	$	138,032,870		$	(129,453,326	)	$	8,723,223

See accompanying notes to condensed consolidated financial statements.

PROVECTUS PHARMACEUTICALS, INC.

(A Development-Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited)


	Nine Months Ended September 30, 2013			Nine Months Ended September 30, 2012			Cumulative Amounts from January 17, 2002 (Inception) through September 30, 2013
Cash Flows From Operating Activities
Net loss	$	(11,100,250	)	$	(10,647,282	)	$	(129,453,326	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		4,650			4,579			450,616
Amortization of patents		503,340			503,340			7,292,837
Amortization of original issue discount		—			—			3,845,721
Amortization of commitment fee		—			—			310,866
Amortization of prepaid consultant expense		—			—			1,295,226
Amortization of deferred loan costs		—			—			2,261,584
Accretion of United States Treasury Bills		—			—			(373,295	)
Loss on extinguishment of debt		—			—			825,867
Loss on exercise of warrants		—			—			236,146
Beneficial conversion of convertible interest		—			—			55,976
Convertible interest		—			—			389,950
Compensation through issuance of stock options		142,310			183,028			14,540,039
Compensation through issuance of stock		—			—			932,000
Issuance of stock for services		312,000			409,250			9,365,511
Issuance of warrants for services		1,527,518			1,381,329			7,724,087
Issuance of warrants for contractual obligations		—			—			985,010
Gain on sale of equipment		—			—			(55,075	)
Loss (gain) on change in fair value of warrant liability		917,102			(1,435,898	)		(4,995,099	)
Change in assets and liabilities
Prepaid expenses and other current assets		(45,284	)		(16,284	)		(45,284	)
Accounts payable		(40,971	)		179,513			198,819
Accrued expenses		72,014			1,512,859			489,633

Net cash used in operating activities		(7,707,571	)		(7,925,566	)		(83,722,191	)

Cash Flows From Investing Activities
Proceeds from sale of fixed assets		—			—			180,075
Capital expenditures		(6,650	)		(15,885	)		(96,570	)
Proceeds from sales of investments		—			—			37,010,481
Purchases of investments		—			—			(36,637,186	)

Net cash (used in) provided by investing activities		(6,650	)		(15,885	)		456,800

Cash Flows From Financing Activities
Net proceeds from loans from stockholder		—			—			174,000
Proceeds from convertible debt		—			—			6,706,795
Net proceeds from sales of preferred stock and warrants		2,550,000			—			11,458,131
Net proceeds from sales of common stock and warrants		12,204,174			2,077,796			55,018,695
Proceeds from exercises of warrants and stock options		21,000			—			21,099,014
Cash paid for preferred dividends		(29,063	)		—			(29,063	)
Cash paid to retire convertible debt		—			—			(2,385,959	)
Cash paid for deferred loan costs		—			—			(747,612	)
Premium paid on extinguishments of debt		—			—			(170,519	)
Purchase and retirement of common stock		—			—			(48,000	)
Net proceeds from sale of non-controlling interest in Pure-ific Corporation		—			—			443,500

Net cash provided by financing activities		14,746,111			2,077,796			91,518,982

Net change in cash and cash equivalents	$	7,031,890		$	(5,863,655	)	$	8,253,591
Cash and cash equivalents, at beginning of period		1,221,701			7,705,773			—

Cash and cash equivalents, at end of period	$	8,253,591		$	1,842,118		$	8,253,591

See accompanying notes to condensed consolidated financial statements.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ended December 31, 2013. The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued.

2. Recapitalization and Merger

Provectus Pharmaceuticals, Inc., formerly known as “Provectus Pharmaceutical, Inc.” and “SPM Group, Inc.,” was incorporated under Colorado law on May 1, 1978. SPM Group ceased operations in 1991, and became a development-stage company effective January 1, 1992, with the new corporate purpose of seeking out acquisitions of properties, businesses, or merger candidates, without limitation as to the nature of the business operations or geographic location of the acquisition candidate.

On April 1, 2002, SPM Group changed its name to “Provectus Pharmaceutical, Inc.” and reincorporated in Nevada in preparation for a transaction with Provectus Pharmaceuticals, Inc., a privately-held Tennessee corporation (“PPI”). On April 23, 2002, an Agreement and Plan of Reorganization between Provectus Pharmaceutical and PPI was approved by the written consent of a majority of the outstanding shares of Provectus Pharmaceutical. As a result, Provectus Pharmaceuticals, Inc. issued 6,680,000 shares of common stock in exchange for all of the issued and outstanding shares of PPI. As part of the acquisition, Provectus Pharmaceutical changed its name to “Provectus Pharmaceuticals, Inc.” and PPI became a wholly-owned subsidiary of Provectus. This transaction was recorded as a recapitalization of PPI.

On November 19, 2002, the Company acquired Valley Pharmaceuticals, Inc., a privately-held Tennessee corporation formerly known as Photogen, Inc., by merging PPI with and into Valley and naming the surviving corporation “Xantech Pharmaceuticals, Inc.” Photogen, Inc. was separated from Photogen Technologies, Inc. in a non-pro-rata split-off to some of its shareholders. The assets of Photogen, Inc. consisted primarily of the equipment and intangibles related to its therapeutic activity and were recorded at their fair value. The majority shareholders of Valley were also the majority shareholders of Provectus. Valley had no revenues prior to the transaction with the Company. By acquiring Valley, the Company acquired its intellectual property, including issued U.S. patents and patentable inventions.

3. Basic and Diluted Loss Per Common Share

Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Loss per share excludes the impact of outstanding options and warrants and convertible preferred stock as they are antidilutive. Potential common shares excluded from the calculation at September 30, 2013 and 2012, respectively, relate to 66,238,507 and 26,042,116 from warrants, 15,322,206 and 15,140,956 from options, and 3,705,000 and 2,941,665 from convertible preferred shares.

4. Equity Transactions

(a) During the three months ended March 31, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $48,750. During the three months ended March 31, 2012, the Company issued 175,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $160,000.

During the three months ended June 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $49,500. During the three months ended June 30, 2012, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $64,500.

During the three months ended September 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $51,250. During the three months ended September 30, 2012, the Company issued 225,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $184,750.

As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model.

(b) During the three months ended March 31, 2013, the Company issued 1,924,973 warrants to consultants in exchange for services. Consulting costs charged to operations were $409,640. During the three months ended March 31, 2013, 859,833 warrants were forfeited. During the three months ended March 31, 2012, the Company issued 1,003,000 warrants to consultants in exchange for services. Consulting costs charged to operations were $475,668. During the three months ended March 31, 2012, 1,500 warrants were forfeited.

During the three months ended June 30, 2013, the Company issued 2,605,000 warrants to consultants in exchange for services. Consulting costs charged to operations were $931,655. During the three months ended June 30, 2013, 1,051,500 warrants were forfeited. During the three months ended June 30, 2012, the Company issued 454,500 warrants to consultants in exchange for services. Consulting costs charged to operations were $183,908. During the three months ended June 30, 2012, 4,368,644 warrants were forfeited.

During the three months ended September 30, 2013, the Company issued 442,000 warrants to consultants in exchange for services. Consulting costs charged to operations were $186,223. During the three months ended September 30, 2013, 136,500 warrants were forfeited. During the three months ended September 30, 2012, the Company issued 1,732,135 warrants to consultants in exchange for services. Consulting costs charged to operations were $721,753. During the three months ended September 30, 2012, 122,833 warrants were forfeited.

As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model.

(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 and 2012, there was a loss recognized from the revaluation of the warrant liability of $311,062 and $148,364, respectively. For the three months ended June 30, 2013 and 2012, there was a gain recognized from the revaluation of the warrant liability of $221,149 and $222,546, respectively. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $337,244. For the three months ended September 30, 2012, there was a gain recognized from the revaluation of the warrant liability of $429,818.

During the three months ended March 31, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,045,510. The Company accepted subscriptions, in the aggregate, for 5,394,013 shares of common stock and five year warrants to purchase 7,277,264 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $522,640 and issued five year fully vested warrants to purchase 539,401 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

During the three months ended June 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,641,501. The Company accepted subscriptions, in the aggregate, for 3,522,001 shares of common stock and five year warrants to purchase 5,283,003 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $314,173, accrued $32,500 at June 30, 2013 which was paid in July 2013 and issued five year fully vested warrants to purchase 352,200 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

During the three months ended September 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,613,037. The Company accepted subscriptions, in the aggregate, for 6,150,718 shares of common stock and five year warrants to purchase 9,226,077 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $564,686 and issued five year fully vested warrants to purchase 615,072 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

During the three months ended September 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,687,500. The Company accepted subscriptions, in the aggregate, for 3,583,333 shares of common stock and five year warrants to purchase 5,375,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Maxim Group LLC served as placement agent for the offering. In connection with the offering, the Company paid $349,375 and issued five year fully vested warrants to purchase 358,333 shares of common stock with an exercise price of $1.00 to Maxim Group LLC, which represents 10% of the total number of shares of common stock sold to investors solicited by Maxim Group LLC.

(d) In March and April 2010, the Company had an issuance of 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 and 2012, there was a loss recognized from the revaluation of the warrant liability of $446,698 and $114,800, respectively. For the three months ended June 30, 2013 and 2012, there was a gain recognized from the revaluation of the warrant liability of $399,057 and $229,599, respectively. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $275,279. For the three months ended September 30, 2012, there was a gain recognized from the revaluation of the warrant liability of $817,099.

Dividends on the 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. In January 2013, the Company issued 61,022 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of January 15, 2013. At March 31, 2013, the Company recognized dividends of $21,921 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended March 31, 2013 there were 593,000 shares of the Company’s redeemable preferred stock that converted into 593,000 shares of the Company’s common stock. In April 2013, the Company issued 29,384 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of April 15, 2013. At June 30, 2013, the Company recognized dividends of $22,164 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended June 30, 2013 there were 403,520 shares of the Company’s redeemable preferred stock that converted into 403,520 shares of the Company’s common stock. In July 2013, the Company issued 34,598 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 15, 2013. At September 30, 2013, the Company recognized dividends of $10,586 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2013 there were 734,999 shares of the Company’s redeemable preferred stock that converted into 734,999 shares of the Company’s common stock.

(e) On February 22, 2013, the Company entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of an aggregate of $2,550,000 of Units at a purchase price of $0.75 per Unit. Each Unit consists of one share of Series A 8% Convertible Preferred Stock, par value $.001 per share, and a warrant to purchase one and one-quarter shares of the Company’s common stock, par value $.001 per share (subject to adjustment) at an exercise price of $1.00 per whole share (subject to adjustment). The total Series A 8% Convertible Preferred Stock issued was 3,400,001 shares, and the total warrants were 4,250,000. The Company used the net proceeds of the private placement for working capital, FDA trials, securing licensing partnerships, and general corporate purposes.

The Company determined that warrants issued in February, 2013 with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. The proceeds received from the issuance of the preferred stock were first allocated to the fair value of the warrants with the remainder allocated to the preferred stock. The fair value of the preferred stock if converted on the date of issuance was greater than the value allocated to the preferred stock. As a result, a beneficial conversion amount was recorded upon issuance. The fair value of the warrants recorded from the February 2013 issuance was $1,297,950 resulting in a beneficial conversion amount of $1,025,950. The beneficial conversion has been recorded as a deemed dividend as of March 31, 2013 and is included in dividends on preferred

stock on the consolidated statements of operations. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 there was a loss recognized from the revaluation of the warrant liability of $165,750. For the three months ended June 30, 2013 there was a gain recognized from the revaluation of the warrant liability of $289,000. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $290,275.

Dividends on the Series A 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock although was required to pay the initial dividends due in cash. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. At March 31, 2013, the Company recognized dividends of $29,063 which are included in dividends on preferred stock on the consolidated statement of operations and were paid in April 2013. At June 30, 2013, the Company recognized dividends of $50,860 which are included in dividends on preferred stock on the consolidated statement of operations. In July 2013, the Company issued 79,401 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 15, 2013. At September 30, 2013, the Company recognized dividends of $28,104 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2013 there were 441,667 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 441,667 shares of the Company’s common stock.

On June 23, 2013, our agreement with Lincoln Park Capital Fund, LLC expired. On July 22, 2013 the Company entered into a Purchase Agreement with Alpha Capital Anstalt pursuant to which the Company may, in the Company’s sole discretion, direct the purchase up to $30,000,000 of the Company’s common stock over the 30-month term of the Purchase Agreement. From time to time during the term of the Purchase Agreement, the Company may, in its sole discretion direct the purchase up to 100,000 shares of the Company’s common stock at a per share purchase price equal to the lesser of (i) the lowest sale price of the Company’s common stock reported on the OTCQB on the purchase date and (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 12 consecutive business days ending on the business day immediately preceding the purchase date. The Company may, under certain circumstances, at its discretion, increase the amount of common stock that it sells on each purchase date. The committed obligation under any single regular purchase shall not exceed $250,000, unless the parties mutually agree to increase the dollar amount of any regular purchase. In no event may Alpha Capital Anstalt purchase shares of the Company’s common stock for less than $0.75 per share. In consideration of entering into the Purchase Agreement and making the commitment to purchase the Purchase Shares, the Company issued 250,000 shares of the Company’s common stock to Alpha Capital Anstalt. Costs charged to operations for this commitment fee were $162,500. The Purchase Agreement may be terminated by the Company at any time, at its discretion, without cost to the Company.

5. Stock-Based Compensation

One employee of the Company exercised 18,750 options at an exercise price of $0.32 per share of common stock for $6,000 and 25,000 options at an exercise price of $0.60 per share of common stock for $15,000 during the three months ended June 30, 2013. One former non-employee member of the board forfeited 25,000 stock options on May 29, 2013. On August 19, 2013, the Company issued 250,000 stock options to its re-elected members of the board. All of the stock options issued in 2013 vest on the date of grant and have an exercise price equal to the fair market price on the date of issuance. On May 14, 2012, the Company issued 50,000 stock options to a newly appointed member of the board. On June 28, 2012, the Company issued 200,000 stock options to its re-elected members of the board. All of the stock options issued in 2012 vest on the date of grant and have an exercise price equal to the fair market price on the date of issuance.

The compensation cost relating to stock options issued in 2013 is measured based on the fair value of the stock options issued. For purposes of estimating the fair value of each stock option on the date of grant, the Company utilized the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock (as determined by reviewing its historical public market closing prices). Because the Company’s employee stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee and board member stock options. Included in the results of operations for both the three and nine months ended September 30, 2013 is $142,310 of stock-based compensation expense which relates to the fair value of stock options. Included in the results of operations for the three and nine months ended September 30, 2012 is $0 and $183,028, respectively, of stock-based compensation expense which relates to the fair value of stock options.

The following is a summary of nonvested stock option activity for the nine months ended September 30, 2013:


	Number of Shares			Weighted Average Grant-Date Fair Value
Nonvested at December 31, 2012		—		$	—
Granted		250,000		$	0.57
Vested		(250,000	)	$	0.57
Canceled		—			—

Nonvested at September 30, 2013		—		$	—

As of September 30, 2013, there was no unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the Plan.

6. Related Party Transaction

The Company paid one non-employee member of the board $48,000 for consulting services performed as of September 30, 2013. The Company paid another non-employee member of the board $75,000 for consulting services performed as of September 30, 2013. The Company paid a third non-employee member of the board $75,000 for consulting services performed as of September 30, 2013.

7. Fair Value of Financial Instruments

The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are measured and reported on a fair value basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. The fair value of certain of the Company’s financial instruments, including Cash and cash equivalents and Accounts payable, approximates the carrying value due to the relatively short maturity of such instruments. The fair value of derivative instruments is determined by management with the assistance of an independent third party valuation specialist. The warrant liability is a derivative instrument and is classified as Level 3. The Company used the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used at March 31, 2013 for the 2010 warrants include a weighted average term of 2.0 years, a 5% probability that the warrant exercise price would be reset, volatility range of 58.0% to 59.1% and a risk free interest rate of 0.25%. Significant assumptions used at June 30, 2013 for the 2010 warrants include a weighted average term of 1.7 years, a 5% probability that the warrant exercise price would be reset, volatility range of 55.7% to 56.5% and a risk free interest rate of 0.36%. Significant assumptions used at September 30, 2013 for the 2010 warrants include a weighted average term of 1.5 years, a 5% probability that the warrant exercise price would be reset, volatility range of 59.0% to 59.4% and a risk free interest rate of 0.33%. Significant assumptions used at March 31, 2013 for the 2011 warrants include a weighted average term of 2.8 years, a 5% probability that the warrant exercise price would be reset, volatility range of 58.0% to 59.1% and a risk free interest rate of 0.25%. Significant assumptions used at June 30, 2013 for the 2011 warrants include a weighted average term of 2.5 years, a 5% probability that the warrant exercise price would be reset, volatility of 59.1% and a risk free interest rate of 0.66%. Significant assumptions used at September 30, 2013 for the 2011 warrants include a weighted average term of 2.3 years, a 5% probability that the warrant exercise price would be reset, volatility of 58.6% and a risk free interest rate range of 0.33% to 0.63%. Significant assumptions used at March 31, 2013 for the 2013 warrants include a weighted average term of 4.9 years, a 5% probability that the warrant exercise price would be reset, volatility range of 58.0% to 66.7% and a risk free interest rate range of 0.25% to 0.77%. Significant assumptions used at June 30, 2013 for the 2013 warrants include a weighted average term of 4.7 years, a 5% probability that the warrant exercise price would be reset, volatility of 64.6% and a risk free interest rate of 1.41%. Significant assumptions used at September 30, 2013 for the 2013 warrants include a weighted average term of 4.4 years, a 5% probability that the warrant exercise price would be reset, volatility of 64.3% and a risk free interest rate of 1.39%.

The warrant liability measured at fair value on a recurring basis is as follows:


	Total		Level 1		Level 2		Level 3
Derivative instruments:
Warrant liability at September 30, 2013	$	3,514,622	$	—	$	—	$	3,514,622
Warrant liability at December 31, 2012	$	1,299,570	$	—	$	—	$	1,299,570

A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2013 to September 30, 2013 follows:


Balance at January 1, 2013	$	1,299,570
Issuance of warrants		1,297,950
Net loss included in earnings		917,102
Exercise of warrants		—

Balance at September 30, 2013	$	3,514,622

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion is intended to assist in the understanding and assessment of significant changes and trends related to our results of operations and our financial condition together with our consolidated subsidiaries. This discussion and analysis should be read in conjunction with the accompanying unaudited financial statements, our Annual Report on Form 10-K for the year ended December 31, 2012 (“2012 Form 10-K”), which includes additional information about our critical accounting policies and practices and risk factors, and Item 1A of Part II of this report, which updates those risk factors. Historical results and percentage relationships set forth in the statement of operations, including trends which might appear, are not necessarily indicative of future operations.

Plan of Operation

We have implemented our integrated business plan, including execution of the current and next phases in clinical development of our pharmaceutical products and continued execution of research programs for new research initiatives.

Our current plans include continuing to operate with our four employees during the immediate future, as well as four primary consultants and various vendor relationships, and anticipate adding additional personnel if necessary in the next 12 months. Our current plans also include minimal purchases of new property, plant and equipment, and increased research and development for additional clinical trials.

We believe that our prescription drug candidates PV-10 and PH-10 provide us with two products in multiple indications, which have been shown in clinical trials to be safe to treat serious cancers and diseases of the skin, and important immunologic data has been corroborated and characterized by institutions such as Moffitt Cancer Center in Tampa, Florida and another leading research facility. We continue to develop clinical trials for these products to show their safety and efficacy, which we believe will continue to be shown based on data in previous studies, and which will result in one or more license transactions with pharmaceutical and or biotech partners. Together with our non-core technologies, which we intend to sell or license in the future, we believe this combination represents the foundation for maximizing shareholder value this year and beyond.

Results of Operations

Comparison of Three and Nine Months Ended September 30, 2013 and September 30, 2012

Revenues

We had no revenue during the three and nine months ended September 30, 2013 and 2012.

Research and Development

Research and development costs of $1,296,654 for the three months ended September 30, 2013 included payroll of $411,119, consulting and contract labor of $451,024, legal of $93,515, insurance of $61,049, lab supplies and pharmaceutical preparations of $258,756, rent and utilities of $19,641, and depreciation expense of $1,550. Research and development costs of $1,129,921 for the three months ended September 30, 2012 included payroll of $302,064, consulting and contract labor of $670,449, legal of $62,568, insurance of $60,228, lab supplies and pharmaceutical preparations of $13,122, rent and utilities of $19,864, and depreciation expense of $1,626. The decrease in consulting and contract labor is due to decreased costs of current preclinical and clinical trial activity. The increase in lab supplies and pharmaceutical preparations is the result of securing drug substance and drug product for pivotal clinical studies with the newly patented synthesis of Rose Bengal.

Research and development costs of $2,815,519 for the nine months ended September 30, 2013 included payroll of $1,135,095, consulting and contract labor of $1,006,049, legal of $174,539, insurance of $148,549, lab supplies and pharmaceutical preparations of $290,921, rent and utilities of $55,716, and depreciation expense of $4,650. Research and development costs of $4,352,940 for the nine months ended September 30, 2012 included payroll of $2,258,622, consulting and contract labor of $1,737,376, legal of $178,236, insurance of $85,228, lab supplies and pharmaceutical preparations of $32,564, rent and utilities of $56,335, and depreciation expense of $4,579. The decrease in payroll is the result of no bonuses being paid during the nine months ended September 30, 2013. The decrease in consulting and contract labor is due to decreased costs of current preclinical and clinical trial activity. The increase in lab supplies and pharmaceutical preparations is the result of securing drug substance and drug product for pivotal clinical studies with the newly patented synthesis of Rose Bengal.

General and Administrative

General and administrative expenses decreased by $110,881 in the three months ended September 30, 2013 to $2,185,756 from $2,296,637 for the three months ended September 30, 2012. General and administrative expenses were very similar for both periods, although investor relations expense decreased slightly in the three months ended September 30, 2013.

General and administrative expenses decreased by $363,360 in the nine months ended September 30, 2013 to $6,864,865 from $7,228,225 for the nine months ended September 30, 2012. General and administrative expenses were very similar for both periods, although payroll expense was lower for the nine months ended September 30, 2013 versus the nine months ended September 30, 2012 as a result of no bonuses being paid during 2013.

Investment Income

Investment income was insignificant in both the three and nine months ended September 30, 2013 and 2012.

Loss on change in fair value of warrant liability

Loss on change in fair value of warrant liability increased by $2,149,715 in the three months ended September 30, 2013 to a loss of $902,798 from a gain of $1,246,917 for the three months ended September 30, 2012. This activity results from accounting for the warrant liability described in Footnotes 4(c), 4(d), 4(e) and Footnote 7 to the financial statements.

Loss on change in fair value of warrant liability increased by $2,353,000 in the nine months ended September 30, 2013 to a loss of $917,102 from a gain of $1,435,898 for the nine months ended September 30, 2012. This activity results from accounting for the warrant liability described in Footnotes 4(c), 4(d), 4(e) and Footnote 7 to the financial statements.

Liquidity and Capital Resources

Our cash and cash equivalents were $8,253,591 at September 30, 2013, compared with $1,221,701 at December 31, 2012. The increase of approximately $7 million was due primarily to sales of common stock, preferred stock and warrants to purchase common stock in the nine months ended September 30, 2013.

By managing variable cash expenses due to minimal fixed costs, we believe our cash and cash equivalents on hand at September 30, 2013, together with approximately $6 million received in the three months ending December 31, 2013 due to sales of common stock and warrants, will be sufficient to meet our current and planned operating needs until 2015 without consideration being given to additional cash inflows that might occur from the exercise of existing warrants or future sales of equity securities, although we may, in our sole discretion, direct Alpha Capital Anstalt (“Investor”) to purchase up to $30,000,000 of our common stock per an existing agreement with Investor.

We are seeking to improve our cash flow through both the licensure of PH-10 on the basis of our Phase 2 atopic dermatitis and psoriasis results, and primarily the geographic licensure of PV-10 on the basis of our Phase 2 metastatic melanoma and Phase 1 liver results in certain areas of the world, as well as pursuing a strategic investment strategy, including equity sales to potential pharmaceutical and/or biotech partners. In addition, the data now available and forthcoming from Moffitt Cancer Center in Tampa, Florida has been and is expected to be particularly helpful in supporting our development plans with both the FDA and prospective partners. The geographic areas of interest for PV-10 principally include China, India, Japan and Middle East and North Africa (MENA). We are encouraged by the interest in both PV-10 and PH-10 on a geographic basis and are continuing discussions with potential partners.

We are also considering the global licensure of PV-10 as well since it has come to our attention that this is of interest to potential partners. We have provided data on a confidential basis to both potential global and geographic partners for both PV-10 and PH-10 via a secure electronic data room that is monitored 24 hours a day, seven days a week and houses formal data submissions to the FDA as well as various corporate governance related documents.

We also expect to continue with the majority stake asset sale and licensure of our non-core assets. However, the primary objective of the Company is to strategically monetize the core value of PV-10 and PH-10 through various transactions, leveraging value creation up to and including an appropriate merger and acquisition transaction that includes upfront cash and acquirer stock in exchange for Company ownership as well as a contingency value right to facilitate potential upside post-acquisition. We believe regulatory clarity is determined by specifying the expected approval pathways of both PV-10 and PH-10. This may include the potential for breakthrough therapy designation for PV-10 to treat metastatic melanoma and an accelerated approval path for PV-10 to treat refractory recurrent melanoma. Such clarity will help facilitate transactions with potential partners. Additionally, the existing and forthcoming mechanism of action related clinical and nonclinical data for both PV-10 and PH-10 will further aid in both regulatory clarity and transactions with potential partners.

However, we cannot assure you that we will be successful in either licensing of PH-10 or PV-10, any equity transaction, or selling a majority stake of the OTC and other non-core assets via a spin-out transaction and licensing our existing non-core products. Moreover, even if we are successful in improving our current cash flow position, we nonetheless plan to seek additional funds to meet our long-term requirements in 2014 and beyond. We anticipate that these funds will otherwise come from the proceeds of private placements, the exercise of existing warrants outstanding, or public offerings of debt or equity securities. While we believe that we have a reasonable basis for our expectation that we will be able to raise additional funds, we cannot assure you that we will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to shareholders.

Critical Accounting Policies

Management’s discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. Management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe there have been no material changes to the items that we disclosed as our critical accounting policies under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our 2012 Form 10-K.

New Accounting Pronouncements

None.

Contractual Obligations — Leases

We lease office and laboratory space in Knoxville, Tennessee, on an annual basis, renewable for one year at our option. We have no lease commitments as of September 30, 2013. We are currently leasing on a month-to-month basis.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We had no holdings of financial or commodity instruments as of September 30, 2013, other than cash and cash equivalents, short-term deposits, money market funds, and interest bearing investments in U.S. governmental debt securities. We have accounted for certain warrants issued in March and April 2010, January 2011 and February 2013 as liabilities at their fair value upon issuance, which are remeasured at each period end with the change in fair value recorded in the statement of operations. See notes 4 and 7 of interim financial statements contained in this Quarterly Report on Form 10-Q.

All of our business is transacted in U.S. dollars and, accordingly, foreign exchange rate fluctuations have not had a significant impact on us, and they are not expected to have a significant impact on us in the foreseeable future.

ITEM 4.

CONTROLS AND PROCEDURES.

(a) Evaluation of Disclosure Controls and Procedures. Our chief executive officer and chief financial officer have evaluated the effectiveness of the design and operation of our “disclosure controls and procedures” (as that term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of September 30, 2013, the end of the fiscal quarter covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the chief executive officer and chief financial officer have concluded that our disclosure controls and procedures are effective.

(b) Changes in Internal Controls. There has been no change in our internal control over financial reporting that occurred during the fiscal quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS.

Except as described below, we are not involved in any legal proceedings nor are we party to any pending claims that we believe could reasonably be expected to have a material adverse effect on our business, financial condition, or results of operations.

On January 2, 2013, Glenn Kleba, derivatively on behalf of the Company as a nominal defendant (the “Plaintiff”), filed a shareholder derivative complaint in the Circuit Court for the State of Tennessee, Knox County, against H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Stuart Fuchs, Kelly M. McMasters, Alfred E. Smith, IV and Peter R. Culpepper, and against the Company as a nominal defendant (the “Shareholder Derivative Complaint”). The Shareholder Derivative Complaint alleges (i) breach of fiduciary duties, (ii) waste of corporate assets, and (iii) unjust enrichment, all three claims based on the Plaintiff’s allegations that the defendants authorized and/or accepted stock option awards in violation of the terms of the Company’s 2002 Stock Plan (the “Plan”) by issuing stock options in excess of the amounts authorized under the Plan and delegated to defendant H. Craig Dees the sole authority to grant himself and other executive officers of the Company cash bonuses that the Plaintiff alleges to be excessive.

In April 2013, the Company’s Board of Directors established a special litigation committee to investigate the allegations of the Shareholder Derivative Complaint and make a determination as to how the matter should be resolved. The special litigation committee has begun its investigation and proceedings in the case have been stayed pending the conclusion of the committee’s investigation. In view of the inherent uncertainties of litigation and the early stage of this litigation, the outcome of this case cannot be predicted at this time. Likewise, the amount of any potential loss cannot be reasonably estimated.

ITEM 1A.

RISK FACTORS.

There have been no material changes to the risk factors listed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2012. Such risk factors should be considered carefully with the information provided elsewhere in this report.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the three months ended September 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. On July 22, 2013 the Company entered into a Purchase Agreement with Alpha Capital Anstalt. In consideration of entering into the Purchase Agreement and making the commitment to purchase the Purchase Shares, the Company issued 250,000 shares of the Company’s common stock to Alpha Capital Anstalt.

During the three months ended September 30, 2013, the Company issued 442,000 warrants to consultants in exchange for services.

The issuances of the securities were exempt from the registration requirements of the Securities Act of 1933 by virtue of Section 4(2) and Regulation D thereunder as transactions not involving a public offering.

The Company has used and intends to use the net proceeds of these issuances for working capital, FDA trials, securing licensing partnerships, and general corporate purposes.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4.

MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5.

OTHER INFORMATION.

None.

ITEM 6.

EXHIBITS.


Exhibit No.		Description

31.1		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

31.2		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

32		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 (Section 906 Certification).

101		Interactive Data Files.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	PROVECTUS PHARMACEUTICALS, INC.

November 11, 2013	By:	/s/ Peter R. Culpepper
		Peter R. Culpepper
		On behalf of the registrant and as Chief Financial Officer and Chief Operating Officer (Principal Financial Officer)

EXHIBIT INDEX


Exhibit No.		Description

31.1		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

31.2		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

32		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 (Section 906 Certification).

101		Interactive Data Files.

EX-31.1 2 d612308dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

I, H. Craig Dees, Ph.D., certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Provectus Pharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d612308dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

I, Peter R. Culpepper, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Provectus Pharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32 4 d612308dex32.htm EX-32 EX-32

Exhibit 32

CERTIFICATION PURSUANT TO RULE 13a-14(b) UNDER

THE SECURITIES EXCHANGE ACT OF 1934 AND

SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE

Each of the undersigned, H. Craig Dees, the Chief Executive Officer of Provectus Pharmaceuticals, Inc. (the “Company”), and Peter R. Culpepper, Chief Financial Officer and Chief Operating Officer of the Company, certifies, pursuant to Rule 13a-14(b) under the Securities and Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code, that (1) this Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act, and (2) the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This Certification is signed on November 11, 2013.

By:

/s/ H. Craig Dees

H. Craig Dees, Ph.D.

Chief Executive Officer

By:

/s/ Peter R. Culpepper

Peter R. Culpepper

Chief Financial Officer

Chief Operating Officer

EX-101.INS 5 pvct-20130930.xml XBRL INSTANCE DOCUMENT

0.75

3400001

1.00

34598

802

-1316198

6680000

6680

1310320

29384

30000000 100000 250000 0.75

1842118

7277264

1.00 1025950 0.75 1297950

539401

1.00

593000

5283003

1.00

352200

1.00 32500

403520

139974331

9226077

139974331

25000000

250000000

0.001

3705

427615

180001

138032870

61282

542467

98720

8723223

-129453326

202464

7292837

139974

12780312

4057089

8298875

27000

12780312

8253591

4422608

45284

31829

1.00 3514622 0.001 1

358333

1.00

615072

1.00 75000 75000

-129453326

139974331

139974

3705000

3705

138032870

3514622

3514622 2958334

0.75

2958334

2246855 0.08

734999

746666

0.75

746666

441667

746666

570585 0.08

11723580

-7066135

9423689

9424

18780291

10251052

-10221448

10867509

10868

20461632

9161701

-14565973

16133876

16134

23711540

14387141

-26329826

27822977

27823

40689144

15522400

-35200405

42452366

42452

50680353

14831510

-45206036

49399281

49399

59988147

10055536

-55475607

53017076

53017

65478126

9406510

-67797921

67410226

67410

77137021

10699573

-86350023

91297883

91298

5389998

5390

96952908

10019740

7705773

-105784722

110596798

110597

3531665

3531

115690334

118427925

25000000

250000000

0.001

2478

422965

206706

122625654

61283

511424

4393484

-118353076

243435

6789497

118428

6204478

1810994

1221701

27000

6204478

1221701

4925948

29829

1299570

-118353076

118427925

118428

2478185

2478

122625654

1299570

0.75

2246855 0.08

0.75

2478185

1896117 0.08 0.646 0.0141 0.565 0.591 0.0066 0.557 0.05 P4Y8M12D 0.05 P1Y8M12D 0.0036 0.05 P2Y6M

250000

P30M 162500

126587

-5749937

48000

27000 12226320 453 -3645 5144000

-5749937

400000

400

265763 25 500 453 266 25000 452919 500007 1900 1900000

126587

47600

26975 12225820 -3911 5142100 PROVECTUS PHARMACEUTICALS INC false Accelerated Filer 2013 10-Q 2013-09-30 0000315545 --12-31 Q3

<div> 5. Stock-Based Compensation  One employee of the Company exercised 18,750 options at an exercise price of $0.32 per share of common stock for $6,000 and 25,000 options at an exercise price of $0.60 per share of common stock for $15,000 during the three months ended June 30, 2013. One former non-employee member of the board forfeited 25,000 stock options on May 29, 2013. On August 19, 2013, the Company issued 250,000 stock options to its re-elected members of the board. All of the stock options issued in 2013 vest on the date of grant and have an exercise price equal to the fair market price on the date of issuance. On May 14, 2012, the Company issued 50,000 stock options to a newly appointed member of the board. On June 28, 2012, the Company issued 200,000 stock options to its re-elected members of the board. All of the stock options issued in 2012 vest on the date of grant and have an exercise price equal to the fair market price on the date of issuance. The compensation cost relating to stock options issued in 2013 is measured based on the fair value of the stock options issued. For purposes of estimating the fair value of each stock option on the date of grant, the Company utilized the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock (as determined by reviewing its historical public market closing prices). Because the Company’s employee stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee and board member stock options. Included in the results of operations for both the three and nine months ended September 30, 2013 is $142,310 of stock-based compensation expense which relates to the fair value of stock options. Included in the results of operations for the three and nine months ended September 30, 2012 is $0 and $183,028, respectively, of stock-based compensation expense which relates to the fair value of stock options.   The following is a summary of nonvested stock option activity for the nine months ended September 30, 2013:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="65%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Grant-Date Fair Value</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Nonvested at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">250,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.57</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(250,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.57</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Canceled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Nonvested at September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> As of September 30, 2013, there was no unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the Plan. </div>

<div> The warrant liability measured at fair value on a recurring basis is as follows:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="66%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Derivative instruments: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Warrant liability at September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,514,622</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,514,622</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Warrant liability at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,299,570</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,299,570</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

3583333

<div> The following is a summary of nonvested stock option activity for the nine months ended September 30, 2013:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="65%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Grant-Date Fair Value</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Nonvested at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">250,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.57</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(250,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.57</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Canceled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Nonvested at September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

<div> 7. Fair Value of Financial Instruments  The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are measured and reported on a fair value basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. The fair value of certain of the Company’s financial instruments, including Cash and cash equivalents and Accounts payable, approximates the carrying value due to the relatively short maturity of such instruments. The fair value of derivative instruments is determined by management with the assistance of an independent third party valuation specialist. The warrant liability is a derivative instrument and is classified as Level 3. The Company used the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used at March 31, 2013 for the 2010 warrants include a weighted average term of 2.0 years, a 5% probability that the warrant exercise price would be reset, volatility range of 58.0% to 59.1% and a risk free interest rate of 0.25%. Significant assumptions used at June 30, 2013 for the 2010 warrants include a weighted average term of 1.7 years, a 5% probability that the warrant exercise price would be reset, volatility range of 55.7% to 56.5% and a risk free interest rate of 0.36%. Significant assumptions used at September 30, 2013 for the 2010 warrants include a weighted average term of 1.5 years, a 5% probability that the warrant exercise price would be reset, volatility range of 59.0% to 59.4% and a risk free interest rate of 0.33%. Significant assumptions used at March 31, 2013 for the 2011 warrants include a weighted average term of 2.8 years, a 5% probability that the warrant exercise price would be reset, volatility range of 58.0% to 59.1% and a risk free interest rate of 0.25%. Significant assumptions used at June 30, 2013 for the 2011 warrants include a weighted average term of 2.5 years, a 5% probability that the warrant exercise price would be reset, volatility of 59.1% and a risk free interest rate of 0.66%. Significant assumptions used at September 30, 2013 for the 2011 warrants include a weighted average term of 2.3 years, a 5% probability that the warrant exercise price would be reset, volatility of 58.6% and a risk free interest rate range of 0.33% to 0.63%. Significant assumptions used at March 31, 2013 for the 2013 warrants include a weighted average term of 4.9 years, a 5% probability that the warrant exercise price would be reset, volatility range of 58.0% to 66.7% and a risk free interest rate range of 0.25% to 0.77%. Significant assumptions used at June 30, 2013 for the 2013 warrants include a weighted average term of 4.7 years, a 5% probability that the warrant exercise price would be reset, volatility of 64.6% and a risk free interest rate of 1.41%. Significant assumptions used at September 30, 2013 for the 2013 warrants include a weighted average term of 4.4 years, a 5% probability that the warrant exercise price would be reset, volatility of 64.3% and a risk free interest rate of 1.39%.   The warrant liability measured at fair value on a recurring basis is as follows:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="66%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Derivative instruments: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Warrant liability at September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,514,622</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,514,622</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Warrant liability at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,299,570</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,299,570</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2013 to September 30, 2013 follows:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"> <tr> <td width="84%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr>  <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Balance at January 1, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 1,299,570</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Issuance of warrants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,297,950</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Net loss included in earnings </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">917,102</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Exercise of warrants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Balance at September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,514,622</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2013 to September 30, 2013 follows:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"> <tr> <td width="84%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr>  <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Balance at January 1, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 1,299,570</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Issuance of warrants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,297,950</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Net loss included in earnings </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">917,102</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Exercise of warrants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Balance at September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,514,622</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   </div>

<div> 2. Recapitalization and Merger Provectus Pharmaceuticals, Inc., formerly known as “Provectus Pharmaceutical, Inc.” and “SPM Group, Inc.,” was incorporated under Colorado law on May 1, 1978. SPM Group ceased operations in 1991, and became a development-stage company effective January 1, 1992, with the new corporate purpose of seeking out acquisitions of properties, businesses, or merger candidates, without limitation as to the nature of the business operations or geographic location of the acquisition candidate. On April 1, 2002, SPM Group changed its name to “Provectus Pharmaceutical, Inc.” and reincorporated in Nevada in preparation for a transaction with Provectus Pharmaceuticals, Inc., a privately-held Tennessee corporation (“PPI”). On April 23, 2002, an Agreement and Plan of Reorganization between Provectus Pharmaceutical and PPI was approved by the written consent of a majority of the outstanding shares of Provectus Pharmaceutical. As a result, Provectus Pharmaceuticals, Inc. issued 6,680,000 shares of common stock in exchange for all of the issued and outstanding shares of PPI. As part of the acquisition, Provectus Pharmaceutical changed its name to “Provectus Pharmaceuticals, Inc.” and PPI became a wholly-owned subsidiary of Provectus. This transaction was recorded as a recapitalization of PPI. On November 19, 2002, the Company acquired Valley Pharmaceuticals, Inc., a privately-held Tennessee corporation formerly known as Photogen, Inc., by merging PPI with and into Valley and naming the surviving corporation “Xantech Pharmaceuticals, Inc.” Photogen, Inc. was separated from Photogen Technologies, Inc. in a non-pro-rata split-off to some of its shareholders. The assets of Photogen, Inc. consisted primarily of the equipment and intangibles related to its therapeutic activity and were recorded at their fair value. The majority shareholders of Valley were also the majority shareholders of Provectus. Valley had no revenues prior to the transaction with the Company. By acquiring Valley, the Company acquired its intellectual property, including issued U.S. patents and patentable inventions. </div>

-7707571

250000

<div> 3. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Loss per share excludes the impact of outstanding options and warrants and convertible preferred stock as they are antidilutive. Potential common shares excluded from the calculation at September 30, 2013 and 2012, respectively, relate to 66,238,507 and 26,042,116 from warrants, 15,322,206 and 15,140,956 from options, and 3,705,000 and 2,941,665 from convertible preferred shares. </div>

<div> 6. Related Party Transaction The Company paid one non-employee member of the board $48,000 for consulting services performed as of September 30, 2013. The Company paid another non-employee member of the board $75,000 for consulting services performed as of September 30, 2013. The Company paid a third non-employee member of the board $75,000 for consulting services performed as of September 30, 2013. </div>

<div> (c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 and 2012, there was a loss recognized from the revaluation of the warrant liability of $311,062 and $148,364, respectively. For the three months ended June 30, 2013 and 2012, there was a gain recognized from the revaluation of the warrant liability of $221,149 and $222,546, respectively. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $337,244. For the three months ended September 30, 2012, there was a gain recognized from the revaluation of the warrant liability of $429,818. During the three months ended March 31, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,045,510. The Company accepted subscriptions, in the aggregate, for 5,394,013 shares of common stock, and five year warrants to purchase 7,277,264 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $522,640 and issued five year fully vested warrants to purchase 539,401 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended June 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,641,501. The Company accepted subscriptions, in the aggregate, for 3,522,001 shares of common stock, and five year warrants to purchase 5,283,003 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $314,173, accrued $32,500 at June 30, 2013 which was paid in July 2013 and issued five year fully vested warrants to purchase 352,200 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended September 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,613,037. The Company accepted subscriptions, in the aggregate, for 6,150,718 shares of common stock, and five year warrants to purchase 9,226,077 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $564,686 and issued five year fully vested warrants to purchase 615,072 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.   During the three months ended September 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,687,500. The Company accepted subscriptions, in the aggregate, for 3,583,333 shares of common stock, and five year warrants to purchase 5,375,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Maxim Group LLC served as placement agent for the offering. In connection with the offering, the Company paid $349,375 and issued five year fully vested warrants to purchase 358,333 shares of common stock with an exercise price of $1.00 to Maxim Group LLC, which represents 10% of the total number of shares of common stock sold to investors solicited by Maxim Group LLC. (d) In March and April 2010, the Company had an issuance of 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 and 2012, there was a loss recognized from the revaluation of the warrant liability of $446,698 and $114,800, respectively. For the three months ended June 30, 2013 and 2012, there was a gain recognized from the revaluation of the warrant liability of $399,057 and $229,599, respectively. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $275,279. For the three months ended September 30, 2012, there was a gain recognized from the revaluation of the warrant liability of $817,099. Dividends on the 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. In January 2013, the Company issued 61,022 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of January 15, 2013. At March 31, 2013, the Company recognized dividends of $21,921 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended March 31, 2013 there were 593,000 shares of the Company’s redeemable preferred stock that converted into 593,000 shares of the Company’s common stock. In April 2013, the Company issued 29,384 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of April 15, 2013. At June 30, 2013, the Company recognized dividends of $22,164 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended June 30, 2013 there were 403,520 shares of the Company’s redeemable preferred stock that converted into 403,520 shares of the Company’s common stock. In July 2013, the Company issued 34,598 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 15, 2013. At September 30, 2013, the Company recognized dividends of $10,586 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2013 there were 734,999 shares of the Company’s redeemable preferred stock that converted into 734,999 shares of the Company’s common stock. </div>

<div> 1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ended December 31, 2013. The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued. </div>

-12288898

576

-10183724

45284

-11100250

-29063

6650

48000

142310

6864865

14746111

1188648

7031890

72014

-6650

2815519

503340

29063

4650

142310

-40971

2687500 -917102 <div> 4. Equity Transactions  (a) During the three months ended March 31, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $48,750. During the three months ended March 31, 2012, the Company issued 175,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $160,000. During the three months ended June 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $49,500. During the three months ended June 30, 2012, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $64,500. During the three months ended September 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $51,250. During the three months ended September 30, 2012, the Company issued 225,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $184,750. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model.   (b) During the three months ended March 31, 2013, the Company issued 1,924,973 warrants to consultants in exchange for services. Consulting costs charged to operations were $409,640. During the three months ended March 31, 2013, 859,833 warrants were forfeited. During the three months ended March 31, 2012, the Company issued 1,003,000 warrants to consultants in exchange for services. Consulting costs charged to operations were $475,668. During the three months ended March 31, 2012, 1,500 warrants were forfeited. During the three months ended June 30, 2013, the Company issued 2,605,000 warrants to consultants in exchange for services. Consulting costs charged to operations were $931,655. During the three months ended June 30, 2013, 1,051,500 warrants were forfeited. During the three months ended June 30, 2012, the Company issued 454,500 warrants to consultants in exchange for services. Consulting costs charged to operations were $183,908. During the three months ended June 30, 2012, 4,368,644 warrants were forfeited. During the three months ended September 30, 2013, the Company issued 442,000 warrants to consultants in exchange for services. Consulting costs charged to operations were $186,223. During the three months ended September 30, 2013, 136,500 warrants were forfeited. During the three months ended September 30, 2012, the Company issued 1,732,135 warrants to consultants in exchange for services. Consulting costs charged to operations were $721,753. During the three months ended September 30, 2012, 122,833 warrants were forfeited. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model. (c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 and 2012, there was a loss recognized from the revaluation of the warrant liability of $311,062 and $148,364, respectively. For the three months ended June 30, 2013 and 2012, there was a gain recognized from the revaluation of the warrant liability of $221,149 and $222,546, respectively. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $337,244. For the three months ended September 30, 2012, there was a gain recognized from the revaluation of the warrant liability of $429,818. During the three months ended March 31, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,045,510. The Company accepted subscriptions, in the aggregate, for 5,394,013 shares of common stock and five year warrants to purchase 7,277,264 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $522,640 and issued five year fully vested warrants to purchase 539,401 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended June 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,641,501. The Company accepted subscriptions, in the aggregate, for 3,522,001 shares of common stock and five year warrants to purchase 5,283,003 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $314,173, accrued $32,500 at June 30, 2013 which was paid in July 2013 and issued five year fully vested warrants to purchase 352,200 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended September 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,613,037. The Company accepted subscriptions, in the aggregate, for 6,150,718 shares of common stock and five year warrants to purchase 9,226,077 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $564,686 and issued five year fully vested warrants to purchase 615,072 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.   During the three months ended September 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,687,500. The Company accepted subscriptions, in the aggregate, for 3,583,333 shares of common stock and five year warrants to purchase 5,375,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Maxim Group LLC served as placement agent for the offering. In connection with the offering, the Company paid $349,375 and issued five year fully vested warrants to purchase 358,333 shares of common stock with an exercise price of $1.00 to Maxim Group LLC, which represents 10% of the total number of shares of common stock sold to investors solicited by Maxim Group LLC. (d) In March and April 2010, the Company had an issuance of 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 and 2012, there was a loss recognized from the revaluation of the warrant liability of $446,698 and $114,800, respectively. For the three months ended June 30, 2013 and 2012, there was a gain recognized from the revaluation of the warrant liability of $399,057 and $229,599, respectively. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $275,279. For the three months ended September 30, 2012, there was a gain recognized from the revaluation of the warrant liability of $817,099. Dividends on the 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. In January 2013, the Company issued 61,022 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of January 15, 2013. At March 31, 2013, the Company recognized dividends of $21,921 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended March 31, 2013 there were 593,000 shares of the Company’s redeemable preferred stock that converted into 593,000 shares of the Company’s common stock. In April 2013, the Company issued 29,384 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of April 15, 2013. At June 30, 2013, the Company recognized dividends of $22,164 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended June 30, 2013 there were 403,520 shares of the Company’s redeemable preferred stock that converted into 403,520 shares of the Company’s common stock. In July 2013, the Company issued 34,598 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 15, 2013. At September 30, 2013, the Company recognized dividends of $10,586 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2013 there were 734,999 shares of the Company’s redeemable preferred stock that converted into 734,999 shares of the Company’s common stock. (e) On February 22, 2013, the Company entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of an aggregate of $2,550,000 of Units at a purchase price of $0.75 per Unit. Each Unit consists of one share of Series A 8% Convertible Preferred Stock, par value $.001 per share, and a warrant to purchase one and one-quarter shares of the Company’s common stock, par value $.001 per share (subject to adjustment) at an exercise price of $1.00 per whole share (subject to adjustment). The total Series A 8% Convertible Preferred Stock issued was 3,400,001 shares, and the total warrants were 4,250,000. The Company used the net proceeds of the private placement for working capital, FDA trials, securing licensing partnerships, and general corporate purposes. The Company determined that warrants issued in February, 2013 with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. The proceeds received from the issuance of the preferred stock were first allocated to the fair value of the warrants with the remainder allocated to the preferred stock. The fair value of the preferred stock if converted on the date of issuance was greater than the value allocated to the preferred stock. As a result, a beneficial conversion amount was recorded upon issuance. The fair value of the warrants recorded from the February 2013 issuance was $1,297,950 resulting in a beneficial conversion amount of $1,025,950. The beneficial conversion has been recorded as a deemed dividend as of March 31, 2013 and is included in dividends on preferred stock on the consolidated statements of operations. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 there was a loss recognized from the revaluation of the warrant liability of $165,750. For the three months ended June 30, 2013 there was a gain recognized from the revaluation of the warrant liability of $289,000. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $290,275. Dividends on the Series A 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock although was required to pay the initial dividends due in cash. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. At March 31, 2013, the Company recognized dividends of $29,063 which are included in dividends on preferred stock on the consolidated statement of operations and were paid in April 2013. At June 30, 2013, the Company recognized dividends of $50,860 which are included in dividends on preferred stock on the consolidated statement of operations. In July 2013, the Company issued 79,401 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 15, 2013. At September 30, 2013, the Company recognized dividends of $28,104 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2013 there were 441,667 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 441,667 shares of the Company’s common stock. On June 23, 2013, our agreement with Lincoln Park Capital Fund, LLC expired. On July 22, 2013 the Company entered into a Purchase Agreement with Alpha Capital Anstalt pursuant to which the Company may, in the Company’s sole discretion, direct the purchase up to $30,000,000 of the Company’s common stock over the 30-month term of the Purchase Agreement. From time to time during the term of the Purchase Agreement, the Company may, in its sole discretion direct the purchase up to 100,000 shares of the Company’s common stock at a per share purchase price equal to the lesser of (i) the lowest sale price of the Company’s common stock reported on the OTCQB on the purchase date and (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 12 consecutive business days ending on the business day immediately preceding the purchase date. The Company may, under certain circumstances, at its discretion, increase the amount of common stock that it sells on each purchase date. The committed obligation under any single regular purchase shall not exceed $250,000, unless the parties mutually agree to increase the dollar amount of any regular purchase. In no event may Alpha Capital Anstalt purchase shares of the Company’s common stock for less than $0.75 per share. In consideration of entering into the Purchase Agreement and making the commitment to purchase the Purchase Shares, the Company issued 250,000 shares of the Company’s common stock to Alpha Capital Anstalt. Costs charged to operations for this commitment fee were $162,500. The Purchase Agreement may be terminated by the Company at any time, at its discretion, without cost to the Company. </div> 21000 0.57 1527518 -917102 P5Y 21000 12204174 0.10 312000 -1527518 2550000 1252050 12204174 149500 -0.10 6680000 0.75 126503388 142310 250000 0.57 29063

349375

1.50 0.643 0.0139 0.594 0.586 0.0063 0.590 0.0033

-11100250

2173186

2173

43750 44 18854 475 18854470 475000

-2173186

-2173

3400001 3400

-29063

29063

20956 1527518 1248650 12185320 311525 142310

15322206

66238507

1297950

917102

3705000

0.05 P4Y4M24D 0.05 P1Y6M 0.0033 0.05 P2Y3M18D

0.08

-7925566

-10792991

1325

-12084505

16284

-10647282

15885

183028

7228225

2077796

145709

-5863655

1512859

-15885

4352940

503340

4579

183028

179513

1435898 1435898 2077796 409250 -1381329 -0.10 112073836

15140956

26042116

2941665

2550000 4250000

0.08

200000

61022

79401

0.08

50000

25000

250000

601000

-3155313

145479 281500 239800 380347 34659

-3155313

679820 764 680 764000

601000

145479 281500 239036 379667 34659

1633176

-11763853

3049362

196031 1574900 6513176 1439795 1534405 985010 39529 152285 144128 15752

-11763853

3405541

3405

264 1571849 6221 1572 263721 227 226733 6221257

1633176

3045957

195767 1574900 6506955 1438223 1534405 985010 39529 152058 144128 15752

-8870579

1576336

183596 4130421 1189816 370023 16447 676743 1862456

-8870579

2377512

2377

195 1245809 10092 1246 194327 719 719246 10092495

1573959

183401 4120329 1188570 370023 16447 676024 1862456

-10005631

367500

1258 1848138 3985641 472635 298950 2340619

-10005631

490000

490

1 3928957 2377 3929 1141 150 150000 2376817

367010

1257 1845761 3981712 472635 298800 2340619

-12322314

6518688 2524453 1064210 695000 870937

-12322314

3480485 10117 3480 796 796012 10116653 6508571 2520973 1064210 694204 870937

-18552102

3103680 1141593 4217390 6346989 856613 419250 3759650

-18552102

7893326

7893

3491014 559000 3491 11169 776 559 11168067 776250

-7893326

-7893

13283324 13283 3100189 1141593 4204107 6335820 855837 418691 3759650

-19434699

443500 6623311 945116 7041239 332750 3368950

-19434699

1858331

1859

7185522 7185 9905 350 9905062 350000

-1858333

-1859

443500 6616126 945116 7031334 332400 3368950

360256

-4344525

105250 1288861 5000 495480 449923 793137 258345 15612

-4344525

2469723 1930 133 132608 734 2469 733872 1930164

360256

105250 1286930 4867 495480 449190 790668 258345 15612

-10269571

2639711 517820 390000 1946066

-10269571

3267795 3268 350 350000 2636443 517820 389650 1946066

-12568354

1512026 4790544 456500 183028

-12568354

1053480

1053

6228 550 6227647 550000

-1053480

-1053

1512026 4784316 455950 183028

-83722191

-8098004

24541

55075

25648

-141480036

653793

-825867

-126233422

45284

36637186

-129453326

48000

2385959

39757

96570

14540039

73050754

91518982

12026710

15216

37010481

8253591

489633

180075

456800

45914372

443500

2261584

7292837

450616

3845721

198819

6706795

174000 170519 4995099 -932000 389950 4995099 747612 21099014 55018695 9365511 -7724087 11458131 310866 236146 373295 1295226 14109 -985010 55976 29063

5394013

75000

409640 4045510 P5Y 859833 311062 0.10 1924973

522640

1.50 0.667 0.0077 0.591 0.591 0.0025 1.00 0.580 0.0025 0.580 0.580 0.05 P4Y10M24D 0.05 P2Y 0.0025 0.05 P2Y9M18D

29063

593000 446698 48750

21921

165750

175000

475668 1500 148364 1003000 114800 160000

75000

183908 4368644 222546 454500 229599 64500

3522001

75000

931655 2641501 P5Y 1051500 221149 0.10 0.75 2605000

314173

1.50

0.60

25000

15000

0.32

18750

6000

50860

403520 399057 49500

22164

289000

225000

-2390995

310

-3594338

-2347111

2296637

43884

1129921

167780

721753 1246917 122833 429818 -0.02 1732135 113166988 817099 184750

6150718

75000

-4591385

293

-4552695

2185756

38690

1296654

167780

142310

186223 4613037 -902798 P5Y 136500 337244 0.10 -0.03 0.75 442000 131573656

564686

1.50

28104

734999 275279 51250

10586

441667 290275

-1316198

25000

932000 360000

-1316198

50000

510 6000 6000000 120 510000 120000

24950

931490 -6000 359880 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-01-18 2002-04-23 0000315545 us-gaap:CommonStockMember 2002-01-18 2002-04-23 0000315545 us-gaap:RetainedEarningsMember 2002-01-18 2002-04-23 0000315545 2002-01-18 2002-04-23 0000315545 pvct:WarrantOneMember 2013-07-01 2013-09-30 0000315545 us-gaap:ConvertiblePreferredStockMember 2013-07-01 2013-09-30 0000315545 us-gaap:CommonStockMember 2013-07-01 2013-09-30 0000315545 us-gaap:WarrantMember 2013-07-01 2013-09-30 0000315545 us-gaap:RedeemablePreferredStockMember 2013-07-01 2013-09-30 0000315545 us-gaap:MaximumMember 2013-07-01 2013-09-30 0000315545 pvct:NetworkOneFinancialSecuritiesMember 2013-07-01 2013-09-30 0000315545 2013-07-01 2013-09-30 0000315545 us-gaap:CommonStockMember 2012-07-01 2012-09-30 0000315545 us-gaap:WarrantMember 2012-07-01 2012-09-30 0000315545 2012-07-01 2012-09-30 0000315545 pvct:WarrantOneMember 2013-04-01 2013-06-30 0000315545 us-gaap:ConvertiblePreferredStockMember 2013-04-01 2013-06-30 0000315545 us-gaap:CommonStockMember 2013-04-01 2013-06-30 0000315545 us-gaap:WarrantMember 2013-04-01 2013-06-30 0000315545 us-gaap:RedeemablePreferredStockMember 2013-04-01 2013-06-30 0000315545 pvct:OptionsExercisedPriceOneMember 2013-04-01 2013-06-30 0000315545 pvct:OptionsExercisedPriceTwoMember 2013-04-01 2013-06-30 0000315545 us-gaap:MaximumMember 2013-04-01 2013-06-30 0000315545 pvct:NetworkOneFinancialSecuritiesMember 2013-04-01 2013-06-30 0000315545 2013-04-01 2013-06-30 0000315545 us-gaap:CommonStockMember 2012-04-01 2012-06-30 0000315545 us-gaap:WarrantMember 2012-04-01 2012-06-30 0000315545 2012-04-01 2012-06-30 0000315545 us-gaap:CommonStockMember 2012-01-01 2012-03-31 0000315545 us-gaap:WarrantMember 2012-01-01 2012-03-31 0000315545 2012-01-01 2012-03-31 0000315545 pvct:WarrantOneMember 2013-01-01 2013-03-31 0000315545 us-gaap:ConvertiblePreferredStockMember 2013-01-01 2013-03-31 0000315545 us-gaap:CommonStockMember 2013-01-01 2013-03-31 0000315545 us-gaap:WarrantMember 2013-01-01 2013-03-31 0000315545 us-gaap:RedeemablePreferredStockMember 2013-01-01 2013-03-31 0000315545 pvct:TwoThousandElevenWarrantsMember 2013-01-01 2013-03-31 0000315545 pvct:TwoThousandTenWarrantsMember 2013-01-01 2013-03-31 0000315545 pvct:TwoThousandThirteenWarrantsMember 2013-01-01 2013-03-31 0000315545 pvct:TwoThousandElevenWarrantsMemberus-gaap:MinimumMember 2013-01-01 2013-03-31 0000315545 pvct:TwoThousandTenWarrantsMemberus-gaap:MinimumMember 2013-01-01 2013-03-31 0000315545 pvct:TwoThousandThirteenWarrantsMemberus-gaap:MinimumMember 2013-01-01 2013-03-31 0000315545 us-gaap:MinimumMember 2013-01-01 2013-03-31 0000315545 pvct:TwoThousandElevenWarrantsMemberus-gaap:MaximumMember 2013-01-01 2013-03-31 0000315545 pvct:TwoThousandTenWarrantsMemberus-gaap:MaximumMember 2013-01-01 2013-03-31 0000315545 pvct:TwoThousandThirteenWarrantsMemberus-gaap:MaximumMember 2013-01-01 2013-03-31 0000315545 us-gaap:MaximumMember 2013-01-01 2013-03-31 0000315545 pvct:NetworkOneFinancialSecuritiesMember 2013-01-01 2013-03-31 0000315545 2013-01-01 2013-03-31 0000315545 2002-02-01 2013-09-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0000315545 us-gaap:PreferredStockMember 2012-01-01 2012-12-31 0000315545 us-gaap:CommonStockMember 2012-01-01 2012-12-31 0000315545 us-gaap:RetainedEarningsMember 2012-01-01 2012-12-31 0000315545 2012-01-01 2012-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2008-01-01 2008-12-31 0000315545 us-gaap:CommonStockMember 2008-01-01 2008-12-31 0000315545 us-gaap:RetainedEarningsMember 2008-01-01 2008-12-31 0000315545 2008-01-01 2008-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2004-01-01 2004-12-31 0000315545 us-gaap:CommonStockMember 2004-01-01 2004-12-31 0000315545 us-gaap:RetainedEarningsMember 2004-01-01 2004-12-31 0000315545 2004-01-01 2004-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-12-31 0000315545 us-gaap:PreferredStockMember 2011-01-01 2011-12-31 0000315545 us-gaap:CommonStockMember 2011-01-01 2011-12-31 0000315545 us-gaap:RetainedEarningsMember 2011-01-01 2011-12-31 0000315545 2011-01-01 2011-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-12-31 0000315545 us-gaap:PreferredStockMember 2010-01-01 2010-12-31 0000315545 us-gaap:CommonStockMember 2010-01-01 2010-12-31 0000315545 us-gaap:RetainedEarningsMember 2010-01-01 2010-12-31 0000315545 2010-01-01 2010-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2009-01-01 2009-12-31 0000315545 us-gaap:CommonStockMember 2009-01-01 2009-12-31 0000315545 us-gaap:RetainedEarningsMember 2009-01-01 2009-12-31 0000315545 2009-01-01 2009-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2007-01-01 2007-12-31 0000315545 us-gaap:CommonStockMember 2007-01-01 2007-12-31 0000315545 us-gaap:RetainedEarningsMember 2007-01-01 2007-12-31 0000315545 2007-01-01 2007-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2006-01-01 2006-12-31 0000315545 us-gaap:CommonStockMember 2006-01-01 2006-12-31 0000315545 us-gaap:RetainedEarningsMember 2006-01-01 2006-12-31 0000315545 2006-01-01 2006-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2005-01-01 2005-12-31 0000315545 us-gaap:CommonStockMember 2005-01-01 2005-12-31 0000315545 us-gaap:RetainedEarningsMember 2005-01-01 2005-12-31 0000315545 2005-01-01 2005-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2003-01-01 2003-12-31 0000315545 us-gaap:CommonStockMember 2003-01-01 2003-12-31 0000315545 us-gaap:RetainedEarningsMember 2003-01-01 2003-12-31 0000315545 2003-01-01 2003-12-31 0000315545 pvct:ReElectedBoardMemberMember 2013-08-01 2013-08-31 0000315545 2013-05-01 2013-05-31 0000315545 pvct:NewlyAppointedBoardMemberMember 2012-05-01 2012-05-31 0000315545 us-gaap:ConvertiblePreferredStockMember 2010-03-01 2010-03-31 0000315545 us-gaap:ConvertiblePreferredStockMember 2013-07-01 2013-07-31 0000315545 2013-01-01 2013-01-31 0000315545 pvct:ReElectedBoardMemberMember 2012-06-01 2012-06-30 0000315545 us-gaap:ConvertiblePreferredStockMember 2010-04-01 2010-04-30 0000315545 pvct:SeriesConvertiblePreferredStockMember 2013-02-01 2013-02-28 0000315545 2013-02-01 2013-02-28 0000315545 us-gaap:ConvertiblePreferredStockMember 2012-01-01 2012-09-30 0000315545 us-gaap:WarrantMember 2012-01-01 2012-09-30 0000315545 us-gaap:EmployeeStockOptionMember 2012-01-01 2012-09-30 0000315545 2012-01-01 2012-09-30 0000315545 us-gaap:ConvertiblePreferredStockMember 2013-01-01 2013-09-30 0000315545 pvct:SeriesConvertiblePreferredStockMember 2013-01-01 2013-09-30 0000315545 pvct:TwoThousandElevenWarrantsMember 2013-01-01 2013-09-30 0000315545 pvct:TwoThousandTenWarrantsMember 2013-01-01 2013-09-30 0000315545 pvct:TwoThousandThirteenWarrantsMember 2013-01-01 2013-09-30 0000315545 us-gaap:ConvertiblePreferredStockMember 2013-01-01 2013-09-30 0000315545 us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2013-01-01 2013-09-30 0000315545 us-gaap:WarrantMember 2013-01-01 2013-09-30 0000315545 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-09-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-09-30 0000315545 us-gaap:PreferredStockMember 2013-01-01 2013-09-30 0000315545 us-gaap:CommonStockMember 2013-01-01 2013-09-30 0000315545 us-gaap:RetainedEarningsMember 2013-01-01 2013-09-30 0000315545 pvct:TwoThousandElevenWarrantsMemberus-gaap:MinimumMember 2013-01-01 2013-09-30 0000315545 pvct:TwoThousandTenWarrantsMemberus-gaap:MinimumMember 2013-01-01 2013-09-30 0000315545 pvct:TwoThousandThirteenWarrantsMemberus-gaap:MinimumMember 2013-01-01 2013-09-30 0000315545 pvct:TwoThousandElevenWarrantsMemberus-gaap:MaximumMember 2013-01-01 2013-09-30 0000315545 pvct:TwoThousandTenWarrantsMemberus-gaap:MaximumMember 2013-01-01 2013-09-30 0000315545 pvct:TwoThousandThirteenWarrantsMemberus-gaap:MaximumMember 2013-01-01 2013-09-30 0000315545 us-gaap:MaximumMember 2013-01-01 2013-09-30 0000315545 pvct:MaximGroupLlcMember 2013-01-01 2013-09-30 0000315545 2013-01-01 2013-09-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-04-24 2002-12-31 0000315545 us-gaap:CommonStockMember 2002-04-24 2002-12-31 0000315545 us-gaap:RetainedEarningsMember 2002-04-24 2002-12-31 0000315545 2002-04-24 2002-12-31 0000315545 2013-07-01 2013-07-22 0000315545 pvct:TwoThousandElevenWarrantsMember 2013-01-01 2013-06-30 0000315545 pvct:TwoThousandTenWarrantsMember 2013-01-01 2013-06-30 0000315545 pvct:TwoThousandThirteenWarrantsMember 2013-01-01 2013-06-30 0000315545 pvct:TwoThousandElevenWarrantsMemberus-gaap:MinimumMember 2013-01-01 2013-06-30 0000315545 pvct:TwoThousandTenWarrantsMemberus-gaap:MinimumMember 2013-01-01 2013-06-30 0000315545 pvct:TwoThousandThirteenWarrantsMemberus-gaap:MinimumMember 2013-01-01 2013-06-30 0000315545 pvct:TwoThousandElevenWarrantsMemberus-gaap:MaximumMember 2013-01-01 2013-06-30 0000315545 pvct:TwoThousandTenWarrantsMemberus-gaap:MaximumMember 2013-01-01 2013-06-30 0000315545 pvct:TwoThousandThirteenWarrantsMemberus-gaap:MaximumMember 2013-01-01 2013-06-30 0000315545 us-gaap:ConvertiblePreferredStockMember 2012-12-31 0000315545 pvct:SeriesConvertiblePreferredStockMember 2012-12-31 0000315545 us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0000315545 us-gaap:WarrantMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0000315545 us-gaap:WarrantMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0000315545 us-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0000315545 us-gaap:PreferredStockMember 2012-12-31 0000315545 us-gaap:CommonStockMember 2012-12-31 0000315545 us-gaap:RetainedEarningsMember 2012-12-31 0000315545 2012-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0000315545 us-gaap:PreferredStockMember 2011-12-31 0000315545 us-gaap:CommonStockMember 2011-12-31 0000315545 us-gaap:RetainedEarningsMember 2011-12-31 0000315545 2011-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2010-12-31 0000315545 us-gaap:PreferredStockMember 2010-12-31 0000315545 us-gaap:CommonStockMember 2010-12-31 0000315545 us-gaap:RetainedEarningsMember 2010-12-31 0000315545 2010-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2009-12-31 0000315545 us-gaap:CommonStockMember 2009-12-31 0000315545 us-gaap:RetainedEarningsMember 2009-12-31 0000315545 2009-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2008-12-31 0000315545 us-gaap:CommonStockMember 2008-12-31 0000315545 us-gaap:RetainedEarningsMember 2008-12-31 0000315545 2008-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2007-12-31 0000315545 us-gaap:CommonStockMember 2007-12-31 0000315545 us-gaap:RetainedEarningsMember 2007-12-31 0000315545 2007-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2006-12-31 0000315545 us-gaap:CommonStockMember 2006-12-31 0000315545 us-gaap:RetainedEarningsMember 2006-12-31 0000315545 2006-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2005-12-31 0000315545 us-gaap:CommonStockMember 2005-12-31 0000315545 us-gaap:RetainedEarningsMember 2005-12-31 0000315545 2005-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2004-12-31 0000315545 us-gaap:CommonStockMember 2004-12-31 0000315545 us-gaap:RetainedEarningsMember 2004-12-31 0000315545 2004-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2003-12-31 0000315545 us-gaap:CommonStockMember 2003-12-31 0000315545 us-gaap:RetainedEarningsMember 2003-12-31 0000315545 2003-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-12-31 0000315545 us-gaap:CommonStockMember 2002-12-31 0000315545 us-gaap:RetainedEarningsMember 2002-12-31 0000315545 2002-12-31 0000315545 us-gaap:ConvertiblePreferredStockMember 2013-09-30 0000315545 us-gaap:RedeemablePreferredStockMember 2013-09-30 0000315545 pvct:SeriesConvertiblePreferredStockMember 2013-09-30 0000315545 us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2013-09-30 0000315545 us-gaap:WarrantMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2013-09-30 0000315545 us-gaap:WarrantMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2013-09-30 0000315545 us-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember 2013-09-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2013-09-30 0000315545 us-gaap:PreferredStockMember 2013-09-30 0000315545 us-gaap:CommonStockMember 2013-09-30 0000315545 us-gaap:RetainedEarningsMember 2013-09-30 0000315545 pvct:NonemployeeMember 2013-09-30 0000315545 pvct:ThirdNonEmployeeMember 2013-09-30 0000315545 pvct:NetworkOneFinancialSecuritiesMember 2013-09-30 0000315545 pvct:MaximGroupLlcMember 2013-09-30 0000315545 2013-09-30 0000315545 us-gaap:RedeemablePreferredStockMember 2013-06-30 0000315545 pvct:NetworkOneFinancialSecuritiesMember 2013-06-30 0000315545 2013-06-30 0000315545 us-gaap:RedeemablePreferredStockMember 2013-03-31 0000315545 pvct:NetworkOneFinancialSecuritiesMember 2013-03-31 0000315545 2013-03-31 0000315545 2012-09-30 0000315545 2013-07-22 0000315545 us-gaap:RedeemablePreferredStockMember 2013-04-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-04-23 0000315545 us-gaap:CommonStockMember 2002-04-23 0000315545 us-gaap:RetainedEarningsMember 2002-04-23 0000315545 2002-04-23 0000315545 us-gaap:RedeemablePreferredStockMember 2013-07-31 0000315545 us-gaap:CommonStockMember 2013-02-22 0000315545 pvct:SeriesConvertiblePreferredStockMember 2013-02-22 0000315545 2013-02-22 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-01-31 0000315545 us-gaap:PreferredStockMember 2002-01-31 0000315545 us-gaap:CommonStockMember 2002-01-31 0000315545 us-gaap:RetainedEarningsMember 2002-01-31 0000315545 2002-01-31 iso4217:USD shares iso4217:USD shares pvct:NonEmployee pure

EX-101.SCH 6 pvct-20130930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statements of Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements of Cash Flow link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Recapitalization and Merger link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Basic and Diluted Loss Per Common Share link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Equity Transactions link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Related Party Transaction link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Fair Value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Equity Transactions (Policies) link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Fair Value of Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Recapitalization and Merger - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Basic and Diluted Loss Per Common Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Equity Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Stock-Based Compensation - Summary of Nonvested Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Related Party Transaction - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Fair Value of Financial Instruments - Warrant Liability Measured at Fair Value on a Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Fair Value of Financial Instruments - Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 pvct-20130930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 pvct-20130930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 pvct-20130930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable Trade Current Accounts payable - trade Accretion of united states treasury bills. Accretion Of United States Treasury Bills Accretion of United States Treasury Bills Accrued Professional Fees Current Accrued consulting expense Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Accumulated depreciation on equipment and furnishings Additional Paid In Capital Paid-in capital Additional Paid In Capital [Member] Paid in Capital [Member] Adjustments to additional paid in capital beneficial conversion related to interest expense value. Adjustments To Additional Paid In Capital Beneficial Conversion Related To Interest Expense Value Beneficial conversion related to interest expense Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature Beneficial conversion related to convertible debt Adjustments to additional paid in capital employee compensation from stock options value. Adjustments To Additional Paid In Capital Employee Compensation From Stock Options Value Employee compensation from stock options Adjustments to additional paid in capital issuance of convertible debt with warrants value. Adjustments To Additional Paid In Capital Issuance Of Convertible Debt With Warrants Value Issuance of convertible debt with warrants Adjustments to additional paid in capital issuance of warrants for contractual. Adjustments To Additional Paid In Capital Issuance Of Warrants For Contractual Obligations Value Issuance of warrants for contractual obligations Adjustments to additional paid in capital repurchase of beneficial conversion feature value. Adjustments To Additional Paid In Capital Repurchase Of Beneficial Conversion Feature Value Repurchase of beneficial conversion feature Adjustments to additional paid in capital stock to be issued for services value. Adjustments To Additional Paid In Capital Stock To Be Issued For Services Value Stock to be issued for services Adjustments To Additional Paid In Capital Warrant Issued Warrants issued in connection with convertible debt Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Adjustment to additional paid in capital sale of non controlling interest and warrants. Adjustment To Additional Paid In Capital Sale Of Non Controlling Interest And Warrants Sale of non-controlling interest in Pure-ific Corporation and warrants Aggregate liquidation preference. Aggregate Liquidation Preference Aggregate liquidation preference Allocated Share Based Compensation Expense Stock-based compensation expense Amendment Flag Amendment Flag Amortization of commitment fee. Amortization Of Commitment Fee Amortization of commitment fee Amortization Of Debt Discount Premium Amortization of original issue discount Amortization Of Financing Costs Amortization of deferred loan costs Amortization Of Intangible Assets Amortization Amortization of patents Amortization of prepaid consultant expense. Amortization Of Prepaid Consultant Expense Amortization of prepaid consultant expense Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Common shares excluded from the calculation Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Assets Total Assets Assets [Abstract] Assets Assets Current Total Current Assets Assets Current [Abstract] Current Assets Award Type [Axis] Award Type [Axis] Basic and diluted loss per common share. Basic And Diluted Loss Per Common Share Basic and diluted loss per common share Beneficial conversion of convertible interest. Beneficial Conversion Of Convertible Interest Beneficial conversion of convertible interest Business Combination Disclosure [Text Block] Recapitalization and Merger Business Combinations [Abstract] Business Combinations [Abstract] Cash And Cash Equivalents At Carrying Value Cash and cash equivalents, at end of period Cash and cash equivalents, at beginning of period Cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Net change in cash and cash equivalents Cash paid for deferred loan costs. Cash Paid For Deferred Loan Costs Cash paid for deferred loan costs Cash paid for preferred dividend. Cash Paid For Preferred Dividend Cash paid for preferred dividends Class Of Stock [Domain] Class of Stock [Domain] Class Of Stock [Line Items] Class of Stock [Line Items] Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Common Stock to be Issued on Exercise of Warrant Class of warrants or right exercise price of warrants or rights. Class Of Warrants Or Right Exercise Price Of Warrants Or Rights Exercise price of common stock Commitment fee. Commitment Fee Costs charged to operations for commitment fee Common stock issued under recapitalization transactions. Common Stock Issued Under Recapitalization Transactions Common stock shares issued Common Stock [Member] Common Stock [Member] Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common stock unit beneficial conversion amount. Common Stock Unit Beneficial Conversion Amount Common stock unit beneficial conversion amount Common stock unit fair value of warrants recorded on issuance. Common Stock Unit Fair Value Of Warrants Recorded On Issuance Common stock unit fair value warrants recorded on issuance Common Stock Value Common stock; par value $.001 per share; 250,000,000 authorized; 139,974,331 and 118,427,925 shares issued and outstanding, respectively Compensation through issuance of stock. Compensation Through Issuance Of Stock Compensation through issuance of stock Consulting costs. Consulting Costs Consulting costs charges Consulting costs relates to warrant issued. Consulting Costs Relates To Warrant Issued Consulting costs charges related to warrants Convertible interest. Convertible Interest Convertible interest Convertible Preferred Stock [Member] 8% Convertible Preferred Stock [Member] Convertible preferred stock par value per share securities purchase agreement. Convertible Preferred Stock Par Value Per Share Securities Purchase Agreement 8% convertible preferred stock, par value Convertible Preferred Stock Shares Issued Upon Conversion Preferred stock converted into shares Convertible preferred stock shares to be converted to common stock shares. Convertible Preferred Stock Shares To Be Converted To Common Stock Shares Converted preferred stock Cost Of Goods And Services Sold Cost of sales Current Fiscal Year End Date Current Fiscal Year End Date Depreciation Depreciation Derivative Contract Type [Domain] Derivative Contract [Domain] Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Derivative instruments. Derivative Instruments [Abstract] Derivative instruments: Derivatives Policy [Text Block] Derivatives Policies Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stock-Based Compensation Dividends Preferred Stock Dividends on preferred stock Dividends on preferred stock Dividends Preferred Stock Cash Dividends on preferred stock Dividends Preferred Stock Stock Common stock shares issued in lieu of cash dividends for Preferred stock Document and Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Text Block] Basic and Diluted Loss Per Common Share Employee Related Liabilities Current Accrued compensation and payroll taxes Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Unrecognized stock-based compensation expense Employee Stock Option [Member] Stock Options [Member] Entities [Table] Entities [Table] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Equity transactions. Equity Transactions [Text Block] Equity Transactions Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value, Hierarchy [Axis] Fair Value By Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Fair Value Inputs Level 1 [Member] Level 1 [Member] Fair Value Inputs Level 2 [Member] Level 2 [Member] Fair Value Inputs Level 3 [Member] Level 3 [Member] Fair Value Liabilities Measured On Recurring Basis [Text Block] Warrant Liability Measured at Fair Value on a Recurring Basis Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Measurements Recurring [Member] Recurring [Member] Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings Net loss included in earnings Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues Issuance of warrants Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Exercise of warrants Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Ending Balance Beginning Balance Finite Lived Intangible Assets Accumulated Amortization Amortization on patents Finite Lived Intangible Assets Net Patents, net of amortization of $7,292,837 and $6,789,497, respectively Gain loss on change in fair value of warrant liability. Gain Loss On Change In Fair Value Of Warrant Liability (Loss) gain on change in fair value of warrant liability Gain loss on fair value of warrant liability. Gain Loss On Fair Value Of Warrant Liability Loss (gain) on change in fair value of warrant liability Gain loss on revaluation of warrants liability. Gain Loss On Revaluation Of Warrants Liability Gain Loss on Revaluation of Warrants Liability Gain Loss On Sale Of Property Plant Equipment Gain on sale of fixed assets Gain on sale of equipment Gains Losses On Extinguishment Of Debt Loss on extinguishment of debt Loss on extinguishment of debt General And Administrative Expense General and administrative Gross proceeds from sales of common stock and warrants. Gross Proceeds From Sales Of Common Stock And Warrants Gross proceeds from private offering of common stock and warrants to accredited investors Gross Profit Gross profit Income Statement [Abstract] Income Statement [Abstract] Increase Decrease In Accounts Payable Trade Accounts payable Increase Decrease In Accrued Liabilities Accrued expenses Increase Decrease In Other Operating Assets And Liabilities Net [Abstract] Change in assets and liabilities Increase Decrease In Prepaid Expense Prepaid expenses and other current assets Interest Income Expense Net Net interest expense Investment Income Interest Investment income Issuance of common stock and warrants pursuant to regulation D. Issuance Of Common Stock And Warrants Pursuant To Regulation D Shares Issuance of common stock and warrants pursuant to Regulation D, shares Issuance of common stock and warrants pursuant to regulation D value. Issuance Of Common Stock And Warrants Pursuant To Regulation D Value Issuance of common stock and warrants pursuant to Regulation D Issuance of stock for services. Issuance Of Stock For Services Issuance of stock for services Issuance of warrants for contractual obligations. Issuance Of Warrants For Contractual Obligations Issuance of warrants for contractual obligations Issuance of warrants for services. Issuance Of Warrants For Services Issuance of warrants for services Legal Entity [Axis] Legal Entity [Axis] Liabilities Total Liabilities Liabilities And Stockholders Equity Total Liabilities and Stockholders' Equity Liabilities And Stockholders Equity [Abstract] Liabilities and Stockholders' Equity Liabilities Current Total Current Liabilities Liabilities Current [Abstract] Current Liabilities Liabilities Noncurrent [Abstract] Long-Term Liability Loss on exercise of warrants. Loss On Exercise Of Warrants Loss on exercise of warrants Maxim group LLC. Maxim Group Llc [Member] Maxim Group Llc [Member] Maximum [Member] Maximum [Member] Medical device revenue. Medical Device Revenue Medical device revenue Minimum [Member] Minimum [Member] Net Cash Provided By Used In Financing Activities Net cash provided by financing activities Net Cash Provided By Used In Financing Activities [Abstract] Cash Flows From Financing Activities Net Cash Provided By Used In Investing Activities Net cash (used in) provided by investing activities Net Cash Provided By Used In Investing Activities [Abstract] Cash Flows From Investing Activities Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net Cash Provided By Used In Operating Activities [Abstract] Cash Flows From Operating Activities Net Income Loss Net loss Net Income Loss Available To Common Stockholders Basic Net loss applicable to common shareholders Net proceeds from loans from stockholder. Net Proceeds From Loans From Stockholder Net proceeds from loans from stockholder Net proceeds from sales of common stock and warrants. Net Proceeds From Sales Of Common Stock And Warrants Net proceeds from sales of common stock and warrants Net proceeds from sales of preferred stock and warrants. Net Proceeds From Sales Of Preferred Stock And Warrants Net proceeds from sales of preferred stock and warrants Network one financial securities. Network One Financial Securities [Member] Network 1 Financial Securities [Member] Newly appointed board member. Newly Appointed Board Member [Member] Newly Appointed Board Member [Member] Non employee. Nonemployee [Member] Non Employee [Member] Number of non employee to whom consulting services paid. Number Of Non Employee To Whom Consulting Services Paid Number of non employee to whom consulting services paid Number of warrants issued securities purchase agreement. Number Of Warrants Issued Securities Purchase Agreement Purchase price of preferred stock with warrants Operating Expenses [Abstract] Operating expenses Operating Income Loss Total operating loss Options exercised price one. Options Exercised Price One [Member] Options Exercised Price One [Member] Options exercised price two. Options Exercised Price Two [Member] Options Exercised Price Two [Member] Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Basis of Presentation Other Accrued Liabilities Current Other accrued expenses Other Assets Noncurrent Other assets Payments For Repurchase Of Common Stock Purchase and retirement of common stock Payments Of Stock Issuance Costs Payment of fully vested warrants Payments require to pay to placement agent. Payments Require To Pay To Placement Agent Warrant accrued Payments To Acquire Investments Purchases of investments Payments To Acquire Property Plant And Equipment Capital expenditures Percentage of aggregate shares called by warrant. Percentage Of Aggregate Shares Called By Warrant Percentage of Aggregate Shares Called by Warrant Percentage of common shares issuable on exercise of each warrant. Percentage Of Common Shares Issuable On Exercise Of Each Warrant Investors received five year warrants Period of warrants to purchase common stock. Period Of Warrants To Purchase Common Stock Period of warrants to purchase common stock Preferred Stock Dividend Rate Percentage Convertible preferred stock The percentage rate used to calculate dividend payments on preferred stock. Preferred Stock Dividends Rate Percentage Convertible preferred stock Preferred stock issued during period pursuant to regulation of value. Preferred Stock Issued During Period Pursuant To Regulation Of Value Issuance of preferred stock and warrants pursuant to Regulation D Preferred stock issued during period shares pursuant to regulation of value. Preferred Stock Issued During Period Shares Pursuant To Regulation Of Value Issuance of preferred stock and warrants pursuant to Regulation D, shares Preferred Stock Liquidation Preference Preferred stock, liquidation preference per share Preferred Stock [Member] Preferred Stock [Member] Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, shares issued Preferred Stock Shares Outstanding Preferred stock, shares outstanding Preferred Stock Value Preferred stock; par value $.001 per share; 25,000,000 shares authorized including; 8% convertible preferred stock, 746,666 and 2,478,185 shares issued and outstanding, respectively, liquidation preference $0.75 (in aggregate $570,585 and $1,896,117, respectively); Series A 8% convertible preferred stock, 2,958,334 shares issued and outstanding in 2013, liquidation preference $0.75 (in aggregate $2,246,855) Premium paid on extinguishments of debt. Premium Paid On Extinguishments Of Debt Premium paid on extinguishments of debt Prepaid Expense And Other Assets Current Prepaid expenses and other current assets Proceeds From Convertible Debt Proceeds from convertible debt Proceeds From Divestiture Of Interest In Consolidated Subsidiaries Net proceeds from sale of non-controlling interest in Pure-ific Corporation EX-101.PRE 10 pvct-20130930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R17.htm IDEA: XBRL DOCUMENT

Recapitalization and Merger - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]
Common stock shares issued	6,680,000

EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`2PA3]O@$``&`1```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%U/@S`4AN]-_`^DMP9* M4>AX:\X3V#T;*N M@@486RJ9$A;%)`"9*5'*:4H^)B]AGP36<2EXI22D9`66C(:7%X/)2H,-_&YI M4U(XIQ\HM5D!-;>1TB#]3*Y,S9V_-5.J>3;C4Z!)'/=HIJ0#Z4+7U"##P1/D M?%ZYX'GI'Z])#%26!(_KA8U62KC659EQYTGI0HH]E7"C$/F=[1I;E-I>>0Q" M.Q6:F=\%-OO>_-&84D`PYL:]\MICT&5%OY29?2HUBPX7Z:!4>5YF(%0VK_T) M1%8;X,(6`*ZNHG:,:E[*+?W`S@S2O%];^$2.!`G'-1*.&R0D@X[I!P])%PW"/A8#$6$"R.RK!8*L/BJ0R+J3(LKLJPV"K#XJL,B[$R+,Z: M8''6!(NS)EB<-<'BK`D69TW^RUF=SZ]`V^O?/].VS)$`9=VJ`GOFGYYUT6/* M!3<@WIWQ2?_L`#]K'^+P.7ALE+:^(V#@]%/81OYF=ZA](3"NA%WH[PK/.T7? M33A=<"^]0].O$"`ZM&G;'QE^`P``__\#`%!+`P04``8`"````"$`M54P(_4` M``!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."2F/; MT?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA5]W> M;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;J)I" MRTF#%?.&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0`````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````"\ETUKPS`,AN^#_8?@^^K(_1Y- M>QF#7K?N!YA$34(3.]C>1__]3+>E*W3:)>@2L$/DET?2&WFU^6B;Y`V=KZW) M!(Q2D:#);5&;,A,ON\>[A4A\T*;0C368B2-ZL5G?WJR>L-$A?N2KNO-)C&)\ M)JH0NGLI?5YAJ_W(=FCBF[UUK0YQZ4K9Z?R@2Y0J36?2_8XAUA_K'!]L_MJB"5>.D._6'7R%&&)0[4H,F>BWO#R]68RB8B&O MBX$QLQH8DW*XX0!)1\V&I!-B#>$Y3Z>E/#V!8L*=(3)!"H8DTI?JF4J_]5V] MBF0S9U8SIQ(%BED-*%(.-QP@Z:@I,QTUI>APYXI.U:`^T[?0WUT%,Y)-_&>R M_J)42LGAMAS2<;@S128*V-&0;-2$NVXF5-UP&P[I-\"M!D@YBGNJ4/18,>C< MYROML'@.+L[\_FR"%]M4X0"W_P'M?TOFMH(E18>[RYT9#D@%N-$"R4>PS M#CGDJ$'G41^.3;RY][?>K_5/W(Q/?MA:.G=G."OOTNW9I>IN4"IX2Q[TGYQ[_[/3T M[+F2T5\P5F@UC+.]-(Y`E9H+-1O&OR?77X[BR#JF.)-:P3!^`1N?C3Y_.EUH M\_2H]5.$`LH.X[ES]4F2V'(.%;-[N@:%,U-M*N9P:&:)K0TP;N<`KI))GJ:' M2<6$BI<*)^8]&GHZ%25'0Z%1+NEQU%K*Y_L0I] M/\LXDLRZ*RX<\&%\@$.]@(T'IJDO&B%Q]GB0#N)DU#8Y-A&'*6NDFV![*W7, M*]_/\T/_2Q_%O8"%71?Y8?3\(!37"_]3C/:E'0W0P"),/0CNYCB?IFG[[#N( MV=RM'J)\0O1#@OB><(U4:&^52($K55PI)]Q+<:.6Z0N-2^A3O\'.LC@R)P)O MS`W/O'&J\DTK#LH"+_#.:BDXP["*"R:9*H&HY$0E_Y@*&FC-#(A,R/L=9NX< M>JJHF7VBLK_%S+J1UUKE;*&GQ9VCP6#V;3`'6U2V!?.J1ULZ)#(!#-K2!;,B MO'ILP"*_`5N2!Z*T-O&U:^(62E8+QZ3X%PK#6O\$,P-#-;X2C:.NAG=0AL)+ M(1N_N#^TM<48#"YY165PW[=Y''=EKOXTGK")8XQ>,V&*>R8;\"1<"X6` M"R9QSUAG&JI#4<]ZD&X)HACCQBD%GI,$=$IZUH/TC42*"7N4FSJ4]:R'Z>ZN M**;^^%DGW`-U!VK%.2>-990V''0.E-VX44,9Y0T'':%M.9]S/,OQW&=XM*^/ M%+J%LAZX;R6]U*(ZM#$\NCM^WM*Y:ZJ*;6Q'RF'^?I0Q9BZH'YI/_D&>D>$V MH)RBB(-.8[L1PMJU$&4Q[S&]6PAKUT*4Q3Q`G81)_,:53);X\?47__4*ZY"L M_GJ,_@,``/__`P!02P,$%``&``@````A`&D\^&FG!@``K!L``!@```!X;"]W M;W)K(N.\$VYA#U.G1<-H= M:59:K?9P32>D@R8)$=#3,V^_9>P$JIQ.Z)M.!SY^7+^K[`H\?OIQV,^^ETU; MU<>5P^:N,RN/ZWI3'5]6SC]_YP^A,VN[XK@I]O6Q7#D_R];Y]/3K+X]O=?.M MW95E-P.%8[MR=EUW6BX6[7I7'HIV7I_*(YS9ULVAZ.!K\[)H3TU9;/J+#OL% M=UU_<2BJHZ,5ELT4C7J[K=9E6J]?#^6QTR)-N2\Z&'^[JT[M6>VPGB)W*)IO MKZ>'=7TX@<1SM:^ZG[VH,SNLEU]>CG53/.\A[A_,*]9G[?Z+)7^HUDW=UMMN M#G(+/5`[YF@1+4#IZ7%3003*]EE3;E?.9[;,N7`63X^]0?]6Y5L[^G_6[NJW MWYIJ\[4ZEN`VS).:@>>Z_J;0+QMU""Y>6%?G_0S\V]A`/!W=JA4:H`CQ8_^\ZW:=+N5(_RY M#%S!`)\]EVV75TK2F:U?VZX^_*(KB(^1Y(RHJ52RZ?G`(,OP)=F9 M.%^2ZP/P=QA)<+EF`4%?(H>9'4=^/:O.`2I8!7B^3ZP/C._#+[?I!Y_8A!]B M)+41(I+9!!7);60000%#"D\/6,%0,&,?(SSZ6".0VA>K/4PD=XGT+I'=)?); M!#(`ACK=``6O'##W$EW@XO!BC8P-"$A^)C9"/$IM@HID-D)$5QZ7M# MHB$#8/F9;H""B0%#8O4I'FL$;CYX1`VP$3+VU"8L`VR$B.2:\'L#F,?<(5>1 M`;#"33=`P<0`03)`(S<-L!$R]M0F+`-LA(CDFM`&B"B0[RQZL$1/-T#!Q`!R MVU@C-PVP$2*2VH1E@(T0D5P3)@,D9\/F@C)`-8>C_>[VJJ]@8@#=UC1RTP`; M(6-/;<(RP$:(2*X);0#WI#=4(C(@^H@!"L:[0##XJM<`C8P-(`-+[A+I72*[ M2^2W"&0`@T9T>@KT-,F!H;:T!88QN<)44(#YF4;%C% M>B1#B"*$#^$W8PVDQE"`LY#SDEAYA@1KG2#T:Q@(U0+-=T(W7`A(\A$ MQ4PS)B/\(`C)/"5WB101TA6"SG5VE\@1$?"(AR.WL0>JBYKN@>ZYQA[0"&-V MJR_K\R4QB+;I0W[$ANGI M\RE%R`.<9RY)N0PAL"/*D-XH1X@71=*-AD4=^Z$:K9$?=WS0;1GR82@U4Q%V M*<*/0=0<&6Z&:KNE6Z!8-64':@YAIQMS< MDY+[$;$KP0P77L`866Q3S,!YU^625%!&(-?W`N@D+NM@/SDY@:#EDD+P8=S( M$/ZAWK*GR:Y!LCLVC#%$A'Y$HD@PX8DP'&9+5P@F&`M53X7#S`CCPAUBXZV`C26TY;-+C=8X9DH+%A]+..!P\Z7!'2#,$,%Q$4,V%2S##H M(4-K5<@(Y`81=.XDUW(">N[-DX/TFU.=,'N.FDUQ/!"0CFEZX4))@/A6S]" M,`24[TCEY0._5Z+C]MX_R[+SE M=5-4EZT;>H'KY)>LVA>7X];]Y^^GFUO7:=KTLD_/U27?NC_RQOWV\/-/]^]5 M_=*<\KQU(,*EV;JGMKW>^7Z3G?(R;;SJFE_@G4-5EVD++^NCWUSK/-UW@\JS M'P7!RB_3XN)BA+MZ2HSJ<"BRG%79:YE?6@Q2Y^>TA?R;4W%M/J.5V91P95J_ MO%YOLJJ\0HCGXERT/[J@KE-F=]^/EZI.G\^@^R-[O<%*.#3[M3Y8>L^AG:4_7^ M:UWL?R\N.>J>N'H]SW_$PSVM=%/W0K\63O[_)"^GMN_JO??\N)X M:F&YEZ"("[O;_V!YD\&,0A@O6O)(676&!."G4Q:\-&!&TH_N]WNQ;T];-UYY MRW40AX`[SWG3/A4\I.MDKTU;E?\A%(I0&"020>"W"!(MO$6T7-_.B1*+*(LA M2CPYBH^ZNFEB:9L^W-?5NP.U!YDWUY17Z>ER>.M"['XN MX\VZCXL*D($U[1DU?RO!3`3)'CYF>O8P.O=J]LC(V<>;#568Z,PB""C#QI@ORGTU1P.'J89%,-0EU@\R8="U<^`% M2C\GEO?9U^^3N8=-8_K< M0WRJE%OC['(+T5!E+UD$BNGN!&1:,CO"C`B5PFU3DF)9-#19LZ&$"!DE6!%F MC$(E<.^<+@&=%A(8W%K=<77X!9??X$,V7B`B'@YWH"9-#=T@BXI`%4XZ01H1* MX9XJ2;%LNNC`EIXPV;208$58:$*(A&B6V7>TNC,II\.=@,2F.^4\24>LO)5\ M/L3V4)&OCY"18NKF1>EH59&RS>\$--B(Y?@RDV<:?TN/U,/>3]<.ND$NOVF= M%/%1BN)0O901D*%-$CO"C`B5PHUT6R_-O]#016O,@-#2/Y0PF@II$,S-# MEV66Z4>ZZ2]";5E&3)]Z2"+BR"*4ZTUF1*B$678?H9-;F@,A0WZ)B&-`F!&A M$A33MVS*NMGK1Z]HQ.SU+QS'(*5"V6BDX=*`"N'..GVC0A\FIQ;M:Z,(H;Y! MU*N8Q`8P`T"2Y\7R,5ZRFWM" M0$8)&,>`,&,4*D&Q;W-/Q".VK1F&@$0IK3UZ]1I$VKDJH2-";P%?]RF'`:8R M\2V]BI9'4(7<7R\J5KF]3%/\O.Y<;+JE=]7#N'V2?_7_I[W8]3=M>[?@%O. MU_28_Y'6Q^+2..?\`$,#;PUE5.--:WS15M?NENUSU<+-YN[I"?ZY((<[EO`U MM.L&ULE%9;;]L@%'Z?M/^` M>*\O<2Y.%*=J5W6KM$G3M,LSP3A&-<8"TK3_?@=PG$NSE;[8QO[X/LYW#APO MKY]%@YZ8TERV!4ZC!"/64EGR=E/@7S_OKW*,M"%M21K9L@*_,(VO5Q\_+'=2 M/>J:,8.`H=4%KHWI%G&L:"M<:3*-80`^O7->_TGDW0$#I!U..VNZ)2=$"QY@TW M+XX4(T$7#YM6*K)N(.[G=$SHGML-7M$+3I74LC(1T,5^H:]CGL?S&)A6RY)# M!-9VI%A5X)MT<9N.<+Q:.H-^<[;31\](UW+W6?'R*V\9N`UYLAE82_EHH0^E M?063XU>S[UT&OBM4LHIL&_-#[KXPOJD-I'L"$=G`%N7+'=,4'`6::#2Q3%0V ML`"X(L%M:8`CY-G==[PT=8&S:329)5D*<+1FVMQS2XD1W6HCQ1\/2GLJ3S+J M2>#>DZ23:#R:S/(`EMBOR`5X1PQ9+97<(:@:T-0=L368+H#Y6'"! M9QC!8C6DX6F5Y;-E_`36T1YSZS%P'3#I@(A!=%`&M7!E"[;*UEN[E%O_XEAF M=%DF>X^,!9_(^!?',EF>7Q8:OT?(@J$*CES*\OG`ZT/T&+@.3HX'Q(F34$/A M3EIP@<&^@36;)P.O5_:8W&5XG"?)X?N)[O14U^Z*#/;6_VO(3CK7/U2(U_>8 ML=,_?#O1AB(,C]F"SS4/Y>(U/2;`;7NH!^\8"WXKSQX3H#P_50[SVTXZCST[ MR[?'3)W?L\D_\YU"]=[4$#PJ3U8@GUWZ+>,[T$AXF>'59CU MT)+>]KX'^&ULE%;OCYI`$/W>I/_#9K\?"(BH$2]WO5S; MI$V:IC\^K[#(YH`EN^MY]]]WEE%$\"SG!Q5]\^:]F6&'U>U+69!GKK2054P] M9T()KQ*9BFH;T]^_'F_FE&C#JI05LN(Q?>6:WJX_?ECMI7K2.>>&`$.E8YH; M4R]=5R3JF0&+M76U;7B+&V"RL+U)Y.96S)14618JC$<,LM$ MPA]DLBMY99!$\8(9T*]S4>LC6YF,H2N9>MK5-XDL:Z#8B$*8UX:4DC)9?MU6 M4K%-`;Y?O"E+CMS-Q8"^%(F26F;&`3H7A0X]+]R%"TSK52K`@2T[43R+Z9VW MO/<"ZJY738'^"+[7G>]$YW+_68GTFZ@X5!OZ9#NPD?+)0K^F]B<(=@?1CTT' M?BB2\HSM"O-3[K]PL6*9$%"(!W4@H[&E`1 M]M)\[D5J\I@&,R>,)H$'<++AVCP*2TE)LM-&EG\1Y!VHD,0_D,#G@<0+G:D? M1O,1+"XJ:@P^,,/6*R7W!*8&GW+*GBT)'>6):81 M)1"NH3_/ZR":K=QGJ&ERP-PC!MY;C-#AT??V=$P/UD^"$+0J#Y=."'_ M/RNPAX?#,M@%PS-R<$+A-L9E57*UY9]X46B2R)W=M!ZTN/VU?0JX\YL]WOX! M2[AF6_Z=J:VH-"EX!J$3)X*)5[C&\<+(NEF%&VE@_39?(8`FV"R]\;#X\I.L/PN2+']^9B?IG915 M6N0K69NHLD3RI-BE^6$E__N/]V,A2U4=Y[OX5.1D)7^12OZY_OVWY4=1OE9' M0FH)%/)J)1_K^FPI2I4<2197D^),5"JYS!2L\AZ-8K]/$^(4R5M&\IJ)E.04U]#_ZIB>JTXM2^Z1R^+R]>W\(RFR M,TB\I*>T_FI$92E+K/"0%V7\&8 MGY0G!936RUT*(Z!IETJR7\G/FK75-%E9+YL$_9>2C^KJMU0=BP^_3'=_I#F! M;(-/U(&7HGBE:+BC(6BL#%I[C0-_E=*.[..W4_UW\1&0]'"LP>X9C(@.S-I] M.:1*(*,@,]%G5"DI3M`!^)2RE$X-R$C\V7Q_I+OZN)(-JI!>?`CWG0M+ET3 MW'"&A+G@1=PA(HAX0T(4\1D">;BX;AK\C8(;C":,*&2,,6N'K)HJ+Q+=$A%N MM!UG.(?@"<(Y1`O#@"(<=XJVXIQB`7"J\VXC(HX8<,6`)P9\%N"3.N7S$=S! MA+<8(?'1+4:HR>TM9M[WA\OK]$9>I]^^9+H*H*T@_]PL$J:KS1CX[&>:D)(- M2C@HX:*$AQ(^2@0H$:)$A!+;,8(S#?SABF&\""B]DJ'6>B,,4WC0VXR!#O2, M:!9*."CAHH2'$CY*!"@1HD3$"/9`UQ;SF?!TVUY?UV>J>KG.&07K')`"5"E(@8L6A<,J^KIIG4 MV^O+VO=513>XUXOD<9\H+?HD3`^;,:S<^7)N.K9AUT=\=%#"10D/)7R4"%`B M1(D();9C!%=2L,EZP"I*BU8):T:;,2-6;%#"00F7$5<30GC^>JB$CTD$'`#% M`W0:A#Z$*%]V(X1G$]T/_N`40TN.B6L&.P6&K.J1=KW[%0W-&&, M3B]"-['"11=M[O'$PE!U89GJ]S?X=ND3X$B((Q&.;$<1WB^ZD[U^!MZWLJ!' M"H,*$W88=@N-^L9TV(-<<,7!V[LMXP/Y,RX/:5Y))[*'G*B3.2RQ2W;HR?[4Q;DY'WLI:CBL;'X>X7":P)F3 M.@%X7Q1U]X?>H#_N7O\"``#__P,`4$L#!!0`!@`(````(0#,16>=R2,``&A- M`0`9````>&PO=V]R:W-H965T45`,48?M$JN9Y'M]H&]O$L8T#Z.'\^[N%4H64$KDVOOT`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`5]=\'`73!T%XS2!2_K M#?*K':=$NMI)LD!^G@Y*XS+_GFF*I.^9N0OFR8+LD77W=Y$B:(&=OR+I^[>\\[9AM:9LFII;WDN'MAVUYF+TY-[>5- MA9476I\I-#]CVU]F9E"NW+V`:6R3DUJ%..;3\O>Q'9]I-969?I%I.!5B4$2J03T?,RQCG`(P*C+. M3HV+A+LQDR+BA$R+1#5P3O"S(A,Z6SM/D.SII!HX!V]19)R-61:)PL>T*F.< M-:V+C+.F#1+;(E'8EET9XVS+OL@XVW)`XE@D"MMB3!GD;(RQ6F8_)[?-&*ME MEBFT8&.]S$-.HS!6S#SD-"YCW;EJG\\I*K*J-S?"XC?E>L%N`M:[H*VNZ#C+NBZ M"WKN@KZ[8.`N&+H+1NZ"L;M@XBZ8N@MF[H)YLB`K8#5PN@>+,L;IG"\5S$K! MK!7,IH0)G7[:5L'L%,R^C''.](QG;JKV,;>A9)G1VW=BV[V6L#E[&&I)CG-.%L=)X&>N1E[%J>1EKFY>Q`GH9 MZZ27*=$T=/>]3-.*^V&4>5J`RD0M0&6F%J`R50M0F:L%J%169XQB2FUUH1)= MJZ$+E0A;@*(28XM0B;+5T.E01B7.%J$2:;-0KA;*1;Y$"N?#V']#/MG6$##!AI6T+"#AB4T;*%A#0U[:%A$PR8:5M&PBX9E M-&QCQ#9&;&/$-D9>&W,E7)[LR95P_S@\IIW2776*9I0P'FU:2+21Z"#11:*' M1!^)`1)#)$9(C)&8(#%%8H;$'(D%$DLD5DBLD=@@L45BA\0>B4-"7#UW,>OR MS+-CRS'[>JTI7<3\4PW&Y`!Y4-D%K&_)&H*K6I&POB5$HU9@F2LA1XDLA[Z$*Y\$9>^R%O[ MB0,21R2,882=,RR=8>N,U<[36(T5SX=8\WR(5<^'6/=\B+7/A[!^AOTS+*!A M`PTK:-A!PQ(:MM"PAH8]-"RB81,-JVC81<,R&K8Q8ALCMC%B&R.OC;D2'G_9 MUOV2#3\1%K_++>7NPVL)X]&GA40;B4Y")*4\N&J$[C,?W2S0K`:-NE.%>UF@ M5FDV:DYGH)\%+D.Y".Y4^D$6"*ZJ3??K1<,L(,.CAOLPY"@!/,=JC,0$B2D2 M,R3F2"R06"*Q0F*-Q`:)+1([)/9(')`X(F$,(Q$C+)QAXXQ5SM-8C97.AUCM M?(@5SX=8]7R(E<^'L'Z&_3,LH&$##2MHV$'#$AJVT+"&ACTT+*)A$PVK:-A% MPS(:MC%B&R.V,6(;(Z^-N3(N7^3-E7'_1?28=LNW4]2BA/%HTT*BC40G(6SY MKC8*5P:[.:`B\RVX8_5>EKBJ-Z^JSI[TLT`0A@5@D`5JU<95H^8\MS?,$L5- M&"4O>X[5&(D)$E,D9DC,D5@@L41BA<0:B0T26R1V2.R1."!Q1,(81M@WP\(9 M-LY8Y3R-U5CI?(BUSH=8[WR(-<^'6/5\".MGV#_#`AHVT+""AATT+*%A"PUK M:-A#PR(:-M&PBH9=-"RC81LCMC%B&R.V,?+:F"O?\3PTN?JM>X[M^6UN(7=J M5V0ACT$M1MJ,="R2%/-J]3)TRV@W1X1A$-2%CJ'#3*.0T"CM-JF=R\@POZ^&E@%)]4P0 M.8]?N<,RF1&%C[#"3Z,0U"@,E9E5<'NBU%"[Y\V*?!#Y\B-3K62/7WC5+-R3 ME;E7LHA<<Q"_S2W[[H9:R"-3BY$V(QV+V#;7 M"*J5JM,NNSDD;-1D".W<^._ED%JE5J^[\\KT>5L&C`P9&>6V)8SG9G1;]YA3 M)HQ,&9DQ,F=DPD4OH8A95&H:51>"DSCO&^*\R4XL\Y"C>E^'..PDXI_IRC\%/* M/^D"\/8H+)4N`.0[%.2 M4J\V:Q5W/K<^;\N`D2$C(V=SY;:!>V=AS"D31J:,S!B9,[)@9,G(BI$U(QM& MMHSL&-DS@',*(247@#GI$KZMB=UTL?T%.M26"F]`-YF MA9?2"^`@&^G'PO()ZWZC=Z``")M3NE8)!G--T/Y(MUEX2DW$/)( MG[=EP,B0D5%N6TKW:,PI$TZ96*?(ZKU^+I.GCA8PB/(D1'I`:!$T@-@IJ5@%#;*GQ3A=745 M3"JDY_#('QGA=2F4E+L"G)-*Z=L>A972`^!U*;R4'@#G*,R4'@#G*-R4'@#G M*.R4'@#GI((*>1J..B=KZ0%P3BJI+T>AJ3P8@.N2'@`S"D_ER0#.\7N:[P'$ M\V9EKP?\4_I7$]._U!(DTVSEK@.XWV2++.0YJBU&VHQT&.DRTF.DS\B`D2$C M(T;&C$P8F3(R8V1N$7D2)?Z#9\YMEH7SZCOGV9$EO+Z"U]?P^L:^[FF'6T9V MC.P9.3!R9$2*O6*:.P6C\$^&^[PNA8$RW.<\Y1>"C/_W&. MPD2C4%&*/:\KE='3W*789(L6=&42:EV'..W]-\L8_GV'I#L4^FY,H7>^E8Q$[> ME1]+=7TO]GPO]GG-`T:&C(Q\6S'F]T]\[Y_R^V>,S!E9,+)D9,7(FI&-14I; MQ-;WXL[WXM[WXL&^Z&GN1T:DCJ,U,FAG1J&6U''.\E$^J>""4,&3>;GR%=RYVAD%.'E7 MBY$V(QU&NHST+-)\'G)6WKE?G>ASQ("1(2,C1L:,3!B96N2U/9YQQ)R1!2-+ M1E:,K!G9,+)E9,?(GI$#(T=&I.*C95+QF5&H*!6?ET%.^NLS3&HV: M3)64O]RSS1'5H!:XTR+O+:3R)*^^+T'K_=Y$P:, M#!D9P8:,.6+"R)21&2-S1A:,+!E9,;)F9,/(EI$=(WM&#HP<&9'*CWY)Y6=& M(:%4?LY)-?2=35,5?4RJHX]1*"EC?MYFA90RYN<YR@LE8?S.4?AJ51^S)&'\YE1>"H/Y_MR M7OE?WZ;\W!^S7GT*K*0Q^`6(VU&.A9Y[=IU%U[O\2KZC`P8&3(R MLLAK^S+FB`DC4T9FC,P963"R9&3%R)J1#2-;1G:,[!DY,')DQ!@%H]#0*#PT M"A%-:J)'>9/:Z&,41AJ%DD;AI%%(:5(K?=NL,-,HU#0*-XU"3J.PTRCT-`H_ MC4)0HS#4*!0U"D>-0E*CL-0H-#4*3R.%IY'"TTCA:>3W-%_\XWE]LL7?_UQ^ MF$P#E!_N.U=-(PMY3&DQTF:DPTB7D1XC?48&C`P9&3$R9F3"R)21&2-S1A:, M+!E9,;)F9,/(UB+)/8&J_'E9Y\\G[3ACS\B!D2,C4OM]LW)].GOX<&X4-DKM MYQR%CU+[.4=AI%$H*;6?UZ604FH_YRBT-`HOI?;SNA1F2NWG'(6;4OLY1V&G MU'[.4?@IM9]S4D,]U45J/^DQTF=DP,B0D1$C8T8FC$P9F3$R9V3! MR)*1%2-K1C:,;!G9,;)GY,#(D1$I_NB:%']F%$+*P)]S%$K*P)]S4BE/-_'< MOS\II9]3%%)*Z4]R7E]3*N7KA,))*?N\O0HKI>S3]BJLE*+/6Z/P4HH^YRC, ME*+/.0HWI>ASCL).*?J9,?Q-9R%O]?7,&/8]8VC8EG3>E$CI?).CP:KJ,]!CI,S)@9,C( MB)$Q(Q-&IHS,&)DSLF!DRE$/Z0%PCL)0Z0%PCL)1Z0%PCL)2Z0%@CO0`F%%8 M*CT`7TZ^!R`FYWH`<,D_QO/#_JM"X4\8SRFB%2+29J1C$7MY]JK1="[/=CFC MQT@_MYI:]>K*>:)QP!E#1D:YU03!E?RI7F=VX7$>J=7E#USESV23/!%6PL:E M^[>&IKPM,T;FC"P863*R8F3-R(:1+2,[1O:,'!@Y,B)E'R62LL^,0D89\G-. MJJ.0IU&!8XH,^3E'H:0,^CE'H:44?LY)Q?3MEV-FI>Y^>42&_AIMSEYQR%G'*7GW-2/>TQO@HJ;OM+ M[4R(>N6JX90,*??)>FQ&L])POL$F]_=Q2Z38,Z-P4^[O<,)@=Y0^9/Y@_*5WQEK1B%.,M1BI,U(AY$N(SU&^HP, M&!DR,F)DS,B$D2DC,T;FC"P863*R8F3-R(:1+2,[1O:,'!@Y,B*5'UV3RL^, M0DBI_)RC4%(J/^1:JW>=$?!J:!)HPB; M5?D^#.3"NDY`TGQYQR%DE+\.4@&=?SDW9;HRG5_7TZ^^,<3_V2+/]SQ3^8)RA;]NO,,113ZYA)Z M?FB_Q4B;D8Y%7BN278[H,=)G9,#(D)&115[;G3%'3"!BRA$SB)ASQ(*1)2,K M1M:,;!C9,K)C9,_(@9$C(U+PT2\I^,PH))2"SSFIAOZ"SSD*%V6TSSD*&V6T MSSFIC[[]4C@I!9_7I1!3"C[G*.R4@L\Y"C^EX'..PE`I^)RC<%0*/N$1I,=)FI&.1 MURIDER-ZC/09&3`R9&1DD==V9\P1$XB81 MPM/([VF^X,1'B-]1@:,#!D9 M,3)F9,+(E)$9(W-&%HPL&5DQLF9DP\B6D1TC>T8.C!P9D>+OFZ#+3MJG8!1" M2O'G=2F4E.+/.:F4Z?-0]:MJU;F0*,4_R4F8:BU^/LBYP2C%G]>E\%**/^>D M9B;;<8A9I2^[.[7KJJU$U[!&N75\&5,Z&ZE'[>'(6=4OHY M1^&GE'[.41@JI9]S%(Y*Z><[ZO& M;\N/^>7[$/F6'EG(VP=(D#H$A&X:-I*7(41LH%`-Z>U,FD.M7B MJ9'=AWOE`@#G**R4/@#G*+R4/@#G*,R43@#G*-R43@#G*.R47@#G*/R47@#G M*`R57@#G*!R57@#G*"R57@#G*#R57@#F2"^`&86GT@OPY>1[`?% M0#)%D*SF]'6$:MUYK"ZJ^N812N[U,])FI,-(EY&>19*34A`V+YON]Q;ZG#)@ M9,C(B)$Q(Q-&IHS,&)DSLF!DR"F]`,Y1F"F]`,Y1N"F]`,Y1V"F]`,Y1 M^&D4@LIM`%Z70E&Y#<`Y"DGE-@#G*#25VP"8([T`9A2>RFT`SO%[FN\%R##\ M=WH!\=O<:P'.A;JHFD">@7Z+D38C'4:ZC/0L8GL!E;!>T@O`/1KPBH:,C!@9 M,S)A9,K(C)$Y(PM&EHRL&%DSLF%DR\B.D3TC!T:.C$@O`%NF]`*840@I]P,X M1Z&DW`_@G%1*(4_##>AI3P,P#D*,8W"3.D%\+H4;DHO@',4=DHO M@',4?DHO@',4ALJU`,Y1."K7`CA'8:E<"^`6?Y,==DJ@9S>?9N1#B-=1GJ,]!D9,#)D M9,3(F)$)(U-&9HS,&5DPLF1DQ<+O3FM<3:"D M^)<]Y-NRA/?*OV^VHN=KFAU.Z3+28Z3/R("1(2,C1L:,3!B9,C)C9,[(@I$E M(RM&UHQL&-DRLF-DS\B!D2,C4OS1$BG^S"B$E)$_YRB4E)$_YRBDE)$_YRBT ME)$_YRC$E)$_YRC4E)$_YRCDE)$_YRCTE%D`.$7Q/\Y12"J/ M_W&.0E-Y_`]SI/@SH_!4'O_C'+^G^>(?3Q"4+?[*+P$D\PKE.P'NW_FI)E`R MCTWEW:5SA:!E7_=V`7SS%]DN`")=7E&/D3XC`T:&C(P8&3,R863*R(R1.2,+ M1I:,K!A9,[)A9,O(CI$](P=&CHQ(%P`5D"X`,PHAI0O`.1T%HW!2QO^\+H65 M,O[G'(67,O[G'(69,O[G'(6;,O[G'(6=,O[G'(6?,O[G'(6A,O[G'(6C,O[G M'(6E,O[G'(6GT@7`'!G_,Z/P5,;_OIQ<%Z#VMIG_GG'GR?_"3$`6\HS_+>$K M_HQT&.DRTF.DS\B`D2$C(T;&C$P8F3(R8V3.R(*1)2,K1M:,;!C9,K)C9,_( M@9$C(\8HF$C!M!1,6\$HE#0*)XU"2J.PTBBT-`HOC4),HS#3*-0T"C>-0DZC ML-,H]#0*/XU"4*,PU"@4-0I'C4)2H[#4*#0U"D\CA:>1PM-(X6GD]S1?_.-) M@]X^_J\E1 M'B-]1@:,#!D9,3)F9,+(E)$9(W-&%HPL&5DQLF9DP\B6D1TC>T8.C!P9D4X` M6F)2'3VRF98BIZU@.@I&X:1T`GB_%%9*)X!S%%Y*)X!S%&9*)X!S%&Y*)X!S M%'9*)X!S%'Y*)X!S%(9*)X!S%(Y*)X!S%)9*)X!S%)Y*)P!SI!/`C,)3Z03X MMFZ_?W\\^W3_YT_Y/EY8E\I]6GSVJ+P.BK;L%9XW2I;W@ZOVV7+.^%UIVQY-[SN MEBTWLJEERV5#2[>S$UP/R_9L%%R/RY;/@^M5V?)-<+TK6]X+KWMEV],/K_ME MRP?A]:!L^3"\'CXOOSBUL,>/[W_=?+V=W#Q\O?OY>/;]]HLTPOB^T?G9P]W7 M^,94\H^G^U\?SJ5Q_W'_]'3_X_E_O]W>?+Y]B`&!O]S?/Z7_D)9Z\??]PW^> M&_K'_Q,```#__P,`4$L#!!0`!@`(````(0`#S823_`(``(X*```9````>&PO M=V]R:W-H965TO[SG/<;V^OZUR+T7*B3C982P M/T(>+6.>L/(0H5\_G^X6R).*E`G)>4DC]$8ENM]\_+`^JM%D5?$JR^' MD@NRSZ'N5SPA\5F[OKB0+U@LN.2I\D$N,$8O:UX&RP"4-NN$004Z=D_0-$(/ M>+7#(0HVZSJ@WXR>9.>W)S-^^B18\I65%-*&/ND.[#E_UNB71/\%@X.+T4]U M![X++Z$I.>;J!S]]INR0*6CW%"K2A:V2MTZ^\32U06H?',G\Y'8PRXMZ=2/3$MB;SX*!4O_A@(-U)&)&Q$QN"^N1_Z MX6**I[/;*H%Q5!?X2!39K`4_>3!KX)FR(GH.XA4HZ\KF_ZT,2M)C'O2@>BC0 M$MKQLIG@Y3IX@0CCAME>,F&?V%TA9BT2@+_6))3>-7D]]K,Y#4/`R&O-A0O< MZM8%;`TSZ3"3/K%S$3UO\*#AWC0<(=!NO4VL5+8&6=2ICJ=X,@LM8ML07W#K6G8MO9/U\1F&%=L+J+G#>;8<&\:OM52P[B\N8B>M]E[O&G8 MSJUMAXG-(%UK8T;)NS'KTU3->=_2ZXB)XWO=]U%A/W>ZKA M6TTUC,N;B^AY6[['FX;MW*RF&J1K[:*I3J1G#L.6-#RYFK;M6:O$MH&Z!NV^ M.I&^/VN;<'<6FY4=UJEVF;M<@AO(Z<_H7$?Z_O1R/7CFP5'A9GL;QK4.]Y#K M"[$Y49@-MR('^HV(`RNEE],4HAGY>JL5YCQA+A2OZHUUSQ6<`^J?&9S[*.RZ M(Q_@E'-UOM`GEO8DN?D+``#__P,`4$L#!!0`!@`(````(0"#@#83U@(``,,' M```9````>&PO=V]R:W-H965T*H3+;PIE&ZXA5M=^J;3@N?]HJ;VPR"8^PV7+74, M*WT)ARH*F8D[E>T:T5I'HD7-+?@WE>S,D:W)+J%KN'[<=5>9:CJ@V,I:VI>> ME)(F6SV4K=)\6T/N9Q;Q[,C=W[RB;V2FE5&%]8#.=T9?9T[\Q`>FS3J7D`#+ M3K0H4GK#5K<)]3?KOCY_I=B;T34QE=I_U3+_+EL!Q89MP@W8*O6(T(<<'\%B M_]7J^WX#?FJ2BX+O:OM+[;\)6586=CN&0)AKE;_<"9-!08'&"V-DRE0-!N!( M&HF=`07AS_UY+W-;I70V]^)%,&,`)UMA[+U$2DJRG;&J^>=`[$#E2,(#"9P/ M)"SVHC!>+"]@\9VC/N`=MWRSUFI/H&E`TW0<6Y"M@!F3+<"3\S%D/1<5,B+) M#;+`0DI@N8'M>=I$X6SM/T%-LP/FUF'@.@/#!S6`);(PMO5WDHS*"41F+ MCE9NW8.Q3/BVS.Q4!I//H#/>E\-%*06-(4041@._<^`PT1@S($Z"`F0<%!U$ M9[OJ&!@7@=,Q>Q@/_,Z!PUS@`-3&#M[/CN!I]OE$V6&6?0NP,$F@R0?$2?;Y M1Y01?*H<+A<#K\OL,/.C\B*)SRA#EUZ>&<%3Y>5$V6&<#A@-)N"KL; MJ[I^DFV5A>G97U;PLQ0P#P(/P(52]GB#:9F66%.B0-))?1O:XX`!P[IA MEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.( MH4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ M)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7" M-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9 MVP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51 MK;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P M;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@. M<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$ M'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z M@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6 MG'X#0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SVN2J# M[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ M4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_ MJ]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+ M:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&W MUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1 ML;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8> M\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D M-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-=`YMZ M;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF M_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+A MP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[ M.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P M8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO=V]R:W-H965T&ULE%C9CNHX$'T?:?XARGN3>,F&@*N; MM'KF2G.ET6B6YW0($#6)49+>_G[**4-L`X%^H:%]7#EU:K.S^/91[YVWLNTJ MT2Q=,O-=IVP*L:Z:[=+]Y^^GA]AUNCYOUOE>-.72_2P[]]OJUU\6[Z)]Z79E MV3M@H>F6[J[O#W//ZXI=6>?=3!S*!E8VHJWS'GZV6Z\[M&6^'C;5>X_Z?NC5 M>=6X:&'>WF-#;#9543Z*XK4NFQZ-M.4^[X%_MZL.W=%:7=QCKL[;E]?#0R'J M`YAXKO95_SD8=9VZF/_8-J+-G_?@]P?A>7&T/?PX,U]712LZL>EG8,Y#HN<^ M)U[B@:758EV!!U)VIRTW2_<[F62>RZY\J M:=)UBM>N%_5_""*2U,D(5488L%?K=$;C@`3A;2L>,AH-(UIP(*$F(A,1Q!*2>2/"(,:^*=3NR^R/(2LI,1TQJ%YK4I'8<-D]3 ME)LLBF-H,/,0@A09`9*F"YF^#AYHZX9RT3F]VT4K-UGTJ/GX%"$JM)S2T+?R M,S,0"0T2/B(,BG+T:7UE6CD)MJ@QBQI"D!J-?-\*?G9]W:"5?(66!%NTQE3& M@"($:1$:Q;*EF\PS'1)2G_/HBF0$^N[]F@UHL]$Q*]]3A;EPJB@^I2'EKR9B>",:RZ:Y&3'UO+MOFY'L,_K'9G9PT)A MD&021]3./`6X++))\DO3@IR/"S9FCE(0,4@N)#2VDT\9&0%C79G49-?6]+L1 M7(FV@FNULI0@!I],8JA8JQEF!H+Z8>2/"6*2DWW[?G+8Y?6@5;8,Q-!"&!.=6V2LV;%#>6PPT/8QNEHZ9(2Q%Q.*%6U4Q"3GC4K;M`[ M'Q+<2JF4Z#.`!82'U()D!H30)(&S[A7UOC0GR/F@X&-"JY+0)P'WX(GR;7@?FE>$&SU1G!'PXH>8B:#.P4Q@DNMB2&['I3:K8/*L,TL7VZ/ M#H5!C5CD6^N9L4ZOSC1J#0W),+Q-$.\&1@F/O0&%'"P?2YBP)(DLJ3,306). MQ_9IRBC'P-W]A4JTI9[5/5*%41G&X%A`8ZT$L(A-$)RV:!`&HQ,F1=GH-8KW MS3>*X\'0<=1`Z8@8I/H`Q'(;K^+/HX>W! M\'4';XM*N*O[,P!OA.B//^1[CM/[I]7_````__\#`%!+`P04``8`"````"$` MD?=L?Q($```J$```&````'AL+W=O$.`F:@!%F)C/_OL<^3(C-A))< M9,+P^/">#Y^#5U_>JI/UREI1\GIM$\>S+587?%?6A[7]XY^GA]BV1)?7N_S$ M:[:VWYFPOVQ^_65UYNVS.#+666"A%FO[V'7-TG5%<615+AS>L!KN['E;Y1U< MM@=7-"W+=VI1=7*IYX5NE9>UC1:6[1P;?+\O"_;(BY>*U1T::=DI[T"_.):- M^+!6%7/,57G[_-(\%+QJP,2V/)7=NS)J6U6Q_':H>9MO3^#W&UGDQ8=M=3$R M7Y5%RP7?=PZ8UDSB#;D269@R_FS1+_MY+]@L3M:_:0R\%=K[=@^?SEU?_/S M'ZP\'#M(=P`>2<>6N_=')@J(*)AQ:"`M%?P$`N#;JDI9&A"1_$W]/9>[[KBV M_=`)(L\G@%M;)KJG4IJTK>)%=+SZ%R'ET<4([8WXH+Z_3QT:!R0(_]^*BXJ4 M@X]YEV]6+3];4#7P3-'DL@;)$BQ+SWR(S^>>@4MRS5>Y2"T%6D`Z7CGB"1*&OGMP5">W;RMB8*BGQ\O"1NBAC2H/*6(8+QHX*F/KCN;1#1Q MX3WB)&R(&XH8Q2%R,V(W;VNBHGM$2=@0-50'BD)$CYAGA&R:T>3)07?51:8W M@(0->;'^Z!01E$?\)(D6OF]TF$QC2`P;.*%#86CRDGOD2=B0EQCR$)F6IS'3 M\@@TW.OPS6S":%186G/ M8""C10@?/=*91M!%%)/X1HZ);-:S:U#1ACJCP-*>F5*'`P*):77&B)B9XO&L M",TA1I#!_N(YT1`>G&&W[^O)E9U[?OBPSX/[E[H*1[6'#`8'7G:"J\SUTJX) M$B@>J7KR^>XQDM*)L`=&G&O)B9V?'@H".) MR$"0+D$VD(Q,(;K,NR8(&8^0\>;5YD,2Q+X_DH?(YQ[H\NZ:(&0\0L+1[KV> M#_1S>8C,D6=,D)E)'H^2\?9%YO;VO7E?BQ\U1LAT;U:TT?W,[=LS^'9,Z2*, M`[.U3"*ZO+M&!\6C@=9=C-)*>^;V_IT`4!J>]O`PU.0']F?>'LI:6">VA_TF M.ZEMM7C6PXN.-^K0L^4=G-'4SR.%/$U>3OF;_P```/__ M`P!02P,$%``&``@````A`$3O;^KH+P``E=8``!0```!X;"]S:&%R9613=')I M;F=S+GAM;.Q]V6X)DF\]D/C]K-UB,5ST;S<3*[_.'1SVJ705S<;19#Z+ M?WAT$Z>/_NW'__[?OD_3E4+?6?K#HZO5:O'MTZ?IZ"J>1FESOHAG^'(Q7TZC M%?ZZO'R:+I9Q-$ZOXG@UG3SMM%J#I],HF3U2H_EZMOKA47>_WW^DUK/DMW5\ MI'_J=0X>_?A]FOSX_>K'X_EH/8UG*X5UJ.>S5;*Z42]G>@*L^_NGJQ^_?\JF MNOE0O9[/5E6G"8[F:V\@'^6("F0=6[^#))5\L("'P3 M30MK?'SR[NV?GA^=_7RJ3O['X;O7AT?/?SY[>73XZE2]?',4KM.,>01R6&)# M+X'B#^I_QC=AN\_"B:&+]7*6I%=`3MI0DSC%7"-(J?5$0#*.(?%&2;2" M>%+S"[73Z^PW!NV^+`A_Z32&@P)=GJ`K-M50LWC%3M%T#@3_-1MDO]$9=AH' MW7T]S*"Q?S!L](;[#05Z6<2C5?(^GA2H\*WLOV[?%5`W$'N51.?))%F!=$+$ M@+XIK5.UB&XB4N*>`E>."RR.=LLUR&8TGQ(Q>D?$#?HMYY.)6D4?2DK("J"UBPW68+9I9+/;#5GDDUVSKU7QVN7<6+Z?*-BH`]9=H*0)M8H!3:*`G ML_U+8"?,?C6?C''X/E8DKE5AD(RQ4XJ&[P"OI0+MKV.UTVRUVFH!RDXI+KY3 MG7X#$H__Z%]`D.O5U7R9_!6`3V:CR9J'^G?D_9$G.T"G1G;(%`VUWQLT!H.! MD%BGT=L_:+0/^G;()$V)1V&K3#SEZ0_L@'.'3H$EMYK[?;6;S%1T M>;F,+T'N:J>_WVKT,0&'W&DW#H:#1KL=4/23[Y0ONFJ7#\[J'S2ZW5[]D@$1 M40!NM]A.HP/H'/3[3T+:,A)\&S0)C@1/&8*^4^WNL#'<[V'E;8%%NWW0H-`8 M=FX%_'!=)Q"'>]CK*%HD$''AY^/X(ADE4*Q\V;5>DM4@-=0XAD"9:Z&'L^BR MP-B:RK:@?/-;CFJ::YYOGX!IND\DPEA^P(P M:D>O:GV;"2JDD!.9X0H/G5`J[QFV!UTZ#4Q+.6I@(@%*FI8I3JW8$$3X?KT`DR35?2`FK`O&B`[7*\)^K2K&!T%)T-5VH1'GNE9V8A:!`GB2&L1E>W\ MT]6J%E7&Z#-X!68SLH.U'Z.5^D,T:RJJ?_`1%6342RB?8F@"V1>P.ZC/UJ)[ M8X>&41)#X)T:)BP5YKF/52.XJ4$C,@HI-)XN)O.;N"C,ZEMO/P=<8BJ-EQ2Y M!0%3G,-O734'_"(!B@X7RZ;J=,M1E&]N!U7`;&VW4^WQ2+1U`4+CD;!,8S6- MEY=%K\F&YG;:$*LG:TC\"*/2UEA"45S*X2M'#,VKV[:OFD#K;J-4K>GYAW@Y2K#W3)`79BQK4S6> ML7]3E>$,9MF,/@AL\CI97>6LS+)S26^0N#`GBQNL!&;`7;R7P%@)D72W4:JV ME:=?TJWGMBI*I'QS.^C&;GK-$`CG.&8US?N\&&[QI95['NX@`&_#ZHOUDK)S M12D$=RR]5,33:=U4*7E"5?6TFPU'>&YD'$_&S-=SL9Q/C1R<+SAU@?B>0=.B M+0IE"X1$[N<"E['VIV'9^E?M\"PCISPN0AQT"^O,"3:[FXW=?%R$*])D;XDY MG-#OJ4&;(_T*.!_?TS!V@^%P[V),K*4BJ.N\%`D7<;0"^X5=ZP'>JV]NUQ," MO-"M"#92OE,SC>,QG&R[7G81=;TM.H7A@'&H_Z/5&E0Z/Y\D<&&5T7*9()5# M1^.]@@.VZU6UYHW\XT!FW*/AIC.%45;Y]!BFA,>*$,XSX4*M9)>>ET[EW':$ MJLW4DU8_7'J^N1TT)*T-W<+F@[O-LJ%;.,O^W6;9T"V!NLVSH%LXRO-LL MA6X^\UK[2LZB3Q:8MQ_-$E.X-7^-BSS="Z<[L7$7N7ZG`:M6FF>.`&?M5KBQ M?',[Z,9NUBB:S6=[(B41U:'AX*0.E/H3J\,A?+AM^L6$BR@)ROK& M2M7:-W0+9RF8H=M!:$,WSN([Y&ZAG]1V.RH/T>:="T<,H[Z8S*^K/`JN0:I> M4'/+'&J'##*6QP+'?UEK-U-*+1/AS_ELA)BW1#/%S8)?&=F4(.Z:46301.84 MP[%:,?*Q%TP-*<1WN]&V692[XL-F"(O!^X!3/*'ZK<;(CF`@<]/HE!^)=J5= MQ`6%*)P$;"S1:`""\4NJWQ5G;]AS;&-RDWF$V`W\H`5]F2%5F+#:HOQYEM`] M)5A.U1F2;=+U\D8]2R:30D65X$3\/)BH5F,Z\DV,RM[AND)/*_,)).P3-A1([=(M^H0`@Y9\-[_H MD>NHW;DB\FS@N"0R#-3FHNKANHAZ1F&KXMSTC]Z:R4*6UUYCBO!JEC]9SD=Q M#)^M-N^V\%Q;!Z(L?9S0K"@0:'%4T.L%A(5U8Q=[&!-F4SL'F%TC?IXP@$#' M\UB=WY@9N.5J612"Z06D",1<+9@X+>;Q0$6VME"C9J/=U2&>\X#P6:[,_BW. MPE""@*1.GP@GK1FF4GL*Q\@O/#:N)UF*TXNHR]4S-P\ID9\T^+(MC&VD()Q5 M4",=Y/BA>R\GI\J`EO7A)%N(W1/X#)/U5"\,0B$?@I$MELT#U:?*]>A#-=Q2 M.3+(#;?6L\J&'@F(/0ZX<-18V,N)/4,V1X1S9;J(9C?#9"1TAQ+'@9=C.;+%\\N_0YOB-`ODDHR2!071I8ZE8A_X'B\X M-?HRS22OO@"-2(E=(K`G/A=1+Y(I`J(B::FS9:F_E>[)O7]OXN#BLK"*R4V# M\]RH,330^0H#,!L*`$'F&6;C$OPQ2:47\_D*3;'L)8F:&\4)<:\;(S(F,7*@ MLIUED&XBLU46-E\@Z*RU/!`#@H\,Y()GL/3(T[AWB3L$IPES;&G&Y.L)ULZT M1_Z&E2_AM4*85QHBZ0P[@KL>B8L1-$5*/X";\5ZA9<,C*L.W@=FXZ1D#H'KH MM3C(-#$K1/,0LM&YUV!(S`!;!1D.B)7^_M&F7"M0C6#!SD[*3N"-'8$M05T& M(7;LU17$PS2ZH:^<6L.(=&,GO&$ZLYX)?GH[DQR;^RV9PD ML=>EL:UGZQ10A(J.A9^#Y,7!>`=!U/F\@FCC#O/B"!K">Z!RG891L`;H?M1L M$,.0`:",7V?S:TB85/W];_^GJI?N]/>__5_1K-'P].2U0H+(>F&&XZ=KC`$B M-IX'T,`:%+H$F"&*(PB&271-+?]U=//[1U!0>[A_T%1N(#6"385.QEX%LV$P M-!JB*9%Y#@Q/(5'\E+D]L#.2!8S05?'%!<-C('%$N=?@.C,/4GIUY(`4-X/8 M=VND=%O,==`NC>-?A;G7S-9S\42CWW%93-!MJ'-#/_PSV%('4'$Z@\%(UOB5 M(AJ)"LC2A"TK]$7P0F>2^<75;YG0#N9O&X->QO/+9;2X0B[%9$ZVU?*)_;VE M99,6^.'MC/'@9"(08*@?2>\694:YP.$`KIP1J%C:ULA?QCD<`T=OP/7CB-B" M9,.1I9>K!1[.=F0C`RG8@)Q<510&L&FZC'BBO0<@)S=[5_%DK,YB1#V1I4,\ M9TZM72[XY"7H[@D$IMNM#9N39M0AH+]78P+,]',"HKS>'7- MX[9J84)\F$G(&_DPY"LYJHB,ZV6R6J$S13Y%'8:/($O_`N\';M`80>OGK*0Z M#H\O5?/A5$5:(@X62OY&93,#+QO=1$;Q02XU&3.`+21=1SR[P$[\P6B5@AKO M9-8!4L*H8JDG+V55P*UL,2##ZD7>EM+,IJR<(=0=VU_#A`-)0%:9TR49)SQ8 M?5#R0((>FB,Z<-X2GK(E#TO\F9`-C@J.@!V&1PJ(Z@UPK<_6]E"G8XB:XXX\ MX46>\^4)![#(K(%_!U.S#?$$ M-]5[V'/XF\\]8)Y_A[D"2AIR(&\I,+^:>:O;%A\4?8%F#1T=4,8OY2 M!"3YF-(@$AL*#+,'D1"I%*EDJ[WY!=3!N4J1)4?4400)3YA\,JU2&"\.$9.# M@/`9=#`L`$)B&D'`.2YS3B8+$?B2>'>'Z'*=R(4&LX"UT53/J#E3BR:B]3HJ*)40H,*/!!D=905^>+1!@8=< MUU<8K%#YN7G:M/Y>@9#V_4HZ()U%,$`@]PJ,D^4`'IL<0/'SG8@NH*]A40J& M_/8\PGT?7/91;'C*%G=0RKJ?5RF[U5;S"EK6M393$KB@(%](+N6YUI"TW7)] MAYS)IA)4`.&:ZW@FT%`3KE`)J`E9R"!E_QPPP73-(CI#%6(4_()#S[F?%V&$ M3D8$50*+$#20U<@&A6;6A.F/`W.ELU"R=%*8#GHE1K20ND?19&3S:'0PIVCI M8!FX5@GM!N>ENY_%OY'ER3N#0:/3/6CT6_I*5V?0:/4ZN``ST"+,>LN@CO8; M7=P:Z[3TQ1S\%>G>N.IB&AHH:%VTV]AOR64@@0,NQ/3:N-'3UT-6@$4._@*O M/`?30E,XR]2D@N_U#!XP]0QJX*]WX(?>Y^6'RNWD:7\W>J*.LTLPL`RAW>7, MVM?,'8=):RS-O#"3D-)8[6L4B!@6+3VG\`#WU,IT6$ALB9S^8Y,XFQ"B[O*; MQ(&HM"`GL[O8/&?K_5O-7J09V>L+;"M?TEEM\>B))8(,-Z9/QA M/8LS]T+I;K[$9GI#L/5&7.067XZ*+['X04\6'QZ"]8@HYQ'TF=@[O9!3[@[1`H,,C*P*()0.G^%?_Z]7!'%LO`![@,K M341+GL$!RFH,5$['<#\NH8Q39Q)4Y1K3H24CP:#TC_;"3`TW$.02_0]:N7\V MB4:_[IV.H#SC"-='U![41@F73>?C>%+@]-WS^Q"];=R:[.$V91<;EFNZ@-## MR-O6L#'H;63RPG%QT!_B&K>W/!'?L+`N8KKD[T6`XX9I5VZ9/C0,()\&`_C* MZH5#'@9@JS8E3(:@``(AD=@;TA^&*]D&W,6QMI(APP;C[/#@`._6R]7T2412% M>3EE]*!Q\];\`]-%^P"Z?@<68#TIEZZZW1U\"FD4QRRGCW9COPOKH]M_:%CL M=S!5_PZPH-R`&50G.T/)L3MZD@L$V3./*C1C2P[M1F_/G/,@%UAO^CJ^,R#! M,O#3G2(^B3/M4/UB#QB:G.;7H^S7%)YV.(G/82Y.X#;"!19,B_Y>]H_XHH(` MZN'ID3I`M1"Z%Y&J(N=[MLZ90N0*H3XXK6%#K)"?!//4)'/Q>.5U6Y11429O MG^H!]FGBF#)6T%PK"ADDL%P=6\1B$QT?-;X<;1[`YH=/AO/JVBIT;L%,M)ZL M9(:@^5K?:\;$$8($8&0ZC+`T9]QK=Y6OJ=@%..C.XJ6 MD[DZ3:3R"D$BB@5S"J@4N4B>@YZ(%(UJO0+SQ9N4/MHKN,WAZJ(>!80A2AC! M&>E%#7]#``>Z4Q/%E"20CQZ;K$1MC8L[`,-#M^+F"!P$^^C7NX33'Y.)[Y)K MU]/GHBO%M0)U.]TV#H]!1\;?:<,&[$)]1_?,Y5"[S)P<[E:L4BX'?](J.^#Y M=F^H5]D!$_=12F/[519E6)=8ND\P=E%?IP>71`U*BZO0DM0MX]/AU.M`-VP? M%%3C^F,CKUX):*S_E;:))!J`D,F$C%[!9+F`"(.B'MHNXFJV0HW"CGFF.E%$ M9^#-ESK@?VDOX.N\-A)B#]ZK?J/?AD)\!@*V,@-#Z'0/\L]HF>@+8/3H"H^Z M8C`2]55P=`TQ4+M;95UQA1<,HTKTWS$VUHIP*;PCD)=`Y#[^&;@B,,$NF5W! M;$+N!40=8S1_S(LU8CFHBB>N_-()U@M:%.U6ZQOY;Q__Q13DVNQJN/'\V$6Y MJ%P&1@,`BXNO)8Q#G$$Q,2W*4R8HKK^5+"TB9H)=RM#P63[@/JTV%1=-31[+2) MF.R*'54;5=%L5L\I<1JI?#%_7P8DB92BE%QL!F9FP'NI1R%N>NG M7*IMD+<()$=PIP\1!-M-5FR._HRJ-E-`'_5Z>JC`5.'?TWE0U<@#]6P#!$3K M$66_`I$N>*8S4:6=T=I*JI85*"[$-7*ZQ%V8$1ZSO%#V!]!%S&Z;=81*5;TP M"DX48L+*@L\FBXAXWV/NP,2<\#.^[`_J(/`!IGP$1:#E`VB_C"T?&'-0XI5NV\ MJPCK]AE0%].I!FV(C^[^I\@QU-3KMQK[[8,*&204E)U^ M3A7P=:HAO!<(3^[O5XSQ58[]"^M2,#@'!SHT?0=="H5105B="L+28*U1A/^_ MUJ7^8001%*J#?1Y.GR*(H%!!&>IVJY2A;001#,3:D.A70?1E!-'KZ`.N:4C: MM7KUZNBA[;V.G\"S@1QV^$$$ M,(?P]TRH)*+>O6^&,9D/$I6RVMZTW5`37`!B%8.\"-CD49>NG+V^]##$_U=G M^5=GN01=JMS0G^XL[[&\]?!`N&.G#?OK`$6SMW=#!U89[7^=X0?ZOD;[2&PX(@/+:7A'FE MQX@>9-*YA-`3%\\[U95EY$H]S6Y(Q6B&ZSD3A;1P20*'U()IS$&"JA$ZH$42 M8!ZI+8$/RQQ)''2MRI58N"KA\W(W':"W*:5D&5G3QX#]A&"6!P83(&,&O!ZAW4=:^!@7^:(+!,[,:B6(MH<;?/D3 MA3FYN#6**0@=6/%[%83HX('<._PE_@095+*_FAN&@& MMO05#,9O4+TV&B/D@6@BP$KD>!74J5W:"USB?%V&-A0KP5Z`H2Q,W=<2$W=@5OKDKTI,]<)WWO0()R`R-^RT MC:N9\-"Y]O!';5JIP2U36=US(.X2*Y>9I:AN2GPHB6!A)1*N[0]U)E/FA"4* MC_3U@K__[7\SB#/&72I)_0^!*<%O+)"\+SN"N;AYP#QU`>5.DX*WSIO=YLM" M1'<`"LIUK-0]2P]Q=9%%!@\BHT>]_+[CF_`&J2X[T_.(J\0W= MOP_?S)?%=\GR?:3O`Z;#X="#Z2$? M<;9*,0$Y:/#LFT8+QW-Y3_76HOZK2;KQA%:QXZ$+LE<.R1P5A. M%S%D(LL&T2`-Z2&MPZW.PQQQVHC:O[[C(_`Q)7RXZ#VQQ'&!;$CXRHF'T M/`C;-]2+XT-<3,6]IQ1E\X2,D1N"(#%>:V*6"._6XB4$O'>U0`/BJ":\'P:+ MS[+#VD_F*LV^`Z%;IC.&H/,>;`O>KVX$LGM-SEVH(9$0?1_.7*>>0'ZQ]`W2 MA)!K.$J16(![B])"YJ&;3T\K1^S*7Z'ULPEC>>P$F:XU3!#+3*N M#8.>)WB?#94)\(,>UT^^!'#LJUV:D1S/X`PUN4"L>LBIG2AV[)1?BLY03I:T M&292#"%;=G8UEZ*3HV7L;._(HIP4+(XQ9'"A>X`FO=3BF$$S)FQFVJ[1SR4- M$FMPNR'*47X``*(E!AQR=3H7<_,Z#GUC*@*XRRIW&\N3$U$S$>MJO0D=@,)6>'IL`X>PAOV6YB.9AZEEIR:ML\Z*E7 M5-Z>-J74/7*KP@\T,I&7-';6G+'-0E.&)`@S_WZL*GTHX]26S-!4+_I?*8U6 M.%^0?A_)L^U!7]^9?&&2RDH2>T?/6H2=*[$?__1!XU'$>L$H1JK%J"LWJ#/MG@C],G M(PP%WI//7$EC.*<@7ERY;&O6P`PX&N+/TH$O7ODZ;9I9?&8]Q$,1^;18LJ"$C#YS] M!5UE&T?G??I".GC-M/6E?5\UTIQ>L)Z4:_#3K*B<&5X2!]BV,KC,];EY=-^N M+IP'<(IH>M6EK)":AFH<4%Y=+2LQU_!@^F@^0=4JA!73Q57D9CF$^QZRB^X.]^*-YA(/BBPHZ.X? M^)"%%YMA!MQ2D-K:N-B,A=)U``Q@1.W2TBV]J20A(+B/;7=BAM#6$T,$%0"I4&SXG_'R(Z'3LN5U'?.\ZG=J90RRN^N M9G.XV2`;RWR<'O2$!G/[TPXF[%':9Y#2KB83GM*5@G`5/$5#G(B[R9/?/W)8 MFJJPG\31Y9Q3M?,A'1Y/8T/\&/L&KU3^\9G]B\.36#W4O7<3.Q5J,JWP6"+L M6?>6GSF;M=IGED([E,#.EI05N:Q$LH>@=D=<:/"CK'A1Q9710_@+I63TRT-F MZ?XWE+B!-8%7PVD#0U:.\!>#\MRF\J>K8%@7,QR9:WFC9(EG;L$(>':9_IJ5 M5++RZ1H,RBKQH"4@P(L2>J%*?)*.\`>AC#RA*Y?@2E9"6F"E.>##/8ICRBNB M_I,B*,%6>/$9]7)P#]#R$8@%P4M:[JA]0MM]Q[BW&NA,.I'%T?7$NY;3-9_= MH:.`LH9LD=O#&/77,'BV%PUG"K]B^@V.N\ZE4 M\LG+`'U6PXEM',-;[@ISE(*'16GP(D%%)1K"8L4Z=]YJ\5B"]F#NM`>2X*XI MN&3'(&;Z;RCA6/P41($;*IXLT`8%?H)(+"5LGC^L;LEB.2([`5G#LH7#[)2Q M_SV4NL(T;&.?I@\=F,N(5T/A7QII+?PT-M7+.WQ9:#K[B"/%9XN1QDB4_%#AQ]*;T*U MFMU.=HV-XY%F(&BTH41*VD'*.>]#@!%,S157\`L>MXI1H1B[:\;EHS+A&,-Z M(GNCV4]M!556I"ZME`YT<)A*%48+CO-YM,1E0EO+PR[;V'[Z[B.%Z6L6FD78 M6)Q9NDCH^G*=KA#W,S^6,3&&,R>SY*U88%`:@B/Q1F+,RGF@9[TH<1:1?615 M,#>RNIKY!1EU'@J[W"CAW4=[GEKG(4J^(I6$F)"JT$7@Y\YYOTB,.=1-)@FX MFK#*_(!O;=5=W%IVR526::4=]E.U;91QC*]Y*BP6A+(*<%F%PE#H2AT?M'E`9(DW"A5(,B+M& MSLUDAN*,9(8KO&$-/C'!4*JEB(FLIT8@:=^T531+ M`$E12OF95Q##G\[)XCS5"9A'01PK35!I`;EAD&:`QSCA37AH8[;P@JFWG<>; MX.3<3(X!\1"0%.TC*#R(:F#[<,4LV`S4&;C***6D!KA`T"-U0T!0:"!_LRK_ M`DA3_U\3>?S!E/@7B@10]7L&?B5]Q++XH`UB$V!JA+D8P`:<\1_#N!:#WOR4 MQD"#`R)EO#[&S-&6@RJ)4,IR2GH8(:`C+D%@0FYIG^,NN.Q6'Z\<>+M'`B!H M4,JBT^BVQ;J6!>QIB9,37_*0$-A0F_@Z;@B[0=N:^2W>>1/K M+3LLA]3BL0,P>45``?3[WU69N+^`9337O,:0%7@>S"N%B?&(C"ERX,,&EU%A MM0K+BRJ/F@;;O.OP;3CW[Q]__QC^]F:M"U;/+W[_*,IRH9[H+Z9N[.\?#^$T M0?W\<(B?J(;L'8.GPB\O\'S%[Q__Q)HMX:U3$)WPE%E*7'AI9H_@9^+O^X:S2TX2(THSE436/8*AF5G&D%(Z1+]2PA`S<(73 M3WLGR$#"8/#W_8>F3Q(I8Z78K\@*:**-/*N)8E8 M1#-=T&/S].9:WCU/#]F;P*+Z+-.'!$>1PHKEB&Q!7F?%2EYF):YJNF1^@[O0 M)VY\.]+X#&Z`K;=:I-07AZ?/1%F)UG"^P,4*G1'ZY>4:3XY`DE%K]XYBHX?H M^F`0E=!1DA1U2G$V72SQWH=4AB$-Z894$K/>.OD,ISY4"=YB<(Z9Z)Q>GZRA M57=D&E(U3F2WH%@JGFK_(FNA:HD*'DIE7^1B6,X$V$2 M@$JI.>8V!T77[8_;B*#IXDQ#&$&_N`3IZ'Q[O,+!,Y*Q]'MV'2JCB"NI21='G1K6/_PPODUZ]#1 M0!O;AII*@61L@4S!T%H2\ZXN009Q6M`)7A%8JOVM^B,NJF`@WXP0A5IT#VM> M:*<[M%E>!T&HV6P"I.'MH7":Z#DZWZJW>.-I^5Y48#./5B`-`C',>C;/VIB? MQ>M-\PM)2\OY.9\IQD*!2C,&W"%1Q9S=;P'\FA$A2&\UZDOFUFD9P`3[GW^[@X++>+)3.@:X?U="'M<8[DQ+^#)&.6TX#9N:)@=28M9 MJ,6\$*:3C0#+!-1V:&KCZ79<)DX9/-\'DH.OJ8+LR-U94*Z<::E".Q>#9[.5 M(DWPE:NPJ*F@J\\S;P;0K(V2&/(UH!,!EK&_5\30?WNB\A5"`=:A?OA.+BV1 M[@"$!0PRW(L&OK2X(9,&&L%7"]RDT8ZI.B*=B-B?I`)6&BZ1FZV MMZ:R?8'MF>M+T>NU)!PM%5E"MN_(91?%@2B8EO8N,(Q6)B7"2T3>HRS!`XXW\:J;)L.250FT\-F7,*G*X*<)NW+N<^1RO6R;RV M=Z%A-<:KAO(\,3@V,`F(HG_0;'U#\ND/F^UO!*8P^Y/T5QRDB+C0'4K'DKO) MV&IV^M]LWG\^(>7NVV\W]Q]V^_WFOM[^H`GH4EIMV'YWL,7V2PRF3X%!_V%A M,,Q(H+<=#+I;P*"&!7!/T):'W(H%#AYV_Y^;!6Z[_0=!/WE_6Y8?W`/-WW;3 MW8?`N19X@TU$[J0CHHM=$0^MYN`3:=ZKU+\%S?>:PX?8O]N8$_N#`05@O=QS MO43X\[!H-??WMQ`!U:?`;:'Q(*<`J&'0:VZD!C1K-WOM+?:[0>S?=M.]AR`! MO6E0=3W.9=/=X3<%,^4LTX,\-2W3]W-6(%0\!A%PI5$2ST3?%Y6.9AE=RA7F M'0+8H4]$%#O$7DM_5]WPY^-21;9@3/ZBSR%O)U#>2M`8#E_:SSJ%W>7YPF(/ M"8PY7K.&\2D*,,#L*7`WWCIN`U%WOPWJIVCZGG9:9I_N&BWYB0Y8974`S'TY M<'@)#"I1]BR"1Q;Z)D`7#A7"#8C%)1O4(MEOA9]>>H6$K'H0MD&=65WLW(A0 M<2/@[I<\JQVM!-G7@MM?!1F- MD#)!UO]:<%O'LNY?F_J'D42?I>#V5I+H:\7M?TQ)%)2#_EIQ^_X?1PI`7/"H MGO)V0LD5,K5[Q@2`M.!\.LW2;]^XI%091;W5Z?R')OTV=$F]V)R+5CFK=7F^ M^,.P5$GS^P>3: M2Q4DJL-KIM?!.0^=_;GQGLH"]CA\GP*K=Y$F1]V([;4[L^GQVJG@+6V8L;'5:J>(PNED&2-N@%-9]"M$%N+F;-O6[^''-CZ@(SFMPX;!P^V[7LQ`[\'L6/NK5F@*3 MA3F3&=XVG5;2C0BHFN_U"E+]L,H\YC`95;83-)@\^@*\4.C$`;,0,O!!4OCX M+JOG>^**(VL:K&0@;[+"2JS\:U=NY(C98^0I,TL-&_G!CI$O6A!Z,6G72'M/ M0TP>91G9S*NW]Z<+[?SAKVVJQ=V&1L0*[`PIANYVJ'!93C)!CNKGY\,6/Z%" MG9:#D#KOY%%<)X%<;R?U"[WS[X2*&+N7N$@X$64C+_VC\M16SXV&_2'DD;=( M$K"@(MC<+7L?TV'7QR;+(_S="%Q-4A@,.;7$+A`"2#[_$"]'B0[Z&3"&_6M? M*;6K##NY<74B6>#:"5N[._C;M3;5WS%HZ1.9A=&Q1600,BD.70Y=H5HYJU(4 M;9DP017)M14`J%^=3E^L@H,9TKZM%R[-X":5ZZ4YI8#>Z8KZZTQ2=2^$,NE;%"%K@I3X:LB+]$L=DWV0E9490N"/L M+<*LS.*YLZ)WN+ZL5JO>Q>JY*6GP3"HK:/VY\AQ_(]4`#ETU@*TZ:B(6"`0*-'QFBE!(*\^GK4N5MS87U2DU#K\FT M(L,7]7Y-?OIB``@U`Z&Y"1Q._+-_N3$5:WW[SGHR&(7@DQR^]M3V=KRR9FF5 MH:,OQ8KN*9990V6>`:##9B99FZ5@/Q3[5UQ,+38LOZI:;%=Y(U7N\U8NW?E2 M*TTJ>]U7F=N^,#GL]5[/+7%;B&P[:@6#KUM>U?!=-O^.2+9#.G*^Z>; MG1F5A#N?/4>RT_RFY)18XV+5;VO>'GG^GO^N$UQ6Q%&[,@84DZ_LO=60I3/R MQ)W0K&H!;9PKE.TN&4'NT!:&H0YNEE\IL3MS1>:^%W]ORNSHPNI%"B3Q6 MPZMJ-ZC0H:Q2'UOC29LMWLV:<,1WY?=APF;E,%#_B=M`N+Y5XV#!\>B9.-DU MG>TGV.#AP!,CUC1 M#FFJ&P,`G@:3A0:L7MPH(J2ARCVZ.G.YV@>GOW6QE<'6#G(,4:(J"EBB;,5]4DKJS$_2_=V;Y-BN)Y-)::=$( M.8L4]YEG7G9V=Y;DU?W,!)SJ.U M&\(OJR@.G!0.X\=>LHY=9YE@H\#O&?W^12]PO%#/$"Z#A0A(X,3/F_79(@K6 M3NH]>+Z7OC(L70L6EQ\>PRAV'GR@^C*PG$6!S0YVX`-O$4=)M$K/`:X7K5;> MPMUE.>E->H!T?15N`CM($VT1;<)TJAOE*2W[Y<-RJE_H6J;R/%H"B3__9Q.E MW_TQ^_/NVW?O^O_^YKM__N@N__7+U[N__?*-WBO$$$SP03/F>;\1%G[.D'NY M!M=7JR@DB@S!3&BMR^YF$T\IY0#:%3F.D MP>EDXAFJ4P`J.7BR62?GUSTZ<;*&[;(.L1\GBVG1K)'J6[;D$,&_3Z:E3KL2,(F\S[(.YFPB^')-#-MTQY)U8R+Q5V_H4#3EFG* M%H'V^]'-R=-V&_CVR\7.*.#GQ@'8NKV#ZGKIQ:,.!EG^_?UW#G#*$ ME0:&0R^[KN7JQ]AY'1AL9B76((E\;XDL'N=L)IO/).87M_;\ELDES$19U(#: M]GQT!-#;V60NG^E\,I$-:MCPD0SZ?H@?R:`V_#>79M-\++%DD2SQM-3#E6?_ M?#293,:#B_%X/+',@64Q(S_D$>V%2_?%Q<6H-#/M,A@"@XDYGEP80*1OC9FH MDS(P@W-BO@[,[,ZN?';"4':\>'*%["YE2Q MXS(P8=V6G;N^\MU5"JO$V'M\PK]IM(9_'Z(TA:V/#UU[1HOC; MT!(VNV!?:ZJG3][B&81QI8*,;R;B6!+*3&3A#-\:6?V1-30NLD64)-&!N_0V MP:YVI>R]L0)F1-NV*TYL&)9"\G"HZGD]]$+N/L$6S-7,TX(-(":*D!!L(4/' MJK8MJB-I(:8C:2"H(VDAJB-TG7V=J[#D,MK`/NNV@VU[W.]G9411. MB-E/@K39M6=KDST6;6W355?(+SM]8V;@A\U8]VC:TF)7SY8&>[1L:2&J(Q\W MA7W.7OXT&",H:%GRVDF">GW![(]O@$$YW^]5MA2=:`T*W MX:K08ZH!? MH7B;?\T&U^P`%*IK9-0VTISUVG^]VP0/;FRSNT:8"'86B\35T8S-"JKC][[W M&`8NJXSI&

KXF#5\!CF0")]#Y%LU\L%.PO8X1#Y47O8Z M$>RB5#X$E[!\F?&`]^_D00TNH$'=Q$F5F.&@@<)#(NA2K*L40MT-/JTP`!PTFL&'4E3/D#>IROC*#D*0+'"J+ M0!IHLHB\J"0Y%V16!)HM,I,X#R%!@:E(-06@HX0"<<1`T?@[H!P4C<`T&A0- MP90"-P:?L$]03W`CI"(.P$=)KZCF"0-NQ#BA&0@%51F21(.A*D52#JIR9.4* M0U6*)!1494CJ"54IDG)0E2.)*U2E2$(!+*(D0U)/J$J1E(.J'%FYPE25(@D% M51F2>,(\#WHGFV>LI6CN`+MI8B M2VE\PLLI:J?:4Q1[O\$B$Y_T6D`QU8UU?#(P]1;TS)?86=^[+[`4S39Y7E;U MM5Y@4M0WMH.19UC+J9(/E6Q=ZR)W6"&DE M@<4=U1S0UCD'Z2$@J8M@SU5M)A@DE7-@-5?5AJ#Q@D;)"]]PFIO(\`G+!M9Y M!JS;6,*56C>PEOS>J5B*<@_ZOF+.J M']3YR%V3_#V39550PW`.L$J\\7QX^`C+?5BQ76P2 MN,=^EIW,5YA-6&5@&;C<(%@PU^B*!0A9D!I8Q2=8,.7MB@7B,RP3M"58<$-I M9RS86N6)4?^3QA">8) MJF/E1][V0T';;V=4/N(-P8C/4"K?P3=B(YQ_B-@H0ZF\QDW M)1C?&9?*4X!'-++@!W&-2A^9O'4M0>O.G&61=?F`P7%&A`:\^V>Q\>%MCQ&^ M*Y)MC>&JE2B$53\AI"=W\:S-X4F'$HCO#SB,B@#=OJQ])W32*'[5<#NLA..= M/A2$^TL4E3;B$0PX%"'T5WBS)KRT4P.[9!;B8QCG@EU@RK[`FP?OC>L"`ZTS M-GS\X:*J"PRTSF#XI(KS)Q&8#^%Z4WJ(SZ4X=(M`?/3"9W?)1PYO82RPB"#= MN9LT=LKXX[N4(6B8.WP^IL3@4T3VDJ[B89Y\_GD'C\,41L29-ND[N+`7(?[W M34K,R&Y2K>8\\/(5(9![+X5G!HM.S/,`6B(\[B/8HBXAMC**(,;/3AQB;^&Z M[E:,UFA4;?C#['_Y4CTKQ>R>XKMGV5-4Y7H`S+MT5\[&3^_+'Z=Z]?UO[&E< M"*;\JA^\SU'*(*9Z]?TC/N8,O1C*QY!N/B;PZ"S\U3:Q-]5_OYV-)C>WMG$V M[L_&9Y;I#L\FP]G-V=":SVYN[$G?Z,__"R;#%_5>PIM>#W@1+GMA+VSY#ZS+ MQ(?7Y<:YLCGY3]6YJ4X.,OKLV4:@#0_]%4KTDO)%PM?_`P``__\#`%!+`P04 M``8`"````"$`O^29]\R5%K*("9U,B<>+1*:B.,3DOW\?WRV) MIPTK4I;)@L?DE6OR?OOVS>8LU9,^*L[2Z*,_\8#J=^SD3!4&'M1KC(?=[D?`'F9QR7A@T43QC!N+7 M1U'JBUN>C+'+F7HZE>\2F9=@L1.9,*^5*?'R9/WY4$C%=AGD_4)G++EX5R\& M]KE(E-1R;R9@YV.@PYQ7_LH'I^TF%9"!+;NG^#XF=W1]3U?$WVZJ`OTO^%EW MGGOZ*,\?E4B_B()#M:%/ANW^X1E/#$^A<\2S'=E)^60O_0QO30&B*X&%Z)\7 MS%U@*7Z#Z3Z_(!^KMGU37LKW[)29[_+\B8O#T0`I@C+8:JS3UP>N$V@#L"9! M9%T3F8$%/'JYL/,$960O&)U(S3$FX7P2+:8A!;FWX]H\"FM)O.2DC7KL'Y]QE! M*E9[9\4Q64#-8Z*AK,_;Z<9_AL(EM>(>%?#8*&BC\`'9<($UGFO%EFLK:P.Y MQS>ZF.#WF/`6C!5#:SK!AXTK*7>ZJ<44N*J)JQ&8TFK5Q.528 MQ/'96K%+I?WI14DW77IE?.W7P>C;QHI[Y'9<,6&4..1V]IR<5[>0K;A';@<6 MR2AQR.WT.60*RW9\TI6ZQVZ'%MFUQH%?:36UFV5TQ2MU#]Y.;@W'7>7`VSET M,[]I6U'<3MW[.>A/6JWIPH,KHT9[.\Q^^830BK^L:EQ53A#]H:N<8S*O;C,: MKE:+61A>BP)"[=9_9!3V*KU9`RZ MM^!&IC_<=,&@":C!)BQF<_AKEJ&;?6_;C0QAN/:"MKQU!X9[KY6X,=RT]RAN MM3]V8+CXKJ%[BV]D^L,-..P`:K`#P2I:AF$_!CPEXL$IY^K`/_`LTUXB3_;4 M1^$&:MYMCK'U^;+Y``Z$)3OPKTP=1*&]C._ATNG$GMT4'BGQA9%E=2S;20-' MP>KI$7XO<#CW3"<@WDMI+B_L`;;Y!;+]!0``__\#`%!+`P04``8`"````"$` M=?Q<&3T#``!I"@``&0```'AL+W=O,">1#2:HF5;=*FS1-^[AVP`2K@)'M-.V_WS%.2'!6TNVF M#?#Z]7/.L7T\OWVI2N^92<5%O4"ACY''ZE1DO-XNT,\?#S<3Y"E-ZXR6HF8+ M],H4NEU^_##?"_FD"L:T!PZU6J!"ZV86!"HM6$65+QI6PY=)3;0#62 MT:P=5)4!P3@)*LIK9!UF\CT>(L]YRNY%NJM8K:V)9"75P*\*WJBC6Y6^QZZB M\FG7W*2B:L!BPTNN7UM3Y%7I['%;"TDW)<3]$HYH>O1N'R[L*YY*H42N?;`+ M+.AES--@&H#3_/56(_2?)LR^\ M9I!MJ).IP$:()R-]S,PK&!QAG+Z:[4W\7^,^/;0D.Y8XC(!#;+ M7N^92B&C8..3V#BEH@0`^.M5W"P-R`A]:?_O>::+!8H2/Q[C*`2YMV%*/W!C MB;QTI[2H?EM1&U%G0@XF$=`?OA.?3.(P3JZ[!):H#?">:KJ<2['W8-7`G*JA M9@V&,W`^1F8YNEC?"A5B-"9WQF6!QLB#*!34YWD9X6@>/$-.TX-F=:D)^XKU M46%*`7@=(T1^SOCWK!]1C-B@F"H8MI5]`=X=&W'FO50DDT[2(X$,O9_$B!<( MS+N)(SSJ?"V-R7K,\E),$C$H8GEQYETJ<< MIC-BE\Z9>F4U0QD<4O388(^Y&;Q>93/H6I6M9HAQ2-%C-&W/.5.N5]D,3U:K>CKI7[(!K"')3T.&PO=V]R:W-H965T0>"^S%(&+.$ M[0F#)/8U>LZYQB`;H@$12&YWO_UDJ194^[X_E3^ZUOP1[-9LDIW:E$J^WX6$5WT6G\$B_O$7GPRJAK^?W2GPZ MAZM-6NBPK[C5ZD/EL-H=R])"^WR-C>CM;;<.O6C]<0B/B31R#O>KA/R/M[M3 MK*T=UM>8.ZS.WS].?ZRCPXE,O.[VN^17:K1<.JS;@_=C=%Z][JG=/YW[U5K; M3K^`^<-N?8[BZ"VY(W,5Z2BVN55I5G\HO37KJU>;<9[XXA19OR)#+P&D7?A72P$8@*5Z!TD&9@?BYM MPK?5QSY91I_]^32C==6J1:%A[\\L+XS5%E,S@ MB*Q^II^?NTVR?2K7'N[JC6K-(7GI-8R38"=,EDOKCSB)#O^7(D>9DD9<980^ M7@I?*"\J1:ZG7]*DJ=!X*/:1?TP+4[;6'5U744N7H4Y5KW#GW MU0<1G`+_',JC#&LF)%=5Z.B0B']NJI)B**NDMM[41J>A2](_JJ13OZJ9%$Y9 MYY5QKEW9F;Y6LGA_/T6>)9@CJ7_%I)>8;I^V0,=V-98Q-Q_ZJ7U.'%E9> MA)FG,C6#NFQ,@_''L]MJ/E9^T`!:*TT'-8ZMZ&J%&"W"K,>!ST'`08^#/@<# M#H8!ST'`08^#/@<##H8AH0Z38X.:D>2&FT++NEJ-.QT M=8U(%_.`^$`"(#T@?2`#($,@(R!C(!,@4R`S(',@"R#+++%R0?L;*Q=RKW#7 MH`+%:1$%[;1(4G/-8M0%X@'Q@01`>D#Z0`9`AD!&0,9`)D"F0&9`YD`60)99 M8N6`MEA6#HH#+]1VX!7)!!Z(!\0'$@#I`>D#&0`9`AD!&0.9`)D"F0&9`UD` M66:)%7C:&]\0>*&V`Z^(/`J*S6W7D,S45&?KOR=%+KEEYJ^6:T]?OM'HZ2LP MIC7I&7*QX_+*^L901M1@V_B!$6G;0V-;DY$A&4.\MK$QE!$UV$HZ,2)M>VIL M:S(S)&.(US8WAC*B)HOVPHBT[:6Q3<3J#[0CNZ$_"+7='Q2A@6X2ZS;Y@4B) MLMF'K'E&I)WV@01`>H9DZN=!ZQN1-CT`,@0R,J3`]-B(M.D)D"F0F2$%IN=& MI$TO@"RSQ,JKN$&X(;&IW,ZL0JZUYVBR0=O5!>F,<>D`/`%>OHKM7WQ=HY.> MO&MUY_[!9?4%VA(=,K^NKZ=5A5[U\U7,JX'VRK;U8$]>0VVKT*^15MFVV/`= MYZN87Y.K_)IJ6X5^S;2JT*]YOHKYM=!^%61QJ2U]Y97=E4EU2U<65KO.IK6[;OS*N! M5M%JD*D1NK*JL="OD;9EU\C:.,Y7,;\F6E7HUU2K"OV::56A7_-\%?-KH51% M65QJ2U]Y97=E&F!65_ZW]Y3"3MK'+XFL55GP.XY4%9[?+QJ]RGB(?$0!HAZB M/J(!HB&B$:(QH@FB*:(9HCFB!:*EA>Q$BOL9?N'LUN_H#'GKE;.\Z:&;&)V` MCKB5H>S:I_TFOR^[J'1!#Y&/*$#40]1'-$`T1#1"-$8T031%-$,T1[1`M+20 MG3EQ1\,S1X\K_OGX[\C;'3*M`]Y1*'L!@,A#Y",*$/40]1$-$`T1C1"-$4T0 M31'-$,T1+1`M+62G15S79--2?",@'E'R15ZAS)V`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``#__P,`4$L# M!!0`!@`(````(0"IK`1&PO=V]R:W-H965T&ULE%7;CILP$'VOU'^P_+XXD)!D4<@JZ6K;E5JIJGIY=HP!*Q@CV[GL MWW>,"0V[44M?``]GSIF+/5X]G&6%CEP;H>H4A\$$(UXSE8FZ2/&/[T]W2XR, MI75&*U7S%+]P@Q_6[]^M3DKO3I4)R,"5'6F>IW@3)MLE)NM56Y^?@I_,U3`\\>$_8(`J*],JB- M5W9@I^QJZT+9>L.U3'1;9OH_,@X,S;D*/@IG/:]7]IC9%>8/8I`@0,8GZ,#0 M@Z'TZ]IZT`AIV%3CI1VXE>Z+VUF@QGT3HS#NZS#(R M?B3Y$RNY+O@'7E4&,75PXR:",]A;^TFXB=PQ>6V?)9MV0I+^!TRHAA;\"]6% MJ`VJ>`Z4D[:$VL\XO["J@P(``#,&```8````>&PO=V]R:W-H M965T&ULE%1;;]L@%'Z?M/^`>*^QG6NM.%6Z*ENE39JF79X) M/K91C+&`).V_W\&D5M)T:O8"YOCC^\Z5Q=V3:L@>C)6ZS6D2Q91`*W0AVRJG MOWZN;^:46,?;@C>ZA9P^@Z5WRX\?%@=MMK8&<`096IO3VKDN8\R*&A2WD>Z@ MQ3^E-HH[/)J*V'X`*S"A2!.E$\\D=(,.X$J4])V!">%/_7Z0A:MSFLZB^60RGLYG M2+,!Z];2@DB-78$F/++@?64;3:#*+1PF*OD/"@D=]@`_<\>7" MZ`/!ID%)VW'?@DF&Q&]'A*%X[,J#E?N@^%4)GU;9O0_,AZ<4UP'Y],D'GB#Y#:`KI+$?KI?VX%YZ2.[1@CD^R<,_RC@]E_*CD"Y[M)S+OBYK&-+0PPI,!9^@:2P1>N<',,6N'*S#V[!*?>.\MH^S M5?]FL.$'SFS'*_C&325;2QHHD3*._(R:,/7AX'2'GN/,:8?#VG_6^#@#-F8< M(;C4VKT<4)@-S_WR+P```/__`P!02P,$%``&``@````A`*@H6F@4"0``1"H` M`!@```!X;"]W;W)K?OFVWTV^EJ=Z6QT64W$732?E85UMMH>7Q?2?OS_/TNFD;E:'S6I7'G[>KLNB6K_MRT.#04[E M;M5`_O7K]EB?H^W78\+M5Z?SUM-[]O#R7,-M3)5N"IJKY8]+>-_0@N MG@=7?VXK\.=ILBF?5V^[YJ_J_7_E]N6U@7+'H,@*N]]\+\IZ#3,*8>YD;".M MJQTD`/].]EO;&C`CJV_MS_?MIGE=3%5R%YM("<`G3V7=?-[:D-/)^JUNJOU_ M"`D7"H-(%T1!]NY[^>$@V@6!G^<@9FR0.:IJ)ZE8-:O'AU/U/H'.@[SKX\KV ML;B'P.?902W=?%V;+I@G&^23C;*8FND$9J*&&G]]%$GR,/\*=5D[)K_`4&)Y M)FP1;-@"/X!_N[")Z:Z9@X).!DRP+^-R<<_96MAF>QXGQP_\<60W3)O),B22 ME")%B/1!2*[0!.-SM3"TG#<%PIN#-KD<&:A>-TV:YK:\211#!,D>AAF?O847 M4YB9+K.4MP4B:=LT,R%$%,DX8NE3)DJTD6D_N=@KE)&9CI62_6!$`RQ<7X-M M>@4;RW#7V(MX)5@/Y,A`*IU>7HF;1#%$$!4)53&JI``B=`I3HVLH]!.B;[2/H6YNFS M19.VA8`SJJS[`PA0N#&B!_$:<]0NMA'<_3,+(>Z).^ M)P@3\WH@Y.<9K`L1,GVB[OR`"&J9*:.@)-U(5(OU/T_+\,H6Z):^!NY'N6.& M)0RYKI.`"$I(99QZ[D\5P$@?4&!IWE']AHWG"H'0L(20":J`B.LHE0C=#T0E M6.OSBC"RH=`P_6((T^_?3DKHJF%#A4P@!1&4$L>9N:;$FJ&GY$8[H752!?QH M(1`:+D;(!`H0004JS3+/YFDQK"EZ$D86`ZV42F$GA5SX?BNT5(([-B52%4DV M'04E=*RC2/7C4"76'S^N!%V5*$E9GKD(S3ELJY`)BH((%B53\(2@'XA*L5[I M2;G15^BL1$+$QLX%M5\R=KMVEH3041:3M#23D/9U=A(0&I80,H$$1%#"+(XC M[XA`)3#C'EF-T,!%X.#2M]Y,&!&QUEL28B:TBM.,]5Y!&6TWW*QO/JK%&N7H MU2TMS6Y(4WZP=9!?#C;5R]M(,8A0"=8@/0DCRX&V"C7O[IOY`LWMTS:0ZSI" MQ]([EN(^10F1!$1!"1J#RK`NZ=_(_X)II_U!V2ULW[2-C$301SX@8B'3N,^NC5%(']%IEJA> M(9U_:XCCYQ_MD\Y_?S)S^?L>.S,&=I2P`I0!IXN]FU&G@3#PI$!*D?6[()7Q M(;N6Z,2PZW2K0'@FY&0@-+B@;R*%&^IR%"+!/A<;7XF6YA;!=L3<0?[@024N M,*S?"HH"&;3-VIPP9Z] M->9$(.0G&+91R`0B$'&E5$FBC/`>4E,5,)A?BG'NINQ5O"3L*)$[:*"C,(H# M+G:43^@X@25QI:.82=\H!AHO3%._+67]ONV*@1!DT$%LHI?J)E(,(K02S*!' M5N*"46J84UQ_/I&"X65UTVT\!YJN6H@ M-"PA9`()B*"$Q$0)G$FN=)0U14_#R'*@E5(MW+>5[[=@R#"/_42V4& M4OPH0N@8[@&OF+9BICU2"YHNU=+?0;JZ(.1Z0LI(0V-T,^K$^(R,C#$9FY*B MS?!\%(89@?WJ6F$TL^]Q8MJK^([%;=Q!*$;"W^UX61PP5!8>(\O\A@IG,HH1M:TM'#$K`1^H7@U`!UBV]-3*\ZVI+4P'P:(;V2NX@ M/[U@J[K`L)8K''*6H.#@[AW=J0CKEN-%H+?ZBP)N'+@(A(9%A$P@`A$GPFB3 MB-YCJ088RMC]O0R^FPUIN>[H+X[1H.)3T74S+T*KWAN@[S/5EHHQ-X9X+*76J?N6PA!,G@;AT> M7/7-3.OR0]ZN0V^7$3.RW$$XH?:5JI3?JBP),H,_?]FGRU1O01CX&YF*O9L% MJN6'O%V'W@ZS2I/('81:!#P4@/LABBP)`D\@8F/8HBL7VV.>YN%^V;]S-NR_@';[CZJ7\8W5ZV1[J MR:Y\AI#1G8$=Y81O`>(O375LWX)[JAIX>Z_][RN\K5G"^V?1'<#/5=69`2K,B+I"%:]=$^/3D4P/T9F'B8O^?XO M?W_Z=O6WAY?7Q^?O'ZZS=X?KJX?O]\^?'K]_^7#]/_\]W[375Z]O=]\_W7U[ M_O[PX?H?#Z_7?_GXS__T_N?SRQ^O7Q\>WJX0X?OKA^NO;V\_?KN]?;W_^O!T M]_KN^'NT_+CYZ^W>:'0WW[=/?X_9HB_/:R M)\;SY\^/]P_C\_V?3P_?WRC(R\.WNS<<_^O7QQ^O:[2G^SWAGNY>_OCSQ\W] M\],/A/C]\=OCVS^6H-=73_>__=N7[\\O=[]_0[O_GI5W]VOLY3^2\$^/]R_/ MK\^?W]XAW"T=:-KF[K:[1:2/[S\]H@4!^]7+P^EY. MP7^^7'UZ^'SWY[>W_WK^^:\/CU^^ON%\5VA2:-EOG_XQ/KS>`RG"O,N7P[A_ M_H8#P#^OGAY#;0#)W=^7?_]\_/3V]<-U4;^KFD.107[U^\/KV_P80EY?W?_Y M^O;\]'\DRL)!'8/D'`3_YB#9X5U;567=-ONC%!P%_^8H>?FNR0Y=<4:0DH/@ MWZ<@67FHSV@.#GEA@G^O,8JSF=0@W0>T%LZ.[CZ^?WG^>84> M!/RO/^Y"?\Q^0\!PD@N4RO9)QHD)O_EK^-'R4ZA?49I_^]AE[V__AF*Z9TF_ M($,020*9/44\:.OJ\2HY]H+_C^'[53<95$<::2E>`"%]V^N_S^N.M\*+A M&`#W-SR(=_GT2"JFM;)9C7G[LG/X/EV=_X1:U;KTQ'SR*C=8,O&5E"$$$@@3CY0693 M(FH@"U9I=R]8U))#>S)6Y(!80PVXR8JLSCIE$@;6&*A&7S+YDMD^&$DB6*;] M),A@X9_'&2P[)"A6%Q:JN3VHL7+(UC^?8J@>-;*$8-:UKO=)_!VL#QARI1F9 MA20Y'Q)!<$[[$9#/D@BT'\XL,[84S.!+1I:<,&ST"C?1;":2(%"99X`(:MDK MLH,J^3XC$7>+HB[5\#&PP.P3%*-<3&%>JW*;5(HN4^9D-E-(`,%!196PSQJ' MQ8($A#;'+#+:.?B2D26$,Z^KIE:S\>0'F4V)Y!$<5<3#-@L9^2_1,[21Z5G$ M!5&V24D/K#!(C4=)&&%N2CWA3BI)@TE9#P^[O6(6G%7$8&=-D!^3+%1A]DOH M#]=&2P=?,K)D)1JF3M7:R8\RFQ)9%,%IG0^$_)D$HJ:&/B,1-27+\[Q.!O:! M-0:T\2A9O'1*0V>IVG3Z(,UV%HDCF*_S<9!EDSA47^XSR]?Q+.)*1HY"4)<+ M*S5;37Z>V90('OE9%G-1JTDD4W:@9Q%-`&6E,`W'/__:4!PEH2*2"-/QS[^, M,)L2">`L;YG3HITHA$,"@$1\"K,2(Y[JX@/'V2[8I59&EG#OZG2(2?R]RLH\ M6>"8S2R2`EH4=PM[ZLB#6I>!L@H]BXPF#KYD9`E1**N\R]14/?E!9E,B.2AS MN6_ZR#=,9J:,3\\B/I]P`ZWJV`,K#&*C+YGLXB:DC=)0P86&,3&HR0, MF+E"/LD,==CZ9/7S*RA&FFB[J3'V,V M)1*'[7[J^( M1:WFCEQ?@;&(.W>;H7NKKL$*JQY\R>3FFYONYB$6'(RJIL MU(D<6&%BH$R&9'+SS&8>B4$9S'T31[%A-'-U0=&SB'`4[:$H]8#)"J.MXU$2 M9M!T"5/F:+JZ5CGF8P!W#BTN\IC+KW0'46-9SR*CH8,O&5E"0.NF2ZZW)S_( M;$ID:>!PSQ@H@EIQ2*[`"A+Q0%%T6+?2`P4I\,_CTKB".7(0NHYM:O7G2>L;!XYC,J`H!#(K\EH_FS'Y0693(CD$ M8[9[N:XD&X>AZ7BQ!'\@>VK/(J.1@R\964('M$\R`1G]&JSE1#!HYB`!M]R<227Z:9S1@2AO*5.V%L^4LUK?6E-(85 M'K>6N`96F#0HB"&9W#RSF4?@J)2WW(=C^94:-@O5V)Y%?-+RMFUKM=8YL,1H M["BC=#K+)/^>MW4BF5R2BIN`9Y;Q2%_`#*PQDHR^9W#RS&43BN,AL M5AMF4U\0]BPB'#=YU1;))Y"#7K#*PQ6CGZDLF7S/;!2!)G^182BP]/;S4&-*@-+ M3!*4BJ(@2&(]19J\:+*L*M58/@O-#6['8&FQ.9EX2>(L^UEMV$]]B#V+C&8. MOF1DR8D$C)<:AJO-*K/`8K#%;C4;(\ M29'.('0@:PX\T:O6`.9C@)-7/EW02`07><]JPWOJ.P\]BXR&#KYD9`DU%@]W M-OJ&[.0'F4V)Y*'LIS-@;ME.9;'[2MC."B.FOFP96&*@&GW)Y">:S2@"1'V1 M\5Q^)6>09(6J9Q&=TJZML/2O^@@K+!Z^9'+SS&80B4,Y3[LNZBW'J=;0>A9Q M-RZ+KNGT1,H2DP.EXBA50&J=LO\5$U<]5_ M^YI$1QAXKSF9/DABXG`EDY]H9LEV(@E$64ZU7'V+#*:.OB2D2549#5H MY%4RAM+1&(EF,Y$$HFSGSO+8L)_ZTK"O8_M9='A[09[9@05&0T9?,GEI9C.& M@-%<9#V77ZF9I=35P2(ZK\6A[(I:V?6!)18.&26Q\Y/\^Z&L.ET]LYE%TE#. M938D$6^IB M8RAEB<%L]"63GV@VHT@@RH3NK)`-,YJL>C:Q&<6Z4IGI1U4&EIA`7,,Z^8EF M,Y$$@H/9;TF;H)8#1[+JR1HJC)L,,VS1)B\5LL@D0;D,R>1'F9VCD2R4+;6O M4,(WWQ2+K%2VN6<1]Y(2JW29[O$#:XR&CB),WK3ZNG02`GQ,KNU0@'+RFH7F M)KS\BR>%3XN&$D7P?-'-$@<%.40,&Z?[S3I]W[@V#IETCE*OM\]F M#HG@(@O:;%E0U=">149#!U\RLH1[65<6R56\'V0V)9*'&A/#H23_'O6MOB8E7LI3 MES63'V4V)1*(\IQ.66QXS62=KR41-:'&/1P]SPZL,%"-1TFX4]3HMQ.@ MGZ&!+1I802##8Z!MNGMG,(SG@?,0N M8I_;;L.OU$B1K/.QB*NZK5'7JIL/+#%K@E(9DLE/-)N))!#E,'<"V7":^N&A M'M]P#M0(2)GA@EVO2PTL,5H[BBAXS:13U\&3$.`2!]\&4Z/);*:1.)3+W(EC MPVWJ6\=]Z[M-7S*RA*LLX,!C]7*JF/PPLRF11)3;W$EDPW4FBUNM<)UUF;QU MR0*S/%;3N34$+M9U\M+,9AH)XR+?V6[X3GW-U;.(3VSXT)>^)S^PQ,1!J2@* M'C?1%R(Z"Y84D\Y"(;:S2!K*=>XLC0WWF2QNM23:/@BZ(O$E(TM.-"K]".WD M1YE-B0#2G>4_%[6<59*E"]90"V[:MCE4R:O:K#%8C;YD\B6S?3"2A/*@MM_H M-KRG?D"O9]':0:H\3[X#-[#&1$&Y*`R^Y:!OQTTB3X6%BT.A%XMFH;DI*GR_ M-%Y(EBC.B'F4V))'&6">TV3&CRQ!:+ MN"CP8*><"@?^NT%J/$J6EV?D[R<=7XVG\_''6]./;#R.X7SGV85?R3$BT_-" MSR*CD8,O&5G"*)-%P8=([DFQGS,8`_7"IOZ2#8\)3)@D7G>TI?,K*$A\GE M\YIZSG#SS&8>40JXXKUDWJ"?J8DC6;)85=28O,!M&KT*A6^YAP.P'];:H<'G MW"F.D0O?<[=R*2[*8>Z[^,@.&U8S6;E857R2V[)-%H;!A2)9_675K&U.+L>D M`,\[XKI//?4`*%8B!45YS;U0-DQGLGZ!SRAXA0`HK@9?_B?-$4K=ZB\:HEC< M..!B:107Y3SWH\9D&/;2N$KM6*`S=/DOV^P`2E29Y M\!I$UA#N\)H=<"SGVU'ZF1I6DHOW564T%Y42#L`;5DA#9,.C@IHLJ+AA@,72 MJ$(YRY?B%>:E$2C$XVWFY!)^%5$K\#62PZ&J=>\"#PJ%0SV&.JWETU-^.S0` MXL8!$-+\ZH@4DK,\*G:'2)!D>F$/?2;VEUG9XM,YR7L$J\A&$@?"$V&=6LX" MD%A1==A-)3D>$(E%-U@4..#EG]/RO2*B_*KM3;+#AE&-OD:SG%L0(9716-2( MJ\'H2IJUSP!(WJHI!4S<0$!B:120L_PJ-HU(2R2YG%M5U)`JPX,5Z;!*@0QF MX.%J@(,TOTX%&E881>,LZXK-&E,:R6WH546'B&O;#F\22M^)\G"-)W"0AN+@ M(Q'J\A$L8@$285E>/4($&%8B"6/9HB=Z;&?GS,L[^\0#:Y9SL,63_D.=J'](,BF=A@*.O*&E^'TJ.( MN7W06B&6T5PTZ#"DH2K9S`4N5AS%!>"^B2895 M#Q]*:J#Z=0BDBP M<6<0(=` MI,Y,;$`$ZQPV#DE&$@UI3E!*_4HMN+AQP,722"[+UC\1%V=2^7= M@B0)=1>NS\P]A;@R?`WVC"2/243Q0?6#O@4%&I8-Y0YC:A0.M.R"#L.;!PDL MZ5J\V*<(#WJDNW9@@S3D=];,?`VP4!PBMY4*16*E4E2"B8NZR\YAA/<0$E32 ME7BQ%Q'>C\4'@=4E*_J-Y2+7?B/U7JTLQ]BM:>$\?!@^XZ"GC$BJ;!-V,.^DE?`(E%-V&) MI>DBE0(2'-T90,@`2B#J.6$`L6SB.N^X&I0(:0CL`@3?IY#TP<0-!"261@$) MKNX,(&0"!9#4QXL]B7#IF55=XEM98_<9RW(N8,&#-#S2;.4"#RN.XA'<7,1C M[YQ#)E!R46U&H9"*CK7$.PGZFA!#B>4FUXZS:H)5J_1SMD`BT^#CFJH/@\@: MXK2J<[HI)(DL^PE%1)QAE;M))="MM:6XD4#.5;=Y8';T8DH.B7;GI\H@.U9[HP0'$UV.R;--1F MU$=R10`L;AA@L30*"UIV0:_AC8D$EG0QWMR^B(=77P,LX2#7UT8*U,I!S^3@ M0AIC5`(72Z.X!%L7]9V]Y4)N4'#1]@GE(GQE@0_VZ])&N5B^RA)_)E5=\\U)V9E`AE7$&0<75H%I( M0VT.5-J#_J`BRL4-A'*Q-`I,\'8*3!B5!M\'3DFL(;:(*A+!UT4DPG"RI^.0 M'11$]"N$(&*9QG68)0UWBE`?A9[&P,0-A!)Q-2@12Z/`!(,7@?%*A/R@`)+> MZO-W1D*'L9SE.KZ2AJ`U39VX/N!PPP"'I5$X@KN+<.R==L@4"BSIN9^2-Q_ M6$/MN6E:?5DT9D*1"J958(Q*LZU12(+)NP`)>4.))+DP-O=&6I%0I`@)GI.0 MLP6HQ*)`)=$`#&EL,)9&@4';8C#.D+*Q35.ZFB2V:;K)VJK*<2=6-G;(S%V4 M>$SQ-0`26F!V,%0*:9A^BFQ9L^XO,D"@=*[1P< M0:[MJSI,X""54<6@01I"5A5MAV2*5C$`KCC>N,)"C.1@A&\7`1C MIR/AW9(D%+5^@SYC&<5UFG$UZ#.D.4'!J\`)%S<.BL32*"[!U%W`A;R@X)(N M$(C]EQIY:(#%2P4J5AA)9=D/25$)PY$S"_,V2I** MNF3OL5T]D)M>8=BA&5?-J50.^DNJTZK!O/*K)839UB@NP=-%7#P>9`$%CW1Y M0.S8!+>)=V_D2``&1/=M5`:I MC+,%%*X&E4$:JHSM!U[],,!AI5(X@IF+"F/GG,/;*"'/L3QQTU6>?6")G2*^ MJ++QWNNJ,=`!"\4Q-.@P;BYPL>(H+DAV"9?P,U4NZ56POST3RH4B42F$RR`U M2(-*K$@%0$("_/-XDM28!B261B$)MNZ"4B$W*$HE?6G-W^T)2"C2"0E6UM15 M$*C$(E"!1ID_@"&-#<;2*##!!D9@O,&57&,,)+T*%ALZW>`![G#K0I4`B%`H MHR$`XFH`Q-6@4DBSTM='I)`$=W<&$C*#,9*L5I,)AA-2T1&$NY1=H[]J!22Q M"-^.42;"SRL.)+'LJ-2Q&/G5,P;,0DN MZ66.V-"IQ,;DE?X@\X`>AQ-B^MMQU5`U87<'M:8R20%>*BA1]A2 M4)1Q#5!V&'K>ETE"49-?C^MUK\&`XFH`A31'*$VMW[D%%S<.N%@:Q05-.Z/S M\+9,@D=JZ,464&$C1/W&-W"$O%Z-K!IZ]$:-XT!!?R=<)9Z]T-<-(+&&V+(N MBD0P=5&W<69?WIT)\8^F"$.WK%!4AN44>6#U-:B,V)56X;'SE(:;"C@LC<(1 M#%V$8^\H$GZFC&MJZ,6^4/A2^4'W?Q0(!=KNVSRX^AH4"<6A(ME*!2I6*D4E MN+D+J)`)%,62VGES;Z>U6"@2-2>8A<2XRBVD$@&(6(YT20,DED8A"7[N`B1D M`R42M0*(_N,:2E2*-)1HS!(U9AFQ*<1U'2$/0`I#DM@28Q)J%"1[V5E,-=L= M5/$(7NX,'F3]!(_TSI;8+RH/'[-):%@6DJ??XWY1P9_IRP"`H!!<8H=./P4% M#%82A0$MBC'LM".\@Y/$H98_^LSBXMA+A6R@H**-!*B0B@LY#X\6-LG`:NX(M=:)"(1M,5048!&*'&-1H;\3 M`RXDVM5I@J-37'9<[?&F3I*+.EAP"<'-H\1Y/`D9Z#2PVE,*MQXUK8'.SJ+7OK'YS&6,; MQ1PHZ.]41'@^H=(3-$BL(4Y7JJ>:5B2"F8M([%PEX2V?!!$]VJ,\7#>)\HC= M9"@/K,[*J0D5XL8!%E<#+I9&<0FF+N+B50AY0,$C71LP-X9:9QV*A`Y^7&4X MG;NU1&+'B0]K)+,Y<+AA@,/2*!S!SD4X]DX[Y`(%%EVN*!-2\;!8XA50-4:@ M2BP[N5)Q-<#BI0(5*XRDLNSM%%%QBH2W@HIIM.H.0I^)+:5N\!1=K=S^L$K, M$C&WG5J`36L'A;;Q[ MN_OX_L?=EX?_N'OY\OC]]>K;PV?TA\.[8'M?'K^$X9;^X^WYQX=K#%._/[^] M/3\M__/KP]VGAY<@@/CS\_/;^A^W']_?_GQ^^6/)\?'_!0```/__`P!02P,$ M%``&``@````A`%?&ULE%3;CILP$'VOU'^P_+X8R'51R&JWJ[0K=:6JZN79,0-8BS&RG=O? M=XP3DE5:*>4!L#ESYIR9,8N'O6K(%HR5NLUI$L640"MT(=LJIS]_K.[FE%C' MVX(WNH6<'L#2A^7'#XN=-F^V!G`$&5J;T]JY+F/,BAH4MY'NH,4OI3:*.UR: MBMG.`"_Z(-6P-(ZG3''9TL"0F5LX=%E*`<]:;!2T+I`8:+A#_;:6G3VQ*7$+ MG>+F;=/=":TZI%C+1KI#3TJ)$ME+U6K#UPWZWB=C+D[<_>**7DEAM-6EBY". M!:'7GN_9/4.FY:*0Z,"7G1@H<_J89$]CRI:+OCZ_).SLQ3NQM=Y]-K+X*EO` M8F.;?`/66K]YZ$OAMS"8746O^@9\,Z2`DF\:]UWOOH"L:H?=GJ`A[RLK#L]@ M!184::)TXIF$;E``WHF2?C*P('S?/W>R<'5.1]-H,HM'"<+)&JQ;24])B=A8 MI]7O`$J.5($D/9+@\TB23*)Q.IG-;V!A05%O\)D[OEP8O2,X-)C3=MR/8)(A M\\E9T#%X_9=5].A)'CU+3F>4H`N+[=DN1W&R8%NLJ3ABG@(&[P/FC&"H9I"$ M,BXE_;W(I\P>[#/[HGLI3V'C,DTZ"'F79O0_:3P8NW8A/DW&`V_('##C"\P9 M\2XS0FXWZ,$Y15=#V4;QV5'('##3OO#3Z3S&:]`6,H?1#IU78"KX!$UCB=`; M/[8)1@Z[PXEZ3/M#,7S`B>YX!:_<5+*UI($20^-HAB-LPID("Z>[?J[6VN$L M]Z\U_KH`NQ-'""ZU=J>%/W7#SW#Y!P``__\#`%!+`P04``8`"````"$`(:OT M-7H"```1!@``&````'AL+W=O"T8$&^KJS8/X`5&"C21.G$,PG=H`%\ M$B7]9&`@?)?3%(5EX>J>9.E9C,TYD[[(-H"ND,9!.97V[4ZG?MS>F<)C MS/Y<[V+(^;"#<0_]3--W.CJ]5$TFHVCV3UE_\%SVL',N^[K#X0J&.5=@*O@, M36.)T&M_O5(RXQ4\:H=WL7^M\=<+.*-QA(676KOC`H79\#-?_`4``/__`P!02P,$ M%``&``@````A`,7#([HY!P``6A\``!D```!X;"]W;W)K&ULK)G;;N,V$(;O"_0=!-VO;KA69#D68EN&I&QV MW[XSXD$D1W;MHGNQBC_-C,B?0W(H/7[]?CQ8WXJZ*:O3D^V,)K95G/)J6Y[> MGNP__PB_/-A6TV:G;7:H3L63_:-H[*_//__T^%G5[\V^*%H+(IR:)WO?MF=O M/&[R?7',FE%U+DYP9U?5QZR%G_7;N#G71;;MG(Z'L3N9+,;'K#S9+()7WQ*C MVNW*O/"K_.-8G%H6I"X.60OM;_;EN1'1CODMX8Y9_?YQ_I)7QS.$>"T/9?NC M"VI;Q]Q+WDY5G;T>H-_?G5F6B]C=#Q+^6.9UU52[=@3AQJRAM,^K\6H,D9X? MMR7T`&6WZF+W9+\X7NHZ]OCYL1/HK[+X;)2_K69??49UN?VE/!6@-HP3CL!K M5;VC:;)%!,YCXAUV(_!;;6V+7?9Q:'^O/N.B?-NW,-QSZ!%VS-O^\(LF!T4A MS,B=8Z2\.D`#X'_K6&)J@"+9]^[Z66[;_9,]78SFR\G4`7/KM6C:L,20MI5_ M-&UU_)L9=3V205P>!*X#0:XX3KDC7+GC4?M9FSX]U]6G!3(<\:RD](3(SR@F&>;)`.4J^!2?7MV9W-'L??8"+DW&9-;1S=8B,L,.LQK&^" MP`2A"2(3Q"9(3)`J8`RR2&U@=OP?VF`8U$;T:BV`(I8AA+`0+KX)`A.$)HA, M$)L@,4&J`$T(F.U$B"DDR_":)7("O6!UTG)BKG=TS6Q%$4.4I2&*-)*B$!(0$A(2$1(3DA"2 MJD03!;8((LK#"DN=>W7!2+HNC!BZ/!BZ2".I"R$!(2$A$2$Q(0DAJ4HT7;"\ M5_?AZQ,%K?6^,S)E91[NG1M"?$("0D)"(D)B0A)"4I5H'86E_HZ.HK7>44:, M05X9@RR-Y"`3$A`2$A(1$A.2$)*J1.L[%EA:YUFU-<)*]OJ`=YZZ$!Q-75E8 M;"CR*0HH"BF**(HI2BA*-:1W'PNMVY/<8749[(UB%-<"J7WF5CWRJ55`44A1 M1%%,44)1JB&]SUA3W=%G5H)I?6;(74@9-HY$RK8XG^B3P!=6L.;TF^?**(H%@NU`R4&C MQ$]Z*]'45*`!=;#@4M494`'*"2D#J\\T&3B"(D5IE'$TV6`QCWN//K!DDDDK MT?1`..I]-HK64%C!9J$TP@@?":L^;^(>J8Y&^9<(JZN-2(75I4;HLQ.+NCN$ M9S6@)CQ#KE;.S\T*S>&.L,A=5L;OK7KA>7B'O8"83^"?/@]#X063YW+L2%CU M>TK<(]61J,Y;X'8MF(SFBY7VS\BQ5$2]U!Q=?\C$>_1'+)XP MXV](?&G5Z\^1EG,+,@3<2LNYA;$M17TC1/BX1VKKR1#(1N!;J!N&8*@YREZJ M#P%T31N"_[8R8Q1C9!C29\;"V$PW#G?\EYDAK81T`7=T=4>R)'''2]G8[2M1 MWP@1/J8HN>F)J7"\]$1=?*RK[UA_T-Q0F2&WWQ(WCD1J4ADYZPNKF;(E MA<*J#Q]1%`O4.R84I0)UL309,$?ND*$SUV402%L&%D;)LN%6>#)7%@M3&1&K MWZ`"@2";%$&COA$RV80CS%O%T5P&A-751J3"ZE(C=.$A2^\1 M'LT-X1G2#Z\+HQK:N-)*]-FG**`HI"BB**8HH0@_@6'KH:G0""8#^Z3%OAX< MB_JMV!2'0V/EU0=^KH*UY?E18O8M;?W@P8L`"&#RE0>'Y`'N3#P\/P[<<>5G M.2,6'"?`IYM,QAWXDO?2[>`&7T.H[CV)R2'0H/W4@]?`M$TO,X@_&&CFP1M1 MZK">>_"V<(`O/'AA-L"7'KPP&N#09:SEZ1TX&7I8TM,[@<.?AT>[H3M3N#,D%YP%X$X7;2R5AR^;Y^RM^#6KW\I38QV* M':32I'LA4K-OH^Q'6YUA*L'WS:J%;YK=GWOXAEW`BR[8XFUK5U6M^`&-&LNO MXL__````__\#`%!+`P04``8`"````"$`N+3D8%D&``"(&0``&0```'AL+W=O MP?#\8&TS``E8!G[4K MK59[N':,"58P1K8SF7G[K78?W-T%'K+:N1@G'U7EKK^KNXO.^I=OU=GX6C1M M65\VICV9FD9QR>M#>7G=F'_]&7Y9FD;;99=#=JXOQ<;\7K3F+]N??UI_U,U; M>RJ*SH`(EW9CGKKNZEE6FY^**FLG];6XP"?'NJFR#GYM7JWVVA39H7>JSI8S MG2ZL*BLO)HW@-8_$J(_',B_\.G^OBDM'@S3%.>M@_.VIO+8\6I4_$J[*FK?W MZY>\KJX0XJ4\E]WW/JAI5+F7O%[J)GLY0][?['F6\]C]+RA\5>9-W=;';@+A M+#I0G//*6ED0:;L^E)`!D=UHBN/&?+:]U%Z8UG;="_1W67RTTL]&>ZH_HJ8\ M_%I>"E`;YHG,P$M=OQ'3Y$`0.%O(.^QGX/?&.!3'[/W<_5%_Q$7Y>NI@NEW( MB"3F';[[19N#HA!FXK@D4EZ?80#POU&5I#1`D>Q;__PH#]UI8\X6$_=I.K/! MW'@IVBXL24C3R-_;KJ[^H48V"T6#."P(/&\$&7&<,4=X,D=G,G?4C#I!,GR<\F:\PH2))E&<29F."9E!S+:RFKUMGM5A;7V$% MY,QFAVULU6+/+4BYD["^#@(=A#J(=!#K(-%!*@$+9!':0&7^']J0,$0;GM6. M`TDL30ANP5U\'00Z"'40Z2#60:*#5`**$+#,D1`S*);;FQ6O">(%VY)<$W-7 M371';1Q8`J)PYJK)7I@(,1`)$`D1B1")$4D0266B:`([&-*$;."?7#@D#*P] M>(T0P%D]J1+LJ-&H2L)$J(1(@$B(2(1(C$B"2"H312401%%IO&*(=2\&3V)' M":FU09[Y2I5G+XRXFX](@$B(2(1(C$B"2"H3)7930*'<1F(HRH# M)3-'["%[1'Q$`D1"1")$8D021%*9*#G#":#D/)XHL583941*%!$?D0"1$)$( MD1B1!)%4)DJBI`^7S\WQ1(FUFB@E3M]A]F?=7A"IU-VI6NH^,X)A#>O!U8[1 M0!CQ]1"*V)Q$B,3"2P[MJ.]/A!$/E,J!%(5@3_^$0L1:58@262%$?$:&LS5` M)$1>$2*Q\))SGVFY"R.1NQQ(R9UT4DKRTMKO3F7^MJMA_J#ON%$V,VB?6%-% MHJBB]($WIJP*1CY'2[%?!!B%'`TU&&$4 M7SPV[<_@C.2Q=QS!/B0-2FLN]MQ*72WZDAJL>/B`(S5GK9\-N154@30(+7S$ MK88:C01)X2G_:`B/$6.4!3W8T?<:CA(X@')CDAU-@*G'\%TXBY6 MRC^MQE(>]=YP5/U)-_D)_6GSJ>C/D%KX>D-$VDFB_P\*7U@-^C.DU-P"30&S M4FINH9U"T3`('CX>T.@4B$&0[Y$/3,&MX4@GISH%I%65I^"_[-_;D2#8/@X6.,DH?>F'+'>V]4 MQ2>]LBS^C>,/+DW$^4=;:T5EBISA+-B3+UU0[(#DHM)JUN=6Z>X.@PM-K M6'KQ517-:[$OSN?6R.MWGBL9WY,*8 M2*ASQX-[E1M\YL'E`N;/<^\9DL(?[.8>?,^^P5T/OH/>X`L/OJ?=X$MO=S.S M_=+;W_S`7WJD?\2APJ5'NDC\0;3T2"^)/XB7'GR'N,%77K*ZQ>VI1YI+\+"$ ML'`/?LU>B]^RYK6\M,:Y.,(D3OLOU@V]2:>_=/45)A=NP^L.;L#['T_P%X\" M;A;A5#&-8UUW_!?R`O$WE.V_````__\#`%!+`P04``8`"````"$`IO1%EP0# M``#S"```&0```'AL+W=O7;`!*N`D>TT[=_OC$U(R*5E7P@,Q^?XC(>9 M+&Y?J])Y85)Q42*J1C&9F455ZH>]/ MO(KRFEB&N1S"(?*I-N*U=J22%92#?M7!6_4GJU*A]!55#YOFYM45`U0 MK'G)]9LA)4Z5SA\WM9!T78+OUV!$TSVW>3BCKW@JA1*Y=H'.LQL]]QQ[L0=, MRT7&P0&FW9$L3\@JF-\%(?&6"Y.@/YSMU-&]HPJQ^RIY]IW7#+(-YX0GL!;B M&:&/&89@L7>V^L&`)X9\V4?N#(29QTJ[2H_EI4 MT')9EK!E@=^6)9JXXZD?!1^3>'9'QN`]U72YD&+G0-6`I&HHUF`P!^++CL`* M8E<(3LB4.+!7!')!=3QUIQ_*XL*^ M;!OIR<973ACJ\&PO=V]R:W-H965TS^^\X8EF(,C;LW^7!FWLF)`YKW9^%,Q\CU4IS_+JN/._ M?[M_O_(]J6B5T8)7;.>_,.E_V+_[9WOAXE&>&%,>*%1RYY^4JC=A*-,3*ZD, M>,TJ^.7`14D5?!7'4-:"T4PGE45(9K-%6-*\\AN%C7#1X(=#GK([GIY+5JE& M1+""*IB_/.6U?%4K4Q>YDHK'<_T^Y64-$@]YD:L7+>I[9;KY*L+!-]G+'9`H=!9F`S%$IY05,`%Z],L>M`1VAS_K] MDF?J!)_604+FRU4$\=X#D^H^1TW?2\]2\?)G&]5J-2JD58'W5B5>!//E+'80 M"9L9Z0+OJ*+[K>`7#W8-(&5-<0]&&Q`>KPA*P=@;#-[Y2]^#N4I8AJ<](?$V M?(+6I6W,;1,#KUU,U$6$`.W(0',G8S"2L;Y83#2Q[8B)78YCT=%[Q\4= MBXDFMATQL:MQ[-K&+I+@:HLQS82V(R9T/0Z-P"?[Q5[Q!HPV85H`AA)MKOVS M'Z%+#/NX`#>[MFETXH#2.HY14SR;J`FBW@;&Q`&X'3+!$VZ')_MMX,9O(+\[ MGEH+YF*")_P/NF^!7?:.SAL4W)J4P253NP=-9+#$\7+FL,28.`"W0P8X_NV. MAB%%(XX4SY?!\OKFLBU)BUFMGC#\:,24',FV*VDQBSQAPM&(+SF2;6/28A9Y MPH>C@35=,0G;D;0`T&R3(`/_0;.-8^+PUZ(S0;-W9EZ'S"TTX?)DQ)[B5>Q" M;LVH3Q[UIPFC)S"_X:E)9NL`=N:?.ZL3!R6CEK6.$\>5C/@3F<\=3HW.')!; MSS*:G4Q8,ADQ*+>26SOJ]WK,H9()2\9'E+?UVG8HK37L=3)AR7!5>2/8-BBM M98&'UMC<;)H'_Y*)(_O(BD)Z*3_CK87`HWPWVMVH;@C^XPS'D\U-<],*NU_@ MIE/3(_N/BF->2:]@!]"&ULK)M;<^*X%H7?IVK^`\7[!&R2 M<*DD4QWP#6PPKCGG/!/B)%0#3@'I=/_[V;(DV]K+<<*I?FG"YZ7M;2W)NJ"^ M^?OG;MOZD1Z.FVQ_V[8NNNU6NE]GCYO]\VW[/_^X?PW:K>-IM7]<;;-]>MO^ ME1[;?]_]^W;X?GQ)TU.+(NR/M^V7T^EUU.D[L5IM]6T88';X2(WMZVJS32;9^VZ7[DPQR M2+>K$^5_?-F\'G6TW?HKX7:KP_>WU[_6V>Z50CQLMIO3KSQHN[5;CX+G?798 M/6SIN7]:EZNUCIU_@?"[S?J0';.GTP6%Z\A$\9F'G6&'(MW=/&[H"42UMP[I MTVW[FS5*[$&[35]!_-^G[L?)WZ_B2O7N'S6.XV:=4V^23<.`AR[X+:?`H M$!7N0&DW=R`^M![3I]7;]I1D[WZZ>7XYD=U7]$3BP4:/OR;I<4TU2F$N["L1 M:9UM*0'ZM[7;B*9!-;+ZF7^^;QY/+[?MGGUA#ZZLJVO2MQ[2X\G=B)CMUOKM M>,IV_Y,J2\6246P5A3YUE.N+JWZW9XD@#05[JN!E4=`BU%"`PN7YTN=Y=[I6 M!:GAJX*?W&FH"M"G*F!3C(;4+#)/UF59#9_<0UR61>B/+]Z%JDH6H6R^]B16 M7Q>A/U21WM?\L:BZY-T^J[>.;%AY.YVL3JN[FT/VWJ+.3RWG^+H2KQ)K),+I M%BIKLFBS'S59:JLBRC<1YK9-#T"-\4C][,>=?3V\Z?R@OK%6FGO46*9BK!6B M(XBP$PX<#EP./`Y\#@(.IAS,.`@YB#B8<[#@(.9@R4%2`1VRI_"(&NSO\$B$ M$1[IVKW7H&(:,T0K=)$)!PX'+@<>!SX'`0=3#F8J-7.TV_:SIP+S4VO>:*GG5I2L:%I'`)B`/$!>(!\8$$0*9` M9D!"(!&0.9`%D!C($DA2)89I]&;^'::),/2RI-L4AN"K3HH:72LDA6M`'"`N M$`^(#R0`,@4R`Q("B8#,@2R`Q$"60)(J,5RCF83A6OW,20]#0IV;HROU7I(> M#?ZE77T^[A0B76P"Q`'B`O&`^$`"(%,@,R`AD`C(',@"2`QD"22I$L,+FM(8 M7HBY@GUU0?HS9PLBD&F3),PFF[WH"E%A$Q`'B`O$`^(#"8!,@$!](`&0*9`8D M!!(!F0-9`(F!+($D56)X03/J,[P0:M,+29@7?`)0B`HO@#A`7"`>$!](`&0* M9`8D!!(!F0-9`(F!+($D56)X07.H,[P0:M,+29@75ZQ?%*+""R`.$!>(!\0' M$@"9`ID!"8%$0.9`%D!B($L@29487HC5N&%&ON[LTH3[S*$D#V3ZI!`SZIH9 M5:H*IQ`YB%Q$'B(?48!HBFB&*$04(9HC6B"*$2T1)08RC1.+U.J&0?/H8LDU M+4V7=2W?*]23>U1BF3]&-$'D('(1>8A\1`&B*:(9HA!1A&B.:($H1K1$E!C( M]$*L3\_P0BYG#2\D8EVES[M*H=(F3BQ`#B(7D8?(1Q0@FB*:(0H118CFB!:( M8D1+1(F!3'O$4K1JC]Q;N^C3A/F37B,7L893$O7LHB.-Q1J4AJ@*FB!R$+F( M/$0^H@#1%-$,48@H0C1'M$`4(UHB2@QDVB+6FE5;/O%"+DTIGF[\]Y9"52\` M35#E('(1>8A\1`&B*:(9HA!1A&B.:($H1K1$E!C(]$*L-<_P0BY-#2\4DK^> MR-&D0)4U_Q7;6)N(GV&H]]@T=2]V!H9LQ>F4(FV^JQ!]:.25J`QE\QOZ9:R* MJC\PW[5!J=+AIV5XC68EJL3B=PS+6!55GVW+1Z5*AY^7X35:E*@2B]\Q+F-5 M5`-6]E2J?N M('(1>26J),'KSR]5.GR`:(IH5J*&\&&ITN$C1'-$BQ(UA(]+E0Z_1)08R+1: M+*//L%JNN@VK);*-[;X!Z]5C\8N;6-O1'*9L$-R+2;V*S8TOWI5U M>6VS^[DZ$LV%/[Z?IU6-6?GU*I95H+,R8[$ET%3':LQKIE5F+-:GPWH5RROZ M4EYS':LQKX56->85UZM87DN=5X.+B8[T459F4Q:[$&7!V)%O8?W\_3JL:L_'H5 MRRK0*GK0RAVA*:MZ:,QKIF,UYA76JUA>D58UYC77JL:\%EK5F%="[F%:ATJ/'!)&#R$7D(?(1!8BFB&:( M0D01HCFB!:(8T1)18B##'C'6&?9\>969ES2=4JBRI!PCFB!R$+F(/$0^H@#1 M%-$,48@H0C1'M$`4(UHB2@QDVD+#A&%+\RJ3Y@^\UVA4664BFB!R$+D&,O.D MX?.=A&L\6M&-=\!/C5:SR=)*C"JJ!;&CUK2Z?6.O87[-8+/BK4[+* MB_+TLEE_O\_(.*J[&NO%E$@>=!,G)GD'4#L)5>C/+S94:D=&:G_?RZ**.R)%*+\RO0';+-D++:+Q$-2;9E:3R[NRFP M/,M-/RR-Q(\EE"%E*/H["E1Y=R1\4K@SIRK`NFMVE0^/YN6]>YFJ4Y-N" MG%^/Z+1&35[]49*_\+A^,$KR0^F<4TJU&5F4$?UDAW>@7KPO-D?6]OTB1I,-__5Y2!/X,LO)]49'K(3'9S/^\4+ M_4^)E'Z0[(HS34]9=M)?Z(D[Q?^]N/L7``#__P,`4$L#!!0`!@`(````(0`% M)_OE>P(``#(&```9````>&PO=V]R:W-H965TKJXIL8YW)6]U!P5]`TMO MEQ\_++;:/-L&P!%DZ&Q!&^?ZG#$K&E#<1KJ'#O]4VBCN<&EJ9GL#O!P.J98E MDTG&%)<=#0RYN81#5Y44<*_%1D'G`HF!ECN,WS:RMWLV)2ZA4]P\;_HKH56/ M%&O92O[YA-PR9 MEHM2H@.?=F*@*N@JSN\RRI:+(3^_)&SMP3>QC=Y^-K+\*CO`9&.9?`'66C][ MZ&/IM_`P>W?Z82C`-T-*J/BF==_U]@O(NG%8[10->5]Y^78/5F!"D29*4L\D M=(L!X),HZ3L#$\)?A_=6EJXIZ'06)==IG&:()VNP[D%Z3DK$QCJM?@=4O.,* M+,F.!=][EBQ*YY-I_&\2%B(:#-YSQY<+H[<$FP8E;<]]"\8Y$I]WA%8\=N7! M!9U3@K%:K,++,LG2!7O!U(D=YBY@\#EBXA'!4'141K7+E3W8*_O<^E#NPL:A M3')>9OH_,AZ,Q3D(/LFRD39'4L-HQ&G$5+\O9?\N6/5W> MYM^_L;$U-5HOT27D0KM1.O>^/LDRQ^=8@=LGL29):6P%GJYVEIFRE!PO#6\J MU#X;#@8_,GSQJ`6*O7KE,.T\GBS\5YT*PP,^]SA]K0EPSL[J6DD.GK+,[R2W MQIG2)UY$!)L8I](K=+_+,5@?@WS/Y4-3>%:8L)OY3R7P8QY&=@Y.MT[%%1Q/0]F,TAWOD4$L/ M2KZU2FV5[]#.T$;U@V?>*EU*U82JWAKGBC%:JG45-;GZVP3.IA:T`QXF8Z/? M5A10`?@S^6]IJVBHW2[8JJ4TM-2&ZRB":YJ5XA%4@Z'0UU)3&TA0U$8T!DW4 M)`*Z&%,G<=I#48,MZ(LI/%'S1TUVPXHSNX.OXDQ$P^RF+!XFEOZ9$#*P![3) M5J2M)VA;`3JS3YE,FJJ">/_=XQ;B*7LAHU%VEWGX!9O#+]@<]6TVEN4_Z_%6 MZF?W4$_-)77XJ#7`?6@\A&L`LD1QRY6NRB=%S2E%M MP$HL4L.E<-4&*V,ZAC7U4KW)-=!)65Y0"U%J&27=`W,_$LF`U&I$^O?0]`"M M*#1@P46DK&#TNQLA6/SS0I\<-:V).Y]F&G2/V5I]A6-[BV8L=EU7=-->(_DS M^KRX>^A'S8W;[TH!$?O]-!+C(JUR94!?[\3V-309XJ:BO[-*J]Z.JP`R@L[2 M>_S+[I`\36]NEW,B)B6;YHSE;+)DC+-S?G;Y4M%#:[@O1J`=!/Y-/`!$[_WS MS\4G````__\#`%!+`0(M`!0`!@`(````(0`2PA3]O@$``&`1```3```````` M``````````````!;0V]N=&5N=%]4>7!E&UL4$L!`BT`%``&``@````A M`+55,"/U````3`(```L`````````````````]P,``%]R96QS+RYR96QS4$L! M`BT`%``&``@````A`*P6G;V:`0``%1```!H`````````````````'0<``'AL M+U]R96QS+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.7: M[,@E`P``!0H``!D`````````````````DQT``'AL+W=O&PO=V]R:W-H965T=R2,``&A-`0`9`````````````````#HF``!X;"]W;W)K&UL4$L!`BT`%``&``@````A``/-A)/\`@``C@H``!D` M````````````````.DH``'AL+W=O&PO M=V]R:W-H965T&UL4$L! M`BT`%``&``@````A`#)(C"KS!```Q!(``!@`````````````````/U<``'AL M+W=O&PO&PO&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*FL!%RC M`@``(0<``!@`````````````````NJL``'AL+W=OP(``#,&```8```````````````` M`).N``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&#RW=OR(```3<<``!@````````` M````````CKH``'AL+W=O&UL4$L!`BT`%``&``@````A`"&K]#5Z`@``$08``!@` M````````````````3-X``'AL+W=O&UL4$L!`BT`%``&``@````A`+BTY&!9!@`` MB!D``!D`````````````````;.@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`';#CGFN"0``P#$``!D````````` M````````5O8``'AL+W=O&PO=V]R:W-H M965T&UL4$L!`BT`%``&``@` M```A`$9$,\4R`0``0`(``!$`````````````````M08!`&1O8U!R;W!S+V-O <&UL4$L%!@`````B`"(`(`D``!X)`0`````` ` end XML 13 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Statements of Operations (USD $)
3 Months Ended 9 Months Ended 140 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Revenues

OTC product revenue $ 25,648

Medical device revenue 14,109

Total revenues 39,757

Cost of sales 15,216

Gross profit 24,541

Operating expenses

Research and development 1,296,654 1,129,921 2,815,519 4,352,940 45,914,372

General and administrative 2,185,756 2,296,637 6,864,865 7,228,225 73,050,754

Amortization 167,780 167,780 503,340 503,340 7,292,837

Total operating loss (3,594,338) (10,183,724) (12,084,505) (126,233,422)

Gain on sale of fixed assets 55,075

Loss on extinguishment of debt (825,867)

Investment income 293 310 576 1,325 653,793

(Loss) gain on change in fair value of warrant liability (902,798) 1,246,917 (917,102) 1,435,898 4,995,099

Net interest expense (8,098,004)

Net loss (4,552,695) (2,347,111) (11,100,250) (10,647,282) (129,453,326)

Dividends on preferred stock (38,690) (43,884) (1,188,648) (145,709) (12,026,710)

Net loss applicable to common shareholders $ (4,591,385) $ (2,390,995) $ (12,288,898) $ (10,792,991) $ (141,480,036)

Basic and diluted loss per common share $ (0.03) $ (0.02) $ (0.10) $ (0.10)

Weighted average number of common shares outstanding - basic and diluted 131,573,656 113,166,988 126,503,388 112,073,836

XML 14 R10.htm IDEA: XBRL DOCUMENT

Equity Transactions	9 Months Ended
Equity Transactions	Sep. 30, 2013
Text Block [Abstract]
Equity Transactions	4. Equity Transactions (a) During the three months ended March 31, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $48,750. During the three months ended March 31, 2012, the Company issued 175,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $160,000. During the three months ended June 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $49,500. During the three months ended June 30, 2012, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $64,500. During the three months ended September 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $51,250. During the three months ended September 30, 2012, the Company issued 225,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $184,750. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model. (b) During the three months ended March 31, 2013, the Company issued 1,924,973 warrants to consultants in exchange for services. Consulting costs charged to operations were $409,640. During the three months ended March 31, 2013, 859,833 warrants were forfeited. During the three months ended March 31, 2012, the Company issued 1,003,000 warrants to consultants in exchange for services. Consulting costs charged to operations were $475,668. During the three months ended March 31, 2012, 1,500 warrants were forfeited. During the three months ended June 30, 2013, the Company issued 2,605,000 warrants to consultants in exchange for services. Consulting costs charged to operations were $931,655. During the three months ended June 30, 2013, 1,051,500 warrants were forfeited. During the three months ended June 30, 2012, the Company issued 454,500 warrants to consultants in exchange for services. Consulting costs charged to operations were $183,908. During the three months ended June 30, 2012, 4,368,644 warrants were forfeited. During the three months ended September 30, 2013, the Company issued 442,000 warrants to consultants in exchange for services. Consulting costs charged to operations were $186,223. During the three months ended September 30, 2013, 136,500 warrants were forfeited. During the three months ended September 30, 2012, the Company issued 1,732,135 warrants to consultants in exchange for services. Consulting costs charged to operations were $721,753. During the three months ended September 30, 2012, 122,833 warrants were forfeited. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model. (c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 and 2012, there was a loss recognized from the revaluation of the warrant liability of $311,062 and $148,364, respectively. For the three months ended June 30, 2013 and 2012, there was a gain recognized from the revaluation of the warrant liability of $221,149 and $222,546, respectively. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $337,244. For the three months ended September 30, 2012, there was a gain recognized from the revaluation of the warrant liability of $429,818. During the three months ended March 31, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,045,510. The Company accepted subscriptions, in the aggregate, for 5,394,013 shares of common stock and five year warrants to purchase 7,277,264 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $522,640 and issued five year fully vested warrants to purchase 539,401 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended June 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,641,501. The Company accepted subscriptions, in the aggregate, for 3,522,001 shares of common stock and five year warrants to purchase 5,283,003 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $314,173, accrued $32,500 at June 30, 2013 which was paid in July 2013 and issued five year fully vested warrants to purchase 352,200 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended September 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,613,037. The Company accepted subscriptions, in the aggregate, for 6,150,718 shares of common stock and five year warrants to purchase 9,226,077 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $564,686 and issued five year fully vested warrants to purchase 615,072 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended September 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,687,500. The Company accepted subscriptions, in the aggregate, for 3,583,333 shares of common stock and five year warrants to purchase 5,375,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Maxim Group LLC served as placement agent for the offering. In connection with the offering, the Company paid $349,375 and issued five year fully vested warrants to purchase 358,333 shares of common stock with an exercise price of $1.00 to Maxim Group LLC, which represents 10% of the total number of shares of common stock sold to investors solicited by Maxim Group LLC. (d) In March and April 2010, the Company had an issuance of 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 and 2012, there was a loss recognized from the revaluation of the warrant liability of $446,698 and $114,800, respectively. For the three months ended June 30, 2013 and 2012, there was a gain recognized from the revaluation of the warrant liability of $399,057 and $229,599, respectively. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $275,279. For the three months ended September 30, 2012, there was a gain recognized from the revaluation of the warrant liability of $817,099. Dividends on the 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. In January 2013, the Company issued 61,022 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of January 15, 2013. At March 31, 2013, the Company recognized dividends of $21,921 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended March 31, 2013 there were 593,000 shares of the Company’s redeemable preferred stock that converted into 593,000 shares of the Company’s common stock. In April 2013, the Company issued 29,384 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of April 15, 2013. At June 30, 2013, the Company recognized dividends of $22,164 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended June 30, 2013 there were 403,520 shares of the Company’s redeemable preferred stock that converted into 403,520 shares of the Company’s common stock. In July 2013, the Company issued 34,598 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 15, 2013. At September 30, 2013, the Company recognized dividends of $10,586 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2013 there were 734,999 shares of the Company’s redeemable preferred stock that converted into 734,999 shares of the Company’s common stock. (e) On February 22, 2013, the Company entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of an aggregate of $2,550,000 of Units at a purchase price of $0.75 per Unit. Each Unit consists of one share of Series A 8% Convertible Preferred Stock, par value $.001 per share, and a warrant to purchase one and one-quarter shares of the Company’s common stock, par value $.001 per share (subject to adjustment) at an exercise price of $1.00 per whole share (subject to adjustment). The total Series A 8% Convertible Preferred Stock issued was 3,400,001 shares, and the total warrants were 4,250,000. The Company used the net proceeds of the private placement for working capital, FDA trials, securing licensing partnerships, and general corporate purposes. The Company determined that warrants issued in February, 2013 with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. The proceeds received from the issuance of the preferred stock were first allocated to the fair value of the warrants with the remainder allocated to the preferred stock. The fair value of the preferred stock if converted on the date of issuance was greater than the value allocated to the preferred stock. As a result, a beneficial conversion amount was recorded upon issuance. The fair value of the warrants recorded from the February 2013 issuance was $1,297,950 resulting in a beneficial conversion amount of $1,025,950. The beneficial conversion has been recorded as a deemed dividend as of March 31, 2013 and is included in dividends on preferred stock on the consolidated statements of operations. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 there was a loss recognized from the revaluation of the warrant liability of $165,750. For the three months ended June 30, 2013 there was a gain recognized from the revaluation of the warrant liability of $289,000. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $290,275. Dividends on the Series A 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock although was required to pay the initial dividends due in cash. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. At March 31, 2013, the Company recognized dividends of $29,063 which are included in dividends on preferred stock on the consolidated statement of operations and were paid in April 2013. At June 30, 2013, the Company recognized dividends of $50,860 which are included in dividends on preferred stock on the consolidated statement of operations. In July 2013, the Company issued 79,401 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 15, 2013. At September 30, 2013, the Company recognized dividends of $28,104 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2013 there were 441,667 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 441,667 shares of the Company’s common stock. On June 23, 2013, our agreement with Lincoln Park Capital Fund, LLC expired. On July 22, 2013 the Company entered into a Purchase Agreement with Alpha Capital Anstalt pursuant to which the Company may, in the Company’s sole discretion, direct the purchase up to $30,000,000 of the Company’s common stock over the 30-month term of the Purchase Agreement. From time to time during the term of the Purchase Agreement, the Company may, in its sole discretion direct the purchase up to 100,000 shares of the Company’s common stock at a per share purchase price equal to the lesser of (i) the lowest sale price of the Company’s common stock reported on the OTCQB on the purchase date and (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 12 consecutive business days ending on the business day immediately preceding the purchase date. The Company may, under certain circumstances, at its discretion, increase the amount of common stock that it sells on each purchase date. The committed obligation under any single regular purchase shall not exceed $250,000, unless the parties mutually agree to increase the dollar amount of any regular purchase. In no event may Alpha Capital Anstalt purchase shares of the Company’s common stock for less than $0.75 per share. In consideration of entering into the Purchase Agreement and making the commitment to purchase the Purchase Shares, the Company issued 250,000 shares of the Company’s common stock to Alpha Capital Anstalt. Costs charged to operations for this commitment fee were $162,500. The Purchase Agreement may be terminated by the Company at any time, at its discretion, without cost to the Company.

XML 15 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 16 R24.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments - Warrant Liability Measured at Fair Value on a Recurring Basis (Detail) (Recurring [Member], Warrants [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
Derivative instruments:
Warrant liability	$ 3,514,622	$ 1,299,570
Level 1 [Member]
Derivative instruments:
Warrant liability
Level 2 [Member]
Derivative instruments:
Warrant liability
Level 3 [Member]
Derivative instruments:
Warrant liability	$ 3,514,622	$ 1,299,570

XML 17 R18.htm IDEA: XBRL DOCUMENT

Basic and Diluted Loss Per Common Share - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common shares excluded from the calculation	66,238,507	26,042,116
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common shares excluded from the calculation	15,322,206	15,140,956
8% Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common shares excluded from the calculation	3,705,000	2,941,665

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

XML 18 R25.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments - Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis (Detail) (Recurring [Member], Level 3 [Member], Warrants [Member], USD $)	9 Months Ended
	Sep. 30, 2013
Recurring [Member] \| Level 3 [Member] \| Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	$ 1,299,570
Issuance of warrants	1,297,950
Net loss included in earnings	917,102
Exercise of warrants
Ending Balance	$ 3,514,622

XML 19 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flow (USD $)	9 Months Ended		140 Months Ended
Condensed Consolidated Statements of Cash Flow (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash Flows From Operating Activities
Net loss	$ (11,100,250)	$ (10,647,282)	$ (129,453,326)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	4,650	4,579	450,616
Amortization of patents	503,340	503,340	7,292,837
Amortization of original issue discount			3,845,721
Amortization of commitment fee			310,866
Amortization of prepaid consultant expense			1,295,226
Amortization of deferred loan costs			2,261,584
Accretion of United States Treasury Bills			(373,295)
Loss on extinguishment of debt			825,867
Loss on exercise of warrants			236,146
Beneficial conversion of convertible interest			55,976
Convertible interest			389,950
Compensation through issuance of stock options	142,310	183,028	14,540,039
Compensation through issuance of stock			932,000
Issuance of stock for services	312,000	409,250	9,365,511
Issuance of warrants for services	1,527,518	1,381,329	7,724,087
Issuance of warrants for contractual obligations			985,010
Gain on sale of equipment			(55,075)
Loss (gain) on change in fair value of warrant liability	917,102	(1,435,898)	(4,995,099)
Change in assets and liabilities
Prepaid expenses and other current assets	(45,284)	(16,284)	(45,284)
Accounts payable	(40,971)	179,513	198,819
Accrued expenses	72,014	1,512,859	489,633
Net cash used in operating activities	(7,707,571)	(7,925,566)	(83,722,191)
Cash Flows From Investing Activities
Proceeds from sale of fixed assets			180,075
Capital expenditures	(6,650)	(15,885)	(96,570)
Proceeds from sales of investments			37,010,481
Purchases of investments			(36,637,186)
Net cash (used in) provided by investing activities	(6,650)	(15,885)	456,800
Cash Flows From Financing Activities
Net proceeds from loans from stockholder			174,000
Proceeds from convertible debt			6,706,795
Net proceeds from sales of preferred stock and warrants	2,550,000		11,458,131
Net proceeds from sales of common stock and warrants	12,204,174	2,077,796	55,018,695
Proceeds from exercises of warrants and stock options	21,000		21,099,014
Cash paid for preferred dividends	(29,063)		(29,063)
Cash paid to retire convertible debt			(2,385,959)
Cash paid for deferred loan costs			(747,612)
Premium paid on extinguishments of debt			(170,519)
Purchase and retirement of common stock			(48,000)
Net proceeds from sale of non-controlling interest in Pure-ific Corporation			443,500
Net cash provided by financing activities	14,746,111	2,077,796	91,518,982
Net change in cash and cash equivalents	7,031,890	(5,863,655)	8,253,591
Cash and cash equivalents, at beginning of period	1,221,701	7,705,773
Cash and cash equivalents, at end of period	$ 8,253,591	$ 1,842,118	$ 8,253,591

XML 20 R8.htm IDEA: XBRL DOCUMENT

Recapitalization and Merger	9 Months Ended
Recapitalization and Merger	Sep. 30, 2013
Business Combinations [Abstract]
Recapitalization and Merger	2. Recapitalization and Merger Provectus Pharmaceuticals, Inc., formerly known as “Provectus Pharmaceutical, Inc.” and “SPM Group, Inc.,” was incorporated under Colorado law on May 1, 1978. SPM Group ceased operations in 1991, and became a development-stage company effective January 1, 1992, with the new corporate purpose of seeking out acquisitions of properties, businesses, or merger candidates, without limitation as to the nature of the business operations or geographic location of the acquisition candidate. On April 1, 2002, SPM Group changed its name to “Provectus Pharmaceutical, Inc.” and reincorporated in Nevada in preparation for a transaction with Provectus Pharmaceuticals, Inc., a privately-held Tennessee corporation (“PPI”). On April 23, 2002, an Agreement and Plan of Reorganization between Provectus Pharmaceutical and PPI was approved by the written consent of a majority of the outstanding shares of Provectus Pharmaceutical. As a result, Provectus Pharmaceuticals, Inc. issued 6,680,000 shares of common stock in exchange for all of the issued and outstanding shares of PPI. As part of the acquisition, Provectus Pharmaceutical changed its name to “Provectus Pharmaceuticals, Inc.” and PPI became a wholly-owned subsidiary of Provectus. This transaction was recorded as a recapitalization of PPI. On November 19, 2002, the Company acquired Valley Pharmaceuticals, Inc., a privately-held Tennessee corporation formerly known as Photogen, Inc., by merging PPI with and into Valley and naming the surviving corporation “Xantech Pharmaceuticals, Inc.” Photogen, Inc. was separated from Photogen Technologies, Inc. in a non-pro-rata split-off to some of its shareholders. The assets of Photogen, Inc. consisted primarily of the equipment and intangibles related to its therapeutic activity and were recorded at their fair value. The majority shareholders of Valley were also the majority shareholders of Provectus. Valley had no revenues prior to the transaction with the Company. By acquiring Valley, the Company acquired its intellectual property, including issued U.S. patents and patentable inventions.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Sep. 30, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

5. Stock-Based Compensation

The following is a summary of nonvested stock option activity for the nine months ended September 30, 2013:


	Number of Shares			Weighted Average Grant-Date Fair Value
Nonvested at December 31, 2012		—		$	—
Granted		250,000		$	0.57
Vested		(250,000	)	$	0.57
Canceled		—			—

Nonvested at September 30, 2013		—		$	—

As of September 30, 2013, there was no unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the Plan.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

XML 22 R9.htm IDEA: XBRL DOCUMENT

Basic and Diluted Loss Per Common Share	9 Months Ended
Basic and Diluted Loss Per Common Share	Sep. 30, 2013
Earnings Per Share [Abstract]
Basic and Diluted Loss Per Common Share	3. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Loss per share excludes the impact of outstanding options and warrants and convertible preferred stock as they are antidilutive. Potential common shares excluded from the calculation at September 30, 2013 and 2012, respectively, relate to 66,238,507 and 26,042,116 from warrants, 15,322,206 and 15,140,956 from options, and 3,705,000 and 2,941,665 from convertible preferred shares.

- Definition

The entire disclosure for earnings per share.

+ References+ Details

EXCEL 23 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]F-&4R9CAD.5\Y93`R7S1C.#5?83(U9E]F9F(Q M-3'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7U-T M;SPO>#I.86UE/@T*("`@(#QX.E=O#I7;W)KF%T:6]N7V%N9%]-97)G97(\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E M;%=O#I7 M;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?;V9?1FEN86YC:6%L7TEN M#I7;W)KF%T:6]N7V%N9%]-97)G97)?060\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I%>&-E M;%=O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O5]4 M#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65? M;V9?1FEN86YC:6%L7TEN#I7;W)K#I%>&-E;%=O#I!8W1I=F53 M:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)V9A;'-E/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!296=I'0^)RTM,3(M,S$\2!&:6QE3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)T%C8V5L97)A=&5D($9I M;&5R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^)SQS<&%N/CPO2!#;VUM;VX@4W1O8VLL(%-H87)E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-&4R9CAD.5\Y93`R M7S1C.#5?83(U9E]F9F(Q-3'0O M:'1M;#L@8VAA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N M/CPO2D[(%-EF5D.R`Q,SDL.33PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]F-&4R9CAD.5\Y93`R7S1C.#5?83(U9E]F9F(Q-3

'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P M.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P M.R9N8G-P.SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XG)FYB'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]F-&4R9CAD.5\Y93`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`@("`@("`\ M=&0@8VQA'0^)SQS<&%N/CPO&5R8VES92!O9B!W M87)R86YT'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65E(&-O;7!E;G-A M=&EO;B!F'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!O9B!W87)R86YT'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO&5R8VES92!O9B!W87)R86YT'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO65E(&-O;7!E;G-A=&EO;B!F'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!O9B!W87)R M86YT'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R M8VES92!O9B!W87)R86YT'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO65E(&-O;7!E;G-A=&EO;B!F'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!O9B!W87)R86YT M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO65E(&-O;7!E;G-A=&EO;B!F'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-&4R M9CAD.5\Y93`R7S1C.#5?83(U9E]F9F(Q-3'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N(&]F('!A=&5N=',\+W1D/@T*("`@("`@("`\ M=&0@8VQAF%T:6]N(&]F('!R97!A:60@8V]N'!E;G-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB'0^)SQS<&%N M/CPOF%T:6]N(&]F(&1E9F5R2!" M:6QL'0^)R9N8G-P.R9N M8G-P.SQS<&%N/CPO'1I;F=U:7-H;65N="!O9B!D96)T M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N M8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P M.R9N8G-P.SQS<&%N/CPO&5R8VES97,@;V8@ M=V%R'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!F:6YA;F-I;F<@86-T:79I=&EE7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQD:78^ M#0H@/'`@3I4:6UE2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E M$$P.S,P M+"`R,#$S(&%R92!N;W0@;F5C97-S87)I;'D@:6YD:6-A=&EV92!O9B!T:&4- M"B!R97-U;'1S('1H870@;6%Y(&)E(&5X<&5C=&5D(&9O65A$$P.S,Q+`T*(#(P,3,N(%1H92!#;VUP86YY(&AA M'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQD M:78^#0H@/'`@3I4:6UE M#(P,4,[4')O=F5C='5S#0H@4&AA M0T*(&5F9F5C=&EV92!*86YU87)Y)B-X03`[ M,2P@,3DY,BP@=VET:"!T:&4@;F5W(&-OF4Z,3!P=#L@9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!/;B!!<')I;"8C>$$P.S$L(#(P M,#(L(%-032!'#(P,4,[4%!))B-X,C`Q1#LI+B!/;B!!<')I;"8C>$$P.S(S+"`R M,#`R+"!A;B!!9W)E96UE;G0@86YD(%!L86X-"B!O9B!296]R9V%N:7IA=&EO M;B!B971W965N(%!R;W9E8W1U2!O9B!T:&4@;W5T6QE/3-$)VUA3I4:6UE0T*(%!H87)M86-E=71I M8V%L2!K;F]W;B!A2!A;F0@;F%M:6YG M('1H92!S=7)V:79I;F<@8V]R<&]R871I;VX@)B-X,C`Q0SM886YT96-H#0H@ M4&AA2P@:6YC;'5D:6YG(&ES'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQD:78^#0H@/'`@3I4:6UE&-L=61E9"!F3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-&4R9CAD.5\Y M93`R7S1C.#5?83(U9E]F9F(Q-3'0O:'1M;#L@8VAA2!42!46QE/3-$)TU! M4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE2`M+3X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[($9/3E0M1D%- M24Q9.B!4:6UE$$P.S,Q+"`R,#$R M+"!T:&4@0V]M<&%N>0T*(&ES6QE/3-$)TU! M4D=)3BU43U`Z(#$R<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[($9/3E0M1D%- M24Q9.B!4:6UE#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4 M+5-)6D4Z(#%P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU43U`Z(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*("AB*2!$=7)I M;F<@=&AE('1H$$P.S,Q+"`R,#$S M+"!T:&4@0V]M<&%N>0T*(&ES$$P.S,Q M+"`R,#$R+"!T:&4-"B!#;VUP86YY(&ES2!I&-H86YG92!F;W(-"B!S97)V:6-E&-H86YG M90T*(&9O6QE/3-$)TU!4D=)3BU43U`Z(#$R M<'0[($9/3E0M1D%-24Q9.B!4:6UE&5R8VES92!P2!IF5D(&9R;VT@=&AE#0H@$$P.S,P+"`R,#$R+"!T:&5R90T*('=A M0T*('1H92!I;G9E&5R8VES92!P M65A2!V97-T960@=V%R&5R8VES92!P6QE/3-$)TU! M4D=)3BU43U`Z(#$R<'0[($9/3E0M1D%-24Q9.B!4:6UE2!P86ED#0H@)#,Q-"PQ-S,L(&%C8W)U960@)#,R+#4P,"!A="!*=6YE)B-X M03`[,S`L(#(P,3,@=VAI8V@@=V%S('!A:60@:6X-"B!*=6QY(#(P,3,@86YD M(&ES2!P86ED#0H@)#4V-"PV.#8@86YD(&ES&EM#0H@ M1W)O=7`@3$Q#('-E2!P86ED("0S-#DL,S2!- M87AI;2!'6QE/3-$)TU!4D=)3BU43U`Z M(#$R<'0[($9/3E0M1D%-24Q9.B!4:6UE2!D971E&5R8VES92!P2!I2!IF5D M(&9R;VT@=&AE(')E=F%L=6%T:6]N(&]F('1H90T*('=AF5D(&9R;VT@=&AE#0H@$$P M.S,P+"`R,#$R+"!T:&5R92!W87,@82!G86EN(')E8V]G;FEZ960-"B!F6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6UE;G0@9&%T92X@5&AE(&1I=FED M96YD2!A;G1I8VEP871E M6EN9R!T:&4@9&EV:61E;F1S(&EN(&-O;6UO;B!S=&]C:RX@5&AE M($-O;7!A;GD@:&%S(&$@9&5F:6-I=`T*(&%N9"P@87,@82!R97-U;'0L('1H M92!D:79I9&5N9',@87)E(')E8V]R9&5D(&%G86EN2`R,#$S+"!T:&4@0V]M<&%N M>2!I28C>$$P.S$U+"`R,#$S+B!! M="!-87)C:"8C>$$P.S,Q+"`R,#$S+`T*('1H92!#;VUP86YY(')E8V]G;FEZ M960@9&EV:61E;F1S(&]F("0R,2PY,C$@=VAI8V@@87)E(&EN8VQU9&5D(&EN M#0H@9&EV:61E;F1S(&]N('!R969E28C>#(P,3D[2!R96-O9VYI>F5D(&1I=FED M96YD28C>#(P,3D[2`R,#$S+"!T:&4@0V]M<&%N>2!I28C>$$P.S$U+"`R,#$S+B!!="!397!T96UB97(F(WA!,#LS M,"P@,C`Q,RP-"B!T:&4@0V]M<&%N>2!R96-O9VYI>F5D(&1I=FED96YD2P@,C`Q,R!W:71H#0H@=&AE(%-E&5R M8VES92!P2!I$$P M.S,P+"`R,#$S('1H97)E('=A2!O9B`D M,C@Y+#`P,"X@1F]R('1H92!T:')E92!M;VYT:',@96YD960-"B!397!T96UB M97(F(WA!,#LS,"P@,C`Q,R!T:&5R92!W87,@82!L;W-S(')E8V]G;FEZ960@ M9G)O;2!T:&4-"B!R979A;'5A=&EO;B!O9B!T:&4@=V%R6QE/3-$)TU!4D=)3BU43U`Z M(#$R<'0[($9/3E0M1D%-24Q9.B!4:6UE0T*(&%N=&EC:7!A=&5S('!A>6EN9R!T:&4@9&EV:61E;F1S(&EN(&-O M;6UO;B!S=&]C:R!A;'1H;W5G:"!W87,-"B!R97%U:7)E9"!T;R!P87D@=&AE M(&EN:71I86P@9&EV:61E;F1S(&1U92!I;B!C87-H+B!4:&4@0V]M<&%N>2!H M87,-"B!A(&1E9FEC:70@86YD+"!A$$P.S,Q+"`R,#$S+"!T:&4@0V]M<&%N>0T* M(')E8V]G;FEZ960@9&EV:61E;F1S(&]F("0R.2PP-C,@=VAI8V@@87)E(&EN M8VQU9&5D(&EN(&1I=FED96YD2`R,#$S+"!T:&4@0V]M<&%N>2!I28C>$$P.S$U+"`R,#$S+B!!="!397!T96UB M97(F(WA!,#LS,"P@,C`Q,RP@=&AE($-O;7!A;GD-"B!R96-O9VYI>F5D(&1I M=FED96YD2!E;G1E2P@:6X@=&AE($-O M;7!A;GDF(W@R,#$Y.W,@2!M87DL(&EN(&ET28C>#(P,3D[7,@ M96YD:6YG(&]N('1H92!B=7-I;F5S2P@=6YD M97(@8V5R=&%I;@T*(&-I28C>#(P,3D[2!B90T*('1E3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]F-&4R9CAD.5\Y93`R7S1C.#5?83(U9E]F9F(Q-3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)TU!4D=)3BU43U`Z M(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE&)R;"QB;V1Y("TM M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-) M6D4Z(#$P<'0G/@T*($]N92!E;7!L;WEE92!O9B!T:&4@0V]M<&%N>2!E>&5R M8VES960@,3@L-S4P(&]P=&EO;G,@870@86X@97AE28C>$$P.S(Y+"`R,#$S+B!/;B!!=6=U28C>$$P.S$T+"`R,#$R+"!T:&4@0V]M<&%N>2!I M2!T0T*('-U8FIE8W1I=F4@87-S=6UP=&EO;G,@ M:6YC;'5D:6YG('1H92!E>'!E8W1E9"!V;VQA=&EL:71Y(&9A8W1O65E(&%N9"!B;V%R9"!M96UB97(@'!E;G-E('=H:6-H(')E;&%T97,@=&\@=&AE M(&9A:7(@=F%L=64@;V8-"B!S=&]C:R!O<'1I;VYS+B!);F-L=61E9"!I;B!T M:&4@2P@;V8@6QE M/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D]. M5"U325I%.B`Q<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)' M24XM5$]0.B`P<'0[($9/3E0M1D%-24Q9.B!4:6UE2!O9B!N;VYV97-T960@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQB/E=E:6=H=&5D)B-X03`[079E$$P.SPO=&0^#0H@/"]T2`M+3X- M"B`\='(@6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($YO;G9E$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(U,"PP M,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-3<\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$ M14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%9E$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R-3`L,#`P/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z M(#$P<'0G/@T*($YO;G9E6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A M8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[($9/3E0M1D%- M24Q9.B!4:6UE'1087)T7V8T93)F.&0Y7SEE,#)?-&,X-5]A,C5F7V9F8C$U-S!E-F5B-PT* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F-&4R9CAD.5\Y93`R7S1C M.#5?83(U9E]F9F(Q-3'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!46QE/3-$)TU! M4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE2!P86ED(&]N92!N;VXM96UP;&]Y964@;65M8F5R(&]F M('1H92!B;V%R9"`D-#@L,#`P(&9O<@T*(&-O;G-U;'1I;F<@$$P.S,P+"`R,#$S+B!4:&4- M"B!#;VUP86YY('!A:60@86YO=&AE$$P.S,P+"`R,#$S+B!4:&4- M"B!#;VUP86YY('!A:60@82!T:&ER9"!N;VXM96UP;&]Y964@;65M8F5R(&]F M('1H92!B;V%R9"`D-S4L,#`P(&9O<@T*(&-O;G-U;'1I;F<@$$P.S,P+"`R,#$S+CPO<#X- M"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&)R;"QB;V1Y("TM/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU43U`Z(#9P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T* M(%1H92!&05-")B-X,C`Q.3MS(&%U=&AO'!A;F1S#0H@ M9&ES8VQO2!O9B!T:&4@:6YF;W)M871I;VX@=7-E9"!T;R!D971E6QE/3-$)TU! M4D=)3BU43U`Z(#9P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($QE=F5L M(#$Z(%%U;W1E9"!M87)K970@<')I8V5S(&EN(&%C=&EV92!M87)K971S(&9O M6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P M<'0G/@T*($QE=F5L(#(Z($]B7-I6EN9R!V86QU92!D=64@ M=&\@=&AE(')E;&%T:79E;'D-"B!S:&]R="!M871U2!O9B!S=6-H(&EN M2!M86YA9V5M96YT('=I=&@@=&AE M(&%S2!V M86QU871I;VX@2!U2!T:&%T('1H92!W87)R86YT#0H@ M97AE2!T:&%T('1H92!W87)R86YT#0H@97AE M$$P.S,P+"`R,#$S(&9O&5R8VES92!P2!R86YG M92!O9B`U.2XP)2!T;PT*(#4Y+C0E(&%N9"!A(')I2!T:&%T#0H@=&AE('=A2!T:&%T#0H@=&AE('=A$$P M.S,P+"`R,#$S(&9O&5R8VES92!P2!T:&%T('1H92!W87)R86YT#0H@97AE2!T:&%T#0H@=&AE('=A$$P.S,P M+"`R,#$S(&9O&5R8VES92!P6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/ M33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B M;&4@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.S(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z M(#$P<'0G/@T*(%=A$$P M.S,P+"`R,#$S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-3$T+#8R M,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XS+#4Q-"PV,C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-) M6D4Z(#$P<'0G/@T*(%=A$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$L,CDY+#4W,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@ M16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)' M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4 M:6UE2!L M:6%B:6QI='D@;65A28C>$$P.S$L M(#(P,3,@=&\@4V5P=&5M8F5R)B-X03`[,S`L#0H@,C`Q,R!F;VQL;W=S.CPO M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A M8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P2`M+3X-"B`\='(@6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z M(#$P<'0G/@T*($)A;&%N8V4@870@2F%N=6%R>28C>$$P.S$L(#(P,3,\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,CDW+#DU,#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XY,36QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE&5R8VES92!O9B!W87)R86YT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P M.S,P+"`R,#$S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F M-&4R9CAD.5\Y93`R7S1C.#5?83(U9E]F9F(Q-3'0O:'1M;#L@8VAA2!4'0@0FQO8VL@6T%B'0^)SQS<&%N/CPO6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[($9/3E0M1D%- M24Q9.B!4:6UE&5R8VES92!P M2!IF5D(&9R;VT@=&AE#0H@$$P.S,P+"`R,#$R+"!T:&5R90T*('=A65A2!P86ED#0H@)#4R,BPV-#`@86YD(&ES65A M2!V97-T960@=V%R2!T:&4- M"B!I;G9E&5R8VES92!P65A2!V97-T960@=V%R&5R8VES M92!P6QE/3-$)TU!4D=)3BU4 M3U`Z(#$R<'0[($9/3E0M1D%-24Q9.B!4:6UE0T*(&-O;7!L971E9"!A('!R:79A=&4@;V9F97)I;F<@;V8@ M8V]M;6]N('-T;V-K(&%N9"!W87)R86YT0T*(&%C8V5P=&5D('-U8G-C2!P86ED#0H@)#4V-"PV.#8@86YD(&ES65A2!U65A<@T*(&9U;&QY M('9E&EM($=R;W5P($Q,0RP@=VAI8V@-"B!R97!R97-E;G1S(#$P M)2!O9B!T:&4@=&]T86P@;G5M8F5R(&]F('-H87)E2!H860@86X@:7-S=6%N8V4@;V8@."4-"B!# M;VYV97)T:6)L92!0&5R8VES92!P2!W87,@9&5T97)M:6YE9`T*(&)A$$P.S,Q+"`R,#$S#0H@ M86YD(#(P,3(L('1H97)E('=A2!O9B`D M-#0V+#8Y."!A;F0@)#$Q-"PX,#`L(')E2X@1F]R('1H90T* M('1HF5D(&9R;VT@=&AE(')E M=F%L=6%T:6]N(&]F('1H92!W87)R86YT(&QI86)I;&ET>2!O9@T*("0S.3DL M,#4W(&%N9"`D,C(Y+#4Y.2P@$$P.S,P+"`R,#$S('1H97)E M('=A2!O9B`D,CF5D#0H@9G)O;2!T:&4@2!T:&4@;6%R:V5T('!R:6-E(&]F('1H92!S=&]C:PT*(&]N M('1H92!D:79I9&5N9"!P87EM96YT(&1A=&4N(%1H92!D:79I9&5N9',@87)E M('!A>6%B;&4@<75A2!R96-O9VYI>F5D(&1I=FED M96YD$$P.S,Q+"`R,#$S('1H97)E#0H@=V5R92`U M.3,L,#`P('-H87)E28C>#(P,3D[$$P.S$U+"`R,#$S+B!!="!*=6YE)B-X03`[,S`L M(#(P,3,L('1H90T*($-O;7!A;GD@$$P.S,P+"`R,#$S('1H97)E#0H@=V5R92`T,#,L-3(P('-H M87)E28C>#(P,3D[3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]F-&4R9CAD.5\Y93`R7S1C.#5?83(U9E]F9F(Q-3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P M<'0G/@T*(%1H92!F;VQL;W=I;F<@:7,@82!S=6UM87)Y(&]F(&YO;G9E$$P.S,P+"`R,#$S.CPO<#X-"B`\<"!S='EL M93TS1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$ M)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-&4R9CAD.5\Y93`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`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-3$T+#8R,CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$2!,:6%B:6QI='D@365A'0^)SQD:78^#0H@/'`@$$P.S,P+`T*(#(P,3,@9F]L;&]W M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.S$L,CDY+#4W,#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#(Y-RPY-3`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T* M($YE="!L;W-S(&EN8VQU9&5D(&EN(&5A$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-3$T+#8R,CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@ M,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\(2TM("]X M8G)L+&YS("TM/CPO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879AF%T:6]N(&%N9"!-97)G97(@+2!!9&1I=&EO;F%L($EN9F]R;6%T M:6]N("A$971A:6PI/&)R/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO&-L=61E9"!F'0^)SQS<&%N/CPO&-L M=61E9"!F'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&EM=6T@6TUE M;6)E&EM=6T@6TUE;6)E'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)S4@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!O9B!787)R86YT/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65A'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@;V8@9G5L M;'D@=F5S=&5D('=A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2`S,2P@,C`Q,SQB'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-&4R9CAD.5\Y93`R7S1C.#5? M83(U9E]F9F(Q-3'0O:'1M;#L@ M8VAA'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P M.R9N8G-P.SQS<&%N/CPO3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-&4R9CAD.5\Y93`R7S1C M.#5?83(U9E]F9F(Q-3'0O:'1M M;#L@8VAA65E/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$65E(%M-96UB97)=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XW-2PP,#`\'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S(@>65A7,\'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M7,\7,\&EM=6T@6TUE;6)E'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)S0@>65A7,\'0^)S0@>65A&5R8VES92!P3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-&4R9CAD M.5\Y93`R7S1C.#5?83(U9E]F9F(Q-3'0O:'1M;#L@8VAA'1087)T7V8T93)F.&0Y7SEE,#)?-&,X 7-5]A,C5F7V9F8C$U-S!E-F5B-RTM#0H` ` end XML 24 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 234 214 1 false 30 0 false 5 false false R1.htm 101 - Document - Document and Entity Information Sheet http://pvct.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://pvct.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://pvct.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations Sheet http://pvct.com/taxonomy/role/StatementOfIncome Condensed Consolidated Statements of Operations false false R5.htm 106 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://pvct.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Consolidated Statements of Stockholders' Equity false false R6.htm 107 - Statement - Condensed Consolidated Statements of Cash Flow Sheet http://pvct.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flow false false R7.htm 108 - Disclosure - Basis of Presentation Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Basis of Presentation false false R8.htm 109 - Disclosure - Recapitalization and Merger Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock Recapitalization and Merger false false R9.htm 110 - Disclosure - Basic and Diluted Loss Per Common Share Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Basic and Diluted Loss Per Common Share false false R10.htm 111 - Disclosure - Equity Transactions Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsEquityTransactionsTextBlock Equity Transactions false false R11.htm 112 - Disclosure - Stock-Based Compensation Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation false false R12.htm 113 - Disclosure - Related Party Transaction Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transaction false false R13.htm 114 - Disclosure - Fair Value of Financial Instruments Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value of Financial Instruments false false R14.htm 115 - Disclosure - Equity Transactions (Policies) Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsEquityTransactionsTextBlockPolicies Equity Transactions (Policies) false false R15.htm 116 - Disclosure - Stock-Based Compensation (Tables) Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) false false R16.htm 117 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value of Financial Instruments (Tables) false false R17.htm 118 - Disclosure - Recapitalization and Merger - Additional Information (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureRecapitalizationAndMergerAdditionalInformation Recapitalization and Merger - Additional Information (Detail) false false R18.htm 119 - Disclosure - Basic and Diluted Loss Per Common Share - Additional Information (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureBasicAndDilutedLossPerCommonShareAdditionalInformation Basic and Diluted Loss Per Common Share - Additional Information (Detail) false false R19.htm 120 - Disclosure - Equity Transactions - Additional Information (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureEquityTransactionsAdditionalInformation Equity Transactions - Additional Information (Detail) false false R20.htm 121 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) false false R21.htm 122 - Disclosure - Stock-Based Compensation - Summary of Nonvested Stock Option Activity (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfNonvestedStockOptionActivity Stock-Based Compensation - Summary of Nonvested Stock Option Activity (Detail) false false R22.htm 123 - Disclosure - Related Party Transaction - Additional Information (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformation Related Party Transaction - Additional Information (Detail) false false R23.htm 124 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation Fair Value of Financial Instruments - Additional Information (Detail) false false R24.htm 125 - Disclosure - Fair Value of Financial Instruments - Warrant Liability Measured at Fair Value on a Recurring Basis (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsWarrantLiabilityMeasuredAtFairValueOnARecurringBasis Fair Value of Financial Instruments - Warrant Liability Measured at Fair Value on a Recurring Basis (Detail) false false R25.htm 126 - Disclosure - Fair Value of Financial Instruments - Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsReconciliationOfTheWarrantyLiabilityMeasuredAtFairValueOnARecurringBasis Fair Value of Financial Instruments - Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis (Detail) false false All Reports Book All Reports Process Flow-Through: 103 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: Removing column 'Dec. 31, 2008' Process Flow-Through: Removing column 'Dec. 31, 2007' Process Flow-Through: Removing column 'Dec. 31, 2006' Process Flow-Through: Removing column 'Dec. 31, 2005' Process Flow-Through: Removing column 'Dec. 31, 2004' Process Flow-Through: Removing column 'Dec. 31, 2003' Process Flow-Through: Removing column 'Dec. 31, 2002' Process Flow-Through: Removing column 'Apr. 23, 2002' Process Flow-Through: Removing column 'Jan. 31, 2002' Process Flow-Through: 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: Removing column 'Feb. 22, 2013' Process Flow-Through: 105 - Statement - Condensed Consolidated Statements of Operations Process Flow-Through: Removing column '3 Months Ended Apr. 23, 2002' Process Flow-Through: Removing column '9 Months Ended Dec. 31, 2002' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2012' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2011' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2010' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2009' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2008' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2007' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2006' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2005' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2004' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2003' Process Flow-Through: 107 - Statement - Condensed Consolidated Statements of Cash Flow pvct-20130930.xml pvct-20130930.xsd pvct-20130930_cal.xml pvct-20130930_def.xml pvct-20130930_lab.xml pvct-20130930_pre.xml true true XML 25 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Accumulated depreciation on equipment and furnishings $ 427,615 $ 422,965

Amortization on patents 7,292,837 6,789,497

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 25,000,000 25,000,000

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 250,000,000 250,000,000

Common stock, shares issued 139,974,331 118,427,925

Common stock, shares outstanding 139,974,331 118,427,925

8% Convertible Preferred Stock [Member]

Preferred stock, shares issued 746,666 2,478,185

Preferred stock, shares outstanding 746,666 2,478,185

Preferred stock, liquidation preference per share $ 0.75 $ 0.75

Aggregate liquidation preference 570,585 1,896,117

Convertible preferred stock 8.00% 8.00%

Series A 8% Convertible Preferred Stock [Member]

Preferred stock, shares issued 2,958,334

Preferred stock, shares outstanding 2,958,334

Preferred stock, liquidation preference per share $ 0.75 $ 0.75

Aggregate liquidation preference $ 2,246,855 $ 2,246,855

Convertible preferred stock 8.00% 8.00%

XML 26 R14.htm IDEA: XBRL DOCUMENT

Equity Transactions (Policies)	9 Months Ended
Equity Transactions (Policies)	Sep. 30, 2013
Text Block [Abstract]
Derivatives Policies	(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 and 2012, there was a loss recognized from the revaluation of the warrant liability of $311,062 and $148,364, respectively. For the three months ended June 30, 2013 and 2012, there was a gain recognized from the revaluation of the warrant liability of $221,149 and $222,546, respectively. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $337,244. For the three months ended September 30, 2012, there was a gain recognized from the revaluation of the warrant liability of $429,818. During the three months ended March 31, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,045,510. The Company accepted subscriptions, in the aggregate, for 5,394,013 shares of common stock, and five year warrants to purchase 7,277,264 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $522,640 and issued five year fully vested warrants to purchase 539,401 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended June 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,641,501. The Company accepted subscriptions, in the aggregate, for 3,522,001 shares of common stock, and five year warrants to purchase 5,283,003 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $314,173, accrued $32,500 at June 30, 2013 which was paid in July 2013 and issued five year fully vested warrants to purchase 352,200 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended September 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,613,037. The Company accepted subscriptions, in the aggregate, for 6,150,718 shares of common stock, and five year warrants to purchase 9,226,077 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $564,686 and issued five year fully vested warrants to purchase 615,072 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended September 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,687,500. The Company accepted subscriptions, in the aggregate, for 3,583,333 shares of common stock, and five year warrants to purchase 5,375,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Maxim Group LLC served as placement agent for the offering. In connection with the offering, the Company paid $349,375 and issued five year fully vested warrants to purchase 358,333 shares of common stock with an exercise price of $1.00 to Maxim Group LLC, which represents 10% of the total number of shares of common stock sold to investors solicited by Maxim Group LLC. (d) In March and April 2010, the Company had an issuance of 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 and 2012, there was a loss recognized from the revaluation of the warrant liability of $446,698 and $114,800, respectively. For the three months ended June 30, 2013 and 2012, there was a gain recognized from the revaluation of the warrant liability of $399,057 and $229,599, respectively. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $275,279. For the three months ended September 30, 2012, there was a gain recognized from the revaluation of the warrant liability of $817,099. Dividends on the 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. In January 2013, the Company issued 61,022 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of January 15, 2013. At March 31, 2013, the Company recognized dividends of $21,921 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended March 31, 2013 there were 593,000 shares of the Company’s redeemable preferred stock that converted into 593,000 shares of the Company’s common stock. In April 2013, the Company issued 29,384 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of April 15, 2013. At June 30, 2013, the Company recognized dividends of $22,164 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended June 30, 2013 there were 403,520 shares of the Company’s redeemable preferred stock that converted into 403,520 shares of the Company’s common stock. In July 2013, the Company issued 34,598 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 15, 2013. At September 30, 2013, the Company recognized dividends of $10,586 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2013 there were 734,999 shares of the Company’s redeemable preferred stock that converted into 734,999 shares of the Company’s common stock.

- Definition

Disclosure of accounting policy for its derivative instruments and hedging activities.

+ References+ Details

XML 27 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Paid in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Jan. 17, 2002
Issuance to founding shareholders			$ 6,000	$ (6,000)
Issuance to founding shareholders, shares			6,000,000
Sale of stock	25,000		50	24,950
Sale of stock, shares			50,000
Issuance of stock to employees	932,000		510	931,490
Issuance of stock to employees, shares			510,000
Issuance of stock for services	360,000		120	359,880
Issuance of stock for services, shares			120,000
Net loss	(1,316,198)				(1,316,198)
Ending Balance at Apr. 23, 2002	802		6,680	1,310,320	(1,316,198)
Ending Balance, shares at Apr. 23, 2002			6,680,000
Shares issued in reverse merger	(3,645)		266	(3,911)
Shares issued in reverse merger, shares			265,763
Purchase and retirement of stock	(48,000)		(400)	(47,600)
Purchase and retirement of stock, shares			(400,000)
Stock issued for acquisition of Valley Pharmaceuticals	12,226,320		500	12,225,820
Stock issued for acquisition of Valley Pharmaceuticals, shares			500,007
Exercise of warrants	453		453
Issuance of stock for services	5,144,000		1,900	5,142,100
Exercise of warrants, shares			452,919
Warrants issued in connection with convertible debt	126,587			126,587
Issuance of stock for services, shares			1,900,000
Stock and warrants issued for acquisition of Pure-ific	27,000		25	26,975
Stock and warrants issued for acquisition of Pure-ific, shares			25,000
Net loss	(5,749,937)				(5,749,937)
Ending Balance at Dec. 31, 2002	11,723,580		9,424	18,780,291	(7,066,135)
Ending Balance, shares at Dec. 31, 2002			9,423,689
Stock to be issued for services	281,500			281,500
Issuance of warrants for services	145,479			145,479
Issuance of stock pursuant to Regulation S	380,347		680	379,667
Issuance of stock pursuant to Regulation S, shares			679,820
Issuance of stock for services	239,800		764	239,036
Issuance of stock for services, shares			764,000
Employee compensation from stock options	34,659			34,659
Beneficial conversion related to convertible debt	601,000			601,000
Net loss	(3,155,313)				(3,155,313)
Ending Balance at Dec. 31, 2003	10,251,052		10,868	20,461,632	(10,221,448)
Ending Balance, shares at Dec. 31, 2003			10,867,509
Issuance of warrants for services	495,480			495,480
Issuance of stock pursuant to Regulation S	793,137		2,469	790,668
Issuance of stock pursuant to Regulation S, shares			2,469,723
Exercise of warrants	5,000		133	4,867
Issuance of stock for services	449,923		734	449,190
Exercise of warrants, shares			132,608
Issuance of stock for services, shares			733,872
Employee compensation from stock options	15,612			15,612
Issuance of convertible debt with warrants	105,250			105,250
Issuance of stock and warrants pursuant to Regulation D	1,288,861		1,930	1,286,930
Issuance of stock and warrants pursuant to Regulation D, shares			1,930,164
Beneficial conversion related to convertible debt	360,256			360,256
Repurchase of beneficial conversion feature	(258,345)			(258,345)
Net loss	(4,344,525)				(4,344,525)
Ending Balance at Dec. 31, 2004	9,161,701		16,134	23,711,540	(14,565,973)
Ending Balance, shares at Dec. 31, 2004			16,133,876
Issuance of stock for interest payable	196,031		264	195,767
Issuance of stock for interest payable, shares			263,721
Issuance of warrants for services	1,534,405			1,534,405
Issuance of warrants for contractual obligations	985,010			985,010
Exercise of warrants and stock options	1,439,795		1,572	1,438,223
Exercise of warrants and stock options, shares			1,571,849
Issuance of stock for services	152,285		227	152,058
Issuance of stock for services, shares			226,733
Employee compensation from stock options	15,752			15,752
Issuance of convertible debt with warrants	1,574,900			1,574,900
Issuance of stock and warrants pursuant to Regulation D	6,513,176		6,221	6,506,955
Issuance of stock and warrants pursuant to Regulation D, shares			6,221,257
Beneficial conversion related to interest expense	39,529			39,529
Preferred stock/Debt conversions into common stock	3,049,362		3,405	3,045,957
Preferred stock/Debt conversions into common stock, shares			3,405,541
Beneficial conversion related to convertible debt	1,633,176			1,633,176
Repurchase of beneficial conversion feature	(144,128)			(144,128)
Net loss	(11,763,853)				(11,763,853)
Ending Balance at Dec. 31, 2005	14,387,141		27,823	40,689,144	(26,329,826)
Ending Balance, shares at Dec. 31, 2005			27,822,977
Issuance of stock for interest payable	183,596		195	183,401
Issuance of stock for interest payable, shares			194,327
Issuance of warrants for services	370,023			370,023
Exercise of warrants and stock options	1,189,816		1,246	1,188,570
Exercise of warrants and stock options, shares			1,245,809
Issuance of stock for services	676,743		719	676,024
Issuance of stock for services, shares			719,246
Employee compensation from stock options	1,862,456			1,862,456
Issuance of stock and warrants pursuant to Regulation D	4,130,421		10,092	4,120,329
Issuance of stock and warrants pursuant to Regulation D, shares			10,092,495
Beneficial conversion related to interest expense	16,447			16,447
Preferred stock/Debt conversions into common stock	1,576,336		2,377	1,573,959
Preferred stock/Debt conversions into common stock, shares			2,377,512
Net loss	(8,870,579)				(8,870,579)
Ending Balance at Dec. 31, 2006	15,522,400		42,452	50,680,353	(35,200,405)
Ending Balance, shares at Dec. 31, 2006			42,452,366
Issuance of stock for interest payable	1,258		1	1,257
Issuance of stock for interest payable, shares			1,141
Issuance of warrants for services	472,635			472,635
Exercise of warrants and stock options	3,985,641		3,929	3,981,712
Exercise of warrants and stock options, shares			3,928,957
Issuance of stock for services	298,950		150	298,800
Issuance of stock for services, shares			150,000
Employee compensation from stock options	2,340,619			2,340,619
Issuance of stock and warrants pursuant to Regulation D	1,848,138		2,377	1,845,761
Issuance of stock and warrants pursuant to Regulation D, shares			2,376,817
Preferred stock/Debt conversions into common stock	367,500		490	367,010
Preferred stock/Debt conversions into common stock, shares			490,000
Net loss	(10,005,631)				(10,005,631)
Ending Balance at Dec. 31, 2007	14,831,510		49,399	59,988,147	(45,206,036)
Ending Balance, shares at Dec. 31, 2007			49,399,281
Issuance of warrants for services	517,820			517,820
Exercise of warrants and stock options	2,639,711		3,268	2,636,443
Exercise of warrants and stock options, shares			3,267,795
Issuance of stock for services	390,000		350	389,650
Issuance of stock for services, shares			350,000
Employee compensation from stock options	1,946,066			1,946,066
Net loss	(10,269,571)				(10,269,571)
Ending Balance at Dec. 31, 2008	10,055,536		53,017	65,478,126	(55,475,607)
Ending Balance, shares at Dec. 31, 2008			53,017,076
Issuance of warrants for services	1,064,210			1,064,210
Exercise of warrants and stock options	2,524,453		3,480	2,520,973
Exercise of warrants and stock options, shares			3,480,485
Issuance of stock for services	695,000		796	694,204
Issuance of stock for services, shares			796,012
Employee compensation from stock options	870,937			870,937
Issuance of stock and warrants pursuant to Regulation D	6,518,688		10,117	6,508,571
Issuance of stock and warrants pursuant to Regulation D, shares			10,116,653
Net loss	(12,322,314)				(12,322,314)
Ending Balance at Dec. 31, 2009	9,406,510		67,410	77,137,021	(67,797,921)
Ending Balance, shares at Dec. 31, 2009			67,410,226
Issuance of warrants for services	1,141,593			1,141,593
Issuance of stock pursuant to Regulation S	419,250		559	418,691
Exercise of warrants and stock options	3,103,680		3,491	3,100,189
Issuance of stock pursuant to Regulation S, shares			559,000
Exercise of warrants and stock options, shares			3,491,014
Issuance of common stock and warrants pursuant to Regulation D	6,346,989		11,169	6,335,820
Issuance of common stock and warrants pursuant to Regulation D, shares			11,168,067
Issuance of preferred stock and warrants pursuant to Regulation D	4,217,390	13,283		4,204,107
Issuance of stock for services	856,613		776	855,837
Issuance of preferred stock and warrants pursuant to Regulation D, shares		13,283,324
Issuance of stock for services, shares			776,250
Employee compensation from stock options	3,759,650			3,759,650
Preferred stock/Debt conversions into common stock		(7,893)	7,893
Preferred stock/Debt conversions into common stock, shares		(7,893,326)	7,893,326
Net loss	(18,552,102)				(18,552,102)
Ending Balance at Dec. 31, 2010	10,699,573	5,390	91,298	96,952,908	(86,350,023)
Ending Balance, shares at Dec. 31, 2010		5,389,998	91,297,883
Issuance of warrants for services	945,116			945,116
Exercise of warrants and stock options	6,623,311		7,185	6,616,126
Exercise of warrants and stock options, shares			7,185,522
Issuance of common stock and warrants pursuant to Regulation D	7,041,239		9,905	7,031,334
Sale of non-controlling interest in Pure-ific Corporation and warrants	443,500			443,500
Issuance of common stock and warrants pursuant to Regulation D, shares			9,905,062
Issuance of stock for services	332,750		350	332,400
Issuance of stock for services, shares			350,000
Employee compensation from stock options	3,368,950			3,368,950
Preferred stock/Debt conversions into common stock		(1,859)	1,859
Preferred stock/Debt conversions into common stock, shares		(1,858,333)	1,858,331
Net loss	(19,434,699)				(19,434,699)
Ending Balance at Dec. 31, 2011	10,019,740	3,531	110,597	115,690,334	(105,784,722)
Ending Balance, shares at Dec. 31, 2011		3,531,665	110,596,798
Issuance of warrants for services	1,512,026			1,512,026
Issuance of common stock and warrants pursuant to Regulation D	4,790,544		6,228	4,784,316
Issuance of common stock and warrants pursuant to Regulation D, shares			6,227,647
Issuance of stock for services	456,500		550	455,950
Issuance of stock for services, shares			550,000
Employee compensation from stock options	183,028			183,028
Preferred stock/Debt conversions into common stock		(1,053)	1,053
Preferred stock/Debt conversions into common stock, shares		(1,053,480)	1,053,480
Net loss	(12,568,354)				(12,568,354)
Ending Balance at Dec. 31, 2012	4,393,484	2,478	118,428	122,625,654	(118,353,076)
Ending Balance, shares at Dec. 31, 2012		2,478,185	118,427,925
Issuance of warrants for services	1,527,518			1,527,518
Exercise of warrants and stock options	21,000		44	20,956
Exercise of warrants and stock options, shares			43,750
Issuance of common stock and warrants pursuant to Regulation D	12,204,174		18,854	12,185,320
Issuance of common stock and warrants pursuant to Regulation D, shares			18,854,470
Issuance of preferred stock and warrants pursuant to Regulation D	1,252,050	3,400		1,248,650
Issuance of stock for services	149,500		475	311,525
Issuance of preferred stock and warrants pursuant to Regulation D, shares		3,400,001
Issuance of stock for services, shares			475,000
Employee compensation from stock options	142,310			142,310
Dividends on preferred stock	(29,063)			(29,063)
Preferred stock/Debt conversions into common stock	(29,063)	(2,173)	2,173	(29,063)
Preferred stock/Debt conversions into common stock, shares		(2,173,186)	2,173,186
Net loss	(11,100,250)				(11,100,250)
Ending Balance at Sep. 30, 2013	$ 8,723,223	$ 3,705	$ 139,974	$ 138,032,870	$ (129,453,326)
Ending Balance, shares at Sep. 30, 2013		3,705,000	139,974,331

XML 28 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets
Cash and cash equivalents	$ 8,253,591	$ 1,221,701
Prepaid expenses and other current assets	45,284
Total Current Assets	8,298,875	1,221,701
Equipment and furnishings, less accumulated depreciation of $427,615 and $422,965	31,829	29,829
Patents, net of amortization of $7,292,837 and $6,789,497, respectively	4,422,608	4,925,948
Other assets	27,000	27,000
Total Assets	12,780,312	6,204,478
Current Liabilities
Accounts payable - trade	202,464	243,435
Accrued compensation and payroll taxes	98,720
Accrued consulting expense	61,282	61,283
Other accrued expenses	180,001	206,706
Total Current Liabilities	542,467	511,424
Long-Term Liability
Warrant liability	3,514,622	1,299,570
Total Liabilities	4,057,089	1,810,994
Stockholders' Equity
Preferred stock; par value $.001 per share; 25,000,000 shares authorized including; 8% convertible preferred stock, 746,666 and 2,478,185 shares issued and outstanding, respectively, liquidation preference $0.75 (in aggregate $570,585 and $1,896,117, respectively); Series A 8% convertible preferred stock, 2,958,334 shares issued and outstanding in 2013, liquidation preference $0.75 (in aggregate $2,246,855)	3,705	2,478
Common stock; par value $.001 per share; 250,000,000 authorized; 139,974,331 and 118,427,925 shares issued and outstanding, respectively	139,974	118,428
Paid-in capital	138,032,870	122,625,654
Deficit accumulated during the development stage	(129,453,326)	(118,353,076)
Total Stockholders' Equity	8,723,223	4,393,484
Total Liabilities and Stockholders' Equity	$ 12,780,312	$ 6,204,478

XML 29 R23.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments - Additional Information (Detail)	3 Months Ended	6 Months Ended	9 Months Ended
	Mar. 31, 2013	Jun. 30, 2013	Sep. 30, 2013
2010 Warrants [Member]
Class of Stock [Line Items]
Weighted average term	2 years	1 year 8 months 12 days	1 year 6 months
Warrant exercise price probability	5.00%	5.00%	5.00%
Risk free interest rate	0.25%	0.36%	0.33%
2010 Warrants [Member] \| Maximum [Member]
Class of Stock [Line Items]
Percentage of volatility	59.10%	56.50%	59.40%
2010 Warrants [Member] \| Minimum [Member]
Class of Stock [Line Items]
Percentage of volatility	58.00%	55.70%	59.00%
2011 Warrants [Member]
Class of Stock [Line Items]
Weighted average term	2 years 9 months 18 days	2 years 6 months	2 years 3 months 18 days
Warrant exercise price probability	5.00%	5.00%	5.00%
2011 Warrants [Member] \| Maximum [Member]
Class of Stock [Line Items]
Risk free interest rate	0.25%	0.66%	0.63%
Percentage of volatility	59.10%	59.10%	58.60%
2011 Warrants [Member] \| Minimum [Member]
Class of Stock [Line Items]
Risk free interest rate			0.33%
Percentage of volatility	58.00%
2013 Warrants [Member]
Class of Stock [Line Items]
Weighted average term	4 years 10 months 24 days	4 years 8 months 12 days	4 years 4 months 24 days
Warrant exercise price probability	5.00%	5.00%	5.00%
2013 Warrants [Member] \| Maximum [Member]
Class of Stock [Line Items]
Risk free interest rate	0.77%	1.41%	1.39%
Percentage of volatility	66.70%	64.60%	64.30%
2013 Warrants [Member] \| Minimum [Member]
Class of Stock [Line Items]
Risk free interest rate	0.25%
Percentage of volatility	58.00%

XML 30 R13.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2013

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

7. Fair Value of Financial Instruments

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

The warrant liability measured at fair value on a recurring basis is as follows:


	Total		Level 1		Level 2		Level 3
Derivative instruments:
Warrant liability at September 30, 2013	$	3,514,622	$	—	$	—	$	3,514,622
Warrant liability at December 31, 2012	$	1,299,570	$	—	$	—	$	1,299,570

A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2013 to September 30, 2013 follows:


Balance at January 1, 2013	$	1,299,570
Issuance of warrants		1,297,950
Net loss included in earnings		917,102
Exercise of warrants		—

Balance at September 30, 2013	$	3,514,622

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References+ Details

XML 31 R16.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2013

Fair Value Disclosures [Abstract]

Warrant Liability Measured at Fair Value on a Recurring Basis

The warrant liability measured at fair value on a recurring basis is as follows:


	Total		Level 1		Level 2		Level 3
Derivative instruments:
Warrant liability at September 30, 2013	$	3,514,622	$	—	$	—	$	3,514,622
Warrant liability at December 31, 2012	$	1,299,570	$	—	$	—	$	1,299,570

Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis

A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2013 to September 30, 2013 follows:


Balance at January 1, 2013	$	1,299,570
Issuance of warrants		1,297,950
Net loss included in earnings		917,102
Exercise of warrants		—

Balance at September 30, 2013	$	3,514,622

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References+ Details

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References+ Details

ZIP 32 0001193125-13-436620-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-13-436620-xbrl.zip M4$L#!!0````(`*XQ;$,L7X(1HGX``*AJ!@`1`!P`<'9C="TR,#$S,#DS,"YX M;6Q55`D``U@-@E)8#8)2=7@+``$$)0X```0Y`0``Y%U=D]LX=GU/5?Z#T@^I MI"ITXQM$UXQ3HCY2KIJQ.VW/SFY>5+)$=S.KECJDY''OK\^]H*BFOBF*0*MW M_3!CBZ3$S<3*]__EJD07# M;)0D5ZUL/IR.AY/9-/[YZCG.KO[S_3__TT__$@2MN[M6=S:=QI-)_-SZ\RB> MQ.EP'K<^3/&)40P71XO'>#K_C];781:/6[-IZ\_1W2\M]HZV6@_S^=/-]?4? M?_SQ+DW'Q=>\&\T>KUM!4/S$G_*WNVFUU#L&;UBZ=#=;3,]RT&*$\H#0@Y@LQ-YS<4/X_Y;MG3\]IL.G\I:=W$6I]_C\;OEE_[XFDY:P.DT^_FJ M!`\_?C=+[Z_A)_AULF3G*K_S!J].#MP_2:9_1?I6]^,':_?_P>W=U!AS;:\6 MMR;93#"J#[U,?L?JN[-DUS?#K?3ZS[_^\GGT$#\.@TT$8"GWP^'3ZLEOP^RK M?6YYX=JV`Z$!I\4CX_CEA^P;9?'HW?WL^S5E M]Y@_/\79SA>Q5W9\-?[Z>+[^,DO,\CJ_N'9KLO-6E=^:%+=F\Z=T-T"\@J]! MUU]C!,8\3Y]W/[.\N./M1XLTA2Z[[[GE57R0K3\8_Q@]['X(K^SXI63Z/<[F MNQ_)K^UX:+IXW&U\XWEZC2UR#7?$:3):/0"][O@SLVFP\=QBGNZU[^3R?C?[Z,)N,035[_[=(YL^MT6PZCW_, M[_#=XMED<-NC6JH`_E!.2?#?!.Q\\/E+=T`&\-WXXG0`/6HQ3?)GE@HQ^.US M%UXO2VZF";S:/%W`KR=CN#X>,,,%)WH@5%M&W:X,A&Z30+1--PB9,0$+F592 M*BV4&5`"=U)G;SXP3$O#?AAX*#YC[1MB$X*`1N.-&8$R&SAJ!>FF$#0@.&H'ZZ-$<8"BW.&0)!PKYS><8 MQM!DGL39[2(=/8#FMN_3.$:G]A:&G_@V3G^#]SD-&8P-C+%]*CMXBM-!86;C M>)0\#B?@TK`M4-UV6[.(](*^"G4@.AT21/TV#SH\%(;RGM$\&C"PL/?DG98_ M79\":+TI;V%DB\&5&-LVK=^["N`#:$L3DA^42!!IM:-[O>#^\+%?#SDT)QOH MJ_=1`0H8GU"NU&O'75X?\#131%H/=*$+[93 M`V/CJB@8W^^AO4`G]530`J>VRX!RA(2]@-]^=S?8JOEP32!5`[,$BN^C:+FI MCZ(]Q\E8Q[G/TSMLQU5!\H%"D/SJO5(A-FP)XY;X.6O+@ZY@$VW)!WK9E@CS M%:WVH)_2!%(Y")=(\74X.P&L#XT&+-XT6J)&PT.A:$"C[4"XY19]^F:?P\

]N%K MCJD/T\_)]'X2W\7WB\DP+;[MX@B$(83)Y@C<`_L$7HLIB_VPR=A&Q#PX?90WLZQO^AQ'\?3N#QK#WO@'?^#(3^:3A9G$H&PVAE/67"*5R? M"14H'K)`B*X*C(S"H-=6F@K9!?#+R9B`V1@-X5MIV:.N@F:#@+6YRG(RLC*R MU02W,YQ,XG'T?/8LC6^$1*MUJUY'@#]`8/CN]?LPFO=4$.%@UC,\ZO84I3VE M<"9FNY5F6C-5'L3.P^A])KO)49V^5)VQQN:N^?.SQ\?9U+H(&/N(XFG\+1DE MP\F+@U!SN#_`RN%.I66[)UG?!%Q)#OY@!SH5C7A`=,08[;5-3W+T/3'P!H,: MDT:NV*B*QD.8RZ]5Z/J1KEW,]8=):M7GQ7CNXM$L'E@AO&W"BP1,;,U7O)C2A'"=^D`.]GS%G/L_Q1\A:# MB=QC,%&@_R<-7PN_G!U-]-TMU8:36(TC\&RB7E^R0'*-,>D>#TS4-4$?.EPH MHTZ/AAHYLIZ09"$&<]YN1]SDJ$[/J\Z8;+SCO89)G:OTE?@22Z7GDK&U7O@6 M#:Q9I:_.7W-*GT^#A\_HD('_`7._-/XR@P_@/Y/AR#IJ[?NXAM==G:`C'E=E M5D*P*HR,%)/["JC\#W?*8UR6X7`G"'2U)H:[<9S<]*;S9/Y<\F3SASXMYG9[ M:C*]/YF0S9!'-0I"I7N1XMU`]90(A##](.R$-)"F1X$507H:E]UMG`S5F1NC M!;@:/UU7@[%I&*\.6`NI>5N3@(?]*!"&@1L8]MH!HU02$X%O8]@`QFZS!K8* M@-<=>6JR`5YQ1X4RZ$6=+K!AND&;$AE$,NPHVH4K1JZ<&1`>1;1N>*S92VW- MN+M;LPBKF<7.14B\$N'6<=Q\'4\SN[F[C9S<6R6-GE]N68IN^X]A.O[TA#>6 M32WGN#%J#F\W:O.H+4V_$_3Z82\0*@H#(R(2M&6OTQ$A(U)VBZ#PYK:I7!]0>_7K<5/^NL>4/\[L M'NMX_'N,2A"/VS!"#N_C_T)]Z`[G\2JH)_-EUB\'::?TL]S`#2V:&HO[E1%U8QU*`P]KNTRJX#I M4,=_FSPPOL5#-5B'J&C`%DS'N#SV]%AG0N2:"[!^P;2B M)3*:PKK.X*?Y0YS"5X,`C7])AE^32>XNV7,NE\<+Q76J<'WWZ6$(&P8S'B?( MSG!R.TS&'Z:=X5,R'TXN#J?`H``/"6>A+@V.>UY_JU,@%6``W^(LLW?WXPMN M4IC2*CA1,J-*TY9BA]AZ?)K/G.+Z+;8]_"RC!=36A M+H_AU$G])A^/X8@T8-V,1Z*9B38GVO?\ZT'X" MKQ7_DGS'35@P0[['F%P[R^)YF:/R`'UQ^$/<-&-8R$LR=3JLO?.0RW0Z^2J@ MN'.BL'Q:[6;76F M_&7=;RKUT)G0`"67AIZUH?3`N/$QOCP+!0=="%Q9""L-?0!A*[SR!!.RW@^, M0\;`551`L7N2\CE.OR>C>/?BPBK.:H.OV9?9'#=.OESO MS++YQ]G\+_$C99S6'W']CFRWVS(*.BKB@>A('AA!14"%I`S\ MPGY;R('=#+ACCN.4@TUKVQ/:N<2N!?X5IS"FEC!WQUZ/R@N8 MC>TMLL\O+Q6NSN5YGM3N#:)",;:$O/G*:WN%]^QEN!VF:Y'M`]N07RF67RUO M`!ZH?(GF-X:Y1&&Q[`UR4\C2E]GO#[-'^)UL,9G#6+V4J0SCAV>S5?J=8Q1U M-/20=C<,(F9$(`ATE#8S.NA)QDF_I_K,D"+OQ?N"GA/Q7,#FA]4>*:(5TZ;& M5IBV[FDC@W8G[`!-+`H,ARX6A1UN=+O;%X*^;)"2(>=O>%_G$<;J2'%U_LQ; MW^:YSE[=;9Y5AJ["WA2(NV9_+_;6S#;/ROPU9F_V^65$'8:)^?,7N"D;CM!1 M7+KN63^=/98^SGY/YC"#FZ$[7WZR-H-*$0T,4B5#6L=_J#H:")R/:OER/K89 MW!=')-/0L5P2R5T2V?3ZC:=L)1B3LNE*:"AVKW:X2UBR!=5APA+$:3.6T%#N MW#GH+F?)49C-MZA-6F);=#.L[[,U]^2X:Z@UU9 M.&S+]7U!KA/0[(#J,@$-0K49:)9FN[7M8Q_>\I0Z6\VI5_L6NTDVFLRR1=T] M;@-<#"02=5A1@?\2&E59P5_JD*%T'_TB%D0D[`>":1&$?=T/:%_V59=&*J0R M/V_+]L0-#H)\=4[@7T8;/`DB-:^95[$J1ZR4Y_(R((=RKRO8#.1=^557('^- MAX@0`R+HJ_PVG7W%3.*X:/]A^K3(SV-/1\",#;CB/Q=IFDSOHV&6O)!VQJ), M-9I,R&MYS!&)#)>=*.A&/5`3$L*STM$K8?/`X=$K9C#D).H=O%J/O$90-_F>C./I.+N#1V_C M=`3CTO"^<0J>0(L;Z_0VZQAN%*B.Q__)Y#5"')],MKN6-!?&F/(>N@L\F?R2 M%YIQK=T,EGEN6!PL86X'?RYTK-RBP-E0F4_H]&4/E34MX@0"U(M!U!HH_:M& M/4KZ7/0YQ\R-\/]`1/UN$'9!1,+0"!`33E5$\N3"##==454^%7%V^AY7[H1[ M^Y#5[,.K,W%()!KP)7+@X=5[J8D,+]&5V"*@(4\B1V[.]23.3[1-6=WD>94B MFW*5^AZ;F5+-N/2;23P'Z&E%21;Y[Q%MH(E2E)\2MCXC__T&3H?+2;+(?X_V M:P3CJKSOWF7^^R,8&V_+//\]MB7`/&4AJ7&D3ICC\<1=E\>^;''[`]+=!7M%W'8E1$K2U6:4P84J$] MP@U=B]$J;$TQ0R(Z@E*>U#D;0NA+C%:GL1!N(*6`5R.GM&A],=I$ZE*,5H>Q M,)6IY`0^\!0Q.H:R^?;,Q0C;TP)]1=MU+$:K`SPVF2F8+OR^SZYJ7(O1*G9- M<2.3@9FH7\?(^-6B(GAMT09*:Z,-.R5$5E^+-I&ZU*(B>DUQ>QY\AHN%?K3H M&,KFVS/7(FQ/"_05;=>Q%A7Q:XM5:\HU.1&OD?&VJB7V-J\52C&WO@`(! M>+;XE/A]?3'>A.IR8"W68JBT>[")-$I[DN-C,)MOT7QDM3T8D7J)'VW#=#BT M\F)HE38#(*=*R==I2[=#*R^&5FQ+Q.E_K/$UM!;K:DNSET92&@FG#2E9[1O'66OW5-YYP55M1I0FI74D_P4ZW>.TQ\X84TPJ6:X7 MY[U`IX$6*"3TK5#OLZ+57JP4=Q[R^&9$3)9./%*CW@ MM,4J:<@E7]M+\WK%*CV8+*;@$O#(^@!T(<4JW>/'<@0:4\I<3K%*]Z!ML4H, M+(0[G6[WQ2H]]&6P:P6SIS4WTU>M2@\N-+H-(27&[!YJFJM5Z:&IK`>T?HC9 M<:U*]Z#\U:KT,$:0'7W)5ZE*#WUIA_V]=JE*]ZCM$08FC:A=JK*QXH'NP=J4 MPW6*!YY9&L]#W\25$(8[U\C!TGA-3S=\+:ZOCA:I<+=S[G`YUF,R++8Z6Z1V M+VTY7)#UFP^+K0X7J7#;"_79F@X7UV6QN(ZMB:%.&KY26[I=7)?%XCJVY7I( MU_GBNM_D9FQU3LR:[7;$;A]>5W4-7N#[KZV2)[#>,_"\8FV5"IQXJZU"L;8* M=UY;Y33(;FNKT+PR[2765CF))J>U56A1F[;H.TYINB#CS^>&9K1^P-2%YG4H[WJ'+BM#=YL8_H0,TDQN?#?*$S#`XX]GYB]-` MA\GQV1G)\7<&T[IQFGP'MKZ#*Y:!IXQ.VLJI:(/=/.9[#K'^\0AW:LTF<#<^ MB3]1G2<:TKR,@"H*/`NNP8GB5."_C%(2Q@X\P4H.$,>WB..1IJI-6`".*@MP M/VT0=F4[D*;+J2$<<_WE8P>U^]&44'O"BNC`ES8,2!";-\]@T$2R4OU8)],(RS(1HV3S!'@JVV2G.N M`;]AB3A*;TV%L/3J?$>P.E>"WY9```&2'Y/@P]&J2A0+*$R9X3N,BS-+Q.J M&2;\6(6C80,S8@SLN"REOE15\\'P'EUKP-B4-3;R5KJ=8R+"9GA8/M?[`7.8 M)(MOTV0$_YE]77[-F;14=(:WIVF5>-#6(&R8DISKJE7@H0FVU\^1?8G3Q\;8 MK<\@O7I_*_X2_DI9]UP6M_&]%1L]-B[4M-'0,OR/;J)+WS!;6W^)'1X]A?UJZO> MOK;W)H_:=Q>X$GX+WSP;Y]'\C_$?]M()^ZH9R]G0C-4X%B\H-T0+'?0EEB\. M>3DRO4C\=5PE*/SBW3T,,SB]CUT7J3OTS=[,]XX MG([B_/GEA]F7612?NE*S044]J.B:<%*80=V7+N'&PRK)W-I+?(*$[&O7ZEO% MJN&U-;RP<9>(UUYW\YSJ_RXR>PF0[CGUN>PW)S>=9*4BH,YVQJF7VKSV)(>2 MH2X?9#T1WSH]'^/YA^EH]AC_,LM.Z<#>H6/J+ZF%,;P$?NWM=TC67?RT[`OC M]G1\%\^3_V?O6I_;-I+\]U3E?\`Y<2JI(FB\0W9EM:2<[OW90LB MAR0V(,``H&3N7W_=/8,77R(EBA)EN"H5D01ZNGNZ>V9ZIG\35SU_SZ-.1Q<; M1H??C-9J#-M-L))#TUOP:,443DD3M+G,"W[V$&A9`_RQ?A2[@S_G?N+O5S)Y M?*%Y\3I>A5:1>YT8JU.<;$)T6OV,M=!X6\UNDJSOX/)CY^%G!O.:A'UD\9CM MBT-S?(\W\+HIRS!7^_L^J>[7!5C,%8MO87Z?S],CW!^':D M6APKOY7^:08[/M][M!*>L$K'RFXCPZHK8PG/:A\ACSX7.%)QCY7=8D83@P-- M"S8MB)9BS&D8#DX3+-.V].U18ZV$1YLO'=M::/)DOIB9T]'%5_`:O!7.\UJ%-2A(Y>HCFJLX.C MK"AA8T`Y)0W03:'PS[XO2FX3_RG6&D,AX/F7_6"U,\!,#&?I*B M4WWRION(;^M\2]/!C?L5:5J6W6M;>E>V>I8A&X;3EUN=EBJ;3D_5#<-0>G;[ M7X14`K*\^>WR\\7OO<[UEROI\J_NYX]NI_?E^KSC?KB2SC]U_OO=)G8+85P8 M5(:TSQEX>U1"WB.%@:C_IMV1^Y;FR$97->26TE;D?D]W.I9J:[HE=IE'T*N, M,UIA95G=?3]@<<=+V3B*]\`=.:"VP9O\$_FQ7WX9I^YVD%4C3750(0SO(&G5::O%[/#F?:.G&+\!JI53I&15?:X MI_;"87>O`H-_NFJ M:>*^T$;F"MX%L&-A,8?6^C[LXVV8LJK)>#70-N8V>6$6X9_!#R&*_'VM%Y9X MJD[>"^"+BU'Y.HW/C$!M.U&2)BL7PR37(%,[@)'M8`)V%;=G&XXB=[NM+G20 MUI9=U^W*'47IP'Q+:YM&B[OO3T'Z?NC?_C1.WX,D^&DF)>DB8+^^^>A^_LOY M)_GZXO),4ENS]+W4O_AT+??=C^\E\7S[XOKZ MXN.9I.1O7)W_7P](P!=O1#MFDYJZP8\TILND$*FL,WS@'3U!?\U*+/Z7+$M? M;^*@<1,-%Y(LW\>]=5#F+T(FL>DLB!:,2=%(2B>,&/?"A<2RG!%HK&&;BA3Q M0W:2ETI>F/\,5&9X4!%?_U%IZIHT8[%$2WC\:D!HP2`)VL0HBJ4?K09T/5`8 M2IJ)?P*!]90K="UE.UV@\J-*]*0A3:=(EG02@V#P8#I))!CF09B_S4/VDS>= MO?_AJZN\UY6&A,;71%4`#:`TA6;"*)1SO4P976LDU',3>?$0GQLQ'P=D+@1G MI"0*\/;16Q0-:4[1D.3.Q["N+GY4Q8^-<@<`,9]G$#13*=K(6T@CR4\3*68R M3`ZPS$#212P)(\-,O8.MCF-ABQHDF8J3V;M(2M<5_2D M=.!:NX)(1+$%N`G#;(^/MEV6S"9ZHV7QG# MA*.#!3GOD^J0\;.7@"I3%D_QP@:,E0M@^-9G=]@V!M8)+%PC(`I.-IO?!/X@ M:PFG1?@0M9C\TI3:;.#-:23B'`?9QXH]#?P1- MARDH?^B/"&XEE49Q-(4VP'Y7^Y5Z[";G!(B&8X;ZY"Y1:)MW15GGT`[(A@QX MV-D>-#=(RV&%FY(P,M9`HN#_'K]4K2IH-/-#L@KN*NRKSXU+V,0P`HM+(5Z# MYA(O]J&Y61PAN`I$<8@&/EJ8A.H-6.'Q6;=6[1H[*=*AIBG\TCJ'>]C+)LSTDO4\6K9!E MBR93[LN\C?;%YV[OL]RY^/#!O;P"(@-0@#=+V'UZ7=8A>&<\9#&E9`LKL+2N/QAF-&TS+C.CM3^_'K=@(AH5?_-=YZ4\P7["'>:-IU9"5J)7L"&*]>B)6'HGV*$[ M5V7,IBW]@'5_Q7&H-`(PMP/ MG4ZOU^]O\(PTFI5_R4/Z=>\?U_+YIV[OT_69)*MLNN/P]:'7AQ>*YU<'K_R2 M7,S6=&$>1[,M7>53A95!X*`>^F@'R"PS1B,LOP^\&P_F`X;LN]B;_?J&___( M,N&//YZB\(\>,,IF^>Q^00$+XMJI.8!(+KYJ.U>:IGT*MOQRH_[O%/)/SKA_ M?J1U_U(;]:L)T!U,?@WTQP_UI MW$Z>AS$;1.,0M\'A]0V;_KA%'I7W.C`!NF;O"/>KL(:`[S4F?,\=GIF'0\:W MM?!BUM5MHG?B)%A1I_'(`VT;KBHK7:4MKN,:7H35B[8.?R;.5ES%[1F*W%&T M+J)+&7);Z[=DUS84K6=9W5[;W.M,'/5_)1H;;P^\X77'2T&D(+\A-S_.`2&Z MO`48TE:PT"">]:##'[A-EHAML^0;WLQRM"?8S++VW\S2GV\OZ]ML6CU/)[>P_JCNZTW/L_75T9W;K*YN7:^:D4)+S(!NJZRJ:MLZBJ;5U0 M'=MHR8;>ZI.O^=8KJ7L5S9R8"AENP2EC!J1?L\PX?I^"/-*WPND M\^)L)G5-D9!\.:C*N//4=Z_:A<4C,J(W3R=1[*?\C.EX[@]QJHSE+J7B%U$3 M0_(!)0BN8#5^,F&X?36*O2F[BV(.I,P?Q;VMXOT&@?2QKS/X'X&%YN8D>3?1 M/-W4%**0^DG!%`O16!,!XA@S;UB@Z8[RO@#F4E&6A2B\2<*2I$#[3!"<=,A1 M_@1HJ<"N++>,N)NYE"B,)TU\%GOQ8$*;<%+LA7_`]V(S#C%OZ:@*B,GA(OG1 M%<&;'R*`,Z\U$ZT7*)]`HA`?1/XB2LA*@C=(BI2#:0;%5K4T\.+8IW&N0D6: MSI-4NF'2((`7_1$]`J\*O7-DQB@L`"RS_4@2![&I!_SF!FACQZW#PYHJ/VFN MGDE_GT>$9%P"4R7P4(^#AO+O.9:D/X2.0UQ4>%^H"[XM:6M'T,:GD$0[DRYN M$A;?4F`7TO"J0F&4")H;1L4SXNMT0EV+D+>#*(ZCFXC?MP'F*:@,O=1[1LGT M,S#8]7P3UPBKNI[S[[_;A_<#5X^>A[D#9J"^WFP61V!AB*(S#5%S8E-^6( MS_PY@O>E`QD0$8*2H2\WA_[`44V7@$Q+,8Z#5^>8U25PW[662"98"B=)9@!- M,;14X5('+`8-A5N1C_.0#11*Q0V-$MHRG9M!Z0;X!R(W0PL4H/%+=S"(YGQ( MFGD+Y+;!N_$K(0+SJ(\QYX#G M8`R(AR!9#/S8NJ,)VF^E9XMR?% M?@+3(AQ1\08`A#*78@'3KC0U\^U&?0`%H9$-5T,\1AUJTWYJ=9A-FZO#:IH[ MJD.W=E+'-GSK>W0"5#*MK-&)>:].\'WA;0_1B<--!*C`G\;;G72B5W7"0_ZR MT^SB,FJN#XHRRU:RQF5:6_4A9KX/UP>JH>(T#W&9#?JXWV7V5\=V\WBP.KAA M<.E1FNWR6UM\I!1"=_01=>\PJC]-W.`!U%HQ`>J;LA)R9R+70-,!G>CWZ`0E MV`I7CVT?R&7T/5W&N&>4>8S+6(:PEOM< M1FT:ZB%=9G\3,9[,94`)^OTN0TK0G;;Y=1TPK3%=7D>E^HL\.U6KX75;_VL_ MD%ECNKP*;ZB#0JV&9\9T.1@._=-EH%W,*$?A``(=/R51/0*QN#^XDMFYC5,.!B^I%*ZNLJ[KA9]A3G?PC'UPO++A$\YQGJ![Z^!M MPV@.ZYYC^??#6]S/P1];A;RU:OCA]]65R\S.,;_QN9)F.7Q=LMNR.H8);[9L MHR<;IMV6VTJW(UM*K]LS6IVVTM/VJTNN,T]UYJG./-69ISKS5&>>ZLQ3G7FJ M,T]UYJG./-69ISKS](U&[SKS5&>>ZLS3`S-/3YT!0&[>$5Q;F)3Y>-0M4KMF ML:IYLO8\\4.6))UH>N.']&217'N"S)=FM5JN9LO=GJW(1L?19,?L=.1.QU"L MGMM36[W>O9FOJ1?#`EV&H'K&`?G$%]SVSJA3,-#(B?\?=J86GT?>U`\69TM1 M->LPK83&![KS9GX*1OT?GO#"6NB/+!Y#%,6>NLG[;&WFJ,2A=3@&+^/HE@W2 M>2)=3KQXZ@W8G&#)DH9T'@Z:#:PFG[(X6$A_0"@+L=2XF/YTWN>O(ZD*`?Y^ M\6SW/.P43,6>[R0'E8=JN.H'.GO!OIER@B"B`#VL+Y)3E*L MBQ]P:"&@P48CQE'&O1("()(PA$I^$.(+>X,^Y MG_B<)9@0(Z(7B]$?&]*-\"'\FW`*T4Q0%N#8'R)<%&\/Z03^E!`1(^H>`1<5 M(C94CFB4D<.<::$&(#QFT1@&J(D_@(79H)*(+;%7-+NE+K_L0MKA+/0BE-Q9 M[`<5A6N*`@K/.UD:3!!+`I:3:0*23QD'KEEKJ;O9:'M'J]]88>&L\L M9C./:Y'@%CPIA:5,@CA_\`W9P6;/R%W+0]R$6Z`?+.0)"V`D82'U.8J`9'13'?4G^\K- MAG=A$.0`F)P(REMBN,SNY3ER]OUW!'>VQE\:F[6X;*E`!#QV%TM--I@J]DD6 MPX#:W20*P*`@6..]?/.;Q!_ZXKZ^G+*`*JT8+80.W)")AQP9A.M]:<02LC]' M#/@$K%<7'*J3&7D9^)!Z`?>*8(X3L,4!O&]U!+R<1&DT9F%&"@'S&,HYY@Z" M_D_(=2&%(P39BZ! M'7+H69\`.F',FI'X:)O9_9+XUAV+66ZX$H>H\>/2-B%G,(M$6=@1W",GHGN( M$"B7#Y]YY%IZNCQE:F:O3CSHV0BXN&7A'+@'41&#AU-:&1G2,FIA4VIG-HNF MP`ENL&B?8'S`8`-LGH`HQ91A44:A%.'K2_.J"?$IS?$G^=_YSN)VO*A:]J++S`).P\O^/0C'`M(;P(&?O15LWX2&9IJ M_^O+5;=\W^SJ8L'45;VO&99LZ2U--HRN!8N%=DONN9:M&F97590V+!8T\\UO MLFTKMFFKA1IV%VGIOMFU^.9N3`!8:/_M1?'(I;?`K]P[+QX*]'.ZL"LY#_GU MMC#C20ZAL]VNYW7UMFLZ_8[V5%50W;;;@NL!6BX1D>33=W2%<5MZ3VK M^UQ+2[VTM,3%^H"4M#S+3,+!H>"0=H&`L?)YV7( M(&&]@K'0$SG8K\"R7$9N"^F2TO+43DS0BCE;D^MA1DLGW@),^G#G26"L0X0= MT`2N/-&+!-P:#2\9?AI';QO@91VP1,.,#RP"1BR.\]N//:*Y(.QA>,4G26'% MV)0N(XR\'#JXRJO@A@_1`@`X&&2(M1L3K=^+\R;((=:@-G"*/.,+U$,,G M1^)K:'JK82HV?]AJ*(;64%4+)S;89B8@+&+-AJYI#4VQZ%'XJ!I*PS$M_J#0 M2D-H0F_8BDE3;*+;<`RU85DF?W:#FDCF7<:;C9Y=#0"?^2SA$C&'KXMA-GG* M;)/9[IF*J;=D%;Z1C:[IR"W+<&53-?LV*,LV'.T2 M")[V:H<O=JK+' M=L]L?S+D%)WFM%+*EI0N>W[]OA=!4J1.2B)#02?G*#N=$AGOB'0R2XK]2P MJ\*.#GL:U'78[_2D'G68T/U`!EW18R?N9JEVCO^?;O]<8/[?*R+@`1AOP/+*_+1T_,:_'G&X^MR$@ MR(0GDU4#B\AX.-8G+'YA8R([O!@=P,E_/1J?,B[,Z[=H6ZZG^9O;C,_&(;66 M;Y\5!]_CG@,P1<#W2]Z'%HG14]9M_+IC+#P\8EV:BHYV?G1^SF8Y.(?^V4^) MKXIK)3;P:#Q1RP)[AN:CG01?P>@$.)UX1N/ZFN4+&/(!F-&K_A=P#QSMY?-1 M,A+6KDL!^V/U!6R/F0WU[!LUO#8N$(^1`75L[3;TM^]F8`&N#9?L*+N*>9\7 MELS\S`BY"20U;_B9@%QGDM^8!ZR-F$.'WC?^UUHFVV>^0V[8<>8=)W[VTYXS M4TK`'M+VS!3L),'ES>X3/_MIUYD/C>S=1+#!19GC[CPL?/MGQL(;ROE!+.X_ M48H_@XT3,;ASQ0-BD%-]HXBZS@J5@=WRM`<3^ZY`3KA8T_UA&AD7)(T=`F`@ M@HW3L!%A+C@/)@P(TA1D=6S3";CR;[ZPNT_NC$/_L)C?1M%D:7$%9KJX$21X MF5<8]B%(-1O9O5W$J5$>6Y$SOKM;1'=P,).X>PX6O89'`219\#KG@N`Y;0KL M,R:V?(82]#\8UX^?YV!!&P2Q9@96#_U\^-T M^OUYLN8P-Y<[_Y+'!_R1!':".!'P9\)0:T0F6U(8&R,YG]0-BU8I9XTUF:$"E:NB.P4^C=[)L MX%JNPU7Z.7@9B@)1L[TE-IQG><"LQ)DO3*HPB<';?(1Y]%TT`Q=XNIUC7+XT M::J5V6]&`@,619``(2EYD.QP,0;-$8[(\P,\03!]PP.R+X>3A-EW6`R6D.;2E4'& M3;)]:!$]H'V"!R$9]QDN1?1O<>'F>9;SJ0U89ZR(56:WL;4Z/GTO=18/A>,> M97LUV8A<16Y$0"Z3C>P&&33(\];CS9.+ZXL%3SI6)"4XOE(F,\!L2LAO#\"@1?V9@26(0;>]. M"RN;$$\F,F`RU__G$5@F,]+/$JY,8*AO;X*\%:YNA.L1K^!:UJ)F$ ME3<@L6Y"HBZ3L/J&8M@Z#%L)VTK8XU:G!.Y5\GS!*(D`9J.M8+S.LIVG+'?! MLE4AF@,76[9@DC)VH=]-.SG\HGH/:FGQ"AI1-06^DGC(.>E(#: M%WM_]M.)":A3DCF;-40AX2PS8\9.0#]HG-;+5ONB%398IMOHCOP*J?VMN:B!"S8Q-PEVR9 M-S,68D0G6H&XF7Z^V#3C[-,FR2GQ=B?!I@VST;+!447Z1SR=HMR#@^%S__4X M!XD^6ZVOY?A^_FA_-@>:9.BQ?\NZ2N['BW^"O"Z(XM1,2#"9'?K!EI`:B6;% MUOJQ>70D0LD6HMMG$`'*93+^_GS\&7Z3G-E\J@-?+ZI!+.V[C;&8VC:`?$^] MC/7;-M!6_/Z7L5UW_QG-"BOE;M)V"]OFLMHZ^KJ^'6_"$KAB,C&-)K8('$C5 MP7=:T]'8=4GIB+G=1:L@;9$A-P&E>TU[A&&29]I-'0Z_G\;18TI">$*.B,BZ MABNV*UA$6O74W;OD^";)/Z4GSLFBW)%0RI`;34GB1YORT?58D<*!=IP_H3Q6 M3.$L`*.:EROXX]XRZK-\I]S+\_/'-HF.HDQHMM&2E`-RW1;;)Y(1G;WB"AEDR`W(WJX"N88KO=28K8I7-)K\\H^Q6MZDX M.LXG](9([@&?[$^EK=F$!YB9JH=-RC][%YMD68>=7,(X6"3[0[U5"10XPQXF M.6#?E)8HX$())3W@E`/`6%C0-L+_A(!WK?5I[&*\C>+I=['+SF>O+USQZ05V M*5%(NK\>M-KF&;!`/X/Y@^Y>VDM28?/,MV7\EUD\_;<7X--%YS;/L!?/?RD" M_2;7F=O/&`KAGDW>V@"'^?'-YRRH^SYEM5K+WWF?#:BFP\Z`!@P@X@J`"7H= M1G78)T+T!U*>U!%389B(25J+U]BZ7O\+&H`8S##W!J_]XVS\:*/"0!D0 M*4O[M[7D^)S2U0CTE+0VHOD)^[1M#[JYJEMQ$OP9[&O;9@UZ%1[T@&V522AQ M^GT=44X"J'^?F<,8)K+J^!ZNRNTX*0?"ML-%?+\^%?P+5I5;O^OA<8$AIA5& MSMY%=VFD*3/LA/WW,`'@4O$?V'`,QB_#GXUCA'W9<\9/X0SQ)'$X@[MO+GQ@!@@T*6 M2']*NEZ3#,$,09K:"$`RJ=;X=^/I\L^V0782(5RSZ#9:+M%JMS,%3`_K0XY_ MX1%K^J>:Z>7SK/\P\2"66:AW%L]."@.@QD/*I"XS2 MN`>_Z1/&S3`0@9R;O-SD`*PVV[D][]E/Z_Z'@G>4>/1)NB,))6%OK7GC8OYX M]R4+726$.7:)\EJ%L5%0?\:+U:T7+V>`0]&PV^HX"(D^`D/(%C0(P_*=;3S_VWP^67K+ M.UM'AY-:KD=J=+^.XRF:IA_FMF/5Q,&2OGO;/>JP2[PL3.K%JPZA5"FE5:%- M_!3`-@4"9IZ0!>TS4@'A(_CLQ2L1RC7@^\Z^?0&7B)H([N#P&RJNQWCY!;_V MYO,@^N0I_])M(SW5NVMJ^TBE`)DT((J%E.?4VO;A-QGQ=H&#LT!WFS_!>4*+ M,YXD2LK'J0WTQ2LNJ.)YECP,11'FQ'U-08KXV!IL-FE@OW@PQM$F4I;&_<@F5=8&32PQPV16] MP4!T>-@-.KP+:%!4ZPY5-)0">\.EA@\'\%$`/R"A!E3`SY+EIF9<`NQN;A[- M%^^BM/P"OYFI(2]YFF]+6CA^`DL!JTZ.: M=WC0'W2Z5(>=H:`L&`WE".2-#=!Q51C7@:+40*\DZN'Y M0"]NZ`P*&"R/HP.]=H"T,P^?A'&_GP) M_IB)*0!_O$_&B;S'\H\4O?-- MI[0<+('Q7CBHZ%+@5D[ M/-#Y(=+E@-FO&QL1_UQ[8P]?;U=9E4#!5%T60M%@(61C"QT24LEN.`RUZ'3[ MJ@^DHKV.9J->IZ?Z3(?=P8AS8L-E5*I08,#L#(ARJ`!K,/^U7^?CF?W^.BWL M)TE9D:2)!'D[CB>;6=SE-=*X9:TRLL&9635(WRSF>#W+]F.]^9R0[]>LC\@_ M\P;CEQU-0A+0E#-/@2B'B;PV^6"KK-+5O6\^^YLMRM4D&3"&IMLR'ZFNO@B6 M]?EHJ()>9ZAZK,,5[X.\@/\,0-0/!D,1\D%PS1G0/%<(:_&1'_Z\/%`&BUOD MS!*Y3UL[RAT,AO[3^,_G-=H4&A*P7-6V)!3&%VQU.*WFZ;SDM'DXOQ`(RVZ3 MF.=+;-5+YRK?6F<-'GEG!^_F]FF9RD*<4PV*`BM?SX&%[H&%G`O,,SM?X"Q@ ML.^42+-)R9P'RCY>N`XHDAM0/.2#0YT_/F%0D!M:1C(< MZXO>AH?2:TD'Q8VTNPI7=.T6#U,GGW0*Y^7:V)W4*5C M$]#ENMGZ.-(KF6Q0&*F0>Q<\PWSB)C\`'!WX)-CQ0QZ>0. M-C+C!\P(AA]R[-*?/E6KP['%E]_HD!6&R1RXGFM>-IUJI\CJ0./`VGQKWK.= MTQ_V0J"$OE$L=]3DFGRV/6C8K'&^3?#LI\V62X)S1\V]+XF;"_082$PIU056 M#3%S+C>GC*PQXZ%>.?%M=;$H4N]%!"3;==WQ^PZ0"*<"?_53$C=^<>KH%Q#EUPZQ$R1M*V7%F M/0@#8?(R?CUD4VUTAV?2-63TAC!1!D>7V%'/?PXIO$RP"RU#0BEJ']\X]\E8 M:>VJH'954+LJJ%T5U*X*:E<%_8"K@L[9%+3]E'-F!ENDM)N"VDU![:8@GY=9 M/-E-0>>L"6K%KG]BMUT3U*X):M<$M6N"VC5![9J@=DU0NR:H71/4K@EJUP2U M:X+:-4'MFJ!V35"[)LB;-4%.'./HS\_?S)Z/HD^+HM*!^[^#;R,S?B@!=6P, MY&RV\-LT6-&]`](8`AH'-/7L]@7U$C[+7&XTQ99C:X.MHX?KR`R@%`V\-'R7 MF/KT1@C3FXF_Q_TFB:>X$9U"AL4`D_$9\6,OGP^M"X8_/$]VE1BZS6?1.H:5 MU8CN,T(1%];>>Q@O$A?TYY>8)\^\4[MH?)S9VOD`#[[,EN'!WSJ)(56&08NV M9O9N1$GQ[<__!$[F?X'?8ZI>LP4M?TX,YL/AOC^P)/CP, M]C0*`I**W?`@R%466'3EX_K%2D^._8.F&W=WL'!FC.`L4IRPV38_[8@DWCP? M#;K/5XMX/(5C+`V/F_5!4\#-S-1+`Z97LVBQ_!(_)"<]$'.\RM7>'8?:'86* MUR(@3:##U4U0=I3W$UKNJ8Y^]M,9(:I\@`H><$:(*A^@@B><'*+:"%"A:CX] M1+4.4*&-D8N9;VB2C7)HN%DF#(]M$N-;W#8%T-\N32P`(!K_$T/X\_0(`"W8 M"=$GD&7=39_H-IN2GM3S/_MIQ\L,R:+Q`I=%`2?CEIYHNH8-/K'ZLLM>2BXH M_#L>:S*/ELG&I.RQG^+/(.+,4^R34\9`+\Y$3M*`0XJ8Y,*N=$'D(X/Y(&@6A%V`KH]G.'9FZP$;+S/'Q:#*YG.W MC;3/.1LA=<`SQ95!A50!E3:VSO38?LX^>/]94DIL4'X,J)\9;]G(HXP%DA`" MOBIUC^$)CP_S=<3;DF$;J@Q7F5^=BW&ELL.*C@)(/Y,;JL,;+8+D="@\C69? M']&8O9N'-*8E^-L"OVM/M1LH#`[@$K`D7&A]?ALO``&_ME83:_A0V7Z\-(FR MS'P]V7A]5MA/AT9$SGHM%YM^]M-9C1'YV'0BM\]HC,C'IE%HGMX8L0._SWXJ M'S`])2)-I##M]H=#N(?\QQ.J]&VXYT#T5FEKB_@33];!#0V%)\';LD9$%L4U M8;XDCGM^%!>9V,1QSXWBIA+6JM-SH[AK[KD@BINIW3.CN,:.2N*X9T1Q#4&R M.&ZI*"YHKM47LZ+0"K9L:R6Z/F,+:`Q^%TKT8N3"A&:77[;"P'B(-!!\5A@8 M'Y`%@K?#P`2P$6`80\*Z4#&H')%DI>CA2%A[L:3@>:-J(E.V*DR5G."-25IHSU`T)]L14 M*T7H(/573X^4Y>-DG),;*A7U]F:V<;DH2WEA M_@C.0S$"]BO0>3Z=/7\+,OUYWXH:M)H?47YA`5+T[0'%XDO[W.F.,-SA*-R^ MT%MW^O!EG+[Q>1?$'PCDPH9BRXO%G,#]^'M6);>3U$L,!DWBY>TB0H:[@;\O M3$#(>F7%.K6?F0G2I*&Y4H&LY_.O41H79$''\.YSM(G3)VP##(:7L9&`J,9+ M@C]1)N0"Q@>_7A0Z*09BV_5=!#<'[8XVO.V44IG@;Q*KS&)U&U'+Q*"8)RB9 M1LNEM4+^%/]YS2OF5_,_<#^FB9\6(ATEKA(6@LWS7NJ;#_U_[Z4_9$;I^/@8;CN^P`5@PEY\,(`Q(&S_DL*>-9;VH^CJX<70FU M[B-&ZW,,8H#%I;9R;'4W2IQ:@+5HA MACD>39`@B0CA`>+%[>,]W"_P>S$>N$+>*=R1.!EUO&D%;O1!?C%??;Z,IE.C MR(P+MN,T^+UX98CU:1K?I3Z*/1<>$_$[1?L'5Y`OUH\`!@,3%<,TT3<,M8!: MLF%4!`HY*PV4@A6(`OW^9%'^=>#-EFZ:!>.9^V1$J0U))+&5';+4,OO] M^)\I=UCDF]_E@_B%K[]/@MA%V\":,SGY+G9(C!+`&EFP$X4X;67_B!5[Q>+T MZB=`?(ZB=$"-I.M:ZAVHL/O-D47L))+5VF/)BCU6AO]0`N^\"*B9YH\K5N?_(YW".DM&L!8WDQ^;WXY,V9[,4K2H)L'/8H?=]_9%DF6#WC_%B8JGQ>AT0 M3][T-_/ZU[/D.%%\]P78IVO5A/GE`/@I&]!<+AT1X0&G/7A-1Q'+;]X%;P488KR*^,J1[:$S-OT'\T7 MZ>(R_UF:OGA%!`T%40F&2X-5F.*=N2%U;0ZO9FPWVS>'W9/YZV4W/`3[YZ^7 MF[MN29I]9/EAGNJ@?A6+>L_;=P"\^%;\(X&HU`GS/(C;KL8QLND@<81QS8&_ M:XYX4&3&RD7;R$Y@PT3M-77`8625U`);>R#6RRQ2O;I<\\J&YO7P!K.P:$J< M!M#^S1[>K#@IBP<)^H<"I4G($U2<`E%1HMT"\P-WO_G<36N6K&_0![<*5^`E MWZH`#>")1(>MFY(BCP1HWI!@+?1*`I&#?&-A1DY/>TAP`@1G<+4SSM]_^IT@ MII3W'$JXWIVB7740A*,7NK@^S?,[+4"V"7!N,QJ?"%,.&\5E8OW,DQY%E9O5 ME2AUN;6O*`?BMDW]-HD0?YB_,W$<"Z;_7@/N=Z:"!F*MO\X&=.@%L="*@=\3^OUI#;36KIZ*1[(QB(P7+0X<) MA.J%Q^%SER07+9Y[IV4%%%AA2>_C>/HFR]OX>9>(*L*34PE6$OX=D,BU,/S9ZS`Q'$NH MQ(W?*@NC7P)>7KUDC3_+#_-N5E"'D<[7LR0C.;Q_F,Z_1U$^;IAM=TU"1MZ; M@HJNUT]7#WD5<=;T>69\4)HQ'JXIL:GK6D]68M3\35[C1)YK.G->0^QI(4\+,.)$MM MB`/'W]A>;M&X3.**J9%X43[HHZ8$%,`W$H22AKJ^U=\@#\$Z?\6X9JAAR\"T M)Q2>5SCF\V`JY=UE;,J],"X.6)& M(];7^0^ZHH]VC#$BFE1)/J MH]PC"90#SQ*NIU=*G854>\T;(KEDPD4\W*XN/AGFLE*_@DIDQV@BAH^.]C%N M@>>7/4:I4/6ARA2Q&'NL\R,;9!M(K%YT$72\C4'6J<^*CRFZPS<17>(731V5C M[(IDP71_8U"D2%:K4`(L;SPC5PR$PQ,"+62USE'M7?CN$55)2_YU);HC3)DV M)*YDX]N0W*/.]"01)1B]R%6ZFL_M"D\!MJO"=3S?[?:B@M>],G10SIMJV>YL M%4^PQ>?H[?/TB:0U89FG#U\D2SRJPBS_Q$'-^$OZ"6=%0!_@[Q<@Y$J(7 M]#03_5YGT!N"F`A4K]/K]ON=7F_0A12CPKM/!+=#/* MP#*O172S1'JP,+#QZQHD]T7E&LGW4G?5=,.]7%W?,Q"(;:6_X/_AOE@TNQN`U?4WCT M6!7?F3RJ#(:?.HLFR#T;@6#\OB7_D+]YR9X5%_Z5Y,C MI91G7G>;LW[:USW%[=GX$W#;Z3_8;T35IH^R!L5"_#7-?B!NU_UZY^,#8%(! MW&7L'94G,=N@VPUI+QAV1E*%'=[O!YW>J,LZ?::X)FRH0]9+6K<,LZE6PPS@G'4XDZ_0"P`$=!01\C6ZOST88&Y$?@\MQ\'NT M,JVZB[E9MM3[_OB"R4 M)I<$Z4!]=O?K.)ZBT_IAGHNR?YE/)]%B::9`N,1'J?D6'`?4O.J0`#"B-=E3 MJWT'O>_P11`SSCBO/-\5=%CB!.]1 M7`0Y$'<Q6#F&8/O"I"6 M9&8@;DB!C_."]P@4I6R043P;SVY]MT$XQW*9,`SU<1-D!T2EJJL\)#H.3@8L MA($^6D15!!'Q`FR!?^`5_SJ>HABPR?E-(>\CN='D%$HR*7+L?@I0Q[1SU^Q[ MG:0^GY]<3U&Z"4*5T(=T]#8LI6Z^-=M\O_F,F-GA!;56'J`B(MY%RPBWK.)H MN>AK-)T;U>>OS`^Q]0R'3.92.P=AV,A_%6:Q@E4^GMUAU6EWN8Q.R_@Y@E>_ M>(53`_/@'H9A0ZY'N$S/9CQ]Y&2@I@CSDCQWW@W*3:?S6UQRMGM4VA4XMDOE MD`^9[`QZ/.SPD#"`D>H.,R-0AS340PX4#+;-L7*PE)#7F)-ZZKV,;FR6E!M@>!2.BW9/0FB.C=2N6*# M8#\&RD%>UR(;5[).YNSU2_;85+/-Q94W"E#S0%-QG6TNKJ`TVUR8(B#[3]SF M4NE@_./@5CL8GU\T&-_9@.<]:*ELP#.WT@U>$3+%LHEHEP]XOEK95AYCCNJ7 MJ:U?)MRV`/U(]0K8K+>DD)JIV9H3*45])86XX&6Y MIUMR_?QTCOYZ$W1YW"F;**;PE[/48;DLN6&]PGJO,R'+&W^)]$R5J7U8]5C9 M7T-0CJ/*UA$0C%[SPB#VDT&LLZ@`+A?%0D=^84T!&W#5ZPYU)QS(H,.'0G1T M'^[:L`M7CDDV9`.9R:M+:PHN'65?7/7\M\5).3R+,1K(1"X)^!R6E6F#CNX&04=1TH.7@#$R%&A]H4L1%.J<:\!!J53!B?D" M1NRE@W\^,_I2IEC%5.M(`E?[:+)@1\:@6DA#A'3O32H-]XCQ$6.JATS!.KP' MG*$&@`:E-`=T,")[R(@!Q^!:J'E`S@&]8F%"K#!A!U%0G3`AS1SU%5!'8EU57N,8+ED(P(="$. M%EG5-:#$/<2FF5_P4%\PD:0,TQCU_6'>B^R3FX0B'&^CR'J3;07@UCE7PSV" M4"\R,`W/7_5[PE"7]]ZC0[QXQ53`>'@8'?N!N_Z($?=(XSC"30I=_TR12I21 MHZGJ*AFJ?J)F.GENX/N+\5#C?%.5C#<-,!,K0ZUHJ?&F.^%T)W@=#1%6R0QA M(X5#>61`M0\BV#EB0!Y+=81E2@GCZH<%7_,R$<,OE\X*OK:?Y&C\E4JF7SEP MFMSX%L[QUG!'PSF^&NUU.,>6=4$"=F0&J5_ZSQ%NT!\)M90_C#_B'(/NG).K MJ5-1LZM':.;KX98"(ADCH?0[\.@2)]PLS0HE4^*P@^=X.+E[5$BT"[429GA\AO'4)T\(7[W&& M,W^)"+D^R:HJ#_MYYL2I`Z:O<"4Q\"*(E=CG@>=\*/X5L,1,IP1./_5^$OX5 ML&.G''.^.>^I<@]P9P4_7-W58GR[>AQ/WWR:QG?C"\Q0EU@#MUDK$9PT;/M4 M!)R(WUXTBS['MW%JD"W-5-8I]L5]F*>Z)NF%\Q[!N).!8?O?"?@]&0$.'&^7 MED=HUEA05>_D_'?10U(X^^;S+HPG!K_WZ`J-6N"$JA-8[!3@O7'/7 MN6Q*3=J5=:*I_KESA*&S3DLD9X]XZHYV5%_UAIHY,2%17)?)2UZ^I;IZC]S] M=43WG-(C@2!O?7/W^&*&QVBU7OJQ_/G&W6[(=33=J"P\QES[H'3G^;B7Z>`& M47HDJ79ZPO'R:I*K,(I0B`T99J/23RLG.:^<:]`,W,C0RF$A5N>0>D"V<,!RUV#1'RB66L'&+**W( M$>[QQW=RB1UB5E8'E-7L+=5OP+O$&@HDR;,)"4VUV5W*<,PAA/#/1R(8%[)9 M?1:D2_8RF[0DY4(VQ&QT51[&T_*PJFS(NJK#-O%29YZ.IWDZA3E,%H;@[/P( MU6''<%@];]G$.%KEB,:FFN3.$1;:O%*SJL.NX11@V35>SNU%T>=IW[B`E=S=FQ,J@KEH==3:B#%@S)$3%UC?*P MJS!*J`PVCMZJ*Y>'7><2R41`\V,V0.GZL"L;FO4F!WB:'$C"OTSG=XHVU=9T MA+,D%FS&RSKTQ@F`;KI6#-M9E_R;D(QX6)'@$A4, MA+L,16%713,L4G=8"C2&I&B)BK.KFZ`N60?*K\9`9QE/YZKC+\^3781,S_LK:5![GR:]C;U(C MG:4B58U1N;*%66_06B9!ZS0F:?J1FVYDND%9&J"\>,['%4PE5TQEHY4BE(UK MGKH:4]G0)0E)Q9/G:@]=ND=5`^*8[I%B@YJ7[-GU(JCI7E8U)\*I:X[[TB"+ M^U(3U*2,PAOYV3ME*U1E+F%G9J&)DJIQN3:76,)[(RCGHC%CDQQBAV`1$O@] M-)OSXY.2@6##*5<"/+5SQ,))_#&'5W2,LL$SF M))1?E79SCB54=6&),3K.@]57$4Q$&6P$Q^(95PY67T=H,T:&H#R-5N M7E/\-Q+4[=32S*GE%%TV)01<,GJVRU:+B':)!H9^&@F8K-J*KDTJ.\5.8`M@ MA+ZD[_'M(OH<+1;1Y`0;XE0%UJ*4S887-/*<16EIFF4NKS)=$0XZ M/E2:,7I\'K?_+2%'<5@]<]DH(],6C<[*]>K)EER'!QGN`^$:7G[$MZTJ6[(_ M?O>^(1CC+UX)H4O6'.\$],K>G?L;2BR35>OGN;?6W2,."VL)D4TRW)TC":WX M,*P\RU2]">^>?9@15148\V MXIX^/10WWFW`7!DG= MC+T?3T&P M_3Z?]7$[^'PZ!>9,V]!S,LYKI%"X;9R)8)M3+@7[6L:H0^QQ$.124L9(4T9@ M.L4.&%*:"Y*M*SW'XG1H-;F\=IB>!1.3LD:$WUTR#9B0C('";&@+HU,N,KB2 MN>&JONMY5]4AZ7;-$Y3^E>+'FXBI,]2>[CDBP@S/!P'C8SBLGKEL M#DPP@T9W*X]JJ@ZY"@]R3/>8NJU2/6N75X?4:FTZYSVN+/H:6_=PM4L+II?6 M@6B0W>6>N="PN,`"U0U,V[H_G::("(CC/%&&K.NV,E&%'E3AZ)=C[]['UEY&;B%ME00GGP1G>,%MSC#?T^Z>N5!=S7.R#7:,*A(J%*J MDEGH"Q<]/"YNOXR7()=WK3Y/%+CWB,/0"EB>C(L35-(I MP/M@<#OG1NP-$S*;V^AC`C^/$U<+/X,D@7^B@5AO8_A.1-2Y<"F=81E@](C" M/X7'I/A%G>'5VWRN=I@%Z0XS8P#"VWRV_MPC!\/\+T M6,E`E4!"V:Q<55:@>WX`DS!DYP^<=&8/NL=,:.5L!:9A':G<*UX@BBS#5.CM M@.GKX0;C\*ASB"PUYZ;$-L1K!T-=[84*TH5:]4=&/8H?NL?NCQ=,=([#)+(H M&V-;NL(+V)9<98--O`HSND=&`V*.[I%B`Y!$5[Y9NDZ#TQ5R3#0RD/*,[7?> M1B/=*[BG%IITSZ=-B5.JNF.W:KUMS]1L!E1JLS#%EV'[SM$`\IU*IL-&-,$Z MQPXXAX*$ZXD8/ID$#O$0F)7;QVO!?:S"FN02SH"'BUE5:2*5]G=7( MWNK[Z78BIK7N]!94O.K(DH.6_"EKSKHJH!]J)SI!BQHW+S MK!IJ/+KGIL98DH36/3=%9O:U#,UB^JNU.N0A#I(H%5#5$U+H:QB13I[V\W'7?^K\3 M,75.29"I%R&%R+^==X$DUZW_^^C."A;QZB!3QB=M>]7<5?3Q3Z'$!! M_+$`#(OS0A`"_/(1Y;(CF:(=S@>RHT5/=89=&1(N!B0(>A_91XIZ4K&04J*+ MR?"20!61D4[KLD[Y\!LB,H*'.04]''(]X'34&83`)UR&70"=\XX*PEZ/B/Y` MR^%'\9$8T`,-#).+*.R#H`CGWQ;SY1*P\SGV$C2!K4B"YPB:._`&).-XAL&3 M-S,[?0T^`T1>?7\[Q5KL?SW&#WAK?`02,X-@#8>YWMYRP&S8R)_QT';%%-?(ZL.[#/22^\E`M`U%BS,;YK<=_[MJ[U$]$1P M(8;?4&X_QLLO^+4WG[$=QTMP*4IEM!/"XKT^"$D1\$Q-G1/H=@AJ8&+:N`2& MXR3S`\??9-_;131>1H/(_OEZ]G81/8`MDZ@K+PT--/D%5055>QB,(M!OQ]]3 M^^T6)/DB6E\"+RTKW)H(9C`+B6I,,:PH#T6XVYC:LJ.V;FW!L.S.)MK`` M?:&<>CT"1ZDHQBB>C6>WWD`8[PY)+G;O0>`(I3]^1*,9^,W8LEL$C]\#SZ3CX#B;1:4Y,R,_>??D-V+ M^6T4398FE`="_C=LS8Q7W^%+_?ET&MV:P-Z;SYZ;DQ0+QL.`!%SEPCIG`+?! M!7!!\,/P!XK\K_`,C+:;L/*F?>XC6G`Z$WB+3.2CEZ<`=+AZCR:_Q M^%,\]58`4C-*04O&#KE7V[``6Z]?'3,I[$XX6GO&`FBR2;6"H`<6/P.?>#N M^P@A;M)07(24[*/@#D!*6#7XZ>7;\7>3-EF,)UZ:=]0T(2E%]!&[9@N:_2*] M"?$W,.=D&$C3D%T"AES!!VCY_`=_G8]GRZR*P6;$O(08"1WR=6EC"3AR4"=L MC_4NR4#+3@+LN8MMQ[IU<[0LWEU55P7YN+LG%Z)W!U1_-%X,D;H=B MSUM;FN,2.1ZN)WL=`J`@K-=R/6W/7V:8V6S@]Q%RAK.>"5`Z(#P3W:<`M5]A MFSS4OBI8+W$A31D643*;'G,*2#L+G\V'SFK/<"C7`&[-I!#9[++]Y]\)9(H! MW^'$SLLPI#Q0V[TY.V`XRMK%I(3OW(T=EO"S@A,NX":!6L]_V'_\')!6XZ4B<,TB/D)HALLP27@*XK[#YXEX"VZG1<'? MX5Q(\/$J6GY`7_1Q\;T73Z=>PFKR1XQF0KH,''MY-RG4PACAXW0UODXXN"3@ M)D6J!:6[^7@?*#G8?XLF\>UX.HA0P"4U(CXZ5#BKG8-9DL"YZ]C'-%$?-V^/ M;U>/X^F;3]/X;NRM#68*@[4"RR,XI)9V`Y1#PZ[YO84")Z^=*XK&EPY3UBX- MS&ZW(U-B:06!CS`SC.'K0+)MKV/K_"6Z6H=] M'@H=Z`X=CD8=WAW*3H]STAEJUAL,)2%#*3\2K/T73'-X3\E>U@(P&TC`#_3& MRVB2UD[\/I]%2>]3:L1]@.NS')OJ@7_'MCMP5,&JS;HX[>-=(4GJ;E>,NJ.. M4!KXHCNB'142U0GI:,BZHW"@%/^(#WX5BD*59G6@%L,NJ"C2!-&[:&K4YKS0 MZGDY:LKKAGZOQ_MP:P03JL-9-^QT.:6=48`\-"(CTF.6A7B@)<]%88Z#D8_+ M)`U$53NJ%\-?\@IA=";@X*VE"#@-H'SXPMRSM9+Y,'^;%`"?5<>\@8#SH`,U M\%;\(PU%E#E@OFWV[&N2T[.?([0A78F$DDP/:%%"JVQ_7860[@Q9@I$UGCXF MAF7ZE3.BEA=?BM&(4^!VUAD&0H#!V"6='IC`G>$(?D_[`S4"@]%<"D9((.E6 MQ/(P),7;<`L^X/@.S*[NW=TB`@LK2@8JC*=3K#-)OGXY^`^/BR@/-SU;GX(T M#%YFHJ`\#)7>&K=:M.25,0O)*-=A=7!M.?")/(X,]DP>YT//PS'MU\NNSV`%,E9 M^$U31OBANW2V=4K-J!#@FI=BUWTZ`<3MV2"9P!F`2OMJJM=?SY:KQ:,).Z5) ME2X\]CZ=]OL0W8)T_H\YCHC`;[Z#JUP)[N`G+:7X1L#A#,)#J&1;B&2]D,AN M0#N:@1#FB@8=-1#=CM`#1G3`J`Y#RU>8+0M>RLVE6!4AH@(,OXN7_QPMHLR1 MO`)^^27XY8A?>,&E"-Z%AZ8P,`.$U,#`1A(8_C75V'[RKP,$:Q$&1%6/7X;X MU9[CMW;Y=E\*/:``9WM=L` MW.@H8>[XYB;('_N.GXC?,R^YQ:]T<\N]9N":;`"12`*O^=]#[;1G_919/_^T%G"VZ`,'PY%\J0,/&1N.WB_@6&^T_)8^Y#"LE M!>5VC*P4&D+#9]0(RDO%9`DT5('L*+[[`LS<_1HMP.KX$"U.:. MO'K+_T&"WR@?7(K%;?@:PJ+'5,V9+*H,AI\XAR:X/1M_H$G>TG]XR9K5*I&2 MO'BF76EP2?TV*^N_ZD>-GC-O.BX`^2B?]$U/47LV^H2YZ/HWHFI31)7-3]G` M`$"A@F^:*AV>M:QAQ/B(,=7KD(#[!V&L1Q.).OT@B[K MT%%`!KUAM]=G(T0)QWBNT"S?HG01N.[2YFL,:4GX.7S#!ESUND/="0@ MR(E(8)2%X3E0EN)_BOQ/L=-'YYNOCXL$5YPM%(BPLVK&1';)#8-D6)-Y=,X^ZHUA\1,H*^SYI"::HDF%AWNP4VU M18?4B`@X0;8:^]2BP^M4IEW$."4Q@_ZVX8I*?KT^O M4)[E@F\0,V!Q!!6RSG:I;[U\X\XPXRB`B!D=?PW#;"?0M1MF1NH2&11,]OV6 MV355L]SH%"EW4T@P#`:L-^IH->AWN!"C3G<`-R64HV#0Y>#0C82]*0W6S)NH M*#3C]0LL/[/=Z!6S'H<"J&K"\&`XVO,#RBF`X:J9G/XYN2F,%A MWTPJF2UT;IIR/IMU2BEG;H(DE(JL9[91RKE6UL$>$\&K-.LZ69J% M-E2+'>-2W.GF(M!GZ^92*BG5S3+'(8=5$(1()@80CW M8,@ZNC?0G1$/B!*]_I"HT/::,4&Q'+2A[8H7(:D<,S3:/ME&3;7VB6$AS8@4 MXDS[I+9VQ4OA+WF%4,E*3D20%OIZTZY81,!YT#6P7?$BD5"2Z:E90]_8N-`% MMZ*4ZTYKM6T9=6G`),1PPJ0#!!)=3C\BPT^U) ML/I[:DB[C`ZD[-EH6_!2[C3U7:#J!+)&RRJM^>>U6$0^NRCF-9A!@.I?=C.>XG+,45JHMYZ1F M7TK`!&U$.>=N#-6=F1`F?JUU(,*K928V@:X],V'+.77)S$1-(J'V=.\&LOY[3@*QV<60]SU9P,M1F[S>FBY03D8*2H&A#2H9QJN/L*+D0@ M>YW^2/?@?RGE?9VX$IN^1,5)F9U;TKM?Q_'4K"[*BUB[Y68)+X]O+T=4M<.& MJ9V_2YD.='Y)T8E@;>ZI2K>4VF>TQ`V?3*FR6KSB3::NP,3!]83J0O/)"6M,JUI6Z0IRETJAWS(9&?0XR%8980!V&!]@+4')MJ0AGK(;4XS#W$I M*&JL[[@4ZD#('AWU@<1Z..KP0`T[W4#V.W(H]4`,56\P3.I/0WB>8.?6=]2S M_,Z9!,/T"^52DVT?\[35=]>IAKC(&"_)(ABSIK2!PYLOY:%2Q1#25)N"XT@N M:#HU-CBJDGCZN,)E;2/[\/OC_:=H44P;OWE<+4%73T"<;Q"E#GR=+85Q92.!UV+G M=GJ++H+.G5QQ%PY5J*L5"7?MM700#MT)]-GAT%)QH*R)2O&2[>VU5&K3W>MT M2E9J#_N\+Y7H#'M]N`$:KD&7!*+3$ZHOR0!^HX5-5DHB@I"HAE9J7X2D-<^PD+(%C"F(#Q9\V;8TE?&V3IYS;'P MNA?O$1L+YT(3IGR+A3L`GN'4)'9J+!SOWA(Q$RTW=]W;5?=>\BX]S+P>4D<: MUA14[DW3[!`0UPW6.V!`++Q64I>MPDD_A&;V MF\^I?94:5>]!8/K(DGR+)2M--M1/)KLE5TK!/4@VU`^NE\F&"\`NE6RP]9.< M%C+7?F0<+@"]5&B,6(=>4GIVQJ&NCM++.;Z4JX_A8HDCY,)+.TIKS;TX4$@< M%T<'<"6V(^>GY5ZJ;JTM(N`\,C>PM?:B&$[)VX_))"8;V%E[Z:4HE4P29A,H M"RF_8.):+9VU>\`OT5E;,@`:7-Y96WD6[2"YJ\VBD2R+QL[(HOT63>+;\12, M0[@NB<_HHW5.B_L\*F^%KI1JI?BV>:W0+J0\VC@@[NH+Y_%01;]XJ>N5](L+R:62'O:+;R#E@G[Q,NBHJU^\VA"6 MN\8R.X=$D>"D+A)WC66EL%)M8YG9^QHR8"#=A,:RW1BJNY(B-"/O0@&>Y]4J M*3:!KKV2P@1>!*&N]@3LAK+NQK)T=E->6W@O$C:Q4DXDE)*2--N*0=:[S)LG M$FKOR&.F(P^#4>*BCKQSDY#2=$4&G++SH@M01*MRR<@#K>N_1W^8WW@,;R#*SB8I0I3WU'9_ M_L-\F+@Q2_-5CW$0XBC'O%-6#J+C.!C-%ZD/YSL.](M7+#^2O21$U5]R$'2A MT!2M'4;.4OQE09>X=ZRR&V]5P*57/H-^T^PII_K*@LX^&EI+'#]1?C#1QNUW M(0+WXJ-R;F"X$-7(PQ+#6ZXD#)UC`T,,I'*Q^&$^FC^:^(SAJZ3$K%&(8>D( MFS/A/(ZDU.3<]8A&"!=N47042X<`=:9BG3,0EG?0LY1M&5QF-[(1G**,E"G- M*!EP9?&1PV,3\($9/T++XB,'W#74,A7GC04LBQ*!FXNMFX+#?_S7S(X08GP6 MPG6CE+,CW(!R[M2LG2M7.XY0@VZ>T$J=I7D2&,T1SH;1/`H>%ID\9O(3_(R1 MR%7\.8X6SY>W7Z+[Z-]>?%FM'O[RRR]__/''RV5T^_)N_O67_NO_^^*5H3$1 M@HN__K+^VOI1R^@.LV"O_OKMTV(ZB?\2?7N8QK?QZK<(DX7/)S'\=AG/9__V M8BU,QBLSZ1);:E;?L;QP/L-$6O=;O'SQ*JM$G$QBC':-IV_'\>3UK#]^B%?C MJ7WN7W_9^;I7?_TE/4\"^2\%T/_Z8#">._UJO%@-<,TWXK`3D`[VOJW_-?M@ M-)OD/L8[6#B8_EOZJMS#__I+0K]JB&D489.)F0O?/D4"VO!*DPGX+EJ-XUDT M&8X7,Y!EXF=9K6/ZV=2XVG?)F%M7'U@33/1U< MX'.0O++$R*?5YZ4/]C9/<_* M*][VSHJCY8A'G1.OM>*:13B_9)(/V#FPC:)I;.TTNL/+*1/IEG!M=.?'(65K M%S27>*U=T%3"M=&=IE.RN&O12U*:#9\?OC]$.<-E=_8F9,<2=NLVGW MX8_YTZ)=&U5M"*':J&ISR>=7!,,;[-#6>SJ9>+0<\:ASXK7>4[,(YY=,\@@[ MC)%6)IU*/%*.>*S#B$/BM3*I683S3B9='3N!M2*+;-UF>HX:N&4(QYP3KLWT M_#BD;.V"YA*OM0N:2K@VT]-T2IJ=)6##A`'Q--$S`)B_FD4^KV?+U>(1O_XN M7N;-F`]_S#]\F3\NQ[/)<(ICM--Q;T^0E`1^I-K3[,%IM/SPQ`F),T]_#$)^ MB1>KZ*E2T^;TX%(*]L3E[459QGA6?Y:Q`:SS).5[RSA5,,Y3U28Y>>:P"D]+4_1":W/YV)FKM15SP?S5Q^UYJ`CD;34UG>5J/ MB=B`0AB5Z>`/>@+5F@Z7,GN@2E$3/N:>FJW6:3@%6ZW3 M9#)ZI74\0@]OM<[%S,[+49-?@9JMUFDX!5NMTV0R^J5UO$"/0%>0M%KG8L>> ME/-A<-I]'M*IKTYN/%Q#ZCWD%/JMRH'E4W_81WW(U@ MBW+8$?5BAUKLK+F;4\4\+ MVL=*U:[5-W@ME59A2\I+%4]83K2&=9.2>*EX2DX8)+5A)RAL86[-JA-UCBRG MZ9VK8R?D5O'H1/$H<`V]%EQ=>,8DGC[B1/;U=.;A MM]OIXR2:C!;S>XQC/<*5@*^]^9P&K=Y&B_=?QHNH]WWW`ZXO^LHOJ*YMCN\> M;O!XP:H3;O!I=;MSVG.E/0U].*']\/YA.O\>1>;VOWG`1STE/O!+87J!'I:; M!-]:^@Z6'CBF96OJ_RCT?-(;S7Y(6C[)%6,_*"6?ZLZO'XV<;<2@-:$VN<%$ M#/`G'F()E(2_X,4/=8"_4XP\84XI%TTH?>;1.%[\QWCZ"&_/_OJ_`0_CQ>V7 M[[^"P3`MOC[[T.L90+(TGV`U'.:W:+Q\7!A;=;2(_O48S6Z_[SE)[J/+=XBU M!6#UZ=Z;]FX\3=JWD3:'D38?^:`MX/\1J=G.=&P^$=LNC(93L.W":#@9[>)O M1K5@3SRP>]$J\GCFS2KRJ_+.DPPDMYQ3"><\USC)[^TE$HH1;3@<+5#24/M%ZDF4?R77Z.[\71H M3I.[R892?UO,'Q]^G=X^)7KY54GK`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`F0:?@#D8EHP8%,G&GJV46:1/%??HWNQM.A.4W^ID2K/^:+?[Z9 M1:-X-I[=QN/IVNK_<8@2A)*&NBE$,?L,_[:8/S[\.KUM/!$\RB*[@%FV2%*ZH4\KK;TCBF>"HFZ866&3:RLH3J4/J[D<**%/*RB\(XIG@J)>F*E_5A2M MWXH**?4+9J!SV*&T3IAY:SE>)'MXG3P9T(!3UB9H+BI;!A)1YI!$;1K`1[*T M:0#O:..1IJT=9K0N6M?K(DT;UFSE4[3^UIT8#1#CASHQG&1R:> M`_/C++8`Q\LYIR3\^/?W@PRD>UM8_2KYW5_@=W_])?U'^S#\_L:3EE@^OMQZ MB/WG$M_/G>0C'/SCQO,F\5?`T1I^_-[OC_?18KR:KSFXS.DM;G9_WSQV$,WF M]_%LWX-W0;1^YO:7__I+[NP[0<^506WA+RUG2S]0`I,/\-OMY\!_]GS77D/X MR_\'4$L#!!0````(`*XQ;$.^)`S-4PT``/.D```5`!P`<'9C="TR,#$S,#DS M,%]C86PN>&UL550)``-8#8)26`V"4G5X"P`!!"4.```$.0$``.5=[6_B.!K_ MOM+^#SE6.MU)1X%V9^]:37=%WT9([;2BS-[HOHS$^9>MWDFWY6#?91[Q)Y>M+\_M M_O/U8-#Z[=#>^=TY.>XTR#8'[1Z;R^OIYP[JVZ/''9K..T MVZOA?H\8NW!^.3D%WE+?#%GH>Q?.6>K1-6:^@-:S.?*73I]2 M9RBIA#/$`O,%]D[B3FD,UP&)^N*RE4+X]L+I">.3#@QSUEDU;/WX@Q,UOG@3 M)$/P>K9JWNM\?;A_=J=XAMK$%P'RW0RA["R/M'=^?MY1WT:M!;D0JI=[YBHI M&3#H:%O(3^U5L[9\U.Z=ML]Z)V_":_TJ!_S(&<5#/'84#Q?!7K?G"#93DN^=G74G_TPUSPQGV`:IWZP,SQ77+D?U^&0[6 M[$MZ-6V">`YV9(M.82>=?5D<`N6WYP#FF1SC<7Q'?'@Q!-$G)H@S0"4UPSOPG-,63E'SU-`/&74`UUV M^]\0IF+?]QY!`EPJ%?@*^X(L\.Z,;S=`Y?BND9C>4?8J!KY'.':#73"\[V1O M/F^(<"D3(0=Z%\U)@"CYGUK_()X'S">8]SU/S4Y$=U(QNPY0(;0K)(@+P]T0 M&@;8NV="/*GW/F.^FA=50=QQH`JA1E-[Q)$OD"L[%U5A,^VY0C#/`7/_N))N MD5RCL$"C>5,1H&UZ/SBHYW`V0WSY./[,_`46,'E4N\>YX@GDO0#A5P;2;+1* ME0NXN\JL9:90=:IEB^XKA'6'"/\=T1"GC/D`_$^NO*K*EMY.PWP_F/]&'&0> MW!/T0BA,G`>,))77#Q)"OP_J/^0<(B:I)$7U4MB)B^\G)!B8P3-*U-MY'(^F M..9X:5EPE7%6C=/TF058C-B:T[7_(Q[Y!/FQ\W`-]H=1XJT\B2<.@28$,A&$ M'.)$'"/\%EQ14'?&HOR.+!U:AE>A(#X6`JS!"WPK>3N,9`P'.C3>6\1]F*#2 M#5,.6)40]7T?'-4[7ZQ27`6]6T3V!(O+)=A<`^XWRJ&1)JL!`KN4;Q;[,M=, M!$)-*^6]/:&EHJKR/>_+0RE'W2D)'0W8VQCP,(X:Y M934X#`^2R0Q)9SKCD=4A8$Q$B^J.A"*]@2A>4=.@PZF@5@]41.CW>W% M18*?XL??^J[+0GA+H%ODJX`%Y^%K<+V!U]5P%+U@>MDRH>C808EN(9(>0E!@-*=&N[-:*V@BC+3,O=7"&"SF0U>;\&6 MLB5>Y?I6J0E2ID3*Z6R@`0-#`GQ/%AC4`IB^"0$M'4WSSU@'I83(!HZ4.#5, MIUM8YA`6H9K$F3)@.=OY9):Q%$_ZFLQR55^-K;@Q[R5$]G!$"XWYK@'[FVUM M4Q MES&&7LL7DMC`,,0!(C[V5OE.6)OA+%36]`:/B4MT2`P(;>`QM@%[:_WWP;Y\ M\FVS5+4Q?'Z;]_[[6EQBXZ0Q6#96QN=;MMIQ7++$WZE@>?YW&N&VR#AEZ`_QK=>6#!)H)\?&_2RK%&RUKO-@6ZFVG)3-@G> M!H499GC?%R`2L`T*,LS`:FN'">8&A1QFF$UR1PG\76Q8K38'9,]M6>(O/L-D MHY8[8SR(M\-*/K))!%UQMYC(3EU4@!P_,>8IKQ3S!7&Q>(;)KJV0:@EL\']# M%L2#*22R]D3#O*ZU#/878.@C,H*$BY/?X'[ MIDV/IUM4DE=^P)[4.S=8SKXA7F#_7<5'W\Z&C#[C(%)6\J2<1DK9-M:Y["\0 MH2H.8RGG);:#ZOR?"0Z#7JS4.>?RI@*PTZ5O):^EG=J4P."UR-PF3&=,F:5-1(TL9I6`+')M M-/6L=KT![ZB>TT+9L$.-C$$K$(/6;=0$J#6?&`76+(TZLV`:6>,T!%IB*S6% MSR-YR65QA2:1?ASHR^)R31Z]YN`U'HC.I">.52.KW`5H"X*__:K:WS]WM=TU M/9:8?'\/3Q71NZQXX&B%?I$;<3PUHAAQ=?9^>44HW8S&S.DJR2]DU8AT+$@@ M)7*'<],,1WS4+9!RH\U1,&B^6!\I>Z#=_@Z']=3GZ;+BIY'W(H6=J[8_PF#J#N M&?+SEF1Y^ZHY6L=TJRBOA*/W[:OA*'6`?C3E+)Q,!T*$\L9.L/XY50I3JHJX M,UH[=5DE-QA<(I?$]TKE%W?232J1T2=$?!EH//JIBX5,MK2;$5JIU:PYDUZV M5-NI;=_K/=^Z,HX9L2U<0O*&@;O;-QDHAD1,(R]6.C(%D(KI;*#95-H#/V]K MG`:2(7%M<&UL?MH&U29I/3!E-V$;X]D@JT2#;9@.,':K/'B>VBIH73$WL2X4 M,`18F(`C-P@1?7RA9*+T=PE[Y>2'X]=,@'D$E?`4Z=_;-\Q=(E(#Y;&C;6NI MMJQ\+LZDD^5=+;\(>?IF'9O%EW'J-<`6'=0(WT!=.[H'OKP.:H1OG9?=%5]> M!];W/AQ@AX9F/4.7(!$78T_<<3:349'Z(U7&REO:)F2'X$_E9J,45UQJ@\"S M2`=M17]`CK.%OIV8UG=AY;QU?/L:6)@AGH?Z^_18T0Q+&%AYHB)Q15=' MX:(+V7.5\98]V'YOTE@\(!!R5-&[9I3BZ,9(*?12E;9#3W5`O)$,,E%U6_1@ M9[_E/%;&F5I!@38IHK!V^T>T+*1(B_,1FL96-P+L4AK9V.QF'+*LMP^<-F@' MY($$E!NS)@)JT`G4`PDH-VFQ%M#/#3JLN7U69KT-QRAR369-@P[O[B84(S=T M+8^S/^4D*0_&$P$U:,=:Y0+2Y5<2Z33HOH\]I+-M])#(IT%6?`_Y%.]Z2*31 ML%,.>VC?0K<]$(P3Z=1!Q-V@>_ESHI3WOTJQ0$AHTZ+*7/>6S17T@$<\1V*H=YX]1'C41 M5(/NE*EX'FD$<@06K&!_@]I/`MD=LHV\XW,_`9@?_6M^;+B32'+/ M`37R9N?=I%)^LJN19Z(K$X;^\$\C;XJN"J?'E5#(W2!G$\WB( MW>C&_C@!TO>]!\PGF"<7^]OZZ?J$276YH[SAC]!0_FJ*O-M079XE:];R?/EX_@S4P4PG-X.%J_;I26. MXQ_S>4(\\][K)-24]5__TL/`%P$/526Q0:QN.B\/*B^)O7Z0$/I]4&LAYZ#2 MI>H0]40"/#)X1DF<>1Y-<0QN65]TGYE,!K,UGO4-@N*13Y`?6Y%DJTQD4L"S M$M`FFV)/$R="&P%75U3F`.H!ZRH4Q,="@#)Z@6_EB/5E=O6+-&`=E5VL'7_O M;&.#.'R"&>U*'Z\>G":S4!4WUY8RMD:J?*4F@;*EZWTD-9/WGBA&,B2IRQO1 M^`$U5FYKHY*P6+L94LACV?O_V)$`L``00E#@``!#D!``#M/6ESXSAVW[=J_X/BK4HE5?&]LTEW3>^6?$U< M<=N.K)G9S9%X[V'Z]WO^[^] MKX+)*X#(C\(O!Z=')P<3$+J1YX>++P<_/AU.GRYO;P_^]M<__N'[?SD\G,QF MDZLH#$$0@,WD[RX(`'1B,)D[[U$8K3:3*_#BAWZ,!YO<^>$OSPX"_S$A_WH3 M_.GO%[.[R=G1Z62RC./UY^/CM[>W(PB]8L0C-UH=3PX/B]E^RN#Z//G+T1D& MK?+++$I"[_/DO/+I$@(GG=C#$'V>G)VGAZ>?)J??/I\?O+Y]/S_JJVC M]0;ZBV4\^3?WWW'CD^\.28_)[&AV5$'Q7R=/48APZ]7:"3>3:1!,9J07FLP` M`O`5>$?YH$&.[@03-$1?#BH8OC_#X"B"BV,\S?EQT?#@CW^89(T_OR._UN'M MO&A^>OSWKW=/[A*LG$,_1+$3NK6.9#!:U]-/GSX=I[]66V,XO'C;O`K6=\?9 MCUEKY']&Z9QWD9O25`"=";,%^=]AT>R0?#H\/3L\/SUZ1][!7\F$W\,H`#/P M,DDA_AQOUN#+`?)7ZP`?SD](_S]=16ZR`B$FC'<= MQGZ\N0U?(KA*H3Z8D'%_G-UNP2?]TTT6YQOVF+0XY@YRW!?$&>[Y[2G&NY+, M\?!RXX=X&7TG>(Q0>E0N`PT&WH^1"X<1<(UHWC MPY^<(`&5Q_P6D4L2J:=")RC&(Q*>.,+?`C]=G8>7^1+D$&\T$TX99&J8IOLH!F@> M;2'=\C_H`2Z<,&<>+O'[$P6^5W`2CQ"+I5B0R5"@="[),0?O\46`KSMA4HX( MTM`TO$B0'P*$\&OPC'\EL`U#&<&)AL;WVH$AWJ"$#4L9,)4HLL<>'*L&+Z84 M+\[H&C%[Q(?+]8'X#=AOEJ$Q+4\#%NPJO%G.RUQ&*$;IMDJYMT=GD_92N_EA?.SYJ^.\S3'I,"`\>"JB#XS" M0P^\.$D0RT'7[#X.K-'*\%P!5;/`$J"6>LZ((Q+/`1TDV=P MN*6,'*2T`7)XO:V1D-@(:S#CHP9"CQA"LJ]DJ%[6FW1&/"<^O[6)`F+9BB"5 M.BE."+A'B^CUV`/^,;FGR!_IA75X&Y\5!SRFA$W2X<)QU!A0(8E1\V84N__PM-:<\O*2JK:O\:-3`Y#34 M`B]1QL'8QY!UZ M5_AAH6P*9M/AH2Q.2S8WEMG\R+O!WQ`%3';;L>$D-!*#LFPY'HR5"P??:.`6 M,Q,\0*G-QX,V6T?VYJ2W&P^^.1Z6`U;Z\_#0I$\)%H!3IH\"3OWWD>#97&(" M0**V],#[_X`-"ZY&N]'@RVQ\Y-Y-14'TD,3$:X7X$[&!Y74:"_(;/P#P$N_T M1039=*VW&@NV&5CX*":JZ'MGQ=R,N\WDH&L*9.3+MR=\"0`D]R1+=-3!7VRE MO2J_,WWW=Z_L]O9;Z$N.=@KK>&!VN!@VYXQEF?R\]PN,5EQ6K9@V$N>))A'T M`"1N?Z>G)R<'DS6^\"'>2%\.S@XF"<*@1NO,HF8LJC*;M,3V3`^VJ7A?Q5&4 MB2"84AZE`J&3DZ.3$X)2)L5])IH+X'TYB&$"RH]1&&/QZCI(]S(6#\&"_&'8 MJLM2I,XT;%?XQ+S]+(O9CF!9HJ9I\PZP:#N<:(GB^=Z@V!!?2B3_O&=(UF3) M$LWOK$>3SH25&/YE3S!L"!Z>NOB8)ZF]_`JL(7`S3SO\=P!R7['I*L("7.9']@@C?(KB MS6.`GUS\&W%666<2"U5,5S:\$KW)=+&`8(&!N?/QP%X^)9%*`0GAHBA,6GI\ M6(X&A??;F29;U_8AP^?S`:9'V4L]$`IW.J:]J[VG9HRRIWF:Q$M\:_]6WFEL M3!H]C,#@%J%$'/J\M1&0L[7O0ET^K+]],+DA;SR^S5^!=TN\$Q8$NBE"($:5 MMZKZ)C&0ZS"0DC>L3LDK_]7W,&^"9G@V?,6XQ.5B07W*Q#KJ6),Z9")OLTQ/ M_1A)/B*"G?7C)?B4M'0R!0_N@\+I8`K\[<]*6Z\/V^1HMDD=T#?4-RRP[Q3X MORB`E^;DP6ADJB&T@\W7/`/$D#9?77:(I@NU$:HR.U6"6$S7CVG#C-]^_U'U MNOMKQ93781D,->5*@QV6.@#\9-<<=DMX'^F!8"D M`_VQI!LI#70?Z(,J0Z=BLBN!&+I"9AV3?0DDT!34_)GL6""WAX7L,-K]"H9` ME_/4&.P4W!'-QCNCRQ-X.!09GC":^*-63QB^*F8@=YBQO3+R;(I:YI9+^*C# M+62;MNO1\;&P/],4)REL(@8\UV`$*\;<;?)]%"HS(8Q MC[#8AKD"%%^_DTP9('U+J'X?@TRD0YTJ@DE%87<%GN.?_7A9HG0#G#AA&JN4 M#3_:_KA>K8-H`T`U6\H-OO8J6091KWTA/L%H.),GEF2I)CEB&FN1)U3KA[3$ M#!JP+@"XB?`%2_RIW3AQ@H?GP%\X_1=<>I[1*#`#ZP2Z2P=AV&C757[X>F$O M-<=HF*>';1Y=@(R[Q`OR!."K[X)^2]TVK*DW?+XQN39N^7$4KR:;ZDX`TGRP MZ:&*`CSHHGA@,>-4G#K^HO8>7;/S6(NKU6X['=!N=1)U505)#[BC$>X;KKTIO:R74THZVC+-!D7LN"/?6L.@:MIG)F MKGRCH3JJ-BF"1>A"V'IT-F2S\:DK/L+`4+?J$T2[#@GG;3@#1`\#LFI&LK!2 MNP\)KQQ#+3_(V+`_J8#]2?.MP;IM2QU?3>O[1"IOI%'TO!NF^Z!#KF$&0_-& MD5A!YA"CP%U<+5T`WO8='M*=BT4:VMW^QIV->_"6_M3I#)2=AU\)ZF4IO1[T M4?1`_Z0$^J<1H*]:!"MZH.MW`%T?->0V!0,.C],\*NR?\G=0M>\8D-Z0@L7X M:]4=HP/0U&&&A+]")UG^HM%U6#AII)$'F3V*0?=^"I!BEDAP3-.HT/'QV^D[ MY,XL;D9\25;OS.U%*;M'Q<93C1'FV:8N%M&SK$(MX.XT'A:6%DT.IXNVO5SZ M,7AX%6<@]J&`=JK3$.;B2-OW7490LKOR0[4]1&*J0H%>@T/'O#[:.ZF$K9O> M2KRS/C]LKL6;'0?3"$#^L[DQ$L(H4GQ$MOA]9VY0A#!^+;[():[F1D8(X\JR M-I9(ZHJ-D(R8YUGTJ@@S**,]G%PR<+X7NA_Q\WL8/T^SM]D?"2]O:]J?^'=6 M5+2M4>X=M/3V![QW5E?9'P7?R0IO?T1\=T7PGH3'2YLZ]R1>7DF8R/Y$TPLJ M;.V/IY?5@.Q/:+V4CF]_PNU%#?':`^_'N]?D0Q]MR$#8_;'C^6;IST8X[ODO M5.5E6NS_VXQ/+.:=Q/W+RH1 MMI5U4^$D5E+!5DZN=[!E20*K6;M6?XH23ZNY-)4Q_R5);&7?^H=.ES2PFI7K M%?I;TL!J]D[`K:3$=!]Y.(Z"YLQJQDU!(/B6$N=6,W@BCETEJK:R=CWR\Y3( M6\W1B0(FNUZA%66CL=6,W`#Y>$MJ6,[S]Z]$3!/+.$3)`+K/O.EE`XC(0$RF'L>P1*_[7R]ER_NT&"L2>R.=FD M29SKXHK8G*(&S705)>$V'F8WJ;*2L;6DE>X'^<6&/@`GM=^0,UI(P<8#H99< MY?#FT.;>60%N]N+6;GN$BW129E4IQV5*=XOVTI(6.]>T5C2K7!S8[;4$[+M+ MX"7$"-[SH'/3?*J=1`>=QPJ/.0R*)):;(A)%F6PJN39>19L"$/N@B:'Q[$A0KD+RJT, MJO8H97%MV2`\GL);@O]J&JFK*S50F8)QCJ\!Y+B9_[0I*J=JN52ND$AIJ$4H MK(#1II>@M]4(=?X4/,"9OUC&]PFY)3!\V\U\B=DHX%UL"@-]WK`%O\ZC*LGP M50>B&+SPJ'N$?C7VCX%0CX'4X!"M5GYJ`+H!U$QD]08?]=/TF%O5IPL( M0"9`4Q>C_[A&K54UA=./ZS2V*+\W9->/,]*P:UI$05[D?D2I.U7EAF$G1NT[ MI(Z59/@-,U:+U=H@R#N`WQ<'!-RC1?2*92\_`Q__L0LU_O3M&DMZ\88JC31^ M-@H:5=5+?\!C$3>%!Y+V#-]ON4Q!2GW)F,QVW M2@I'LN+R'/4V6J#TPW8H:VV4K.4]B-\B^,M#"&[\$#/16#`H.1/VVHIT4P-? MKB,H3E7&/4@R9?*#Z-@!C\XF=>S,U4"%5$.30H2Z**%_,<,,_)KX$,PC_`'_ M$SAN2JCI@D%RH7YJ(`30Q8,Y"Z(17N`57&#Q)_>5KJN3J'"*]U8.;<6O+]V2 M1!_]$!9J)*)8=I>"H,L,I0H//_+*(X77-C]$E=>0`;5`1RWGK\9!%HSE#.^' MDM*L=FZJ+Y#FH#7;?CDAXL`9$%HL!AM`'19,XU"A>(B5K&LS+'&P8087!AW M68$'EJ=4J7B]_"^)0_?C3=4Y@2_/@%^#&CHJ["X0W!E\W]*!M;3PW#/`RSZF+$>0U,9V'V9 M*5IST>!\/GSD9!@F&_)RB"ZE,*KFIML00Y45$V%PN@PQQ-H$/>WY,]295 M6B*F*;<:,P*-ZS%.#R>C"+=['!LF3B"%\IX-T5ZMA*&[MMH0X26&FCKYSX80 ML$[+S?(HUA[Z9=`FJ"@];"A>*486<1\]&RI7"N(LZ>UG0]U*\==/0FMB0^%* ML247=$FQH3JE\$KWCM:SH72E\/)W\ZRRH9:EX(/?+<#1AJJ6@@R`J(7-AK*6 MPI<`WW'4AB*5\B>\S=/3A@*5@E@+>I+84)I2$&,AGV,;2E.*'V$AWU,;"E$* MH\P/]K*A\&1?5.TH/BFL:^@7>VE#64IQMKQ+,*T-)2G%-D-G8[$-)2E[G@>I M^'(;2E=V?./8L0@V%*>4N`D$THO84(JRXS+70S-LJ#2QH?JDG!PJ&.%D0RU*-8BS`VEL*$FI=/'9H6(V%*L"T;2EFJ,;U5''IM*&@I_AA6,A*:7+F2E2.GY.I$LF&87(^P M%4-J[A;]I?/X90`XN6X(8DVDM2>9YZ?GE\3'B+3Y@I4:&B&B-9?3:ORC21AQ M2BB((F3&(K5?ZI08U"I&.VF(;"@[VX91/?V3]GJI'1*=,R-8J34"FX%>VO>E M:IRI%VB.Y=G>8$FY@G(0'I8N;=$FMBG;44C7MSH#?'L_`*(M;::"VAECDA_UNN4,_JE;"P'V=N19D'WX+- M=+V.\!4#O(L(@Y*]T;RL@_PN2N#*D2R\YKS,[X87B=G28SBHYF^1)%1E#R50 MS.TUIPAA'I,IL24L4B?,72Q*=OD[DG912.63Z3G^'HS9C!@9H'< MT!0Q,V5T'M@J>N3G\(?,3!AF^L`T/$$U@3@S::/8SPP\ML]4_O]M;$Y= MM9ZH-FTE-IR@;6'94=]F-['_T,2-0! MYCU?`706H!:G8`P+@],E??>LG,L6LD/9!"^F8=@?W0YX^C`=N['A`V\ M#3WB")PX`4=^I;H-DV;0D^B MH/+)U*Z,%BR=K8,Z1AB1NJBQU0C0M2*L=?I_4(7WDF@W?3!3VJA3(S#RW_2E M\1YGRQF(]AU851M2Z`Q$K9$%*!LR^HRZ+WDBA0VI?@;_6E;;-4&Q#9B5]A*K8KO7G(!)3 MF'#5>%PIK4V?I%VZ%=.)#$4`(]0>`J>EHYYP>Q!X[A(VI"7KBW^KRX]L*BXC MW/Z>DM7*@9N'E^W;6GDPIVZ,:15O#G3`FV7\Q-5M)<*_!19/EUENDV. M%U>CD=)*L7CX@A.:1S\OHU69!K5(`?KH^-1"'[)#Z*G/5*XIUQQ!:6@9O*IJ ME#..02XRI-E!*Y\1N=2F810O`:SVI'NT*1E9][H(@LZAAJI1#:($YGRKO_#* MWHD/H-?/40Q0,9]&F;&T8)T\(_!K@L65ZU?\3T-RWD6,U5S)#31?^M"KO"KL MQY'14F-T%?/^+MFZYJMO@]I/`#/6NNE7PPE&8TI?;?4*(4T"Z1?3Q*(V%2-N MA(3:P03=X<9G$:*-C-K)P[9!MSP%=,NR%.GVV8HL0;W>3*45AF(!@G232*TP MWHIBKTKJDC72CJQCJ20_V^8,N0T1/O"I^MR8F%!N,I<=9IC>5@<7?P6@_XII M]DJRQ\80[Q5B%%HE>VTK3(V/-(3U)^@(:(XAFT8DW>HQL(<*L80(!BU3A3Q]>*<=ZOYC?Z"*/G?!C5 M!!"93B\]ZOZTY0.)V1-/TDZO/"01AG'HEVC:#I,TK?;YK"B-]!!WVK4A3`L(1><:C2ZA;9L7H(MT<)-[B/0E@[ M66VF8[5SV$HEGAE'W?A:J7.QV?[YWSZ`^#E;;NZPN,;+;27863->^1JD>@>8 MNKJX/.]OD9Y:,;H-\1N`4O*>IJ"$6I>1]*XL<"42P)^W2N(!:151*J6*^LW---E&("SN[%IR6`Z)=P<0TCP\B M%U677Z%(L<=&^,&6061+:U?H"NL!EO';ING4S-(0[&SQ#.@GC M5%+0M%PV^-@-0H&S)@7,=9\;A`+G30K8&#Y(DC#B;X&?,Q'S)/\ M/S[\D=3ZROS>78O&<-\RPA^)EZ_APR%)"SU,R_(@N$7VT$=+LYN:&1O!&$6D9%#=N_LH!F@>;=V2GO!3F.']`!=.Z/^6%XP-413X7E8X-/0>(4"X M3?YJ4CJ7OD]S#-5%$+F_C%@5%#(/NU\2O ME\RP!KY'O)-=S,09`6>Y^QY>JO4F\_((I%(S:M3F-8S6/7%(F75:S: MTDKJZ;.OXXT.J@HJ<;M$5I,LV9I?OP`(\`J0(`D"J#X1,VY;(A.9R7P>W!*) M?_T?WU_VX!5&L1\&?_O!>3_Y`W'WZ^?W=^__'JZH?_\6__^3_] MZW]Y]P[E' ML'CO(K4*O[D+C\'V1S`M_.AC!+T$/0VV2)L?@3MQIN\`/G^SVX MPV_%X`[&,'J%V_=4Z)Z:"Y`S@_AO/Q0L_/X8[=^'T>X#:F;Z@3WXPW_^3R!] M^,?OL5]ZX=N4/>Y\^/>?KN\WS_#%>^<'<>(%F]*+6!CO56>]7G\@OTV?COT? M8R+E.MP0+TDH"(1/X'^]8X^]PS]ZY[COIL[[[_'VAW_##?YK%.[A'7P"1((_C$UV(?11_P^Q\"N$/?O/B1"#S&[W:>=_B`0_$#W"W_@P/G^,D\C;)*PU8N/??I!XX4.F/WZE9$$$X_`8;6`GEZ2? MIZ,6O^X?\4LO>_0*IA\8O/OY_@?@;__V@[_]U5U/9]/)\M>UNUHO5[\ZOSH_ M_%LN"S!AX"L3]___:ZJ'6M,2Q$OP>GS[W'[VG4?E^/.B#=,3_;7%0/K$ATV( MJ.:0O"M]QJHRXP\E M_YYB=&S#S?$%64\&,WV5D@LE9[*>39S5KU,:2ZE8$#Z!(Q$,8B(9Q50J&CQB MV>]'`0Z/%$8RURF;>_,$4L$@E0R8:$!DJ[66-V;38_2L]I&[6CTV@W2&*N:1 M;NXRU!='1[B]C<(G&.-9G[?_#&'7XQZ3Z"4\1'#C MD_X2_7U/B.`\V)Z_A%'B_Y/\'*E_@%'R=HL^7X)^]^GWHW]X:82?&O%Z@:I$ M9^E8GRW7&:19RZ#8-,C:!J@!4&P=L.8!:9_\/M/`&`/H]Y];]=^VZ#_T/\C$ M`@^YZ.D8!7[\C-C$2`\]%OHJA*/N,QBAINW63PA1WGK^]BKXZ!W\Q!-&G>!I MG<3!5T$ZCI?NE/)`)@A@2>`J`%26(40K,(P`%+_^S@_`1FR--N@U1U<)20WF M6P2,G^#+(XRZ?4+ZCGF0I(K(1I0[7RW:H`*^IC)-+?`JLS-##O#EC#,,H7(< M2@"IX!,UJU3;_WN,$]QWQ0^AH,T+&,`G'_6)^X]A0'#FR#S3X:;$EB^Z1J*Y]<`Q23%?0!SMNY@9:+5;D]J0^(][>`D?DU_\Y#DW MZS/TDF-4[3N4B]ARK\!-J&K)]>#OOP#4*<:H:XD8SG/B.?W2?AYK>;`_YG M/&BH*M^`C4-4:>TENWD'=?+.M.O0%%(M$)9R-0`.;1!C14"8:F+MB'0D-W:D M<*8%**H!L!Z`*`*H)E8/0$=R)>'R3Y)Q9O5XLS.C=1IG=G._-AJ_BN,C3M*] M>>)T,;]X4>2AMP?Q>(<6;"1R>?4EAT!SUW7G78G7=FZ\3G';^``4)G2GP. M(Z0BR5P^>ON;Q[V_\X8/SSNW8S>YRQDANR;GK!=NY\%ZD>,S-G\*(PQ"II#5 MO#Z&#P?0>T;D2!]04`@4-#H1DA_#LS6N%\4<"/-V3H3QNU%?3][O\%&TL?\= M/*`X??9BI!]O99LN%0UB_DYMV,CZ70R0G0R[\]EBU97QHTP1C#_^/N)3JHRU MP_KQG-F1^G-%,/GS-P^I,F.PONP1`+,N)<<%[N3#SFJ^[T-VG;B^\X?0QO-D MU>@AO("X.X);U`7=P^C5W\!A@_HVL3:R>8O.LH.B*?K+NBN!IXN;Z)E'2(;O M<$L&3S%5P%K25NJSCCR=KIBC9RX@2)LG`W2F@-4C-C6Y`LZ(4@U'[#?7I9C63I%23GI77]GUGD\1QNB'&%O=D1_AQ`"R%8I M*/IQ[X++N6S(%AI9;CVU1`@N#KIF/-3=:ASV=Q`[R-_#+S"Y"C;A"[P.8_3S MCU[\?!N%K_X6;B_>?HXALN+F@*L,^<'N''W(5V1@>Z63,9HR11Z*])>M/K)V M!?R2Z0&0(B#5!&!5\"^Q,H!I`R[>`-8'4U"F$K`2@_0-A'%#KQY`D@'4%`B/U:`3R__TK#5K6U"JM6) MZ;0T#ZYWW.!"@7A[C.`[_\G?(.]%AS!*D[Z*46?![%45LW$FL4J^BAHBW^TB MLNY\[?]^]+?T!#5\0BT&&_YB8/,;V@FW41W9->[)?4AK)]H03=\4.^C"Y@`@&1'(Y$?R3^#"=AFFA>KOSA>EW M:2GD4E:W#?6..H5N:4(F[ZW^F(SAYOTN?/VPA7X*1_27*@K1CWX]1WWB%O>+ MG_?>KO)YZ[_7@*5:H[+K`\YZQCHF]CK`[^N%Q##U73GUQXYQ86#@,.9;J&8, M6:B^@W-:7UY\,LK]#/D#R(;'M8\>Q;K([L@M)HOUC`X=B_6L2`HTDP>>H/:! MHRK3G)II)`$^,PT)-#%F5&6>V_[ES`T7VY&5CQ5;'&)DH%C2":>X7_HQ*>^+ M1K$O_O%%-#)I?4_G\+!-&>D1TG*VX*.)'"%A4@$5:VA0J-1:+KC"R-_Y`4U; MAV!+Y1L=%LH&:FE$*.4J\[C[C)P=;/Q@]S&,:PON4J\80UM9#]DM\O5Z,>4# M+9,'B$`;(#;`1"ZZMGAY($)3KWWHX>5]@9EFD,4/13&H.,XQCZ'3US^@T6(W%7!*DHD$NV\SJ[FA6\^E#^)TMF32W@58P?VYT MF9$A2)#X6W]_3/Q7>`\WQXAD]GSZOMD?MW"+RX'@U>AC0O7_Y$4!+@I^"R.R M7HVL.XJ+VRN1K7-`HT)AV:&VL\A.E!6:!7F[@#61.C_),P0;;[_!-=X%0RUM0Q&5*"N-6)2Y M_03)Y^*-+^#\NR^;7!=9!"QGJUDSBV"9X&LJU2I:Z&EL$]S/VJTU"^!ZC+8#L^(G(X!KW"72 MOQO49>M@NG*R&XI&W-H)$V_?B('N.B^PS@]8<,.FE+9X%F]E]-VR4!F;;>>+ MRP]IC]6N9TY7L_FD&+/F#^#V-\-MAI[>`&X\L%JWT5Q`M]RE7'I&>SAWO$)X MZ52B>=1KD>68N(\)!4*FKUM#S$W7'=?L-1[54FQ=?=94E'D9G:%?;%BZ1,9DRC88\>L`OV]V M);VW%:ZT%=JBG!BN&:LD=>C"B_W->;"]Q#-2N,7U.FYAE&Z#DH4@7MI& M^TNZ$X9:-9(^G3MW%_3N"B*3G/;?IE+3ZB\'&)%S%VR;6'.BD&)+G=Q27`R" M2DT+".$%4[HA3B0;2!!2;*W;X;L:2PR2AF26$R3G)35\P2D26[H@@I6!X'Y- MZ9>U\X>L9M+5B*?N/8 MWG#UH^";FV.:KF#.&:>3[TR,OR^.L1_`.$8L^.@'!/CXV!.B^F,$'^#WY`(U M_IM@9"GYLL81NYQ&TDMVBQ5-#V9R04$PR"6#KU@V(,(-C?)'L-Q-:\33.F,L M31B/"'Z"T0Y&)B<"W>*V.$/HX"A+`-FVH-_XBEGP=5TEG[KSU4H,.?-K_\IL M=/O::!!AC3L&K9XQ@29<4A.-^/%_/OU^]%^]/3X>=9Y\]*+HS0]VO$L2NKVK M$5]2"DGOJKHK>JJ65+_%LUKREX)D<)X`)GO$:OQH1NF'VT\!]ZZ4\6R?9;;C M'HU4J86YY#/@)0"B7^!3,43!$6V_3[PHT6O]O-WZ1[CS`YSM-+(/6CE7O?5N MH_4F6;<3817I5]Y)]O#P+0FJJV`302^&ES#];Z3F3 MD-+7^)8E)A%@D6.43Y&\!D^AD3.ICVAL%5$&:MG"8:M;5*,_K4.+FKGT\?T# M0?7:HO;G#:*_IHSL4O0:=3)+'OH/3"+84I'FP#_0.@[X,XF`B32-_:$VW%\\T2*`3<>+.$\J',P7FN]PZ(F MCU0.MXN+AQ:[3&"B%F(B6%P;/X!(M:&7F=Q$=_[N.?ER?'F$$=(Q.[GUT=OO M\;56[-(3^F`+AGI+U8^VOJI*Q^\D&\PQ7+*;,6\B0&2!M%4"V?S08]HPKO.0 M73')7C!4VD^GQXKU:HIW[-(;A\FM#3#:^.D=Z+0I"VA@*)XXA#'(WVHFG"5% M6`/L`]Q&_@;6?LM?A^HE2/L4M8^6DM$]GTXF-',NZ\_8=5L`37\B0@B0Q?8! M-\9]1ONRUNA.X9)D3GHYX$ECW&=,7/,VOF,(%WZJA01+Y\7L:&Z*/(0:\KES M;Q^JX;>VVS+,WH_1YUX%UUU,LA5RDS=@#%#>J2AOYHZ+`0;004R,&&KS[$4[ M-'!!HQAZF2Y.&<(+7I;<9` MYPRD'5!+C"VV9(A>QG2'6XL,6OXS#1"C?-,/^B52ZN$Z(ZLMN:H_03R!$TVQ M:\_I7!&I-BZ[9CU9S*8 M=!/=)WACD:2TL4IL[1]/^*899(C4D:[&O)PY'*P@L7@6FPI.LW;SDG[&`:3$ MZ%I/=`8.R.I748:R`5"U1:D`9HWN,0P\HDA\?DR>P\C_)ZPFB,B\809H537D MZ7NYX``L%0=R><9!-^1AIB#0$N#T-5&,GK#91F,0XL1A(XZJGE&]OOESX">\ MN@+<.X$ZOFQP-;-9,^E4\.5DXG`6,8](.GCD5IOP2`/FUBY5&EXG$"P=\$N, MF+BW:$SCZPN4K5_=AD5+.3SSUBHEG#<&^7SV_(C,3O.=U#NX":,MW-X$>!3A M!1OAYF=G.88I24I)V3B=S];+F8B=GE!+Z1I&*4TCHJWA3"6?MF>6K$9PB8"W M<$MT":N8I,%:`SS6B3!$1"?O7L.SE\:2$M7' MS,Q2.AV8GR]6@S^]1P,)4N*03$K^"MSYY&PR M(?\OK(?]%3C3]1E"Z-ETZI"3R(ZS.INYR[.U.R^O!I#?%J8V9PBI\0%N\+46 M^S=+)CKBH@(\3ZL:4^`;6-.-U>&8AI9KN`,C!>:%%),CP7J]D\ MG[ID,D&2"LU8'8\.2.#J'P6H--2I&4J%9EUZ=O+$S.%$Q>;.Y#^LR7Y;$I3% M7EK&38HX@US?C%A47)^@\HA^-BBU+SO<6TWF$9O&LP%XNR`$5#!["[%2:B8V^D6QNY`3ZK;>% M;VT-3S3#5<0>#1Y3Q2DR==!MJ'C>N\[U>CU;N/.,'4Q7,!]JAU.UPV!%\J&V MN*)O8A*UK;7$;:H:7M`E*U$BDY/<_);6Q;!&5:1K;$R7RSHT\O(Z=J0OJS.5 M(&?U+Z"OM?K6MJ3BL[S4U>XFU9U?N:%;+RHE?>8'LV]14#Q[,3S?11"^U&]" M5"?78/?:6VG98RS3A;-PZQUR7BO*^8@W6!GF;:M&-\5$R9\/ M89"G7'3M>QLDV3`*$JLG?5##G7,F#57B**4$`]Q2(4')LN&2(I\05KBM]#F4 M(M"_T50DI#N(5@Z@VB$@-:AJ<>:X`ZVT\8?P`GYD?G\(:WF4:Y(1*5-DW;NI&+^U#I@X^-3-:BI.;I[^'X38^#[;W,'KU-S"^ M#_?B`T["%[2.?41:R';GR\4T.Q\8)SA;@4@CMS4P>0`+-#6046)@5GJ&I"=X M>]/CDK9@*P\_&EW0'RTQW+S?A:\?MM!/@8+^4L4'^M&O]);USWZ\\?;_!WK1 MIV![Z275],#&1S5@HJE]V=,]J`66QYM*`JDH@&6!3_C29"1-+Q24V>7VL6ML M3,@$&$9#JQ=,]!J7$/7C&Y\WP/,/5\Y49Z8J,M*&8ODP4EJ'3XA6S4+H*XB0BZQIW?OS;^7=?5".\\14C M4*KK(1MEZ\5B7H-2+@Y@>>`KEF@<2@.-K$*I8*38/OU0$D2U M(KH46N(%W:N0C=I(9^ZLEM-TB;$0.WXN3_-ZH3J;Q*`W=]NU8A.KD"]\MA^- MK=])@2I;G6MWAME.,[X-]_[F+;N_OI7%:R\8Z3"K6DAOI65'B`JR0"H,?,7B M`)%GO+,<9*#+-=`WNP37'G/\#I+K"2.@\>/-/HR/$;QY*AY?2K.>MR0#FJRI M/WHQW-YZ;TW=K2*A.L$W2%/YVG(.S8S,V\-+Y*43<+1)>H0@;Q2P5HUU@`:< MY5:<%38YZRSUUKM.[M+&$$H`5F*1X9_!:J:Y**K=VH9<=XQ#BRKW/M;F++'47`#\#>AT=RZ2$*1[#-O($O4+NU M'G)=.RW%!7@NZ4[/>;#]%"1^\G85(+^]D)%TXW:4S'O:=Z4DE)*]7=-Q)[1\ M#Y-*ZKZEG:V.L`TW^"2]=;X M6;-,E31;\19&?KC]C'Y6S0-I?E93WJQ0`?D$4V==01/-,$V%`2)-?^*L&L/< M/H;IR)QM#3*6.MOL!]UHP+F[;8QFUVB(`JS^/7S<5Q9^5=*>5U MQFPQ)*JAFIEG8A'ZDQ<%?K"+6>V;EI0RX>,:%Y]%.DAG_*\SH1U::,;.3-9DO6&5&165)@02B@4@W!2ZFQ!&;GFTV$ M-S\WQ6Q(C+J#]X:4VH/$^V[V2(%TF);0)N4IDZBC!4?RO,)BYN$77,LG1HJ? M?_.B;?P0)O@*Q_SW."7Q2YC\'YC@:\YV`;YWBFSGWASPKT5G8O6T;0#]HQHD MG:PSGRXK#$+U*B44E_*.,]U`JAP@VI6?(?5UD((`:0AR%6EF!E72+"'9XW]" M:C\'4>XFDJY!ST*46`Y^QW\W.X+0208\?AS_PQGEV%R9QMKSXN=-<%E5"=D9 MYVRU7E7YIT`1ABO-JS$O/Y;`B,^*DO*M`*A3?DIKS)::EO_V\WDI=(D4P,28"N#^MKB= M;-$7S=SP*0=UW6A=L7T'=S[>.0Z2+]Z+9B&^\(A`&:+3=6MN8_JSW2*PK(TN%RRFXYII&2 MR3%=3CPG*#D8',J_@%U)3%"&]YS$.6:M3ZN^QAS@RZ2 M0;)T%^Q>5!HD24&:YKJZJLPI(KDHS6`&G5+[7(%]Q@X=2T`H.VO!'?XOM+(#W;H@2\A3D)(_XES&>-KP M,^]/M^S/,^903^30L.A0KY]#=0TG1L%P<1BB_KN=*M7Q,@O4RS\QBNN2&#!U MG>ET''HSD1]AUHT55F/^(D4\SYKXRV`JQFAH5$U8*E)!%)#5Q5OVU__IPPAY M^/GM&KZB#R6^(4CR91,TTZB1]`FTY7I2XY"+-U#X5R8<$.E&[Q`:P?C:>":W MU_QM0MUBEXO;=D\9!F6!:C]'\/ M\:TJ9496A[7R1FI'5T,H&H[:][\CF%$=;X/8N$NZTMMI6@S?NY< MG9U55(5/X+,?>,'&)_G+V>UNMN&J\>QYNWN,(NLJ.!R3F`QFS_SIJYUFB^(?#]Q8M(MCEKY2UWBY<4]S!PO:*JFZS`>A^@<%F@LZ-MYX>? M@_`QAM$KWCLD%(?KAZ`I]MXGF8PJZ4.Z*4O9159_Z9S?];J^$2%+/D5ETI$# M**MS8O0TBG,)>U7<$CZ!Y!D"RFEO?VQ2ZXKNOIS7Z>L9I43>)E'C:0F9-TT0 MEE@=:8C,.?LS@NU!HR[+1ZS!8IQ/7FB,RC%,@S# M4ZB8]![C=-T(U)B?1V0?:-5XHKHO)&>Q2<2VAG<;=IL=9PV*LT&!W#)>TZNF M,5O11W[CDMT3(8)J/I*T9(%/E=5LL"UAG5$L"H*T%8(\W]B"O%_\Y+DV!H_+ M@_#RB#V;]OP=L0@NYWX5;/;'+=Q>!:P\>H?`&:=]PQPPBE&R/=UBSNYN%0S. ML7:<58"XN@Q073C(Y[M8R;22/U,3_04P1>UA)?/?@5#;%YB`/?:6S[R%W`<; MO&62Y48EA#:J'.^#_0'X]@K?<*Z)6VE;I\NCJ0'25RFXJ^8%C>&'0WHCON$R]*[';(G%Q["'=^$+3XQ';*EV(L%6S?[GPC1.\' M?@*O_5>\E)"@#^\C]6F-ALFU^R`[=($]F07$_24H/H$_ M+<_+PW2)7$I;,B4J*K+(U M^)O@XS-J!?7VV9C@YHGF36;=>^6#]Q"@NQ!K)^TD0W.^G,W6:6E6LJM&]HE0 M*&Y("WBCZ`G/7E[9.6:ZB`#VK!W-U5O'\X&3^8#L+-X$(&T!;RT69G`W3Z!V MJL!`E=?Q_$!HZL]8]E_`#KNC2S08*P[;"_I9N=CNWE3,5[UYRDY^&AZ+Z]G" M77!XR58V4F5QG86TE;:[ M9=O#LNVAK.V:^48.RAS*D7"=B?607,%[;X_H\#8*#S!*WF[1)TQP.?\#I@/! M+%WR98WK(W(:R:X?3.:N`.Q'$/DB2'>'&QDS4#6??.&\H_"$SK%`WJSTE':Z MGE=@B=X>!VQAXNT;>_B>ZB]*8!*HKZW_K@='J:^NV&@B?J\"Q"CP'G6#)`>S MY>((T=,:XUJ@@G1IGM6<=CVI()!),GY1A`K+W!Z6Z4)#2Z@5D='D"D,HB:`7 MPTN8_O&Z]-YRK_!!Y6]$$4?)EO1B2T$CZ"-.2W;#,Y`(F&.?C M,-&`R@9$N#&(J38\3=)E-AY2,89AUB%6*ZB3]8XU((R.L'B)89?O7GW5-``K M^L@.>U9K9]$,/RRX6/+3(NP-L9DACY@'T_4-HWGQ70*T%7<\S]B!NIOD&48W M!X@7EH(=[RK1+U!B(#E(JE&L=E)5-J2=Z7K:`&/2)L@:%5T-C,O'6#".U>8P MP@$?L]0S+[^^?-_,=^8XH1=\FNFBNW_M8)+;"!X\?]N\O]+ZFE$N*.LBO;NW M7C6!G0H=9X]%?C-3K;5D+Y-9QKIK`M60"'1R=*62`%T2H;+,'5%38EI6*,YGYD$Q M4>@#37.U5<3;:C='B/\0/(0WL$=/HKMA\'E_;,7 MU=98!HO3O;$_0%?)9'5GLIRLZ#9_L9"=>//V0-O$N[A1UBJXU+S=K\TU3LDU M37O]@+4)'D)P5W`-2-LUD`N@S4NU2HAR`53TTAF(A6[2D@:@@&BRG("ACC?' MG+S274.EG01O=JB*Y$P6B]EBI8(VT^.'IT">/?RC@CO'*T8V`G7V\)$"YCPM MQJQ5VE+A;L5\25K_'$;W,'KU-VT#R=K3YOBNJHIL+,[FD]6ZSF=I$#Z%$8BI M0&-,-%:8R/00;;UTPFXXQ$AK!'3RN;^<*B(4D#WIHI8<#`I+@/%,/-^UWX M^F$+_70+"/VENO.#?O3K-?IX^T]!XB=OY]_]*B?PGM"PO\-I5C8#W%G/Z;6` M1`!()8"O6(;F7*"A5K@=K!@[NAM"!8>SR%03^YCMF;"&$EY[Y'@N')?.,$=/ M76T[C-17>W(8Z0%+;TN_U;4)V9*):D/":4&'\V!+YJS/X7Z+F`;7'JE5/I-^ MS4RT7CA2S7%B7_]P:+#0"I,4H%Z!+[ MRD;(M21S2[]N$02[GJZ;35?R4#2>@CV*]6[5^E/$95-B=2>O&<;IQS1;MOW[ MLP?-8(^V+G__X\2IHXP*,=[!]3&FT*71URT<"E:"28")HOEV1+]\OU1]P2@: MNK+O>KE:"E%A4U\SQ+[T)(_M$)'L/GB.,`R9+\CM) M'3NY/)O@,]!*6A8QV+U[@-&+V0+(G0)0`"*!.Y1L#J7U3=F-J_DB-&\-7_BL M[BTAD2*R^PBK!;YL=EJN*5F_#M""T`189.$6F MFQBO$EV.+UP`\Y_1.!XM-2P[MYDZ[)@=?=U0E`\WPI4U0M?8DALLQ;%DW58U M?0W<^AMO?PEQKL(=?(4!_V@']SGMO0U'">D\M M9[`M3M&65`Z@@DQT.H/M<<7?QER?TP"/O-,1F6ZDU_&#]EZG](S.7J?8L.QZ M@+N>TPH(]'73O4YO(UQ9([3U.KQ@*?4Z-5M-Q/07F'STXN?;*'SUMW![\?9S MC"_T_>P'7K#!18+PY<1-B4(=!&A$@[Q6\G<`,*C@BAI8.P<4;P/+)K;*L M!9`W869#:B07+)@+-M@%!^:"QS?PE)GN-9JN"X'=0[L(SX[NLQN[+4OY/019 MB>7.Z0J+R:0GIHWO!XSLE72;#7OD\S[\1F]M)70TY,6(3XM`S.@ MM^8),(]PCE:R7=7:7;L2R,Y:L+6W'NJ"N]0'F-H*C'2"7>*S8: M#^7S5\_?D[N9PD*)-WILZ<*+_8W,]Y*08@H.[:I)UTY?NDLN8$#6!JZ36*RF MR([UD7:,#41'<\:BB#S@'0Y[?T/B%Y)3RI)&$(- M%R^RO0Z](+W1-F^2EQXB\YKN="()G61OSUL[#BU-A".P?//Q'LNE5V+GDC6G M&ZFV-:.>\G771"Z]^3J7;"`=2;6];I=O:RQ=J0,XL^PE64^-P1Y2MV@W?-;F M]PWSB8)+U9W)=.;,EB)FBS1U4QV+4H1<7S;OYT?#B&^C'%[$7K1-FVBB32: M7]%/&(WZ2-^:X*ZF*T862")>4$Q%@DS#-P@;2*#VD';85S60[3[K`I@D".1J[-:O!WQ/)NGE`3S",/ MX2_/XYR9P"K-WWK^EOM%.HK0CMUN^LG&TWJ-"WVFR"8MX(EF4,`X MWAG\AIK!UY/0=K*;!P"^[EPW"8SI!Z?@AYLG4$+80PAP,R!O)[MH`N"63+#( MF+YP!\2$.1;J1P0Y1_7PJ%(&8^L<^+8,N,TG,;PHQ MQ6+2&DKN/ZX<=S*OTEAV6XI/6BDL7>`K($D[P&,-&:*Q<1Q1X;'L=IRTE>)T MG[4#LH8,\M@XSB!$EMEYB/ST+IWJ:NHW/WFV8#FU+P_4**R;,TVDM659HY^^ M'V`0MZ9>BY_7F*HF5$+V5,`R2Z3.4X29+..9TFJL<\O602K+9#99:ZP5\\:: MO6`4*JTIS;PG3<"C>VKP;#5?5($Q>I)S6S+F4'L*U>#S,S^FTYX;HHD+@T$I MT((![\V!W/[(2H1N;W&_?!,TK)^UO*%[*-NLCOQ<:S:A\V\J,*OXNF5CE4#W M0IM*TYRB:9E$0$2273>#JW`J[72'V*EE:"F'N&P<*>&<\8C@X5O8D0CR-ZP@ M@DR=+HLNBV8B2+Z%-A!!3],:B0#)M(X(>MK92`1M=IHC@AKBFHF@[!PC0^)H MYP7^/PDL\>IWY!_G`5(1Q@RR-T]Y3@#Z"9GRQI=^O$&CL&,$'^#WY`*I M^9MH`*BZ&9V#<<6Z2U].L9JSCK^@`2BI0#+YBDK@A:I"1DJF!\@5`5^Q*H#H M8FJ";-*EA%KP4262#EALSNAL8B0@EJ8B8[C="&LESS`ZWVRB(]Q*7^[6\I). M1FG41/HHXL)EXP$L#U"!0-L5<*TH5V>FFYOI43.M6`^3BL,2!-M]8@Y0<0R3 MPO5!C9^U^JQV^%04D"[:.E_/2J@A<@HW6YG$RA";BA`AA9 MI[8&<(=&(=LF_*@V>5;:[L1G1"*8^!$9"E6/OYD$FGS$%E$GZ2V3$+QY(GK@ M?53G^ZDGI[RTQ!Y>(D2_0S M\I_,7B+IL)<]"\'#8;-+8*W`6/V5JPM$],=L`/X?F&J)<6D"4_:^D4 MN*\8Z(!Y>DAW3NZTV@$C'%%YH"#0]$AWN)&E,2Y9#/6;S=/=]3:%(*_K%;K$ M"AS=1CAW)7E#.$<8#[:?T$\/G"3D'@),8DRHE?2$:^[,Q(ACX@&13_8[LA:L M@:`B'\S2$J@''R<.36G/=[N( M?-![7)`O_NCM][C@*AT^<`B3[W?JW%]G_V&B_ MGN%V9VCG@^YN#E3.1'1QC31(%@<>][!XN?LG;_,L24M=1)GDJ`YZ2G:4B]EB MSN6K8MG5]*@2*T)_@C?H1>9/+0UD"R[3=76G*MKSPVU^>.HA M9+-,\4Y:AQ<-4%J[5I+!N)ZMEHN,P)#8TA%+O$+)]IR*.TSZN4JQP4[!X.)1 M2KQ$R0P>;QM1EH04&^UV_,HFB4<>KT6:D728D>674NV[2Q_?M!%L[]"8+Z=' MT?1>YE6=2RX2^LB>+)Q/LW%"I28DDPNP8)!+-K3/J-KF]'J9$`T`HL3'0Z#* MR66C2RP=8K6TN"+K)#6].K>UN!%2'5[4WJO+:"5[:&$Z7SET]_'A&<56/@:/ M,)K(A67X<@AOOSGN\4^V#&T'MN:)>H%*2.KN]=4[I)%H8K-,,Y;--A)-=_SF MO;RTAT8@F;3JPN4Q\H-=.MQ`0PR<5Y$\A'=PAZ%$TM7_X>V/$M3339Q90NJD MJW2%Y/ET2JMFWY:CDE5WV9(&,8'A4>N!-HFY*\H:Q8/95]RL48(:T4%Q&-@".[ M^UP+L3X]?%7M, M#T>BSEFVER4F:<^6^@_F5J6O_]R,]A9G^`@8;N84I_IO&UJ6XZD@OT:P6 M2SX[%,2"7*X-BU+##78YG<<9V!2HMB>E:K&V!4O5(D=9QZ.W'HI MC8\:`UR7LAKKJ>O.!>LQ9BJ&*+/)[6J3&:S4RX*T>L`\&FZ]Z"8B)0"VI,]$ M72OI5Z6^I?!E8X@1:20=;_/U@H\A)!G<1&F]C6TZ-L4CV708:P.PE)C.[Z\. MR/97T6C<#-C:XE8,OT8_F0=D.JH]/R;/8>3_$U9K\$N^9`R`54UD1TOK^4PP M>:3SQ%RD#6`;9"8?9'3UP&NTTPS81#$I!AG7/[:`*YU*=OC.]`7#H$JUD*9S M]+=&0*7B[`%3#_,:@>0+[3,)HG+LM0&HX!-;P'-S3.+$"[9^L.OP<8MO&891 M0159UEXX,T%*#<520:8]@.IK:".JPF9+34*+$YEM^*JZR#S(>/LT34\:`U.' ME>[U=#J9S_D`,K#(K\H>'D[^FL^5P)_>3R9.OJCW5^#.SR:3"?Y_?;`'_&"S M/^)`_"M8_0N^,$B477(&EK/%V6*Q(!L#[MELN3IS5O-RMT=^5\#J&4"_.\!- MXK_"_9MP!?)/D_?+.?BS'Q1.A_UIOIRG'F.,NRQ+_\%5_R MA.O1G;>J[YZMYZNSZ736K#+R","0Z::L>^8B[ZSF\[_80T^U[8VV"%2U6_SB M'U_P]4OX.`"N3W_TXV=:P>02/O(/(;6_96"_MT4E2=C.WFAH+*E-T\`"]9]T'H4>V<=/JW)C5))7!9W M0F7\9&CT@AU-+X`Y#[:%>(7,+(AE^< M?E[F#:W`$ZHA&7VSR]TA\^ZX2#6&P MHYK2/<1ZMN9AM-`<'HNR!M%?0+%)4&S3/(['=%)ZH3!,T%RWB/78VT-ZP?`[ M!,<$*;U/I\G48V@B?(OT>><_^1ODN^@01L;O/%"`*!%I]/D$BB;6N1+LF'V< M'Y)%PP(RG:?7P?#G/9TDZ)]P=U%/NK0C3N9AL^]B8+/R'7'I"#4>-J;YKV': MCO:Y^'A.X-!@UD3I\#R>+Z3KI+0=(^G0XSF",Z21C`:#T_<^Z"],Y3M[T_1( MZ!YU/#]Y";X6^0WI]Q'U.WC9%ZF'>;>U.MJ$\:L'WSI+&F:5],JW*"`,NDX+__'6_K6;#:USFPFS#N>K1=SP^!LC=P*&IM=J6:. M3^M\B2"KVWSR1C"%V3O,G[[O_G01HG^%WT4YR2N>ZT^EL M22?XV;5*K`$<>R3=(ZWRP+VT$ MI*V8F-N/YP6WY`4+[M/JC^M\\M[973K)Z,L1GRNCOXL?P@O(3717(M)2PA+I MVR5TUSTH+"#M9@^0`I"/D":VVO2=K,'2('0"VCD-()^=YTT*;;Q M2U>:;'2I#<1Y%=RC4?4>IH4E(B9MA"@2M71B-"LPHP-&YE/5[(NW16.B%2W& M$V6E>4^+F)4X5S%?XUWZ5"M:C";*BCV?'I4K<3!A^+M*H(&]_^(;S#@=E095 MT7Z3^[7T!JS:M8KQLU"6;8PN4K1+U$\ZOGG\:0V,U M_B&,^0"C%U+[K.8G:UFSC2ZD>;'1C7J8+_(WHLHO/018QW%%[;H$9X?5S#-P MP*WDQ_ULX[+^/NA`8,0%AJKBC.T&PE/7>'\E>?8"]$?A8],3GZ?B79ZO M:CY42E)$?':M$?;C+W[";C#BIU/*O6F*EIK5DBT][\YGRWF%CU+*J40=^(:D M9YESAFA(IDE7ZW-YP*ZZO@H-=0<8J@TY4F%9`E.[ M@Y3,G.[@)YQ)#K<7H1=M4^EL3CP M0B1IG@"I,HE"'U!I@(@#J21#N%=JG]O7/BT3FG9$99.8%H>8Z4!)[N^M%R5O MZ9!#R."U![5VE-76I8M_.J[+$)*F.1,AC0,L'?WA('O<;O;HZ_9$P53NZKBV M*^K>.W@/"`59XIO\LE,B63]W:8*M67Y>NXL M5B[K8M/H/)#H3/(V\FH_Y`!0X3=QND3EI>V#J"A!>]>LWVTI"T<-C MQ=;3%4W:/BA),-+KZW==NOR9WIT+GL((%[N)CWM<_`S$,'KU-VGV``LM7!<# MOASVX1LTBU@D/G^,T8!C(SKGVOJ:>1[(=)%>-%LN)BU`C\%7 M)M6"^=!@8SFSHP[&&D9K+40EX%AVDTUXNW@K_J9I@U1>@`48K&LEO4NYF"Q; MT7CQ5NY:S6[$CN,#WA*&^1W;SF$L@TZ!IVS"Z:4?;_9A?(S@`_R>7"`-?NL8 M#CP)%B"5HY;TENQR[K1"-99@>PA MG7+$..U)IEASTQM:(2E40WK:-9]D$&3"TGR^,8LUM]](H-Q$>EI"[AD[_QQ?U3ZXM:4=6FC6S4S6?Y@#&5"9A04)`*J%A3 M^%)J+@$9?;%<3.P8X751?/2E`#L0)][.Z-70\E%;1J"4UVR`84OJ(_=A@W#K ME@&XGCI3$<1,9S@.MHM@B4,4EJ0T-H59$U8,9SCA,ISQ':*@X`C_'H;;6%SF MDONH1FSPVI>^9G+!+I(B4@`5`X@<<]4L!YM$0''S\!'?<+$];A(T,2+"3&*A M*:2*2!`:;QH''=LM$K>MI!INW9)KN-8&+S#+=' M7(7\/$C\K;\_XAN8[^$&WRO@P_C3=WR/--RF]ZJ]'(YI'NG-$QNZL9/[#_A@ MBNACJVU$)P*5:BZ=HN"Z#+BT?;RB7=0`Y"H`I@.[I##3`K^437VR,AK@*]'% M%.[-.=0M.324<.A3U:%A5X=J8Z!18%PB+O4?SBS?R6W%R]%:%UE&V*N#@M*G M3!;NK$Y2G5)6[""BL7Q3XQNQ;\[`8P?GZ">5'ECA%-O'3%-\D.5C$R5L81V=;JPQ$1'\[K'%C8]OI0>EW:B?GQ0!E<]9*KZ4 MC3Q6O!GR'-'PJT^9MRV_3X%@BYBK75O96<9L-9MVH*S23:R`-0U(VQ9D"FKV M6\I1QY<7+WK#%/4E)'<8PO*-M9F;;.8=>6!U(1Q)?QMF&JSDQ=O'O1?'DF.@ MVAMFN*&JAO1*Y&K-&Z>0F$7C$"+0FC''("/KHPABY*.$D0:0*0I$`>2XGE%2 M;R!?(JE50F6E3W\.:HE0G5[573%`4B_9`]JSV7)%+^HHK,)EM;OS,LEY3>0C M$J_YO/\H1CL5HSEUD?,JR%B\@=/ZHQ@N48W4V*G[CHC-CM5W<90B:HE08X7$ M:8D*=QU>U$\K$EI)5WV8.M,%(Q4LMY0G?\@JPI%0TTXER@UU"H86CS[84>-O M+*O=@M7G8/4OO4W7Q"L=X%I@%5FWJ>&4MM4.T6('OCDW>;L*XB0ZID'_T#E[SGAHU1A;1SH$EK MI6ONN8Y+;^E)5S?2!<)-<77#RU7&4X2X\!P]\P,\LI`(B>+`SS4'(5T3>O'J>*@X*FF4.T!41]@_0$V`!`+3'1"I_/%2.?&=^2[BB//P$=\E<:>?Z^3GL[-AGXC M[S2-?V8[.V.B;'P5I)=$V=$?=]7IY+ODC@9++M*M5G-WIJ%3)OUNC.]!I9?O M_BO@?YP.>LP/UZF+)C_^(_70/3N3\3KI/I_:SG[Z M'V3KTZY^NJM.)]]/=S18]CJN^60V=S5TU'3[_#]:1SWJ5QN_IT[5_P_94X_Z MY3IUU:DF?YR>NF=W,EY/W>=3&\ELZ6OXM1_`JP2^B(I9*A"L,T]FL+;R5_1E MZ32#6?8K;AV0YDVEWNCUFYOYK26WMR6UM\5OVK)YE(&OE/2CYIN<%!O5%S$9 M]:H.W(:63H&OQ.K+)MP[8'R3I,&Z+NU?MDP[6>?`FW6ROB$_^%49 M_J*?4)IDI^I,]AB6?8(Z73XQJ<894Q_\:RRJZ2N=-+-VW5TTH,`I\JNJ3`.R MU3P6Q1K<7$HW)3\%C;PFX1X29WDH^G9P!#.T1G7N?>%%R M@NZ=]W;O)=Q0[SK$N^X?HO/KM&%GZ-N>XO+1S3&)$R_8^L$N[=1'F@S7VSFA MI:.:\M)%]QQWJ7KAJ*`,G0P8[IN,.7;&7S:RO;,QYJ^YA+_LZSW&(#>52TW\ M;V(VIY*;8J(T@8G?PLGD.W+5E\VFFBUPM1Y%V8NB5,53R4%4X$G%'60U?5#W MM7?F_2GH&$\UI:^1S88GZ(D];N6`7EAJ+ZVWA_0[#[:W*$Z^>"_P,GSQ_"IU MCMJ43V?\F*/DT4 MIWEY#0ZQ9E0Z`*&=!J9]W7]:M$;I^=-W&&W\&(K.-K'?DS)#R@.ZEQ(G085] M+)/>EIO-.^3-M)`D&]YEFC8=$&$/I:7#3HT^1_\FA:W2JEOQ(D#9>_DU#Z?) MND,(1`T?]_Z>9IF:7,:&NI`O80!?#OOP#<)[&+TBY>)"X?K_??2"!/70-T]Y M\; M"9/(='*B5B\2OL/OX1SI:I%%?(\$J#XN$]PTI@=)*<*>WP"4^)\Q4N<777Z MA2RQ)7E22O,RS'#QYA8W!^LN775ION:=R]X1SL%WPP<%SHD9YR0%SOF=<0X" MV3>J1IZ'96Q14[,'5;$V4R//_S-ZR%FS%]/SRK4@LF`!4QE7<58OU3C9$G+F M#@35RCX]6NXR@'&LZ(W!R>I3@Y`BYC^^4L[&)$;1!_]5&SUD0F1\YC$3 M"EFY]WA9X61>8CIN:D+=;3(WG4Q+XP7I!''3/J;V4PPWW'!&YXBLBN:R[G:[>*';I5G@NT`SZ#S2SF`4@9 MIQU%36'(19+0)T;1=-U6LJO^H`G<7'AI"$8NCD2^,8RHSWZ`)H*^M[\-8Y_D2T@C M2_RJ&80)]9&^Y'>QGG*0ELD%3+!-B%-C=1UYG:TV@,#6X!4@L=EGAA%))F_/ MX7Z+@B`=AX`6"V MQ[``F2U^,PK-QLO"RP^9`%NGV[(7RZ53FW`9O0&\OQG5>98%=WQS0X8;\JIO M\B8K?\&6;F^EJ^:7Q\@/=FE*:[D846GO4O)5[?OY+:;P)0'S5\#J.K`'TJ&">WWAM>)6F>0,A+,#*1D%9/,L3F[B2K M<46&F=Q)!!YG^K017-<*MV)N9C&.#PHS#.ZL`K4!6".`MF)VJC&.'VJG`-+# ML[P0,#O%Z(SU\E2CF_=&IBAVQJ`'-Y5?M8>42GK)'@A<3B;KM10=92>@[**A M`5;+$%!V=LD^XAE@>0/EL,]L(=5P,2O!,75'C4DN5\$=?,6?]"<8[6##'>H= M7K>$9'BZ279UJ]7$=5MYQ@]`E+8`7D@3-I'-8.O;^.8J`+0%D#9A&^D,]D!^ MB6RVHEK[Y+813Q.>V\A'Z+`Q">CV&&%B3Q[".[@[[@G(+[O24(,02\A(K*%D M2"Z7T_F\E9(.M!E\)#?*&@*7-C&3(E>T\1-K!CR$X*[H"LMH2I$[!(.DTK90 M,3J*+K&-Q-HYH8W*6IRJF]#N51#:O?6$=M]Q<#]S9WT9[=YV1NOCBYZ4=G\* ME-;''P).$]#8_2G0V/U@&KOO2V,*-Y-$>3X?\1TB48RTO'E*_Y[XCWN8UXUK MV@KI+U3WIE1O3>6SLJ>K5C:@,Y.\47)>*V^V4.S1X`:7'E\1IKA%80ZC"#F* M\,2'2_B8X,(TM)T8+U"'I9J/5A2F4`*HVG;:,+^/.4!*]:BOIG?H8(0B+!D< MB?23[?[FZX73/C1*8Y>[]6+'N$B-&R1YD+B4Q>2LP%-NIL8R9^MG=@9+N&W:H#%-1 M/]LE=N.LYYXJA*5)I^2R\=FFLB+?^2-7W[>*=2K*R6:A+)<+1Y9X:MLU-K'/ M$/LE":BV1V<;"PWQ@!L,'[QD_M)[EZ^:L%B,I#C[FWGN&[.&$9Q MW)P7VRBNFT,Z)OV<'JG=#R>U>TVD1GY)KZW-:V]D-]CR;_0:)-`JJFO35G:Y M>C%+[,/QAT@J* M22>&3'$5:WYHKQC(.XNDHG2L[7TX6'>CHB;:5_H@V9A'/$NQMD"Q,?L8:[A+RN0E"@3;^:N)%&2I3.C+,5FMP*!=C\?67K6$O:IZ M28[E9Z[KMF_]%3M5FTZ_#C*ZC9:*HR;;CKD.,EQBY&0;XX@`V\8R7#^-RRP\ M0NM.,F(IUO"-4$79KM!=+1;M@R51YV@7#RERA@0G<<=(]O&3(H?(#93LHZM6 M%FAGKF8/6K263)12?/Y>4J;Y%68Y16575N>K:?M6%&GR]`[?C^"IGF?O+5R7 M[H8AB27J#MZVC4IZIGU7WK6$&CIG!2_F3GL%Q)0"+,WY'F!W/1G:5JSVR8'F M.,8V["G8$6Z08PDF!VU^SF0J`*;X/(7M8$4.:=@-%L]-;,#QT*W@%O^-N=;` MDDS.@RU7@:ZK#G+R+%E_D%)6MN:NXTKLVH@3G?+T.)L6)=1[J(WULE0XG!-DAO94UD,]=7 MRRFO.'/E`D9SE#3`JCK?X%/I!6EF:62`96[;]\*\@0"RAV_@]MF+7KP-/";^ MQMM;P1E\@/$(@>.C<=&>[BMW^G+T%6N0G^HCNTZ^F$^GO')8U8!*4PELX8$^ M-K;2@>%+O579.8`<;,H8:<)E.U44'&=LC20=L=RB;_;I^P$&<74RU?*P[M6. MF@;22V_K96G7(14$L"1`11E&MVC4?\=3/R(E_75]+5E1>@&EZ1>TJ6CY\M2^G9! M/)D]TP:XF9)JL;A.'1"06D?M%UZ/X@=R%_8ME4NFR1$1C,=/]I5%Z1CE-=!V M<:&]4.:M+O:18!V0NZSX3%?.8MX=QR.L@:F&<0\O2*'8?O36%KGZ.LX(=H^/ M,?S]B#S^Z17]<>T'\"J!+$N5_2X3E0*=)"N[#=9L@.:F21`1(&O6!@@TDS= MM*[".+>7<=I0U1)R)0@UN<,$7A[@]^0"R?^M>DE\Y3O6G].(D%KCLKSLN!.: M2X)%`"(#?&52#$%BF#5N)VMT84`81L7@YQNN9#GTX=F/ME_"@&6[_P1?'OE% MNP5/ZE[\Y*LA?0)T,5_12MQ$$`C0O)X=7M"\Q*G"$B>W!$G*CIV`KZDPS4!5 M9I;;PRPMJY3-<,D6)QM\8*2O\I,]O'FZ"K;^J[\]>OOS[[YH8,=_5F>?Q5-` M=M0S=Y9T5D7$X`3G7!"B?"3*5.3.@%*W#QBY\\ MW\&T7EG\[!\>PD]!XB=OE^&+YU>[H[Y23&*I637I<)RN&U"&VP#%1LB!2-(, M^)HV9`L&%;J#H+-D=2)EM3&(RL5Z(W@EW*=FD/HM?'@.C[$7;#_M(9K_L0RA MAM%JRRO:AZW-^DA?(C)Q5G3X^BT$"94((!&9Y8OI'L@JM,UAMC&)(!69IPB: M'-HJ-)3P!0IU1\XR/:-;.9SEPUP)?Z@F@(>.Z*\_;Q#Z-65D\SNF4W<]X0`_ ML0+U`\VJ8_[!/L`/M)'!?6(GW(6HXF&=[PKE0$=SZ`1V13O_)9.0YVHD&SS. M9++DXIY*M0'\"@SD,``ST#8:4&`MXX*II5S0"#PN(8B=HH05?@[$!:=H,J. M)+,-Y/-=!,G6,>]3]A6EFT%ZZBD;B!-WO:(3"=(2_^`2.9,$XJPY<,CVZ%F# MFGE'BUN88P@;R['>""/9-0WQ-5*")$2;78BJC534O8MW337 MKI)L?,YFRQ4]S4"%%@Y7\JIH:F8NU98Z14OS0Y+CIWU*D9%J:X5'(XV?6Y"' M8D8?DLX9G2F$Q[S;7[*))[H>M%W*L82)`]EJS92B"%.GJM6:*N0'*WF!?QI: MSB,J6:$^A/D<1O

O4W#?5MY5\VQ!+MFDG&UGJZGDS*;,&=)^%3=C&5;Y(W M%!M>X@_N3`@?HV3R33.)8N-KM6ZS8@S%KVV:7N017*4927>II)MKWWOT]W[R MUO`5\V<,D4>F@/316W?!4@H95O9,AAD:Z&E"">Z9#'.`[FF&R_T2IH%:B_TJ M'LO6C@*[2TA6:/Q7>!7$243@\-GS(X+V<\0'+ZS0R@%N$KC]1XA3._";=U[2 M-!10U8)IR`]37[)[6:XG4[?$%W$>IN`)-6=R"&'"%WSB`;D&(%`"MB`7UI]&1:UA;-'W#4[\BPY3639@T%JN$A(8$J\+=1^KWSX]\^ M1Q`]A>(,QHEJ\N7*/Q7JY2DO.SY8S]%'^N,P[W!7J"!>K`7`:@"FQZGQ[G`_ MIKF_V!%/V!$^)/IF^HZRZ=*+E6%T>NPM)JOA;"WPLXF#O=0&[I$!_C,:#^66&I8]8[I> M.)6<+S/Y\,.-<$OK+R83WQNCI7CPM6ZLRB''3=!0=:7VC*'./U-`]I#C:K6J MS.:0B'&#MJW_[6>#H]4&J3ZPGR&E*8EC_LB)*/RK/5'96I7(B[-.+NO0+OUX MLP_C8]2TXM/\GB&$-BHEO9ZYF#M3:Y?(%9KHE$S,A\:%07`NVAS2%5IL9UZ$ M%`2KC-#N%34L41[1?CEB$L+W8>(+0=-$[9MC$B<>N6WWPHO]S7FPO?3WQZ1V M]9T"@=IY98BVLO6^IO/%G&5#5*=8`6D1;V*S.UA)HR#,6P7OP"-NF!Q%VJ9- MZ^8F?6YR2FYB\_&TQ?0N7^*FM%%0:!609DE=8=JP"4K3YRC^E+UG/)FC2!7\ MDW/G8/>G!$3=<8V$HW^C?Z&_()]!](__!U!+`P04````"`"N,6Q#-2ITA*(H M``!D_`(`%0`<`'!V8W0M,C`Q,S`Y,S!?<')E+GAM;%54"0`#6`V"4E@-@E)U M>`L``00E#@``!#D!``#M75MSXSAV?M^J_0^*MRJ55,5MMWMWD^Z:V2WY-G'% M;3NR9F8W+U,T"4O!%($5<2%"A0+W.Q`/"<#[=SPSG?_?5] M%4S>0`S]*/S^Y..'\Y,)"-W(\\/%]R<_/I].GZ_N[D[^^I??_^Z[?SD]G&OI?8#;* M?>1F*$D0.&&VP/]W6C8[Q7\Z_7AQ^NGCAW?HG?P%?_"[.`K`#+Q.,AJ^))LU M^/X$^JMU`$Z*ORUC\/K]R?K-33+DSS]_.L?]_W`=N>D*KZ+0NPD3/]GBIG:+G)>)X&04>.LMN_IFBI3@-O4>$0(P/%?03"*'_!MH3KO8![?Q=.7!Y M&T3?X%WH^3%PDS8\-`?I3.>U#]T@@FF,^KO.VD^

1^^LE%HOP'D4;-%\WFAA2&;UWII[3U.?G"`% ME7+O.R]^@!;.5^#@7MXT(1W#*3K^TSA& M*A,^)*%^%%I1L3^0T(^5DD15IZZP23H3..;@/;D,T'$G#>4>2>H;P\L4^B&` M$-T&+^A73%L_R$A^J&]^;YPX1`L4BV&9`*:31?;8O7/5D,6T\L49W2!G3VAS MN3Z0/P&[?:5O3LEN0(I=138K9)FK""8P6U:9]/;D;+)>.N>Y*P4#1VCNO`1: M5HL>.OI&BR$#]W3QJ7RM;\ZW(@GYN-9]PA_?*'?:UKC,5PI.UQ6Y!GLO:BRC M+B#TL$$W_RO^;"`O?#(GH[\X!_AO'& M_Y$!?WK^L3#"_P']Z9.L$]F5<(64&3S/:`<+#\;RUBV9')"3R?CO#0E$`"T!^/`-&U M>0+1GT8-$5V$)NC\^8A.4ZTD\/SGJ.%A6QT)0O\U:H2HVC,!Y_,1'(%1A.@5 M]LG-5"-:53_EZ.(E+N>QXH+@V&08U7@\3!D%$3YP"[RF.7@&$V?3> M`@"%3/`Z&>%C&VK\Y/C>77B5O^A@,_A>.3'QS`AR2,TVNG#C>(`DN"\QAA4U(]343 M!K*52;D,[#8S0>O-:AU$&U`^)"GCWGW1$2WN9X(;='W[";CWWP`Z=)$6L,`N MAWRY/P`6*X).)OBHP,D@NMK",(5H$V:+N/;&5$PVO=L0>1$\1,!4.87D)&<97J:X2A:@SC9/`5.[KE'1_D:VPC8 M<@2WBPD>9B!Q_!!XY7,MM#?359K):]?@U7=]%B<2'8T&%U'L-((C5JJK&9XD M):>!R$K*TI$V>8@11+?[^ID6+]=H8]("2[=[5,VN#%U^:WF]L"NN0QX8_J%, M\+$KL$,>'Y'Z2Q"R*[)#'B&&0$B`L2N>0_7,J2+1)G8C2IS@$)!@J)8UWY>< M:=+V&%]IO*14`%OC?)718N+2YNH:_JY3M;!5H>)9A`AN=EYHFG"C6:((='9> M>5V@X[4FN-D5W*AYR3&<`@2]-K&/!W70R=P"O/`.6U\WM(-*PD]IZ[N'UFN+ M&WACZS.(=FB)'!ZVOHEHAQ8?H3;RQ$&=[&S'WO;=8],J211K.P-+I?&AQC@0 M=-I<=L-?/2JNBZ:>2),^[7H9T14G>:F5(&C7\PEY!\V.U:;I:K;U_58[B)K1 M?+8^X&J'#S,RVM977.U@DG'&V_JTJQUB?/M!&RE*14X8V.N3>ET4,P\YR'I% M(+AYUFSTWP'(EE#H35=1G!0YH9FN6E9,NJ[AM0053!>+&"P<[$M%`WO%)_%: M`[C`$B7$0-#CF#U1*6P>K?;'.-L87G;GEHFFQ9'TS)Z&.IA1.?FK)SR#N18#:;D1ZDA> M^V^^AVYZ.$-?0T>,BR6"!?5BD.MH/LQ8YJ93Z6F>(\5+1+*S>;XDKQ)!IZ'P MP;U0.!V&0K_X6A'U.N:2W%LN21/4WS.R%G,:'H/K-?-$2S3,:#3]J@ MU=2;;(_J:8]2J979FNBT.T+T/(/6>LS586(8E.QWGO.@DO(NV>\X%T(D:6ZU MWV$NL^^D'&>VID)M#15''+#T+5]+B!JR@*6/]UK"PT@X;+GN2.8-X5FLMJ^('QP_QK#Z&5TNTZ,!=N*WA_/@JDPY(;0`3:!,*GYT`$56S M*(M"*24[F^(+8MJ0V!3>O"=(9DI]N,P/P&OPPF.)W\\(-R`$L1-@Z[^W\L.L M!D[BOX$B!P:+%T$O(YS$^)2,HU=F2KAJ"Q,4YK?C]KH4>*19KZ/4"]<4K:69_*,0(*T0I]%"FQ$$429X\&]'?A\C041(B(+%,9*) MX^RSF]K4-,URY`Z$4E&D&:.UGDRBP%\L<=S!&]H^"_"0XABAQ]>*YEBU]>VH MF;2+J-N`)BTT`FFK9JIA3:#MSG4%C'C*O^T>=@68:EI(-Y?Z\#-"*.#"D5ML M]Z:KK!Y)FXGMWG5%R`3F&-L][`IHL95AVWWK$B"UL%E<6JHY& MA&[Y<8@[`HE8,DI'0AY?H M/$+WEL%H2'H^2V[*)7X?/2GIO'^DN?4)SB/&]RZ1$(!323I!_O(=IWTO$N;/ MH]+$4!SYM+*B/7[(A&]1AI-*B@!L\/S93Y:$I5O@)"DS89"VX?>V/LHB"GBG MH:G)]O\,7"Y.894Q]'\VRR4<]\F0]1F&VJ*`@R/2R_ M8)'@5.XZ_J1V'MUP`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`[D[C?FD1V)XX78RM91(]XJ%9G('$ MCR7L::V&&"Z/M'7?9@0]&4#R3;7=1'+&38E>O5/'/#[$G732ULYN)=_99$@W M-SZ"70:A46KJCW:^OY&&AQ+7L\7F3W8^MY'&1A![3G"R\TV)-$XLCSH!R-)G M)3)^Y"I0#$1'DV&\X:FN9QEO^J@Z/=M:YW=^XL3)(>.C[M^Q_CF7W'IBE,YJ M\8QK!"N)89>W/6U<>\"XQBW;T\BUAXWI[Q]WT;;VYFK;<\YUQ8WFS+4]Z9Q, MU3L=3Y=L3T>G(+B*3>&VIZ636'0*=BG;L]$I+"U9JVV[W'2'E%VLTWYL!&9T MREB'I.27Z+`768_/E]LENK-E][:-$NR6X.[046OGC6N7Z0T\M3L3VA';M ML9*,"+`]RUU7;8L1D&=[NCLUV';C-FS/;]?=]%&)*>R6ZLY^L,1!I03!,;H' M.JBZRUG6D,HN1BO_Z\PF0^`Q\!+C1:@KR#VX) M6*/5"S1GO26(CE&+D,IE2"!2T0QL-']+I)@A8(U6#9#.&D2P&JW(KSN?-8'T MJ!_(IWTAJ(U64VB3P($\50 M46SE"HL0/,>HAY\<`;28MY7-<-P:Y>^K'T$^PF1)]$3ZVLE M5X:*J-!I*].2N/CV!M<@_[<2>XPAM.R>[`I%F_,VBJ]+D2YR0MH!*FZOFZ*M M?[?T^`HH:K;70U'%,3]?QE&Z6!(O5Z:04>D2]])$G=1)-Y0S[1H@01X=N/E# M#^HNJ#71@M$/CA]BD?$QO'7\/"G0]NGFO>^\^$&S`(A"1Q,X$LKRH&DD!R/) M-]D\!4ZNW*ZQE,E`6+*S*;X@I@T@ZF[>L22?^G"9ZVE8[.2PQ.]G@IO=0_LN M1,H=%IIAD7IC'CL>ZS:0[#P8ON(470;%IF!G=I;J.@R>'I,EB(E"F8G6Z'JN M$(H44H$BVW7482!1B/!TD5^ZF^:"I=DE*BCQP6FMF1IA)@`^>>+N_=$K!R"M M@Q::\INH#%@F'Z*1PVQKJ'PLS02UM2D0$Q1CQR@,,&S^!(=@BX$&Q.\=DIQA MTF$^:0,,F[]V\\D;:$#\4DS$:GS2!A@V?^WF4Y\M71N_)LIUHR$1,BX`'L1Q M^=C>`;Z2X'L[?BFCV$";6*U+3,@\6 MDIBJ$4(59!F+6**C27[F4?;"/0;Y@9_]3<`)M*C9/M"*$=E.%`;0LE<* M]QHV<>X:-B#5(B+;RPCZE2V[$X'(@IO3PS0'UWXF[^#0OLP'EUE5[W#R`A@% MOH?C])[3%^A[OA.SA8PN(VI:882`4K."1+7:20!%7VU*(YB>-WQ9?,41F3A\ M*O2NHB``;D8:!EUXI+48:0@<[YAY98XZA1%,<(CNQN(P;KPV8G#$ZV&F"%4S M!DD@JW.[&"NDE6]MO"SX-D)&8Y,A<7U&-=6>K=8\7[8GQ-\7JJ+HF4Y9]`\B MIZT9I*F18[:GWN\;:G&`H>V)^@T@S`YLLSV;OYF38S=*T_8R`/M9TE*QYNUJ M"!S2R[-]+6F),!7[JP_L966SO<.=RA4<#P[5"&CK:QCL!6\!LD=EL,NIS#)% MM*N)<,1W9^6*PZ#;E5,XWGD[4/-BW&PON+!G@*EA<.VJ,QR7L0S*K.#(=C4? MCIC3=1.9IP'M"D<<$=]9Y9*/2]H5F3@DM#4%T%>7LC@2O5W6F".L4L]2.J6= M.0!98U_0-E[&=,I:L.4%;1L>\$"#8"J1O'97LI``Z3\5`3MRAL4Y@>_T$/1"KO-+N5ELA2IS@(!&5 M>`',6K3"EP6V5X?5!*G"L[1VM60M.%L[+E.I)S^V5Y;M:;DR,!R9(*6(HDJ^ MB6X59P_V9E)T?;)*"IR/RFRD&I[=BY>48#\J^Y(B]IT]4`3F48E7ZN>"="88 M@FB;,-?AG[0R;T[;84=9E;876^N&(5=>&$U9M6X8@)A4E[L+7Z-XE:<*,)#2X3*%?@@@O(I6+^AXS>PD@K04W"ZZTK"7 M_H6\_->/:`KB73#GL1-"QV6FJFDQBLE=)C,3U1<:R@CM3T4VL-,N'>B[:'M= M^T&*;4I(DT5W70$3+B0WF!TW#1/?PU3Z;Y6"IC?O;I`B[O/`K=4Z38HWU#=. M'*(S$W.3\['"T9N,K:EG;".E<;I1?KFA#Y#7>NL#*^X7#Q#!^]U2C'KA(L,/ M!YL'9P6NHY7CL\I3"+L9*3Y#`FOJ<8E?P>JED9]4MI<)3AK'#U_N8#8W0OMJ M'40;`"J1=ES\V>V-)/)RE\!+L3NWX[:NU9;<30"F]R,F<"I"*KDS6V]C]`U4 M_W=HS9D@/%1M+T*K^\H5HZLL)MKN%Y.]V:O0[NQJV]U7;2#B7&^VNZ':P"64 MR;IYFH8/FDB4JZ7NT"Q\V'[+]".L:;QK^(*#_876ASX_]Y:7=R=60.QN2#95 ML^=@S'Y7@0-AD>6%:W2@-#1B9JB0(;(-T=L:I+J0\![CF;]8)@\IOH01?=NM M<^4$`?8KET_FBH8"_EJ/JL_F'YF3]W./)ROE):%D.K34.S< M!ZW-+"\0!TVB.]1[#,N41Q)DRXVCJT8TSFU,.[,Q!D26FC@M_< M22E!#:/C6`WMXDK@]8^@K5S;PN1R>BI>[TT7,0"42B#ZQAW47&74PL)'OHY" MH5B7EWL4SFYG8&QD=Z8HKB]3;&*'2#\54UMKHJCKZ+8I_ M?0Q!$3/N!$1B8<^M3#<]]!6V@W)7Y5*%HK"F/HC)*IR%>:C4=FC:B507/740 MBR_,0/:D=1ZA/Z!_!(Z;`35=,""7ZJ>'0A"[V$BZP&;E!9I!_%0V%\MVS$Q4 M.N5[:Z>V$G.9+4ELU*Y6=;AQW*4DZ2I#Z>+#CSRRI=#<%IN(7*EUT+,?=J\0="3CCY1'V&5]:2\HE`>Q MCFEECK4?3K`CAG&6M1A`*\V%DZARM_WL)TN>EBG9TTAM82=<`,Y#`?*[,>JX M^E.UA9G:S!Y:?XZ:F5S0R6Q0=$;)Y29SE,I%.#=[:-EO'&6NW-W8OT3;<+)= M-=&)T]2I.4P4.AI9#5ED$X+-^R&*/)R7XR$*01D66=2/J42:_"\Z<[%!JAH0 MP)7=-'Y`SQRVIJ=2\N45X(J4U)G6./Q`^&5+%MK&-EJIOAK6P[D?V>V-U:C/ MT;M&NR1;"D&01+4QBZA*!C+"&CVZ]WLI289(43`LK/4IO0*Z_P@L-[=[.$O!&K5W(.J$)7"-5'N1BG@E,8U8;5`*<"6)CU@ID@Z\(6F/6 M">1"_`E6(]<$Y,+$"5PCU0'DWGH2F$8N_3,?\Y(:9V.6ZCL_^28PCE2Z[_3^ MGZ`W9O&^=9R.[>5>.^YAI50<[0J]6H2EZM,NVXNW*IQ\$AF@VI5IM1`MW@N[ M;G57+0"I[=-T`MQ(M8(.N<,(=B-5%51SQ)'PSS%K#HH/51/01JY'R+XK(H"-5)6@)3(FH-BE.K"2 M!!)M02;1EJTEPH7H4%/*V5ZHFIZTD5X`A/+0WM9J'IS,AAB;YEJR%0AFVHW: MPYMJUHM1(%%_MEG%8B>'(KEK[+08B-"HY[TDIZF=FJU$4I*Z%,=\NS^B.CQ< MJ*@'<0F.M6>,XCJJ',XE-!=':'@*PCXK*QG"2907A(72_B4:`Z6G\K6#GT'A M6EP@A/G4#*7\U#3(!@<>>:Y5I?/F'?\G*\^59& MX#Q*L!^(_(X9>XB2OX,$.]06H?];X<[-ZY2R5L%^OJTI??FW8#-=KR,_1*1< M1HB47-[EI2[G=]%"5\%D^6["RR.1>2EG!#WZHVK^+5*DBO300M4,W`3`E9T^ M3FO#J1"IVV2*'=J+3!B`EQO2ICAD\@-7+G%BQ_'-I@9DT,PBN6%/9J8$;#WP M0>%1[,,?\D"3,/4\7_;U_0UYV&/!3W\/5! MKD7F>4*DQ-!["IRP6?%;=3&V^=1A8;9SD6YWUL\`OZ!$4M0;B)T%J#VTU(YF M*R(&E[JQ*D5N!1,65NH##8C?/+*\.[N<<4QP._<3+-#3<4N,R?^D'U0="OD(_#?:S!;2<8,,*<_V9)8](;UG M-YYQ_3!"8.4C#"16XE[VG'-[]S1$OA.\JK2[=T0Q4[OFGHY31JYW;_G,,?9O5*O+%, M0*]JENT.]N%-`TUBZ.9]+@US2RZ5F1))V#AJY1!X2$ M*,)#V&U(O%QNJK]PGE,K#&`VFXX+2R.GRP:POP?F!JQOE4*;VQI$%9/R8#)P#V']#F+WA2O29\(B?`'(M8MPN9GD@ZV+FPU\Y%@5N%Q,\;%=DJW4(FNMS%"9;W<#IW*6ALC-K/=ZDF[)K'M[\:HXR)8;6$XPS6KZ`<[ M9W6CAQX;U;=HOHQ2Z(3>30"09%#6C>88JP1==-,U5R2JV5X[14L_3H`J6?1. M6F@KQKSWG1<_P(]M*3?)]F2>0IBNRL?RZ^SA\D\1?K"+>\Z0!$=C1/,7C'*- M[]3;&*!62,P$,-'-,W5\HQP7_6JYMI[BZ*481C<`,I\SBT<]A&`.XI56_BG# M#[^\K%8P;3=$]`RIS'ZUW6+1+\3T2\#VK'C]8LH2)VSW"LK8*XA_D"O9VNXE M;`L573FQ/F:V[<)B*"C61ZU*&-VJ_A8^OK8[367,>Z,OH:?UR.*KVA;']O:0^;PZF,/SPN]J\9]!0[NY4V)\O88 M3F?`36.<,_[2@6AIF2BG'":^YP>,35^X@.D3+I!BJ#!`0?XQ5":0_CX M>N/$(2(7/H$X?^&UH0_`*\[-%*2FDB,L)BCLIL5(2SOD66YDB0Y&'>%3 M"`&B)?3*387P*K?58[C=2JC!0Q3&M9TE"K_0^XU#18GG#-4WOE%T+C?;__QO M'\3H3EQN[L$;X-7ND^QLF*]B#C+S8)P%F[F\%S0R/8]A+QUYN`O1/0:S)?*1 M&QS!ZS$4#BZ4.;@8&`>?E#GX-`0.:/N3*UK(]!P*1[!YI"KSQAYC,%QN[T6Y M)55=*J MJ.TL>EL=J?)ZXJZ/6K`O;;>W]J*8;C$6S(CMIGWM^FQU9TNI3=9;P'N%N-<; MSGH+_+Y6/]<84J)\<42Y"\IZ;@?[W^JJV>BH4,OIE;;+N@I&01&*#7O#:+"3 M#,O1>(2,!EJQ/4NXN1OF%-M#-UN9SJ@PTFS2MC\8Z`6]BR9Z=KX%Z`6]3TWT MQI>J`!=^1G\+_$(+FB]!85K9'`-'CH$C>PD<&4[XP3%(XQBD<0S2.`9I'`,$ MC@$"QP"!PPH0H!&&LY/]&$8O$,1O^%+)MTU=YIWMW,Z%T/L#FIO[",*[,!?N M[L)2FE,`II_O6X#N'80IV!.2Q;.&$_F_9IW")KRCPO7PJ0^^I0D8E"))T)L?"'%%U&43NKT;" M&5TW2D-_ZPH`63@<3[A/MW>_Z$1[5(7&90B1[ M0XC4IQ?T*_[B0+:^)&7T#2'9V<210"%-=*AQNYCK[)R.:@ON&BN, M[KI=8@0KD]G,0;O[ZV MA,U-;(SMUP6[N=G.Y$9@4KU-QL*=EN,&R)$HA6@3MPG)E@,S,C:B(YG3X;AQ MM&P6^R7D:%-&F27ZHD M"]9PQT&-%)3N.'4=@6",:K3:CY:543LGNF)\/$SDT\MM\425IO6.S"LR8Z530,;-?!H@/I49TM!=1/3ER7]`=BKV61 M)S@CA-U,G`(J4*NQ-31GB^RLU8HNJ:`SJBU*BZHPNBFM2@E`!56>B6%LN-:! M-W3NC]O+O.QLU2;CAW7E<5RRFT]IK*%SW7C-4'_,H!,4Z4\=Y$&FML)&DP2Q M!QCEE^S^'N%2KY'OSC"?6'5$__/_4$L#!!0````(`*XQ;$.NBQ:G1!```'BR M```1`!P`<'9C="TR,#$S,#DS,"YXOSH-T;G%U=M?[X_:>_O?][N^WT^\ZYX)SZ/ITY?[K4IY)$ MU!F21\%%,',&[H0&Y!?GCH342D@B@'0^8.'9>'W:/VMUN M^_#=\/#=\='A`G0P M)7SF]'S?Z2-6Z/1I2.4]]0Y2HJ$2U@$-\O"DI$S+-X4N]&.0Y^4&Z` MH(?OC@XU0`YFB0.SX%XD.SA&!X#:`$4E&$TE68L?((X70TG(G),HT\DH.&4N'2%2T"T"2B/+H4,SNF( MQ#[P]STF/ALQZK4<$D62W<41+0#$?`[R.U)Y3S@7D8H;ZC-^,YTR/A+I1_@" M)\>Q%#X=@I\X^,_G_E69NR@->QV$Z)P+-T;^"/,2BV170E($:J>4P[Z15 M"9&/GHWOT1'C3/'9/>PZ;2=#U_\%4DY"R]&(O>\L4E@D'D-\ON&_J_]=XKNQ MKQ"OX7.*G$)4(4XE1$0>K8$YYVPY7OIM9H8-K3,`-I7[W(PN&8?HRHA_*T+% MPYE/PC#U(K13'Q#^LD2H-ANL5DY.R,$UB'N4X]H(_X7"9[AR>.X,) MI5&XM]Z:UKLE$#>C"8T8**6V*17V"GO^NHX]G5<%QG[>V[?*OE>0?@;4;+WT M6;6-WMC9*`<)'3%R;J:8R0*!_>RKM,Y@`JX\$;X'>?K%]QC6G1[W;L"U)2;, M\`@TS>YIE1'KD:BV]=NRK9=9>!`)]ULZ[#^=9."]K:ML?4;"R:4O'L(K[C%) MWEPC@4?3DG(E,_H@^W= MIH;;G,8AXS0,(1[?P5-D:EUGL"15;>)WBR;N4Y=,603[NL3-U#;H(X7-I-P; MNH:A+XCDC(_#6RK5JES/MLNQ*\W9/33-6%?9\)SY,0;_:Q&&#M#%,EP`]E7T M]Z:M8UJ5X`PEX2%Q56);T[@5^-7F[2Z:-R'EZ+3VIJQARKDR(=F"%!F2)251 MG_J8*9V),`K5!#G%JOLMF2FL>N;>=(QJEWB]Z!(J&6\K6HX^W-XO:OA%:IM; M(HL3==VUN@Z]:GL?E1=L1=I1M/5(L#=X#8-?$B:_$#^F<]W6G.;5%*J-^NNB M49&8HZAAMIV/YESQ,)*J/+V/\UM:LF]A$^4R&FZZ=.=TJDW]QF()=UYEQ/8% MS1^XF@_)G6_I!]L9J=I3WMJN[,ZKA-[>6;86\6NX@@V=:D/_MD;TW]N\XK0X MU^5B,:/'O:24T?,\Q1+QRR?)ZV)7&[E42ZLHM,#3^1#ZX;/SZIQ&A.W/N2JM MKFH>8*RTXH$%CUMU`A((KH*RE?77I%+M!:5RFV5]9N\1&WE$.6VS<@%;M$J; MOR[5Y$P9W]Z^F]A7948J,=+S(BL;UT&MMG.I.+_O&'L1!0.3L9O1) MJ!XZZBFXFZDR)\RR>YAS=L:W(U7M#-9E.7R4C(>Y7CYB`N\D8SK9H'L'LHM_>$I_2$KT3" MI(NN&;EC/H33CY0@EM>+YHB\!QNS6$K&QZK;H::CK#5$M1^5*H9V?I1RXN2L M.!DO#HD*-&#KZ>0>W?;W-U`IP*^\UG:DS.BU$18T%_*549A(NGHI(5SJ)U=-?D+,`X>`S\# MB5B$HYS-Z3A(*/S%(;[?ZNRNY$4S6@@."`;!SW,R#9';)W?4MQ098`TB7R.% MADB[.,TMA`84@]!ZMZ1)]O<=_9H4?"I>HWH/H@L9.;QTF:OB?J.37*&\%JXB M5(&"G]H97AN_:G=?MX^Z!X^AE[)8AX.YINMQD.'5YTZKOO9+ER^ME+"(A9IXA^KOOMV$!>W>:$TV!/^T M'B=5]VHW,`Q^4]%&[56;&0X M^,]&BEB\FVLU>HZD_MMH_/(M7RL.-+3T_XVX6+PU;,5#CJ3^:\_1]?'3V\2* M@9-6SW4E3;8BGR';P6HJP<-TJ1+\V2GS_72+@VOI7W;@25*@;OL?!X)#^B]G M5Q$-,&-N.>0.MAP$+\*/B*\6?04(R0`3WE"A>K%,"T')L[OD7N%)"T;W&*P@ M'`;"(_:3%NQ><#6+@2B+8D3Z($4\S88''H,EDGO_C<,H:?T0\[K.+6'>%3]+ M3G]/*8AOZ+T>T%I(QB M1JE>;[^4(M#*^>$Z.JU!]\7H\BH,8QP8^YW0CR(&8Y[3N^@KBR;I]GTM9=8A M_`*UF4EX*23(K_B/B7]SY[,Q6=M!ZY-_,9KMTVDLW0EL)&Y&IMAW24D4R[5" M:3W23Z=1C][]0(6JH#84IQ2=BGK@2`,J[YE+U_+,E=0:YHC+!24^52?(:MH) M'[:WXVRY[7$OFY=&]6U.M!E:'(\EA3!$K]GW.+W(>BOIB.+VHN!8*P`WEC:I M?D1/*FP`*7G:ZJ=ZA@.F;'U)"Y)6034BHA0$`"--P7_QJG+LHX;31'.IQ,L1 MFB#\RI9!36X+V$1D'@IJL$8$9DV$),P"Z7-VSSS*/;.D!K!F2(JO*)IGR3=2O8_P MXI%*EX7T5C(]ATZ?%HR]'OZ&,SM?KK:A@24K40/7GC1X8H:99)>?N4?E8I^] MWG:[(&]=9%TI(5HQ?+X`K?&/93-3[(6E-N:16>95.$U(L1;$T=HDLAF(S0?2 MP]/V;(>\7!N6Z`U13%ZG&DX`9SR95PB4P$4UK`1N1FQ/DDC8(I66Z,4GS8AN M!::3&BYLM%/G3(+6_O+`-N=&/8Q MW*8%J!YLB!4ILQXV(+=3J:Q0T_FQ`^!AA-$,#$DMW4KB4>J$Z!28^#9/B;;J*F.O]=1&;D-+H MA[DF*2#A0(!H*/ITG/;\GI>6ZXVH[-)2O98@B\=JFQ#9HL]L51U*!NWPSRAN M&:A94V#EV;M1:@NL1L1%HT25]C;"-4+69#G+RKYS230QEX,TP:D_DD<6*-AK MW_U(@SLJ-=F,3PL9JR<"6/6?+0'_")9VB7].T:D@ZZ"\$&'-CQOA>9]HI*<0 M>-(4YJUHR2O9-4&MH)O@CPN"V*9<]=":JXABD:..+BHP&Z*.!R&_W7`Z?U-7 M7NTJQ2TKZ%V*8Y_H@S_K3:>"\8AZIX)(+V'3(-H*R)T2"[PI;:DM"U)^ME.L MQ\B3ZLG*NH*'XNM$!//R>Y;+X%&Y+EA=3'W^H57'5#Y;:39C/HL.R6F"79UZ M#=Q=VM.E_=U9)N>]MV`C!+)Y\N?@VDPB$1 M8CW?=-39UKKG5%1!TOJ>ZX*XDVK!:U'8+2T`X7E,!;]-HZB6W!9EMH'7G3WC M]QF%+.2F6:=9V`<_G=M0%](.?C,S;G-5+3*JRK*OA*X(0XQ MW\AFP5IKRX1MK'XUKZ"!>HA-V`.7\N?T=P&S0JNJUL5!J1NP)MZ3)4(_7!/9 MAF3>#%)JIMJ8TH8Q8JNKS&:R7/$!Q`F?)H%09M2VIZRE`S1(AUE^M8%++2>Q M8UG9*CEPAYBUGM61OXBW0WUI&>=I>[^6,>M7E@VBKD+84,:MFK5/+WSJKJ@R M5@'M4B5@R5M=T\ME:O77^Z[0*CTN\'=S=\?.Q2E-VZ*CXD)76> M9`_/:I7:K+QHPWQ1KW7?"#:(AC&+50`['AVECV6B1KC";+?X67.:@,:?(+=I8Z M,&,U60]6'?UKX+XTG0PVT,G@!>@D6>;*H7"U1I9C[MR26<&\X2*`/4IC!%V( M;[;"EM`:([`QA-F*O02YT<(/-A%^T"#A]7-RK6T\;Q2TU<-J.HU1R5!DC;W6 M8:Z`TB!!+T7,/>Q8QL_)19(:,INQ&R"^9B[+?*:,T>0LQFPZ:U54(#=9*TNZ MA_(09JD?2S)-TQ1D\Q"E@QJ4L,B3+-E-!?!JB!W*?0-)TQZVB65TDGH M,H!=.OHF#'(LM:I:A3\(K"T@9AX#:="'9L2+O0L M/._EK'5%Z[/PVR4$\:S0NR6-F&UL550%``-8#8)2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`KC%L0[XD M#,U3#0``\Z0``!4`&````````0```*2![7X``'!V8W0M,C`Q,S`Y,S!?8V%L M+GAM;%54!0`#6`V"4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`*XQ;$-L M`\'W^1L``/S'`0`5`!@```````$```"D@8^,``!P=F-T+3(P,3,P.3,P7V1E M9BYX;6Q55`4``U@-@E)U>`L``00E#@``!#D!``!02P$"'@,4````"`"N,6Q# M&UL550%``-8#8)2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`KC%L M0S4J=(2B*```9/P"`!4`&````````0```*2!%P$!`'!V8W0M,C`Q,S`Y,S!? M<')E+GAM;%54!0`#6`V"4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`*XQ M;$.NBQ:G1!```'BR```1`!@```````$```"D@0@J`0!P=F-T+3(P,3,P.3,P M+GAS9%54!0`#6`V"4G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``"7 %.@$````` ` end XML 33 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party Transaction
9 Months Ended

Sep. 30, 2013

Related Party Transactions [Abstract]

Related Party Transaction

6. Related Party Transaction

The Company paid one non-employee member of the board $48,000 for consulting services performed as of September 30, 2013. The Company paid another non-employee member of the board $75,000 for consulting services performed as of September 30, 2013. The Company paid a third non-employee member of the board $75,000 for consulting services performed as of September 30, 2013.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Basis of Presentation
9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

Basis of Presentation

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ended December 31, 2013. The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 36 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Equity Transactions - Additional Information (Detail) (USD $)
1 Months Ended 3 Months Ended 9 Months Ended 140 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 1 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 3 Months Ended

Jul. 22, 2013

Feb. 28, 2013

Jan. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Feb. 22, 2013

Dec. 31, 2012

Mar. 31, 2013

Minimum [Member]

Sep. 30, 2013

Maximum [Member]

Jun. 30, 2013

Maximum [Member]

Mar. 31, 2013

Maximum [Member]

Sep. 30, 2013

Maximum [Member]

Sep. 30, 2013

Network 1 Financial Securities [Member]

Jun. 30, 2013

Network 1 Financial Securities [Member]

Mar. 31, 2013

Network 1 Financial Securities [Member]

Sep. 30, 2013

Maxim Group Llc [Member]

Sep. 30, 2013

Common Stock [Member]

Jun. 30, 2013

Common Stock [Member]

Mar. 31, 2013

Common Stock [Member]

Sep. 30, 2012

Common Stock [Member]

Jun. 30, 2012

Common Stock [Member]

Mar. 31, 2012

Common Stock [Member]

Feb. 22, 2013

Common Stock [Member]

Feb. 28, 2013

Series A 8% Convertible Preferred Stock [Member]

Sep. 30, 2013

Series A 8% Convertible Preferred Stock [Member]

Feb. 22, 2013

Series A 8% Convertible Preferred Stock [Member]

Jul. 31, 2013

8% Convertible Preferred Stock [Member]

Apr. 30, 2010

8% Convertible Preferred Stock [Member]

Mar. 31, 2010

8% Convertible Preferred Stock [Member]

Sep. 30, 2013

8% Convertible Preferred Stock [Member]

Jun. 30, 2013

8% Convertible Preferred Stock [Member]

Mar. 31, 2013

8% Convertible Preferred Stock [Member]

Sep. 30, 2013

8% Convertible Preferred Stock [Member]

Dec. 31, 2012

8% Convertible Preferred Stock [Member]

Sep. 30, 2013

Warrants [Member]

Jun. 30, 2013

Warrants [Member]

Mar. 31, 2013

Warrants [Member]

Sep. 30, 2012

Warrants [Member]

Jun. 30, 2012

Warrants [Member]

Mar. 31, 2012

Warrants [Member]

Sep. 30, 2013

Redeemable Preferred Stock [Member]

Jun. 30, 2013

Redeemable Preferred Stock [Member]

Mar. 31, 2013

Redeemable Preferred Stock [Member]

Jul. 31, 2013

Redeemable Preferred Stock [Member]

Apr. 30, 2013

Redeemable Preferred Stock [Member]

Sep. 30, 2013

Warrant 1 [Member]

Jun. 30, 2013

Warrant 1 [Member]

Mar. 31, 2013

Warrant 1 [Member]

Class of Stock [Line Items]

Issuance of common stock to consultants 75,000 75,000 75,000 225,000 75,000 175,000

Consulting costs charges $ 51,250 $ 49,500 $ 48,750 $ 184,750 $ 64,500 $ 160,000

Issuance of warrants to consultants 442,000 2,605,000 1,924,973 1,732,135 454,500 1,003,000

Consulting costs charges related to warrants 186,223 931,655 409,640 721,753 183,908 475,668

Warrants forfeited 136,500 1,051,500 859,833 122,833 4,368,644 1,500

Gain Loss on Revaluation of Warrants Liability 337,244 221,149 311,062 429,818 222,546 148,364 275,279 399,057 446,698 817,099 229,599 114,800 290,275 289,000 165,750

Gross proceeds from private offering of common stock and warrants to accredited investors 4,613,037 2,641,501 4,045,510 2,687,500

Company accepted subscriptions, in the aggregate 6,150,718 3,522,001 5,394,013 3,583,333

Period of warrants to purchase common stock 5 years 5 years 5 years 5 years

Common Stock to be Issued on Exercise of Warrant 9,226,077 5,283,003 7,277,264 9,226,077 9,226,077 615,072 352,200 539,401 358,333

Investors received five year warrants 100.00% 150.00% 150.00% 150.00% 150.00%

Exercise price of common stock $ 1.00 $ 1.00 $ 1.00 $ 1.00 $ 1.00 $ 1.00 $ 1.00 $ 1.00 $ 1.00 $ 1.00

Purchase price of common stock $ 0.75 $ 0.75

Payment of fully vested warrants 564,686 314,173 522,640 349,375

Percentage of Aggregate Shares Called by Warrant 10.00% 10.00% 10.00% 10.00%

Purchase price of common stock with warrants $ 0.75 $ 0.75 $ 0.75

Warrant accrued 32,500

Convertible preferred stock 8.00% 8.00% 8.00% 8.00%

Common stock shares issued in lieu of cash dividends for Preferred stock 61,022 79,401

Dividends on preferred stock 38,690 43,884 1,188,648 145,709 12,026,710 10,586 22,164 21,921 28,104 50,860 29,063

Converted preferred stock 441,667 734,999 403,520 593,000

Preferred stock converted into shares 441,667 441,667 734,999 403,520 593,000 34,598 29,384

Issuance and sale in a private placement accredited to investors 2,550,000

8% convertible preferred stock, par value $ 0.001 $ 0.001 $ 0.001

Preferred stock, par value $ 0.001 $ 0.001 $ 0.001 $ 0.001

Common stock, par value $ 0.001 $ 0.001 $ 0.001 $ 0.001

Preferred stock, shares issued 2,958,334 3,400,001 746,666 746,666 2,478,185

Purchase price of preferred stock with warrants 4,250,000

Common stock unit fair value warrants recorded on issuance 1,297,950

Common stock unit beneficial conversion amount 1,025,950

Purchase of common stock 30,000,000

Term of purchase Agreement 30 months

Purchase of common stock 100,000

Regular purchase limit 250,000

Less than the per share value of common stock $ 0.75

Issue of common stock 250,000

Costs charged to operations for commitment fee $ 162,500

X

- Definition

Class of warrants or right exercise price of warrants or rights.

+ References

No definition available.

+ Details

Name: pvct_ClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights

Namespace Prefix: pvct_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Commitment fee.

+ References

No definition available.

+ Details

Name: pvct_CommitmentFee

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Common stock unit beneficial conversion amount.

+ References

No definition available.

+ Details

Name: pvct_CommonStockUnitBeneficialConversionAmount

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Common stock unit fair value of warrants recorded on issuance.

+ References

No definition available.

+ Details

Name: pvct_CommonStockUnitFairValueOfWarrantsRecordedOnIssuance

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Consulting costs.

+ References

No definition available.

+ Details

Name: pvct_ConsultingCosts

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Consulting costs relates to warrant issued.

+ References

No definition available.

+ Details

Name: pvct_ConsultingCostsRelatesToWarrantIssued

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Convertible preferred stock par value per share securities purchase agreement.

+ References

No definition available.

+ Details

Name: pvct_ConvertiblePreferredStockParValuePerShareSecuritiesPurchaseAgreement

Namespace Prefix: pvct_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Convertible preferred stock shares to be converted to common stock shares.

+ References

No definition available.

+ Details

Name: pvct_ConvertiblePreferredStockSharesToBeConvertedToCommonStockShares

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Gain loss on revaluation of warrants liability.

+ References

No definition available.

+ Details

Name: pvct_GainLossOnRevaluationOfWarrantsLiability

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Gross proceeds from sales of common stock and warrants.

+ References

No definition available.

+ Details

Name: pvct_GrossProceedsFromSalesOfCommonStockAndWarrants

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of warrants issued securities purchase agreement.

+ References

No definition available.

+ Details

Name: pvct_NumberOfWarrantsIssuedSecuritiesPurchaseAgreement

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Payments require to pay to placement agent.

+ References

No definition available.

+ Details

Name: pvct_PaymentsRequireToPayToPlacementAgent

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Percentage of aggregate shares called by warrant.

+ References

No definition available.

+ Details

Name: pvct_PercentageOfAggregateSharesCalledByWarrant

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of common shares issuable on exercise of each warrant.

+ References

No definition available.

+ Details

Name: pvct_PercentageOfCommonSharesIssuableOnExerciseOfEachWarrant

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Period of warrants to purchase common stock.

+ References

No definition available.

+ Details

Name: pvct_PeriodOfWarrantsToPurchaseCommonStock

Namespace Prefix: pvct_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Purchase agreement of share issuance maximum amount.

+ References

No definition available.

+ Details

Name: pvct_PurchaseAgreementOfShareIssuanceMaximumAmount

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Purchase agreement of share issuance maximum number of shares to be issued.

+ References

No definition available.

+ Details

Name: pvct_PurchaseAgreementOfShareIssuanceMaximumNumberOfSharesToBeIssued

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Purchase agreement of share issuance maximum number of shares to be issued in single regular purchase.

+ References

No definition available.

+ Details

Name: pvct_PurchaseAgreementOfShareIssuanceMaximumNumberOfSharesToBeIssuedInSingleRegularPurchase

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Purchase agreement of share issuance period of shares to be issued.

+ References

No definition available.

+ Details

Name: pvct_PurchaseAgreementOfShareIssuancePeriodOfSharesToBeIssued

Namespace Prefix: pvct_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Purchase agreement of share issuance, price per share.

+ References

No definition available.

+ Details

Name: pvct_PurchaseAgreementOfShareIssuancePricePerShare

Namespace Prefix: pvct_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Purchase price of common stock with warrants.

+ References

No definition available.

+ Details

Name: pvct_PurchasePriceOfCommonStockWithWarrants

Namespace Prefix: pvct_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Securities purchase agreement price per unit.

+ References

No definition available.

+ Details

Name: pvct_SecuritiesPurchaseAgreementPricePerUnit

Namespace Prefix: pvct_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Share based goods and nonemployee services transaction quantity of warrants forfeited.

+ References

No definition available.

+ Details

Name: pvct_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Share based goods and nonemployee services transaction quantity of warrants issued.

+ References

No definition available.

+ Details

Name: pvct_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Units issued during period value securities purchase agreement.

+ References

No definition available.

+ Details

Name: pvct_UnitsIssuedDuringPeriodValueSecuritiesPurchaseAgreement

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares issued for each share of convertible preferred stock that is converted.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

+ Details

Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 405

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

+ Details

Name: us-gaap_DividendsPreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 405

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

+ Details

Name: us-gaap_DividendsPreferredStockStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The percentage rate used to calculate dividend payments on preferred stock.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of shares or units of entity securities issued in the transaction in which equity securities were issued to pay for goods or nonemployee services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares issued as consideration for cash for development stage entities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 215

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38297-110927

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForCash

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 37 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation (Tables)
9 Months Ended

Sep. 30, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Nonvested Stock Option Activity

The following is a summary of nonvested stock option activity for the nine months ended September 30, 2013:

   Number of Shares Weighted Average
Grant-Date
Fair Value

Nonvested at December 31, 2012
   —      $ —

Granted
   250,000    $ 0.57

Vested
   (250,000 ) $ 0.57

Canceled
   —      —



Nonvested at September 30, 2013
   —      $ —

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party Transaction - Additional Information (Detail) (USD $)
9 Months Ended

Sep. 30, 2013

NonEmployee

Subsequent Event [Line Items]

Payment for consulting services $ 48,000

Number of non employee to whom consulting services paid 1

Non Employee [Member]

Subsequent Event [Line Items]

Payment for consulting services to another non-employee 75,000

Third Non Employee [Member]

Subsequent Event [Line Items]

Payment for consulting services to another non-employee $ 75,000

X

- Definition

Number of non employee to whom consulting services paid.

+ References

No definition available.

+ Details

Name: pvct_NumberOfNonEmployeeToWhomConsultingServicesPaid

Namespace Prefix: pvct_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition

Related party transaction expenses from transactions with another related party.

+ References

No definition available.

+ Details

Name: pvct_RelatedPartyTransactionExpensesFromTransactionsWithAnotherRelatedParty

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation - Additional Information (Detail) (USD $)
1 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended

May 31, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Aug. 31, 2013

Re Elected Board Member [Member]

Jun. 30, 2012

Re Elected Board Member [Member]

May 31, 2012

Newly Appointed Board Member [Member]

Jun. 30, 2013

Options Exercised Price One [Member]

Jun. 30, 2013

Options Exercised Price Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Options Exercised Shares 18,750 25,000

Stock Options Exercise at Exercise Price Per Share $ 0.32 $ 0.60

Stock Options Exercise Value $ 6,000 $ 15,000

Stock option forfeited 25,000

Stock option issued 250,000 250,000 200,000 50,000

Stock-based compensation expense 142,310 0 142,310 183,028

Unrecognized stock-based compensation expense $ 0 $ 0

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Unrecognized cost of unvested options awarded to employees as compensation.

+ References

No definition available.

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of non-vested options forfeited.

+ References

No definition available.

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock issued as a result of the exercise of stock options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 40 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
9 Months Ended

Sep. 30, 2013

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2013

Document Fiscal Year Focus 2013

Document Fiscal Period Focus Q3

Entity Registrant Name PROVECTUS PHARMACEUTICALS INC

Entity Central Index Key 0000315545

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 139,974,331

8% Convertible Preferred Stock [Member]

Document Information [Line Items]

Entity Common Stock, Shares Outstanding 746,666

Series A 8% Convertible Preferred Stock [Member]

Document Information [Line Items]

Entity Common Stock, Shares Outstanding 2,958,334

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 41 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation - Summary of Nonvested Stock Option Activity (Detail) (USD $)
9 Months Ended

Sep. 30, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Number of Shares, Nonvested at December 31, 2012

Number of Shares, Granted 250,000

Number of Shares, Vested (250,000)

Number of Shares, Canceled

Number of Shares, Nonvested at September 30, 2013

Weighted Average Grant-Date Fair Value, Nonvested at December 31, 2012

Weighted Average Grant-Date Fair Value, Granted $ 0.57

Weighted Average Grant-Date Fair Value, Vested $ 0.57

Weighted Average Grant-Date Fair Value, Canceled

Weighted Average Grant-Date Fair Value, Nonvested at September 30, 2013

X

- Definition

Share based compensation arrangement by share based payment award equity instruments options forfeitures weighted average grant date fair value.

+ References

No definition available.

+ Details

Name: pvct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: pvct_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Share based compensation arrangement by share based payment award equity instruments options grants in period weighted average grant date fair value.

+ References

No definition available.

+ Details

Name: pvct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: pvct_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Share based compensation arrangement by share based payment award equity instruments options vested in period weighted average grant date fair value.

+ References

No definition available.

+ Details

Name: pvct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: pvct_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Share based compensation arrangement by share based payment award options vested in period.

+ References

No definition available.

+ Details

Name: pvct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriod

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average grant-date fair value of non-vested options outstanding.

+ References

No definition available.

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended		140 Months Ended
Condensed Consolidated Statements of Operations (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Revenues
OTC product revenue					$ 25,648
Medical device revenue					14,109
Total revenues					39,757
Cost of sales					15,216
Gross profit					24,541
Operating expenses
Research and development	1,296,654	1,129,921	2,815,519	4,352,940	45,914,372
General and administrative	2,185,756	2,296,637	6,864,865	7,228,225	73,050,754
Amortization	167,780	167,780	503,340	503,340	7,292,837
Total operating loss		(3,594,338)	(10,183,724)	(12,084,505)	(126,233,422)
Gain on sale of fixed assets					55,075
Loss on extinguishment of debt					(825,867)
Investment income	293	310	576	1,325	653,793
(Loss) gain on change in fair value of warrant liability	(902,798)	1,246,917	(917,102)	1,435,898	4,995,099
Net interest expense					(8,098,004)
Net loss	(4,552,695)	(2,347,111)	(11,100,250)	(10,647,282)	(129,453,326)
Dividends on preferred stock	(38,690)	(43,884)	(1,188,648)	(145,709)	(12,026,710)
Net loss applicable to common shareholders	$ (4,591,385)	$ (2,390,995)	$ (12,288,898)	$ (10,792,991)	$ (141,480,036)
Basic and diluted loss per common share	$ (0.03)	$ (0.02)	$ (0.10)	$ (0.10)
Weighted average number of common shares outstanding - basic and diluted	131,573,656	113,166,988	126,503,388	112,073,836

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accumulated depreciation on equipment and furnishings	$ 427,615	$ 422,965
Amortization on patents	7,292,837	6,789,497
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	139,974,331	118,427,925
Common stock, shares outstanding	139,974,331	118,427,925
8% Convertible Preferred Stock [Member]
Preferred stock, shares issued	746,666	2,478,185
Preferred stock, shares outstanding	746,666	2,478,185
Preferred stock, liquidation preference per share	$ 0.75	$ 0.75
Aggregate liquidation preference	570,585	1,896,117
Convertible preferred stock	8.00%	8.00%
Series A 8% Convertible Preferred Stock [Member]
Preferred stock, shares issued	2,958,334
Preferred stock, shares outstanding	2,958,334
Preferred stock, liquidation preference per share	$ 0.75	$ 0.75
Aggregate liquidation preference	$ 2,246,855	$ 2,246,855
Convertible preferred stock	8.00%	8.00%

Related Party Transaction	9 Months Ended
Related Party Transaction	Sep. 30, 2013
Related Party Transactions [Abstract]
Related Party Transaction	6. Related Party Transaction The Company paid one non-employee member of the board $48,000 for consulting services performed as of September 30, 2013. The Company paid another non-employee member of the board $75,000 for consulting services performed as of September 30, 2013. The Company paid a third non-employee member of the board $75,000 for consulting services performed as of September 30, 2013.

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2013
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ended December 31, 2013. The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued.

Equity Transactions - Additional Information (Detail) (USD $)	1 Months Ended			3 Months Ended						9 Months Ended		140 Months Ended			3 Months Ended				9 Months Ended	3 Months Ended			9 Months Ended	3 Months Ended							1 Months Ended	9 Months Ended		1 Months Ended			3 Months Ended			9 Months Ended		3 Months Ended											3 Months Ended
	Jul. 22, 2013	Feb. 28, 2013	Jan. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Feb. 22, 2013	Dec. 31, 2012	Mar. 31, 2013 Minimum [Member]	Sep. 30, 2013 Maximum [Member]	Jun. 30, 2013 Maximum [Member]	Mar. 31, 2013 Maximum [Member]	Sep. 30, 2013 Maximum [Member]	Sep. 30, 2013 Network 1 Financial Securities [Member]	Jun. 30, 2013 Network 1 Financial Securities [Member]	Mar. 31, 2013 Network 1 Financial Securities [Member]	Sep. 30, 2013 Maxim Group Llc [Member]	Sep. 30, 2013 Common Stock [Member]	Jun. 30, 2013 Common Stock [Member]	Mar. 31, 2013 Common Stock [Member]	Sep. 30, 2012 Common Stock [Member]	Jun. 30, 2012 Common Stock [Member]	Mar. 31, 2012 Common Stock [Member]	Feb. 22, 2013 Common Stock [Member]	Feb. 28, 2013 Series A 8% Convertible Preferred Stock [Member]	Sep. 30, 2013 Series A 8% Convertible Preferred Stock [Member]	Feb. 22, 2013 Series A 8% Convertible Preferred Stock [Member]	Jul. 31, 2013 8% Convertible Preferred Stock [Member]	Apr. 30, 2010 8% Convertible Preferred Stock [Member]	Mar. 31, 2010 8% Convertible Preferred Stock [Member]	Sep. 30, 2013 8% Convertible Preferred Stock [Member]	Jun. 30, 2013 8% Convertible Preferred Stock [Member]	Mar. 31, 2013 8% Convertible Preferred Stock [Member]	Sep. 30, 2013 8% Convertible Preferred Stock [Member]	Dec. 31, 2012 8% Convertible Preferred Stock [Member]	Sep. 30, 2013 Warrants [Member]	Jun. 30, 2013 Warrants [Member]	Mar. 31, 2013 Warrants [Member]	Sep. 30, 2012 Warrants [Member]	Jun. 30, 2012 Warrants [Member]	Mar. 31, 2012 Warrants [Member]	Sep. 30, 2013 Redeemable Preferred Stock [Member]	Jun. 30, 2013 Redeemable Preferred Stock [Member]	Mar. 31, 2013 Redeemable Preferred Stock [Member]	Jul. 31, 2013 Redeemable Preferred Stock [Member]	Apr. 30, 2013 Redeemable Preferred Stock [Member]	Sep. 30, 2013 Warrant 1 [Member]	Jun. 30, 2013 Warrant 1 [Member]	Mar. 31, 2013 Warrant 1 [Member]
Class of Stock [Line Items]
Issuance of common stock to consultants				75,000	75,000	75,000	225,000	75,000	175,000
Consulting costs charges																								$ 51,250	$ 49,500	$ 48,750	$ 184,750	$ 64,500	$ 160,000
Issuance of warrants to consultants				442,000	2,605,000	1,924,973	1,732,135	454,500	1,003,000
Consulting costs charges related to warrants				186,223	931,655	409,640	721,753	183,908	475,668
Warrants forfeited				136,500	1,051,500	859,833	122,833	4,368,644	1,500
Gain Loss on Revaluation of Warrants Liability				337,244	221,149	311,062	429,818	222,546	148,364																																	275,279	399,057	446,698	817,099	229,599	114,800						290,275	289,000	165,750
Gross proceeds from private offering of common stock and warrants to accredited investors				4,613,037	2,641,501	4,045,510				2,687,500
Company accepted subscriptions, in the aggregate				6,150,718	3,522,001	5,394,013				3,583,333
Period of warrants to purchase common stock				5 years	5 years	5 years				5 years
Common Stock to be Issued on Exercise of Warrant				9,226,077	5,283,003	7,277,264				9,226,077		9,226,077								615,072	352,200	539,401	358,333
Investors received five year warrants															100.00%	150.00%	150.00%	150.00%	150.00%
Exercise price of common stock				$ 1.00	$ 1.00	$ 1.00				$ 1.00		$ 1.00								$ 1.00	$ 1.00	$ 1.00	$ 1.00							$ 1.00
Purchase price of common stock						$ 0.75							$ 0.75
Payment of fully vested warrants																				564,686	314,173	522,640	349,375
Percentage of Aggregate Shares Called by Warrant				10.00%	10.00%	10.00%				10.00%
Purchase price of common stock with warrants				$ 0.75	$ 0.75					$ 0.75
Warrant accrued																					32,500
Convertible preferred stock																																8.00%			8.00%	8.00%				8.00%
Common stock shares issued in lieu of cash dividends for Preferred stock			61,022																															79,401
Dividends on preferred stock				38,690			43,884			1,188,648	145,709	12,026,710																									10,586	22,164	21,921									28,104	50,860	29,063
Converted preferred stock																																					441,667											734,999	403,520	593,000
Preferred stock converted into shares																																					441,667			441,667								734,999	403,520	593,000	34,598	29,384
Issuance and sale in a private placement accredited to investors		2,550,000
8% convertible preferred stock, par value				$ 0.001						$ 0.001		$ 0.001
Preferred stock, par value				$ 0.001						$ 0.001		$ 0.001		$ 0.001
Common stock, par value				$ 0.001						$ 0.001		$ 0.001		$ 0.001
Preferred stock, shares issued																																2,958,334	3,400,001				746,666			746,666	2,478,185
Purchase price of preferred stock with warrants																															4,250,000
Common stock unit fair value warrants recorded on issuance						1,297,950
Common stock unit beneficial conversion amount						1,025,950
Purchase of common stock	30,000,000
Term of purchase Agreement	30 months
Purchase of common stock	100,000
Regular purchase limit	250,000
Less than the per share value of common stock	$ 0.75
Issue of common stock	250,000
Costs charged to operations for commitment fee	$ 162,500

Related Party Transaction - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013 NonEmployee
Subsequent Event [Line Items]
Payment for consulting services	$ 48,000
Number of non employee to whom consulting services paid	1
Non Employee [Member]
Subsequent Event [Line Items]
Payment for consulting services to another non-employee	75,000
Third Non Employee [Member]
Subsequent Event [Line Items]
Payment for consulting services to another non-employee	$ 75,000

Stock-Based Compensation - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended		1 Months Ended			3 Months Ended
	May 31, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Aug. 31, 2013 Re Elected Board Member [Member]	Jun. 30, 2012 Re Elected Board Member [Member]	May 31, 2012 Newly Appointed Board Member [Member]	Jun. 30, 2013 Options Exercised Price One [Member]	Jun. 30, 2013 Options Exercised Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Exercised Shares									18,750	25,000
Stock Options Exercise at Exercise Price Per Share									$ 0.32	$ 0.60
Stock Options Exercise Value									$ 6,000	$ 15,000
Stock option forfeited	25,000
Stock option issued				250,000		250,000	200,000	50,000
Stock-based compensation expense		142,310	0	142,310	183,028
Unrecognized stock-based compensation expense		$ 0		$ 0

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Entity Registrant Name	PROVECTUS PHARMACEUTICALS INC
Entity Central Index Key	0000315545
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding	139,974,331
8% Convertible Preferred Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	746,666
Series A 8% Convertible Preferred Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	2,958,334

Stock-Based Compensation - Summary of Nonvested Stock Option Activity (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares, Nonvested at December 31, 2012
Number of Shares, Granted	250,000
Number of Shares, Vested	(250,000)
Number of Shares, Canceled
Number of Shares, Nonvested at September 30, 2013
Weighted Average Grant-Date Fair Value, Nonvested at December 31, 2012
Weighted Average Grant-Date Fair Value, Granted	$ 0.57
Weighted Average Grant-Date Fair Value, Vested	$ 0.57
Weighted Average Grant-Date Fair Value, Canceled
Weighted Average Grant-Date Fair Value, Nonvested at September 30, 2013